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Socioeconomic inequalities in the relationship between lower socioeconomic status and 
circumstances with poorer survival of people with head and neck cancer have previously 
been described. However, the extent and nature of socioeconomic inequality in survival of 
people with head and neck cancer is poorly understood and explanations for these 
inequalities are yet to be thoroughly investigated. In particular, the underlying 
determinants of inequality in survival of people with head and neck cancer is yet to be 
explored by comparing factors that might be more modifiable with factors that might be 
more difficult to modify or control. In addition, no study exists from the United Kingdom 
(UK) that has explored socioeconomic inequality in survival of people with head and neck 
cancer using individual measurements of socioeconomic status, such as household 
income or education level, and few studies have investigated the long-term impact of 
inequality on survival of people with head and neck cancer beyond five-years. Finally, no 
studies have examined inequality in survival of people with head and neck cancer by 
utilising metrics of inequality. Further investigations into socioeconomic inequality in 
survival of people with head and neck cancer need to be conducted to describe and 
compare inequality with the aim to explain the underlying drivers of inequality in survival 
for people with head and neck cancer in the short-term, middle-term, and long-term follow-
up.  
Aim 
This thesis has the potential to shine a light on the issue of socioeconomic inequality in 
survival of people with head and neck cancer. This thesis aims to inform the patients, 
public, clinicians, and policy makers who are involved with head and neck cancer services 
on the magnitude of socioeconomic inequality in survival of people with head and neck 
cancer, and what factors can explain these inequalities. A series of epidemiological 
studies of existing UK cohort studies will be conducted to explore this topic from different 
angles with the aim to inform policy and practice to further the development and delivery 
of head and neck cancer services. 
The overall aim of this thesis is to: describe the trends in socioeconomic determinants and 
inequalities in survival from head and neck cancer over calendar time and follow-up time; 
to understand socioeconomic inequality in survival of people with head and neck cancer; 
and to explain the underlying determinants and explanations of socioeconomic inequality 
in survival of people with head and neck cancer. In addition, multiple measurements of 
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survival will be utilised and compared, including overall survival, disease-specific survival, 
and net survival estimates, as well as measurements of inequality including the slope 
index of inequality and the relative index of inequality. Finally, both area-based 
measurements and individual measurements of socioeconomic status will be utilised and 
compared for their association with inequality in survival of people with head and neck 
cancer.  
Methods 
Four studies were conducted with the aim to explore the magnitude, extent, and 
underlying determinants of survival and inequality in survival of people with head and neck 
cancer in the UK.  
Chapter 2 provides an overview analysis of socioeconomic determinants in survival by 
utilising data from the Scottish Cancer Registry of people diagnosed with head and neck 
cancer between 1986 to 2015. Due to the limitations around the availability of data in 
cancer registries, the explanations for socioeconomic inequality were not explored in this 
chapter and therefore, this chapter was an epidemiological analysis of the trends and 
magnitude of socioeconomic inequalities in survival over time.  
Chapter 3 analyses the determinants of survival from head and neck cancer by utilising 
the Scottish Audit of Head and Neck Cancer (SAHNC), a population-based clinical cohort 
study of people with head and neck cancer who were diagnosed between 1999 and 2001. 
Multiple patient, tumour, and treatment factors were examined for their predictive ability 
with survival, including area-based socioeconomic deprivation. Several methods of 
measuring survival were compared and contrasted in this chapter, including overall 
survival, disease-specific survival, and net survival estimates after one year, five years, 
and 12 years of a diagnosis of head and neck cancer. 
Chapter 4 also uses the SAHNC cohort and built upon Chapter 3 by exploring the drivers 
and explanations for the socioeconomic inequality observed after one year, five years, 
and 12 years of a diagnosis of head and neck cancer. The patient, tumour, and treatment 
factors were individually examined for their relationship with socioeconomic factors with 
the aim of determining the underlying causes of socioeconomic inequality in survival of 
people with head and neck cancer. This chapter also explored these inequalities via 
different survival metrics – overall survival, disease-specific survival, and net survival 
estimates.  
Chapter 5 investigated the relationship of individual socioeconomic factors and 
explanations for these relationships using a cohort of people with head and neck cancer 
that were diagnosed between 2011 and 2014 in a population-based clinical cohort study in 
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England; Head and Neck 5000 (HN5000). This part of the thesis aimed to undertake an 
in-depth exploration into the nature and extent of the socioeconomic inequality in survival 
of people with head and neck cancer by considering both area-based and individual 
dimensions of socioeconomic circumstances. Multiple demographic, health, behavioural, 
tumour, and treatment factors were considered to help understand the relationship 
between socioeconomic factors and head and neck cancer survival. This analysis built 
upon the previous chapters with multiple individual socioeconomic measurements and 
several additional potential explanatory factors collected as part of a more recent cohort 
study of people with head and neck cancer, including human papillomavirus (HPV) status.  
Results  
As a whole, this thesis demonstrated strong and consistent socioeconomic inequalities in 
survival of people with head and neck cancer. These inequalities in survival of people with 
head and neck cancer appeared to become worse over calendar time and also across 
follow-up period after one year, five years, and ten years of a diagnosis of head and neck 
cancer (Chapter 2 – Scottish Cancer Registry). Chapter 3 found that socioeconomic 
status was not an independent predictor of survival in a cohort of people with head and 
neck cancer who were diagnosed in Scotland between the years of 1999 and 2001 
(SAHNC), while Chapter 4 investigated the underlying factors that may explain the original 
inequality that was observed in overall survival, disease-specific survival, and net survival 
estimates (also the SAHNC). Chapter 4 highlighted that in models that were adjusted by 
various patient, tumour, and treatment factors, none of the factors could individually 
explain the socioeconomic inequality in survival alone, suggesting that socioeconomic 
inequality in survival of people with head and neck cancer is complex, with multiple factors 
having a combined effect, including background mortality in the long-term follow-up (via 
net survival estimates). The studies that were carried out in Chapter 2 to Chapter 4 only 
utilised area-based socioeconomic measurements – mainly Carstairs Deprivation Index.  
Chapter 5 added to this picture by exploring inequality by using both an area-based (Index 
of Multiple Deprivation (IMD) Category) and individual measurements of socioeconomic 
status including highest education level attained, number of years spent in education, 
annual household income, proportion of income from benefits, and financial concerns of 
living with or after cancer. Only data from England in the HN5000 cohort could be included 
in this analysis since it was not possible to pool and standardise the varying 
measurements of IMD (including Scottish IMD and Welsh IMD) across these countries of 
the UK. This study determined that inequalities were present for all of the measurements 
of socioeconomic status, however inequality in highest education level, number of years 
spent in education, and financial concerns of living with or after cancer were explained 
(fully attenuated) by other factors such as age and smoking status. Inequality across both 
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annual household income and the proportion of income from benefits partly attenuated 
following the adjustment of all of the potential explanatory factors, however, even after full 
adjustment, the relationship with survival of these factors of socioeconomic status could 
not be fully explained by any of the potential patient, tumour, or treatment factors that 
were included in this study.  
The secondary aim of Chapter 3 was to compare methods of measuring survival via the 
use of overall survival, disease-specific survival, and net survival estimates. The 
substantial differences between these survival metrics demonstrated the overestimation of 
deaths that are specific to head and neck cancer when using overall survival, and the 
underestimation of disease-specific mortality from using death certificates when people 
have died only from head and neck cancer. These results suggest that people are dying of 
other causes that are related to their head and neck cancer but are not as a direct result 
of their cancer, which ultimately increases with time following diagnosis. Therefore, the 
use of net survival provides a good compromise to traditional methods to estimate the true 
burden of head and neck cancer in long-term follow-up studies. As a result, throughout 
Chapter 2 to Chapter 4, net survival estimates have been provided alongside overall 
survival and disease-specific survival results to compare and contrast the outcomes of 
people with head and neck cancer. However, in Chapter 5, it was not possible to utilise 
net survival estimations since lifetables for this time point had not yet been generated at 
the time of this analysis.  
Discussion and Conclusions 
The thesis studied socioeconomic inequality in survival of people with head and neck 
cancer in the UK using data from three sources – the Scottish Cancer Registry, the 
SAHNC cohort study of people with head and neck cancer in Scotland, and the HN5000 
cohort study of people with head and neck cancer in England. As a whole, this thesis 
reported that inequality in survival of people with head and neck cancer is a persistent 
problem – a problem which seems to be getting worse. Moreover, the main premise of this 
thesis was to further the understanding of explanatory factors of socioeconomic inequality 
in survival of people with head and neck cancer. Although socioeconomic inequality in 
survival utilising an area-based measurement of socioeconomic status was explained by 
various underlying factors, inequality by annual household income and the proportion of 
income from benefits only attenuated following the adjustment of all potential explanatory 
factors for patients in England. Even after full adjustment, inequality in survival by annual 
household income and the proportion of income from benefits could not be explained by 
any of the potential underlying factors that were included in this study. Therefore, further 
investigations considering individual measurements of patients’ income following a 
diagnosis of cancer should be conducted.  
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In addition, a number of recommendations related to policy, practice, and further research 
were drawn. This thesis has provided a comprehensive examination of socioeconomic 
inequalities in survival of people with head and neck cancer – a relatively underexplored 
field. The research involved in-depth analyses of multiple datasets and from a number of 
perspectives. It has shown that inequalites in survival are substantial and are a growing 
problem, and has endeavored to explore the explanatory factors. This work provides a 
platfrom through which policy and practice development, along with evaluation and 
research, can be based to reduce inequalties in survival and improve the outcome for 
people who are diagnosed with head and neck cancer. 
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1.1 Thesis structure  
This thesis investigates the association of socioeconomic factors with the survival of 
people with head and neck cancer. The primary aim of this thesis is to explore the extent 
and magnitude of socioeconomic inequality in survival of people with head and neck 
cancer. The secondary aim is to thoroughly examine the drivers and underlying causes of 
this inequality in the short-term, medium-term, and long-term following a diagnosis of head 
and neck cancer. Potential explanatory factors for these socioeconomic inequalities are 
explored including multiple participant, demographic, health, behavioural, tumour and 
treatment factors. In addition, a thorough methodological assessment of measurements of 
survival is undertaken to determine the impact of socioeconomic determinants using each 
method of survival analysis. This includes comparing and contrasting results of overall 
survival, disease-specific survival, and net survival estimates throughout the thesis.  
Chapter 1 provides the background to this thesis. This includes an overview of the burden 
of head and neck cancer across the world and a brief review of the risk factors of head 
and neck cancer. In addition, current global survival trends and rates along with the 
determinants and predictors of survival following a diagnosis of head and neck cancer are 
reviewed. An in-depth literature review focuses on the existing research that investigates 
socioeconomic determinants and socioeconomic inequalities in the survival of people with 
head and neck cancer. This review provides the context, background, and rationale for the 
studies that were performed as part of the thesis.  
The next four chapters include the results and analyses of three cohorts which investigate 
socioeconomic determinants and socioeconomic inequality and explore explanations for 
these inequalities in the survival of people with head and neck cancer. 
Chapter 2 provides an overview analysis of socioeconomic determinants in survival by 
utilising data from the Scottish Cancer Registry of people diagnosed with head and neck 
cancer between 1986 to 2015. The primary aim of this chapter is to describe the historical 
trends over time of the socioeconomic inequality in survival of people with head and neck 
cancer in Scotland. In addition to comparing trends over calendar time, the differences in 
inequality over the follow-up time in one-year, five-year, and 10-year survival will also be 
compared. These trends are examined for the whole cohort, for males and females, and 
for people with the three main subsites of head and neck cancer (oral cavity, oropharynx, 
and larynx). Due to the limitations around the availability of data in cancer registries, the 
explanations for socioeconomic inequality will not be explored in this chapter and 
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therefore, this chapter will be an epidemiological overview of inequality in survival over 
time.  
Chapter 3 analyses the determinants of survival from head and neck cancer by utilising 
the Scottish Audit of Head and Neck Cancer (SAHNC), a population-based clinical cohort 
study of patients who were diagnosed between 1999 and 2001. Multiple patient, tumour, 
and treatment factors are examined for their predictive ability with survival, including area-
based socioeconomic deprivation. Several methods of measuring survival are compared 
and contrasted in this chapter, including overall survival, disease-specific survival and net 
survival estimates after one year, five years, and 12 years of a diagnosis of head and 
neck cancer. 
Chapter 4 also uses the SAHNC cohort and builds upon Chapter 3 by exploring the 
drivers and explanations for the socioeconomic inequality observed after one year, five 
years and 12 years of a diagnosis of head and neck cancer. The patient, tumour, and 
treatment factors will be individually examined for their relationship with socioeconomic 
status with the aim of determining the underlying causes of socioeconomic inequality in 
survival of people with head and neck cancer in overall survival, disease-specific survival, 
and net survival estimates.  
Chapter 5 investigates the relationship of individual socioeconomic factors and 
explanations for these relationships using a cohort of people with head and neck cancer 
who were diagnosed in England between 2011 and 2014 in a population-based clinical 
cohort study; Head and Neck 5000 (HN5000). This part of the thesis aims to undertake an 
in-depth exploration into the nature and extent of the socioeconomic inequality in survival 
of people with head and neck cancer by considering both area-based and individual 
dimensions of socioeconomic circumstances. Multiple demographic, health, behavioural, 
tumour, and treatment factors will be considered to help understand the relationship 
between socioeconomic factors and head and neck cancer survival. This analysis builds 
upon the previous chapter with multiple individual socioeconomic measurements and 
several additional potential explanatory factors collected as part of a more recent cohort 
study of people with head and neck cancer, including human papillomavirus (HPV) status.  
Chapter 6 discusses the findings of this thesis collectively by comparing the results of the 
four studies which have investigated different aspects of socioeconomic inequality in the 
survival of those with head and neck cancer. This chapter also explores the potential 
explanations for these socioeconomic inequalities in relation to the literature and 
discusses the overall strengths and limitations of the research. Finally, this chapter makes 
recommendations for further research, policy and practice in relation reducing 
socioeconomic inequalities in survival of people with head and neck cancer. 
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1.2 Methods used in this thesis 
1.2.1 Methods of measuring survival 
Survival analysis investigates the time it takes for an “event” to occur. In cancer research 
this event can be, for example, the time to death, the time to progression of cancer, or the 
time to relapse of cancer. In addition, the event must be a binary variable (for example, 
alive versus dead, progressed versus not progressed, or relapsed versus not relapsed) 
and the first occurrence of the event (should this event not be death) is the only endpoint 
that can be considered. Survival analysis requires a “clear and well defined case 
definition” (dos Santos Silva, 1999) such as a group of people with a specific type of 
cancer who are from one region. Survival analysis also requires a “clear and well defined 
starting point” (dos Santos Silva, 1999) such as the date of diagnosis of a person’s cancer 
or the date of their initial treatment. Survival analysis computes the length of time between 
the starting point and the endpoint of interest in a study, known as the “survival time”, 
which is dependent upon the length of time each person in a study was followed-up.  
1.2.1.1 Kaplan-Meier method 
Kaplan-Meier survival analysis is one method that can be used to analyse survival which 
generates a Kaplan-Meier survival curve (Altman, 1992). The Kaplan-Meier (or product-
limit method) is a mathematical technique that allows the amount of follow-up time to be 
included into the survival time. This curve graphically demonstrates the probability of 
survival of a group of people against follow-up time (measured in in days, months, or 
years). The initial starting point is the date of entry of each person into a study, and 
therefore can be different for multiple participants. As a result, Kaplan-Meier survival 
analysis is a powerful method of measuring survival since the initial starting date of the 
analysis does not need to be the same for everyone included in the study. Over time, as 
people start to leave the study due to the event of interest, the Kaplan-Meier curve 
decreases which is represented by a step-down function. Survival probabilities are 
produced in survival tables which are obtained from the Kaplan-Meier function. From 
these tables, survival rates such as one-year, five-year, or 10-year survival can be 
extracted.  
Censored observations 
Censored observations occur due to early termination of follow-up or when the endpoint of 
interest is not known for an individual included in a study. This may occur due to loss-to-
follow up, such as the participant moving address, or it may occur due to the endpoint not 
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meeting the relevant criteria of the event of interest. All participants who have not 
experienced the event of interest and are alive at the endpoint of a study are censored at 
this point in time.  
1.2.1.2 Overall and disease-specific survival 
In this thesis, two measurements of survival have been estimated from Kaplan-Meier 
survival analysis including overall survival and disease-specific survival. Overall survival 
considers the risk of death by all causes. However, disease-specific survival only 
considers deaths that are specifically caused by the disease of interest but does not 
include deaths that may have been related to or occurred as a secondary effect to the 
disease of interest. These events that are not of interest are censored (National Cancer 
Institute, 2021).  
1.2.1.3 Net survival 
Net survival is defined as the excess mortality between the observed mortality of a group 
of people under study and the expected mortality of a disease-free group in the population 
with the same demographic characteristics as the study group (Pohar Perme et al., 2012). 
Net survival estimation is useful when cause of death information is unknown and 
provides a more accurate representation of the mortality from a disease of interest by 
disentangling other causes of death, particularly in studies which have long-term follow-up 
where competing causes of death are common. 
1.2.2 Measurements of socioeconomic status 
Health inequalities can cover a range of equality domains (for example, age, sex, race, or 
ethnicity) (Equality Act, 2010). However, for the purposes of this thesis it will focus on 
socioeconomic inequalities. Socioeconomic measures that are used in the thesis include 
area-based measurements and individual measurements.  
1.2.2.1 Area-based measurements of socioeconomic status 
Throughout this thesis, area-based measurements of socioeconomic status have been 
obtained from several measurements: Carstairs and Morris Index (Carstairs and Morris, 
1989; Carstairs and Morris, 1990), Scottish Index of Multiple Deprivation (SIMD) (Public 
Health Scotland, 2020b), and English IMD (English Indices of Deprivation, 2020).   
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Carstairs and Morris Index 
The Carstairs and Morris Index was developed in 1989 and ranks the geographical areas 
of Scotland from a person’s home postcode (Carstairs and Morris, 1989; Carstairs and 
Morris, 1990). The Index has been produced using census data from the years 1981, 
1991, 2001 and 2011, and groups areas at the postcode sector using four indicators that 
act as a representation of material disadvantage: (a) low occupational social class, (b) 
lack of car ownership, (c) overcrowded households, and (d) male unemployment. The 
Carstairs and Morris Index is categorised into one of five groups using the Census data: 
for the 1981, 1991, and 2001 categories, group one represents the people from the least 
deprived areas and group five represents the people from the most deprived areas, 
whereas for the 2011 categories, group one represents the people from the most deprived 
areas and group five represents the people from the least deprived areas (the order has 
been reversed).  
Scottish Index of Multiple Deprivation 
The SIMD was developed in 2004 and like the Carstairs and Morris Index, it is measured 
at the postcode sector, however SIMD uses smaller geographical areas (“data zones”) 
than those used in the Carstairs and Morris Index (Public Health Scotland, 2020b). SIMD 
has been produced using census data from the years 2004, 2006, 2009, 2012, 2016, and 
2020 and is calculated from seven domains of deprivation: (a) income employment, (b) 
education,  
(c) housing, (d) health, (e) crime, and (f) geographical access. SIMD is categorised into 
one of five groups using the Census data: for the 2004 and 2006 categories, group one 
represents the people from the least deprived areas and group five represents the people 
from the most deprived areas, whereas for the 2009, 2012, 2016, and 2020 categories, 
group one represents the people from the most deprived areas and group five represents 
the people from the least deprived (the order has been reversed).  
English Index of Multiple Deprivation 
The English IMD was developed in the year 2000 and like the SIMD, it is measured at the 
postcode level (English Indices of Deprivation, 2020). However, the English IMD uses 
Local Authority Districts in England. The English IMD has been produced using census 
data from 2000, 2004, 2007, and 2010 and is calculated from seven domains of 
deprivation: a) Income Deprivation, (b) Employment Deprivation, (c) Health Deprivation 
and Disability, (d) Education Skills and Training Deprivation, (e) Barriers to Housing and 
Services, (f) Living Environment Deprivation, and (g) Crime. The English IMD is 
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categorised into one of five groups – group one represents the people from the most 
deprived areas and group five represents the people from the least deprived areas.  
1.2.2.2 Individual measurements of socioeconomic status 
Measurements of socioeconomic status using individual determinants have been 
thoroughly reviewed (Galobardes et al., 2006a; Galobardes et al., 2006b) and have also 
applied to cancer research in the International Agency for Research on Cancer (IARC) 
publication on Social Inequalities in Cancer (International Agency for Research on 
Cancer, 2019). Individual measurements of socioeconomic status that have been used 
throughout this thesis (namely in Chapter 5) include: (a) highest education level attained, 
(b) number of years spent in full-time education, (c) total annual household income, (d) 
proportion of income from benefits, and (e) financial concerns of living with or after cancer. 
Measurements for education level represent early-life socioeconomic status and are a 
strong predictor of employment, and thus income, in future years, while annual household 
income is a direct measure of socioeconomic status by measuring a person’s access to 
material resources and services (Conway et al., 2019). 
1.3 Head and neck cancer  
1.3.1 Definition 
Approximately 90% of cancers of the head and neck are squamous cell carcinoma (SCC) 
which arise from the epithelium lining of the oral cavity, pharynx, and larynx (Sanderson 
and Ironside, 2002). There are many types of head and neck cancers which are discretely 
categorised using the International Classification of Diseases (ICD-10) from the World 
Health Organisation (WHO) (World Health Organization, 2016). These include the: (a) lip, 
(b) oral cavity, (c) pharynx (including the nasopharynx, oropharynx, and hypopharynx),  
(d) larynx, (e) nasal cavity, (f) middle ear, (g) accessory sinuses, (h) bones of the skull and 
face, (i) mandible, and (j) other ill-defined sites of the head, face, and neck. A 
comprehensive list of each subsite along with the detailed information of the location in 
the head and neck of that subsite (including the individual ICD-10 code) is outlined in 
Appendix 1.2. 
Due to the complexity of head and neck cancer, and the varying symptoms, treatment 
regimens, and prognoses of each anatomical subsite of the head and neck, there is 
debate around the inclusion criteria of the major subsites in the overarching definition of 
“head and neck cancer”. As a result, the subsites that are included under the definition of 
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“head and neck cancer” often vary across different studies. A comprehensive review 
carried out by Kaste et al. (2013) outlined several definitions of head and neck cancer 
from the National Cancer Institute (NCI), IARC, and Cancer Research United Kingdom 
(CRUK), as outlined in Table 1.1. The most important difference between these definitions 
is the inclusion of the oesophagus, parathyroid, or thyroid cancers under the definition set 
out by CRUK. Several articles include these subsites as a form of head and neck cancer, 
however for the purpose of this research, it is important to note that these have been 
excluded from all of the analyses performed in this thesis.  
Table 1.1 – Inclusion criteria of head and neck cancer from three major definitions 
ICD group NCI IARC CRUK 
External lip ✓   
Oral cavity ✓   
Lip and oral cavity combined  ✓  
Mouth and oropharynx combined   ✓ 
Tongue   ✓ 
Oropharynx ✓ ✓  
Tonsil   ✓ 
Throat   ✓ 
Nasopharynx ✓ ✓ ✓ 
Hypopharynx ✓ ✓  
Larynx ✓ ✓ ✓ 
Paranasal sinuses and nasal cavity ✓  ✓ 
Salivary glands ✓ ✓ ✓ 
Eye and orbit   ✓ 
Oesophagus   ✓ 
Parathyroid     
Thyroid    
Abbreviations: NCI – National Cancer Institute, IARC – International Agency 
for Research on Cancer, CRUK – Cancer Research UK 
In addition, the complex nature of head and neck cancer leads to uncertainty around the 
inclusion and exclusion criteria of the individual subsites that are to be categorised as part 
of the major subsites of the head and neck, particularly the oral cavity and oropharynx 
(Conway et al., 2018). A lack of clarity exists around the boundaries of the anatomical 
subsites of the head and neck that belong to the oropharynx or oral cavity. This often 
results in variations of the inclusion criteria between studies that investigate cancers of the 
oral cavity or oropharynx. Due to variations in how head and neck cancer is defined 
across the different studies used in this thesis, the anatomical subsites (with the 
corresponding ICD codes) will be specified in the methods section of each chapter. 
1.3.2 Risk factors of head and neck cancer 
This section focuses on the major risk factors of head and neck cancer by summarising 
the findings from several publications, particularly studies from the International Head and 
Neck Cancer Epidemiology (INHANCE) consortium (Conway et al., 2009). The INHANCE 
consortium aims to improve the understanding of the underlying causes of head and neck 
cancer via the collaboration of several research groups. The investigators have combined 
their data from 35 case-control studies to produce a pooled analysis comprising of 25,500 
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patients and 37,100 controls, and their results have been summarised by Winn et al. 
(2015). 
1.3.2.1 Smoking and alcohol consumption 
Tobacco smoking and alcohol consumption have been well recognised as the leading 
causes of primary tumours of the head and neck for many years (Macfarlane et al., 1995; 
Talamini et al., 1998; Bosetti et al., 2002). Tobacco use and alcohol consumption are 
associated (Duffy et al., 2007), and a person’s intake may be influenced by 
sociodemographic factors such as cohabitation status, education level and gender 
(Allison, 2001).  
The results of a pooled analysis of 15 case-control studies from the INHANCE consortium 
reported that cigarette smoking, and excessive alcohol drinking are independent risk 
factors of head and neck cancer (Hashibe et al., 2007). The article reported that those 
who never drank alcohol were at a more than two-fold increased risk of developing head 
and neck cancer if they smoked cigarettes, which became higher based on the frequency, 
duration, and number of pack-years of cigarette smoking. In addition, the risk of 
developing cancer of the larynx was substantially stronger than the risk of developing 
cancer of the oral cavity or pharynx for those who smoked tobacco products. For 
individuals who never smoked, those who consumed at least three alcoholic beverages a 
day had a more than two-fold risk of head and neck cancer than those who had never 
drank alcohol. In a later study performed by Hashibe and colleagues, it was found that 
approximately 72% of head and neck cancers are attributable to tobacco use, alcohol 
consumption and a combination of the two behaviours (Hashibe et al., 2009). In addition, 
the joint effects of smoking and alcohol accounted for 64% of oral cavity cases, 72% of 
pharyngeal cases, and 89% of laryngeal cases (Hashibe et al., 2009).  
In a further study conducted from the INHANCE consortium, smoking and alcohol 
cessation was investigated (Marron et al., 2010). The study found that quitting tobacco 
smoking could lead to a reduction in the risk of head and neck cancer by 30% after as 
little as one to four years, or by 70% after more than 20 years. However, the results were 
not as clear cut for alcohol cessation, which led to a 40% reduced risk of head and neck 
cancer after more than 20 years of quitting. Tobacco, betel-leaf, or areca nut chewing are 
also strongly associated with the risk of developing head and neck cancer among Asian 
populations, which could be responsible for up to half or oral cancer cases in India 
(Travasso, 2013). 
Chapter 1: Introduction and literature review 
9 
1.3.2.2 Socioeconomic factors 
Low socioeconomic position is an additional and independent risk factor of head and neck 
cancer, and socioeconomic inequalities in the incidence of head and neck cancer have 
been observed both between and within developed and developing countries (Conway et 
al., 2008; Conway et al., 2015). Conway et al. (2008) conducted a systematic review and 
meta-analysis of 41 studies to investigate the relationship between socioeconomic 
inequality and the risk of oral cancer. Conway and authors concluded that low 
socioeconomic status was associated with an increased risk of developing oral cancer 
which was also apparent when adjusting for the major potential confounding factors (such 
as smoking and alcohol consumption).  
A further study undertaken by Conway et al. (2015) explored the association between 
education and income with head and neck cancer risk. Conway and authors used data 
from the INHANCE consortium of head and neck cancer which included 31 studies. The 
results from this study demonstrated that lower levels of educational attainment and lower 
income levels were both associated with a more than two-fold increased risk of head and 
neck cancer, which remained following adjustment for smoking, alcohol, and dietary risk 
factors.  
1.3.2.3 HPV status 
In recent years, HPV has been associated with an increase in the incidence of head and 
neck cancer. There has been a substantial rise in the incidence of HPV-associated 
cancers of the oropharynx, with approximately 70% of oropharyngeal cancers being 
related to HPV positivity (Saraiya et al., 2015). D'Souza et al. (2007) conducted one of the 
first case-control studies that examined the role of HPV infection and the risk of 
oropharyngeal cancer – in 100 people with oropharyngeal cancer and 200 controls without 
cancer they discovered that people with HPV type 16 (HPV-16) were substantially more at 
risk of oropharyngeal cancer. 
1.3.2.4 Diet and nutrition 
Several studies have noted an association between diet and risk of head and neck 
cancer. Chuang et al. (2012) reported that higher intake of fruit and vegetables were 
associated with a lower risk of head and neck cancer, while a higher intake of red meats 
were associated with an increased risk of head and neck cancer. Further studies have 
suggested a reduction in the risk of head and neck cancer in people who have high intake 
of vitamin C or vitamin E from food (Edefonti et al., 2015a; Edefonti et al., 2015b), but no 
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strong associations were observed between vitamin or mineral supplements and the risk 
of head and neck cancer (Li et al., 2012). 
1.3.2.5 Body mass index 
Gaudet et al. (2010) investigated the association of body mass index (BMI) with the risk of 
head and neck cancer using 17 studies from the INHANCE consortium. The authors 
reported that people with a lean body mass (BMI < 18.5kg/m2) were associated with a 
higher risk of head and neck cancer, while those with higher body mass were associated 
with a reduced risk of head and neck cancer. This trend was notable prior to and after 
adjusting for additional head and neck cancer risks, including smoking and alcohol 
consumption.  
1.3.3 Incidence and trends of head and neck cancer 
In 2020, there were more than 930,000 new cases of head and neck cancer diagnosed 
across the world (Table 1.2); collectively ranking it as the sixth most common type of 
cancer (Ferlay et al., 2020). The most prevalent group of head and cancers include the lip 
and oral cavity, followed by the larynx, which accounted for more than 40% (n = 377,713) 
and 20% (n = 184,615) of all head and neck cancers combined across the globe in 2020, 
respectively (Ferlay et al., 2020). Head and neck cancer is more common in men than it is 
in women, with an approximate ratio of 3:1 of men to women, making head and neck 
cancer the fourth most common cancer in men and the twelfth most common cancer in 
women in the United Kingdom (UK) in 2020 (Ferlay et al., 2020). 
The incidence of head and neck cancer varies across the globe. In a comprehensive 
study by Miranda-Filho and Bray (2020), the global patterns and trends in cancers of the 
lip, tongue and mouth were explored across five continents; Africa, the Americas, Asia, 
Europe, and Oceania between the years of 1998 and 2012. The authors reported that 
these cancers had the highest rates in several countries in South and Central Asia, and 
Oceania. Incidence rates were highest in Papua New Guinea (27.5 per 100,000 persons-
year), Pakistan (16.3 per 100,000 persons-year), Latvia (14.6 per 100,000 persons-year), 
India (13.9 per 100,000 persons-year), and Bangladesh (12.4 per 100,000 persons-year). 
Although smoking and alcohol consumption are well recognised risk factors for cancers of 
the lip and oral cavity, the authors report that the high prevalence of betel quid chewing in 
many of these countries is likely to have a strong association with the high incidence of 
head and neck cancer. In addition, the incidence of these cancers was consistently higher 
among males than females, with rates ranging from 0.5 to 21.2 per 100,000 persons-year 
in males, and 0.5 to 12.0 per 100,000 persons-year in females.  
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In an earlier study carried out by Shield et al. (2017), the incidence of cancers of the lip, 
oral cavity, and pharynx were examined by country, sex, and age for the year of 2012. A 
total of 529,500 people were diagnosed with cancer of the lip, oral cavity, or pharynx 
during this year, and the authors predicted that this figure is expected to increase by 62% 
to 856,000 cases by 2035. Several studies have noted an increase in the incidence of 
head and neck cancer since the 1980s (Chaturvedi et al., 2013), particularly for cancers of 
the oropharynx which has notably risen in economically developed countries such as 
northern European countries including the UK, Denmark, Estonia, Finland, Latvia, Norway 
and Sweden (Simard et al., 2014).  
In the UK, there were nearly 14,000 new cases of head and neck cancer in 2020 (Table 
1.2), with cancers of the lip and oral cavity accounting for more than 45% of all head and 
neck cancers in the UK (Ferlay et al., 2020). Louie et al. (2015) investigated the trends in 
the incidence of head and neck cancer in England between the years of 1995 and 2011 
and provided future projections up to 2025. The authors determined that the age 
standardised incidence rates (ASR) of head and neck cancer increased from 14.1 per 
100,000 population to 20.1 per 100,000 from 1995 to 2011, respectively, for males and 
from 5.9 per 100,000 population to 8.7 per 100,000 population from 1995 to 2011 for 
females, respectively.  
Table 1.2 – Number of cases of head and neck cancer in the globe and the UK  
Subsite of the head and neck 
(ICD code) 
Global UK 
Total Males Females Total Males Females 
Lip and oral cavity (C00-C06) 377,713 264,211 113,502 6,317 3,931 2,386 
Larynx (C32) 184,615 160,265 24,350 2,618 2,115 503 
Nasopharynx (C11) 133,354 96,371 36,983 276 184 92 
Oropharynx (C09-C10) 98,412 79,045 19,367 2,810 2,110 700 
Hypopharynx (C12-C13) 84,254 70,254 14,000 798 585 213 
Salivary glands (C07-C08) 53,583 29,694 23,889 980 515 465 
Total 931,931 699,840 232,091 13,799 9,440 4,359 
Numbers based on the Global Cancer Observatory (GLOBOCAN) 2020 “Cancer Today” report (Ferlay et al., 
2020). 
Over the last two decades, there has been an increase in the association in the rising 
incidence of head and neck cancer with HPV (Junor et al., 2010; Chaturvedi et al., 2013; 
Purkayastha et al., 2016). This trend is particularly common for people with cancer of the 
oropharynx, for whom around one to two thirds of tumours may be HPV-driven (Kreimer et 
al., 2005). This trend has notably risen in economically developed countries such as 
northern European countries including the UK, Denmark, Estonia, Finland, Latvia, Norway 
and Sweden (Simard et al., 2014). People with HPV-positive tumours have a considerably 
better prognosis than people with HPV-negative tumours, even following adjustment for 
other baseline covariates (Ragin and Taioli, 2007; Wang et al., 2015). 
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1.3.4 Staging of head and neck cancer 
Cancer staging is useful to help clinicians determine the size and extent of a tumour, and 
whether it has spread to other parts of the body. This allows doctors to plan appropriate 
treatment regimens and predict prognosis. Cancer stage is determined at the point of 
diagnosis via x-rays, scans, or biopsies.  
The most commonly used system for staging tumours is the Classification of Malignant 
Tumours Tumour, Node and Metastases (TNM) system (Sobin et al., 2009; National 
Cancer Institute, 2015) which was developed by the Union for International Cancer 
Control (UICC) and the American Joint Committee on Cancer (AJCC). The latest version 
of the TNM classification of malignant tumours is the Eighth Edition (Brierley et al., 2017). 
However, the analyses throughout this thesis were performed prior to the release of 
Eighth Edition, and were therefore performed using the Seventh Edition (Sobin et al., 
2009). The major change between the Seventh and Eighth editions is the new system for 
HPV-positive oropharynx cancer which is now considered unsuitable to stage in the same 
manner as HPV-negative oropharynx cancer (since these people have substantially worse 
survival) (Lydiatt et al., 2018). This section provides information on the staging system 
using the Classification of Malignant Tumours, Seventh Edition.  
Primary tumour (T) determines the size of the tumour and is given a value of either “X” or 
between 0 and 4 based on: 
• TX indicates that a tumour cannot be measured. 
• T0 indicates that there is no tumour, but abnormal pre-cancerous cells may be 
present.  
• T1 indicates a small tumour that has not spread. 
• T2, T3 or T4 indicate the size and extent of the tumour, with the higher value 
representing a larger tumour or further spread into nearby muscle, bone, or skin.  
Regional lymph nodes (N) determines whether the primary cancer has spread into lymph 
nodes, and is given a value of either “X” or between 0 and 3 based on: 
• NX indicates that the lymph nodes cannot be measured. 
• N0 indicates that the tumour has not spread into the lymph nodes. 
• N1, N2 or N3 indicate the amount and location of the spread of the tumour into the 
lymph nodes, with the higher value representing more lymph node involvement.  
Distant metastases (M) determines whether the tumour cells have spread to other parts of 
the body, and is given a value of either “X”, 0 or 1 based on: 
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• MX indicates that distant metastases cannot be measured. 
• M0 indicates that the cancer has not spread to other locations in the body. 
• M1 indicates that the cancer has spread to other locations in the body.  
The above information is then combined using an algorithm to determine an overall 
“number staging system” of between I and IV. Head and neck cancer is staged according 
to the individual anatomical location of the primary tumour. Each anatomical site of the 
head and neck is staged individually under specific groupings that are outlined by the 
Classification of Malignant Tumours, Seventh Edition, including the relevant ICD-10 
codes, as outlined in the following sections.  
1.3.4.1 Lip and oral cavity (C00, C02-C06) 
Table 1.3 and Table 1.4 indicate a summary of the Tumour and Node classifications, and 
the final grouped staging classification used in the analyses throughout this thesis for 
people with cancers of the lip and oral cavity. 
Table 1.3 – Summary staging system for the lip and oral cavity 
Stage Definition 
T stage  
   TX Primary tumour cannot be assessed 
   T0 No evidence of primary tumour 
   Tis Carcinoma in situ 
   T1 Less than or equal to 2cm 
   T2 Greater than 2cm but less than or equal to 4cm 
   T3 Greater than 4cm 
   T4a Lip: Tumour invades cortical bone, inferior alveolar nerve, floor of 
mouth and skin 
Oral cavity: Tumour invades cortical bone, deep/extrinsic muscle of 
tongue, maxillary sinus, or skin of face 
   T4b Tumour invades masticator space, pterygoid plates, skull base or 
internal carotid artery 
N stage  
   NX Regional lymph nodes cannot be assessed 
   N0 No regional lymph node metastases 
   N1 Single ipsilateral metastases less than or equal to 3cm 
   N2a Single ipsilateral metastases greater than 3cm but less than 6cm 
   N2b Multiple ipsilateral metastases less than or equal to 6cm 
   N2c Bilateral and contralateral metastases less than or equal to 6cm 
   N3 Metastases in lymph node greater than 6cm 
Table 1.4 – Final group staging system for the lip and oral cavity 
Stage T stage N stage M stage 
Stage 0 Tis N0 M0 
Stage I T1 N0 M0 
Stage II T2 N0 M0 
Stage III T3 N0 M0 
 T1, T2, T3 N1 M0 
Stage IVa T1, T2, T3 N2 M0 
 T4a N0, N1, N2 M0 
Stage IVb Any T N3 M0 
 T4b Any N M0 
Stage IVc Any T Any N M1 
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1.3.4.2 Oropharynx and hypopharynx (C01, C05.1, C05.2, C09, C10.0, C10.2, C10.3, 
C12-13) 
Table 1.5 to Table 1.7 indicate a summary of the Tumour and Node classifications, and 
the final grouped staging classification used in the analyses throughout this thesis for 
people with cancers oropharynx or hypopharynx. 
Table 1.5 – Summary staging system for the oropharynx  
Stage Definition 
T stage  
   TX Primary tumour cannot be assessed 
   T0 No evidence of primary tumour 
   Tis Carcinoma in situ 
   T1 Less than or equal to 2cm 
   T2 Greater than 2cm but less than or equal to 4cm 
   T3 Greater than 4cm 
   T4a Tumour invades the larynx, deep/extrinsic muscle of tongue, medial 
pterygoid, hard palate, or mandible. 
   T4b Tumour invades lateral pterygoid muscle, pterygoid plates, lateral 
nasopharynx, skull base and carotid artery 
N stage  
   NX Regional lymph nodes cannot be assessed 
   N0 No regional lymph node metastases 
   N1 Single ipsilateral metastases less than or equal to 3cm 
   N2a Single ipsilateral metastases greater than 3cm but less than 6cm 
   N2b Multiple ipsilateral metastases less than or equal to 6cm 
   N2c Bilateral and contralateral metastases less than or equal to 6cm 
   N3 Metastases in lymph node greater than 6cm 
Table 1.6 – Summary staging system for the hypopharynx  
Stage Definition 
T stage  
   TX Primary tumour cannot be assessed 
   T0 No evidence of primary tumour 
   Tis Carcinoma in situ 
   T1 Less than or equal to 2cm and limited to one subsite 
   T2 Greater than 2cm but less than or equal to 4cm and limited to one 
subsite 
   T3 Greater than 4cm, or with hemilarynx fixation or extension to 
oesophagus 
   T4a Tumour invades thyroid/cricoid cartilage, hyoid bone, thyroid gland, 
or central compartment soft tissue 
   T4b Tumour invades prevertebral fascia, carotid artery, or mediastinal 
structures 
N stage  
   NX Regional lymph nodes cannot be assessed 
   N0 No regional lymph node metastases 
   N1 Single ipsilateral metastases less than or equal to 3cm 
   N2a Single ipsilateral metastases greater than 3cm but less than 6cm 
   N2b Multiple ipsilateral metastases less than or equal to 6cm 
   N2c Bilateral and contralateral metastases less than or equal to 6cm 
   N3 Metastases in lymph node greater than 6cm 
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Table 1.7 – Final group staging system for the oropharynx and hypopharynx 
Stage T stage N stage M stage 
Stage 0 Tis N0 M0 
Stage I T1 N0 M0 
Stage II T2 N0 M0 
Stage III T3 N0 M0 
 T1, T2, T3 N1 M0 
Stage IVa T1, T2, T3 N2 M0 
 T4a N0, N1, N2 M0 
Stage IVb T4b Any N M0 
 Any T N3 M0 
Stage IVc Any T Any N M1 
1.3.4.3 Nasopharynx (C11) 
Table 1.8 and Table 1.9 indicate a summary of the Tumour and Node classifications, and 
the final grouped staging classification used in the analyses throughout this thesis for 
people with cancer of the nasopharynx. 
Table 1.8 – Summary staging system for the nasopharynx 
Stage Definition 
T stage  
   TX Primary tumour cannot be assessed 
   T0 No evidence of primary tumour 
   Tis Carcinoma in situ 
   T1 Tumour only present in the nasopharynx or invades the oropharynx 
or nasal cavity 
   T2 Tumour with parapharyngeal extension 
   T3 Tumour invades bony structures of skull base or paranasal sinuses 
   T4a Tumour invades intracranial, cranial nerves, hypopharynx, orbit, 
infratemporal fossa, or masticator space 
N stage  
   NX Regional lymph nodes cannot be assessed 
   N0 No regional lymph node metastases 
   N1 Metastases in unilateral cervical, unilateral, or bilateral 
retropharyngeal lymph nodes, above supraclavicular fossa and is 
less than or equal to 6cm 
   N2 Metastases in bilateral cervical above supraclavicular fossa and is 
less than or equal to 6cm 
   N3a Metastases in lymph node greater than 6cm 
   N3b Metastases in the supraclavicular fossa of any size 
Table 1.9 – Final group staging system for the nasopharynx 
Stage T stage N stage M stage 
Stage 0 Tis N0 M0 
Stage I T1 N0 M0 
Stage II T1 N1 M0 
 T2 N0, N1 M0 
Stage III T1, T2 N2 M0 
 T3 N0, N1, N2 M0 
Stage IVa T4 N0, N1, N2 M0 
Stage IVb Any T N3 M0 
Stage IVc Any T Any N M1 
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1.3.4.4 Larynx (C32.0, C32.1, C32.2, C10.1) 
Table 1.10 to Table 1.13 indicate a summary of the Tumour and Node classifications, and 
the final grouped staging classification used in the analyses throughout this thesis for 
people with cancer of the larynx. 
Table 1.10 – Summary staging system for the larynx – supraglottis 
Stage Definition 
T stage  
   TX Primary tumour cannot be assessed 
   T0 No evidence of primary tumour 
   Tis Carcinoma in situ 
   T1 Tumour in one subsite and larynx has normal mobility 
   T2 Tumour invades mucosa of more than one adjacent subsite of the 
supraglottis or glottis, or adjacent region outside the supraglottis, and 
larynx does not have fixation 
   T3 Larynx has cord fixation or invades the postcricoid area, pre-epiglottic 
tissues, paraglottic space or thyroid cartilage erosion 
   T4a Tumour invades through the thyroid cartilage, trachea, soft tissues of 
the neck, deep/extrinsic muscle of the tongue, strap muscles or thyroid 
   T4b Tumour invades the prevertebral space, mediastinal structure, or 
carotid artery.  
N stage  
   NX Regional lymph nodes cannot be assessed 
   N0 No regional lymph node metastases 
   N1 Single ipsilateral metastases less than or equal to 3cm 
   N2a Single ipsilateral metastases greater than 3cm but less than 6cm 
   N2b Multiple ipsilateral metastases less than or equal to 6cm 
   N2c Bilateral and contralateral metastases less than or equal to 6cm 
   N3 Metastases in lymph node greater than 6cm 
Table 1.11 – Summary staging system for the larynx – glottis 
Stage Definition 
T stage  
   TX Primary tumour cannot be assessed 
   T0 No evidence of primary tumour 
   Tis Carcinoma in situ 
   T1a Tumour is limited to one vocal cord with normal mobility 
   T2b Tumour is limited to both vocal cords with normal mobility 
   T2 Tumour invades supraglottic, subglottis and larynx has impaired 
mobility 
   T3 Larynx has cord fixation, or invades the paraglottic space or thyroid 
cartilage erosion 
   T4a Tumour invades through the thyroid cartilage, trachea, soft tissues of 
the neck, deep/extrinsic muscle of the tongue, strap muscles or thyroid 
   T4b Tumour invades the prevertebral space, mediastinal structure, or 
carotid artery.  
N stage  
   NX Regional lymph nodes cannot be assessed 
   N0 No regional lymph node metastases 
   N1 Single ipsilateral metastases less than or equal to 3cm 
   N2a Single ipsilateral metastases greater than 3cm but less than 6cm 
   N2b Multiple ipsilateral metastases less than or equal to 6cm 
   N2c Bilateral and contralateral metastases less than or equal to 6cm 
   N3 Metastases in lymph node greater than 6cm 
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Table 1.12 – Summary staging system for the larynx – subglottis 
Stage Definition 
T stage  
   TX Primary tumour cannot be assessed 
   T0 No evidence of primary tumour 
   Tis Carcinoma in situ 
   T1 Tumour is limited to the subglottis 
   T2 Tumour extends to vocal cord(s) with normal or impaired mobility 
   T3 Larynx has cord fixation 
   T4a Tumour invades through the thyroid cartilage, trachea, soft tissues of 
the neck, deep/extrinsic muscle of the tongue, strap muscles or thyroid 
   T4b Tumour invades the prevertebral space, mediastinal structure, or 
carotid artery.  
N stage  
   NX Regional lymph nodes cannot be assessed 
   N0 No regional lymph node metastases 
   N1 Single ipsilateral metastases less than or equal to 3cm 
   N2a Single ipsilateral metastases greater than 3cm but less than 6cm 
   N2b Multiple ipsilateral metastases less than or equal to 6cm 
   N2c Bilateral and contralateral metastases less than or equal to 6cm 
   N3 Metastases in lymph node greater than 6cm 
Table 1.13 – Final group staging system for the larynx 
Stage T stage N stage M stage 
Stage 0 Tis N0 M0 
Stage I T1 N0 M0 
Stage II T2 N0 M0 
Stage III T1, T2 N1 M0 
 T3 N0, N1 M0 
Stage IVa T1, T2, T3 N2 M0 
 T4a N0, N1, N2 M0 
Stage IVb T4b Any N M0 
 Any T N3 M0 
Stage IVc Any T Any N M1 
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1.3.4.5 Nasal cavity and paranasal sinuses (C30.0, 31.0, 1) 
Table 1.14 to Table 1.16 indicate a summary of the Tumour and Node classifications, and 
the final grouped staging classification used in the analyses throughout this thesis for 
people with cancers of the nasal cavity or paranasal sinuses. 
Table 1.14 – Summary staging system for the nasal cavity and ethmoid sinus 
Stage Definition 
T stage  
   TX Primary tumour cannot be assessed 
   T0 No evidence of primary tumour 
   Tis Carcinoma in situ 
   T1 Tumour exists in one subsite 
   T2 Tumour exists in two subsites or invades adjacent nasoethmoidal 
site  
   T3 Tumour invades medial wall/floor of orbit, maxillary sinus, palate 
or cribiform plate 
   T4a Tumour invades anterior orbit, skin of nose/cheek, anterior 
cranial fossa (minimal), pterygoid plates or sphenoid/frontal 
sinuses 
   T4b Tumour invades orbital apex, dura, brain, middle cranial fossa, 
cranial nerves other than V2, nasopharynx or clivus 
N stage  
   NX Regional lymph nodes cannot be assessed 
   N0 No regional lymph node metastases 
   N1 Single ipsilateral metastases less than or equal to 3cm 
   N2a Single ipsilateral metastases greater than 3cm but less than 6cm 
   N2b Multiple ipsilateral metastases less than or equal to 6cm 
   N2c Bilateral and contralateral metastases less than or equal to 6cm 
   N3 Metastases in lymph node greater than 6cm 
Table 1.15 – Summary staging system for the maxillary sinus 
Stage Definition 
T stage  
   TX Primary tumour cannot be assessed 
   T0 No evidence of primary tumour 
   Tis Carcinoma in situ 
   T1 Tumour invades mucosa 
   T2 Tumour causes bone erosion/destruction to the hard palate or 
middle nasal meatus 
   T3 Tumour invades posterior bony wall maxillary sinus, 
subcutaneous tissues, floor/medial wall of orbit, pterygoid fossa, 
or ethmoid sinus 
   T4a Tumour invades anterior orbit, skin of nose/cheek, anterior 
cranial fossa, pterygoid plates, or sphenoid/frontal sinuses 
   T4b Tumour invades orbital apex, dura, brain, middle cranial fossa, 
cranial nerves other than V2, nasopharynx or clivus 
N stage  
   NX Regional lymph nodes cannot be assessed 
   N0 No regional lymph node metastases 
   N1 Single ipsilateral metastases less than or equal to 3cm 
   N2a Single ipsilateral metastases greater than 3cm but less than 6cm 
   N2b Multiple ipsilateral metastases less than or equal to 6cm 
   N2c Bilateral and contralateral metastases less than or equal to 6cm 
   N3 Metastases in lymph node greater than 6cm 
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Table 1.16 – Final group staging system for the nasal cavity and paranasal sinuses 
Stage T stage N stage M stage 
Stage 0 Tis N0 M0 
Stage I T1 N0 M0 
Stage II T2 N0 M0 
Stage III T3 N0 M0 
 T1, T2, T3 N1 M0 
Stage IVa T1, T2, T3 N2 M0 
 T4a N0, N1, N2 M0 
Stage IVb T4b Any N M0 
 Any T N3 M0 
Stage IVc Any T Any N M1 
1.3.4.6 Major salivary glands (C07, C08) 
Table 1.17 and Table 1.18 indicate a summary of the Tumour and Node classifications, 
and the final grouped staging classification used in the analyses throughout this thesis for 
people with cancers major salivary glands.  
Table 1.17 – Summary staging system for major salivary glands 
Stage Definition 
T stage  
   TX Primary tumour cannot be assessed 
   T0 No evidence of primary tumour 
   Tis Carcinoma in situ 
   T1 Less than or equal to 2cm, without extraparenchymal extension 
   T2 Greater than 2cm but less than or equal to 4cm, without 
extraparenchymal extension 
   T3 Greater than 4cm, without extraparenchymal extension 
   T4a Tumour invades skin, mandible, ear canal or facial nerve 
   T4b Tumour invades skull, pterygoid plates, or carotid artery 
N stage  
   NX Regional lymph nodes cannot be assessed 
   N0 No regional lymph node metastases 
   N1 Single ipsilateral metastases less than or equal to 3cm 
   N2a Single ipsilateral metastases greater than 3cm but less than 6cm 
   N2b Multiple ipsilateral metastases less than or equal to 6cm 
   N2c Bilateral and contralateral metastases less than or equal to 6cm 
   N3 Metastases in lymph node greater than 6cm 
Table 1.18 – Final group staging system for the major salivary glands 
Stage T stage N stage M stage 
Stage I T1 N0 M0 
Stage II T2 N0 M0 
Stage III T3 N0 M0 
 T1, T2, T3 N1 M0 
Stage IVa T4a N0, N1 M0 
 T1, T2, T3, T4a N2 M0 
Stage IVb T4b Any N M0 
 Any T N3 M0 
Stage IVc Any T Any N M1 
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1.3.5 Treatment for head and neck cancer 
The primary goal of the treatment for head and neck cancer is to remove the tumour, 
however due to the location of these tumours and the origin of the complex anatomical 
sites, another main goal is to consider the patient’s quality of life post-treatment by 
preserving the function of the organs, tissues, and nerves that are involved (Rogers et al., 
2016b). The leading treatment for head and neck cancer is surgery, radiotherapy, 
chemotherapy, targeted therapy, or a combination of two or more of these treatment 
modalities (Macmillan Cancer Support, 2019).  
Multidisciplinary teams of several specialised clinicians in the field of head and neck 
cancer decide the treatment paths of each individual patient based on a number of factors 
including the stage of the tumour, the anatomical site of the tumour, the patient’s age, 
their health status at diagnosis, and the future impact of any long-term side effects from 
the treatment on the patient. Several factors need to be taken into consideration following 
a person’s treatment of head and neck cancer, namely dental status (whether the person 
can continue to chew and swallow food), disfigurement, the impact on existing 
comorbidities, or the impact on the carer or family (Rogers et al., 2016b). 
1.3.6 Determinants of head and neck cancer survival 
Globally, more than 467,000 deaths were attributable to head and neck cancer in 2020 
(Ferlay et al., 2020) and there were more than 4,000 deaths from head and neck cancer in 
the UK in 2016 (Cancer Research UK, 2017). Due to the complex nature of head and 
neck cancers, survival from the disease is complex and difficult to report. Survival 
significantly varies by the anatomical subsite of the head and neck cancer and the stage 
of the tumour at diagnosis, both of which impact on treatment decisions. This section 
explores the existing literature outlining most of the determinants and prognostic factors of 
the survival of people with head and neck cancer. Following this section, a comprehensive 
literature review explores previous studies that investigate socioeconomic inequality in 
survival of people with head and neck cancer across the globe.  
1.3.6.1 Age 
Age is a strong predictor of survival for people with head and neck cancer. Jones et al. 
(1998) conducted a study of 2,647 people with SCC of the oral cavity, oropharynx, larynx, 
and hypopharynx to investigate the effects of age on survival. The participants were 
followed-up for a median of 40.3 years and actuarial survival was computed to examine 
the findings. The study concluded that there was little difference in survival for those who 
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were between the years of 40 and 70, but survival substantially decreased in those who 
were over the age of 70. In addition, the authors reported that the older patients presented 
with worse disease at the primary site and were less likely to receive radical treatment. A 
further article assessed the impact of age on survival of 1,160 people with SCC of the oral 
cavity, oropharynx, and larynx. These patients were diagnosed in Washington University 
Medical Center between the years of 1980 and 1991 and had a minimum of five-year 
follow-up. The study showed that people who were younger than 40 years of age had 
substantially better survival than older patients even after adjusting by race, smoking, 
comorbidity, tumour site, tumour stage, and histologic variation.  
1.3.6.2 Sex 
Many groups of cancers exhibit a survival advantage towards females over males. 
However, there is conflicting evidence on whether the same disparities exist between 
males and females with head and neck cancer. Several studies have found differences in 
the survival between males and females, with survival favouring women (Franco et al., 
1993; Goldberg et al., 1994; McLean et al., 2006). Goldberg et al. (1994) examined 
people diagnosed on the United States (US) Surveillance, Epidemiology and End Results 
(SEER) Program of people with cancer of the oral cavity and pharynx who were 
diagnosed between the years of 1973 and 1987. The SEER database collects data on the 
incidence, prevalence, and survival of people who have been diagnosed with cancer and 
aims to reduce the burden of cancer in the United States of America (USA). Goldberg and 
authors found a difference in mortality rates between men and women with cancer of the 
oral cavity and pharynx, which favoured females. However, the results of other articles 
conflict with these findings and suggest no difference in survival between males and 
females (Kokoska et al., 1995; Garavello et al., 2008; Roberts et al., 2010). Roberts et al. 
(2010) conducted a matched-pair analysis of 286 males and 286 females with SCC of the 
oral cavity, oropharynx, larynx, and hypopharynx at the University of Texas M.D. 
Anderson Cancer Center. The patients were diagnosed between the years of 1995 and 
2008, and the aim of the study was to investigate whether females had better survival 
outcomes than males. Males and females were matched based on age (±10 years), 
race/ethnicity, smoking status, tumour site, tumour stage, and treatment, and recurrence-
free survival, disease-specific survival, and overall survival estimates were compared 
between the two groups. From this small study, there was no evidence of recurrence or 
poorer survival in men compared with women diagnosed with head and neck cancer.  
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1.3.6.3 Tobacco smoking behaviour 
Many studies have investigated the influence of smoking history on the survival of people 
with head and neck cancer, with survival favouring those with no history of tobacco use 
(Browman et al., 2002; Duffy et al., 2009; Sharp et al., 2014; Abrahão et al., 2018; Beynon 
et al., 2018). Browman et al. (2002) explored two-year overall survival of people head and 
neck cancer who were undergoing radiotherapy in Canada and the USA. In a multivariate 
analysis that included smoking status at baseline, T stage, N stage, and the number of 
years smoked (measured in pack-years), the number of years smoked had the strongest 
association with survival. Browman reported that those who had quit smoking less than 12 
weeks before their diagnosis were 40% less at risk of dying than those who continued to 
smoke, and those who had quit smoking more than one year before diagnosis were 70% 
less at risk of dying than those who continued to smoke. Sharp et al. (2014), examined the 
relationship between smoking status and survival in 5,652 patients who were registered 
with the National Cancer Registry in Ireland. Those with a history of smoking, and who 
remained current smokers at the time of their diagnosis, had substantially reduced five-
year disease-specific survival and were 36% more at risk of a cancer-specific death than 
those who had never smoked.  
More recently, Beynon et al. (2018) investigated outcomes from the HN5000 cohort study 
of 1,393 people with cancer of the oral cavity, oropharynx, and larynx who were 
diagnosed in the UK between the years of 2011 and 2014. Beynon and authors found that 
even after adjusting for several confounding factors including tumour stage, BMI, 
comorbidity, treatment, HPV status, education, annual household income, IMD, marital 
status, ethnicity, and alcohol consumption, poor survival remained associated with 
tobacco smoking at diagnosis. Abrahão et al. (2018) conducted an analysis using data 
from the Alcohol-Related Cancers and Genetic Susceptibility in Europe (ARCAGE) case-
control study. A total of 1,210 people were included in the study, of whom 91% were ever 
smokers, and a strong association between smoking and survival was observed, 
measured as overall smoking history, duration, and intensity.  
Following a cancer diagnosis, continued smoking while undergoing treatment increases 
toxicity, decreases treatment efficacy, and may lower survival outcomes (Kashigar et al., 
2013). Smoking while undergoing treatment for head and neck cancer can also lead to 
secondary primary tumours, co-morbidities, and a diminished quality of life (Gritz et al., 
2005). Of the patients who are current smokers at their time of diagnosis, only half decide 
to refrain from smoking during their treatment period (Duffy et al., 2008), and those who 
are living with their partner and those with higher education levels are less likely to 
continue smoking following a cancer diagnosis, suggesting that family and social support 
are important factors associated with quitting smoking and continued abstinence (Allison, 
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2001). Due to the serious and potentially fatal interactions that smoking has with various 
treatment modalities for cancer, Gritz et al. (2005) has recommended that smoking 
history, current smoking status, and on-going smoking behaviours are recorded as routine 
data collection in all oncological trials.  
1.3.6.4 Alcohol consumption 
Several papers have reported poorer survival for people with head and neck cancer with a 
history of excessive alcohol consumption (Fountzilas et al., 1992; Deleyiannis et al., 1996; 
Fortin et al., 2009; Mayne et al., 2009; Lopez et al., 2011), while other papers have 
reported an association prior to adjustment for other factors, but not following adjustment 
(Duffy et al., 2009; Beynon et al., 2018).  
Deleyiannis et al. (1996) carried out a study involving 649 people with head and neck 
cancer to determine the features of alcohol (such as recency of alcohol use, alcohol-
related health problems, alcohol dependency, and weekly and lifetime alcohol 
consumption) that were associated with five-year survival. Those of higher alcoholic 
severity, as defined by the Michigan Alcoholism Screening Test (MAST), had an 
increased risk of dying not only from head and neck cancer, but also cardiovascular 
disease, pulmonary disease, and alcohol-related diseases. Those who abstained from 
drinking alcohol after their diagnosis, including those with a history of alcohol-related 
health problems, had better survival than those who did not abstain from drinking.  
Mayne et al. (2009) investigated the impact of pre-diagnosis and post-diagnosis use of 
alcohol and tobacco smoking on survival of 264 people with early-stage cancers of the 
oral cavity, pharynx, and larynx. Mayne et al. (2009) reported that a history of alcohol 
consumption was associated with poorer survival, with those who drank more than 35 
drinks per week having nearly five-times excess risk of death compared to those who did 
not drink. However, this excess risk was only observed for beer or liquor drinkers, but not 
for wine drinkers. In addition, continuous drinking following a diagnosis of head and neck 
cancer led to twice as much risk of dying compared to those who did not drink following 
their diagnosis. 
However, several papers conflict with the message that alcohol consumption affects 
survival of people with head and neck cancer. Beynon et al. (2018) investigated the 
association of a history of smoking and alcohol consumption with survival of 4,276 people 
diagnosed with cancer of the oral cavity, larynx, and oropharynx. Beynon et al. (2018) did 
not report an association with drinking behaviours and risk of mortality. Additionally, Duffy 
et al. (2009) also could not confirm an association with alcohol consumption and poor 
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survival for 504 people with head and neck cancer following adjustment for additional 
factors. 
1.3.6.5 HPV status 
The recent rise in the incidence of head and neck cancers that are associated with HPV 
(mainly for those with tumours of the oropharynx) has led to a surge of research in the 
field, and the positive impact of HPV-positive tumours on the survival of people with head 
and neck cancer has been discovered. A meta-analysis of 5,681 people with SCC of the 
head and neck from 34 studies was carried out by Dayyani et al. (2010) to assess the 
impact of HPV on overall survival. The study confirmed that there was improved survival 
for individuals with HPV infection, particularly for those with HPV-16 positivity. A 
systematic review conducted by Wang et al. (2015) investigated the evidence of the 
positive effect of HPV positivity on the prognosis of people with cancer of the oropharynx. 
A total of 56 eligible studies were eligible which included 1,367 people treated with 
primary surgery and 4,747 people treated with radiation therapy. The study confirmed the 
findings of the earlier meta-analysis that HPV-16 positivity led to a substantially improved 
survival for individuals with cancer of the oropharynx.  
A further study by D'Souza et al. (2016) explored the effect of HPV on the survival of 
people with head and neck cancer, and the authors performed stratified analyses by 
geographic region and anatomical site of the head and neck. Patients were recruited to 
one of three studies: the Brazilian Head and Neck Genome Project (GENCAPO) in São 
Paulo, Southern Brazil; the Caroline Head and Neck Cancer Study (CHANCE) in North 
Carolina, USA; and the ARCAGE study in Europe. A total of 1,362 people who were 
diagnosed with cancer of the oropharynx, hypopharynx, larynx, or oral cavity between the 
years of 2002 and 2011 were included in the study. The authors reported that there was a 
significantly lower risk of death among the people who had HPV-related tumours of the 
oropharynx compared to those without HPV-related tumours, which was observable 
across all three continents. However, this difference was not as evident for people with 
tumours that were outside of the oropharynx.  
More recent studies have explored the interaction of HPV and smoking with head and 
neck cancer. Anantharaman et al. (2016) investigated this using data from the ARCAGE 
study, and the head and neck cancer case-control study nested within the European 
Prospective Investigation into Cancer and Nutrition (EPIC) cohort. A total of 1,904 head 
and neck cancer cases and 3,024 controls were included in the study, and the authors 
reported that smoking increases the risk of cancer of the oropharynx whether or not the 
person has HPV-16. In addition, earlier studies have also suggested that smoking 
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consumption, alcohol consumption, and HPV status are three independent risk factors of 
head and neck cancer incidence and survival (Gillison et al., 2008; Smith et al., 2012). 
1.3.6.6 Comorbidity 
Several studies have reported that comorbid conditions have a substantially negative 
effect on the survival outcomes of people with head and neck cancer (Reid et al., 2001; 
Allareddy and Konety, 2006; Datema et al., 2010; Eytan et al., 2019b; Eytan et al., 
2019a). Eytan et al. (2019b) examined the effect of comorbidities on overall survival of 
people with HPV-related and HPV-unrelated head and neck cancer in the USA. A total of 
10,524 people were included in the study, including 2,499 people with HPV-related 
tumours and 8,025 people with HPV-unrelated tumours who were diagnosed between the 
years of 2004 and 2011 on the SEER database. The authors determined that those with 
pneumonia, anaemia, dysphagia, malnutrition, weight loss, hypertension, cerebrovascular 
disease, or dementia that was present at the time of their diagnosis had an increased risk 
of death in those with both HPV-related and HPV-unrelated head and neck cancer. In 
addition, individuals with HPV-unrelated head and neck cancer had an increased risk of 
death if they had paralysis, rheumatologic disease, hip fracture, anxiety, angina, or 
myocardial infarction at the time of their diagnosis. However, this was not observed in 
those with HPV-related head and neck cancer, and dental disease was associated with an 
increased risk of death for people with HPV-related head and neck cancer, but not HPV-
unrelated cancer. A further paper by Eytan et al. (2019a) explored the prevalence of 
comorbidities in older survivors of head and neck cancer using the same cohort of people 
as the previous study. Eytan et al. (2019a) reported that hypertension, chronic obstructive 
pulmonary disease, diabetes, and hyperlipidaemia were “highly prevalent” at the time of 
diagnosis, while other comorbidities that are related to treatment therapies such as 
pneumonia, anaemia, dysphagia, weight loss, and malnutrition, were less prevalent at 
diagnosis but rose substantially in the first one to five years after diagnosis.  
Allareddy and Konety (2006) investigated the effects of comorbidity on 24,803 people who 
were hospitalised for head and neck cancer in the USA from the Nationwide Inpatient 
Sample of the Healthcare Cost and Utilisation Project between the years of 2000 and 
2003. Comorbidity was recorded on various conditions that the inpatient had, and 
univariate and multivariate logistic regression models were produced to investigate 
mortality. Individuals who had congestive heart failure, neurologic disorders or 
coagulopathy were at a substantially increased risk of mortality in a multivariate model. 
Datema et al. (2010) investigated the impact of comorbidity on survival of 1,662 people 
with SCC of the head and neck at the Leiden University Medical Centre between 1981 
and 1998. Comorbidity was measured using the Adult Comorbidity Evaluation (ACE-27) to 
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assess the impact on short-term mortality. Datema and authors reported that poorer 
survival was particularly observed in people with cardiovascular comorbidity, respiratory 
comorbidity, gastrointestinal comorbidity, and diabetes.  
1.3.6.7 Anatomical site 
Survival from head and neck cancer depends on the anatomical site of the primary tumour 
within the head and neck. Five-year net survival is highest for people with cancer of the 
oropharynx at 65.6% (95% CI 64.2% to 67.0%) and lowest for those with cancer of the 
hypopharynx at 27.8% (95% CI 25.7% to 30.1%) (Cancer Research UK, 2017). 
Individuals with cancer of the oral cavity had five-year net survival estimates of 56.1% 
(95% CI 54.7% to 57.4%), while men with cancer of the larynx had five-year net survival 
estimates of 65.4% (95% CI 64.0% to 66.8%) (Cancer Research UK, 2017).  
A study involving people diagnosed with head and neck cancer on the SEER database 
were included in a site-specific study to investigate survival outcomes (Carvalho et al., 
2005). A total of 96,232 cases diagnosed between the years of 1973 and 1999 were 
identified and included in the analysis. Carvalho and authors determined a substantial 
difference in survival between those with cancer of the lip and those with cancer of the 
oral cavity, oropharynx, hypopharynx, and “other mouth and pharynx”, who had 
approximately a three-fold increased risk of mortality than those with cancer of the lip in a 
multivariate model (oral cavity HR = 2.83, 95% CI = 2.67 to 3.00; oropharynx HR = 2.84, 
95% CI = 2.66 to 3.03; hypopharynx HR = 3.62, 95% CI = 3.38 to 3.88; other mouth and 
pharynx HR = 3.08, 95% CI 2.66 to 3.56). Additionally, those with cancer of the larynx, 
nasopharynx, and salivary gland were approximately two times more at risk of mortality 
than those with cancer of the lip (larynx HR = 1.70, 95% CI = 1.59 to 1.80; nasopharynx 
HR = 1.97, 95% CI = 1.81 to 2.14; salivary gland HR = 1.97, 95% CI = 1.83 to 2.12).  
1.3.6.8 Tumour stage 
Tumour staging is important to determine the extent and spread of disease by considering 
the size of the tumour (T), the nodal involvement (N) and whether any distant metastases 
(M) have emerged from the primary site. As a result, tumour stage is highly associated 
with survival – a person with a tumour of higher stage is likely to have substantially poorer 
survival. Rudolph et al. (2011) carried out a systematic review and meta-analysis to 
assess the effects of tumour stage on survival of people with cancer of the larynx. The 
authors reviewed 29 articles and reported that five-year survival by tumour stage varied 
between 0% and 100% depending on the T- and N-category of the tumour, with an overall 
five-year relative survival rate of 64.2% (95% CI 63.7% to 64.7%) for all stages combined.  
Chapter 1: Introduction and literature review 
27 
1.4 Literature review: Socioeconomic determinants and 
inequalities in survival of people with head and 
neck cancer 
In the 1997 landmark IARC publication Social Inequalities in Cancer, Auvinen (1997) 
assessed the socioeconomic factors that are associated with cancer survival and 
identified gaps in the understanding the determinants of survival from cancer. Auvinen 
concluded that there was an “urgent need” to understand the drivers of socioeconomic 
inequality in cancer survival, and more than twenty years later, the evidence-base is not 
much further forward. In 2019 IARC produced an updated publication: Reducing Social 
Inequalities in Cancer: Evidence and Priorities for Research (International Agency for 
Research on Cancer, 2019), in which Dr Christopher P. Wild, director of IARC, wrote that 
“cancer is undoubtedly a disease of inequalities” and that “tackling these inequalities is a 
matter of social justice and human rights”.  
Explanations for socioeconomic inequalities in survival of people with cancer are complex 
and are rarely described for cancers of the head and neck. Auvinen (1997) reviewed 
articles with the aim of explaining the possible explanations for the differences in all-
cancer patient survival by socioeconomic status. Although Auvinen reported that cancer 
stage at diagnosis is particularly important, in many of the studies included in the review, 
socioeconomic inequalities in survival of people with cancer by social class remained 
following the adjustment for stage. Woods et al. (2006) carried out a comprehensive 
review to determine the origins of socioeconomic inequalities in all-cancer survival and 
concluded that stage at diagnosis, access to health services, and comorbidity may explain 
some of the association. 
This section of the thesis reviews the current evidence of socioeconomic inequality in 
survival of people with head and neck cancer and provides the basis and rationale for this 
research.  
1.4.1 Literature search strategy 
Searches in several databases were conducted between October 2014 and March 2020 
to identify studies that investigated the effects of socioeconomic status on survival 
outcomes of people with head and neck cancer. The databases searched included 
Medline 1950-; Embase 1980-; and Pubmed. The following search was conducted: 
(survival or survivor or mortality or outcome* or prognosis or death).m_titl. and 
(socio* or economic or social or inequalit* or income or financ* or education* or 
Chapter 1: Introduction and literature review 
28 
depriv* or poverty).m_titl. and (cancer or tumour or tumor or malignan* or 
carcinoma or neoplasm* or (squamous cell)) adj3 ((head and neck) or (head or 
neck) or oral or mouth or laryn* or pharyn* or oropharyn* or hypopharyn* or 
nasopharyn* or sinus* or tonsil* or jaw or tongue or lip* or cheek* or gum* or palat* 
or gingiva or maxilla or (parotid gland*) or oesophag* or esophag* or UATD or 
(upper aerodigestive tract) or (upper aero-digestive tract)).tw. 
This returned 240 articles which were screened for suitability for this literature review. A 
final 40 papers were selected for inclusion for a full review as outlined in the following 
section. This review is also summarised briefly in Appendix 1.3.  
1.4.2 Inclusion criteria for the literature review 
This literature review focusses on articles with the following criteria: 
1. Studies that involved any form of head and neck cancer. 
2. Studies that involved all types of cancers providing a subgroup of people with head 
and neck cancer was included and sub-categorised throughout the analysis.  
3. Studies that measured any type of socioeconomic status including area-based or 
individual measurements.    
4. Studies that assessed survival or prognosis.  
5. Studies written in English.  
1.4.3 Exclusion criteria for the literature review 
The articles that were excluded from this literature review satisfied any of the following 
criteria: 
1. Studies that investigated people with cancer of the thyroid. 
2. Studies that investigated skin cancer of the face or neck. 
3. Studies that focussed only on mortality rates rather than survival.  
4. Studies that only reported inequalities in racial disparities, marital status, or 
religious status. 
Chapter 1: Introduction and literature review 
29 
1.4.4 Effect of socioeconomic status on survival of people with head and 
neck cancer in the United Kingdom 
1.4.4.1 Overview of studies in the United Kingdom 
A total of 11 articles were found which investigated socioeconomic determinants and 
inequalities in survival of people with head and neck cancer in the UK. Five of these 
studies were produced by a group of researchers from the London School of Hygiene and 
Tropical Medicine (LSHTM) (Coleman et al., 2001; Coleman et al., 2004; Shack et al., 
2007; Rachet et al., 2008; Ellis et al., 2012). All of the papers that were produced by the 
LSHTM involved cancer registry data from across the UK – four included people from 
England and Wales (Coleman et al., 2001; Coleman et al., 2004; Rachet et al., 2008; Ellis 
et al., 2012), and one included individuals from Scotland (Shack et al., 2007). Two of the 
studies in England and Wales investigated individuals with all types of cancer (Coleman et 
al., 2001; Coleman et al., 2004), but included a sub-cohort of people with cancer of the 
larynx, while the other studies examined only those with cancer of the larynx (Shack et al., 
2007; Rachet et al., 2008; Ellis et al., 2012). Of the six UK-based studies that were 
produced outside of the LSHTM, four articles included data from cancer registry sources 
(Edwards and Jones, 1999; Paterson et al., 2002; Warnakulasuriya et al., 2007; Anandan 
et al., 2008), one included data from hospital records (Rylands et al., 2016), and the final 
study analysed data from a cohort study (Robertson et al., 2010). Four of the papers 
focused on people who were diagnosed with any type of head and neck cancer (Edwards 
and Jones, 1999; Paterson et al., 2002) or cancer of the oral cavity (Warnakulasuriya et 
al., 2007; Rylands et al., 2016) in England, while two studies focused on individuals with 
any type of head and neck cancer (Robertson et al., 2010) or cancer of the nasopharynx 
(Anandan et al., 2008) in Scotland. All of the UK-based studies used area-based 
measurements of socioeconomic status and none of the studies used individual-level 
measurements. All of the articles produced by the LSHTM reported relative survival, as 
did two other studies outside of the LSHTM (Paterson et al., 2002; Anandan et al., 2008). 
Four papers reported overall or disease-specific measurements of survival analysis 
(Edwards and Jones, 1999; Warnakulasuriya et al., 2007; Robertson et al., 2010; Rylands 
et al., 2016). All of the studies provided up to five-years of follow-up and only one study 
provided follow-up beyond five-years (Rachet et al., 2008).  
1.4.4.2 Studies from the United Kingdom 
The earliest article, written by Edwards and Jones (1999), investigated one-, two-, and 
five-year crude and cause-specific survival of people with head and neck cancer. Data 
were utilised from the Thames, West Midlands, West of Scotland, and Yorkshire cancer 
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registries of 25,903 individuals who were diagnosed with head and neck cancer between 
the years of 1984 and 1993. Edwards and Jones linked the data to Carstairs 1991 
Categories and grouped people by quintile 1 (most deprived), quintiles 2 and 3, and 
quintiles 4 and 5 (least deprived). Edwards and Jones discovered that those who were 
living in less deprived areas had substantially better crude and cause-specific survival 
than the people who were living in more deprived areas. In addition, the authors produced 
a multivariate analysis which adjusted by subsite, extent of the spread of the disease and 
age which suggested that deprivation had an independent effect on both crude and 
cause-specific survival following the adjustment by these variables. Although this study 
investigated some of the potential explanatory factors of socioeconomic inequality, many 
determinants were not included due to the limitations of cancer registry data, such as 
smoking and alcohol behaviours. Moreover, this study noted that there were high 
proportions of missing data for the people who were living in the most deprived areas in 
this study, which could have led to biased results.  
Two of the largest UK-based national studies of population-based cancer survival were 
produced by the Cancer and Public Health Unit at the LSHTM. These articles investigated 
the trends of socioeconomic inequalities in cancer survival in England and Wales 
(Coleman et al., 2001; Coleman et al., 2004). The studies included all diagnoses of cancer 
from the regional cancer registries. However, the authors also included a stratified 
analysis for each cancer subsite which included individuals with cancer of the larynx. The 
first paper written by Coleman et al. (2001) included nearly three million people who were 
diagnosed with one of 39 solid tumours or eight types of leukaemia and lymphoma in 
England and Wales between the years of 1971 and 1990. The participants were followed 
up for five years to produce one-year and five-year relative survival estimations. The study 
utilised Carstairs 1991 Categories and variance-weighted least squares regression to 
produce a “deprivation gap” in the fitted rates between the least deprived and most 
deprived groups. A total of 8,671 people with cancer of the larynx were included in this 
analysis and there was a gap of 9.3% in the relative survival estimates of those who 
resided in the least deprived and most deprived areas, in favour of those from the least 
deprived regions. However, the study had several limitations, particularly around the origin 
of the data from national databases of cancers which do not include information on the 
stage of the tumour or any behavioural information of the participants that are included. As 
a result, the determinants of socioeconomic inequality in survival of people with cancer 
was not investigated as part of this study.  
A robust study undertaken by Paterson et al. (2002) included 20,131 people with head 
and neck cancer from four regional cancer registries in England and Wales between the 
years of 1981 and 1994. This study examined the effect of deprivation on one-year and 
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five-year relative survival using Carstairs 1991 Categories from several perspectives 
including age group, sex, and calendar year. Firstly, the authors reported that survival of 
the individuals who lived in the most deprived areas was substantially worse than those 
who lived in the least deprived areas. Secondly, they found that the socioeconomic 
inequality in survival was not apparent for those who were below the age of 39, while 
differences were more pronounced in those above the age of 39. Thirdly, Paterson and 
colleagues investigated the association of deprivation with survival by grouping the data 
into the years of 1981 to 1985, 1986 to 1990, and 1991 to 1994 and found that the effect 
of deprivation on relative survival was stronger in the period of 1981 to 1985 and 1991 to 
1994, with survival favouring those who lived in the least deprived areas. Lastly, the 
authors discovered that there was no difference in survival between the deprivation 
groups for those who survived beyond 18 months. This thorough analysis provided a 
snapshot of inequality for those who were diagnosed with head and neck cancer between 
the years of 1981 and 1994. However, there were several limitations due to the use of 
cancer registry data which does not contain information on the stage of the person’s 
tumour or data on smoking or alcohol consumption. Therefore, the underlying causes of 
socioeconomic inequality could not be explored as part of this analysis.  
A second comprehensive study carried out by Coleman et al. (2004) was similar to the 
group’s earlier paper (Coleman et al., 2001) and analysed cancer registry data on 2.2 
million people. These individuals had been diagnosed with one of the 20 most common 
cancers in England and Wales between the years of 1986 and 1999. The authors linked 
Carstairs 1995 Categories to those who were diagnosed between the years of 1986 and 
1995 and 2000 English and Welsh IMD scores to those who were diagnosed between the 
years of 1996 and 1999. Similar to the earlier study, relative survival up to five-years and 
a “deprivation gap” were presented for each of the cancer sites which included 5,666 
individuals with cancer of the larynx. However, unlike the previous article, comparisons of 
the difference in the deprivation gap every five years were also provided. Coleman and 
colleagues discovered that the deprivation gap in relative survival for males with cancer of 
the larynx was increasing and in the period of 1996 to 1999 reached 17%, which was in 
favour of those from the least deprived areas, and this was the highest out of all 20 
cancers presented. The authors concluded that for many cancers, survival improved for 
those who were from the least deprived areas and as a result, led to a widening in the 
deprivation gap in the late 1990s in favour of those from the least deprived areas. The aim 
of this paper was to examine trends in survival over time and therefore, the underlying 
causes of socioeconomic inequality were not explored. Similar to the other papers that 
have been reviewed in this section, the limitations around the use of cancer registry data 
also apply to this study.  
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A further study conducted by Shack et al. (2007) investigated the socioeconomic 
inequality in survival of people with cancer in Scotland. This study investigated a cohort of 
357,658 adults with any primary cancer registered on the Scottish Cancer Registry 
between the years of 1986 and 2000 and followed-up to 2005. The people who were 
diagnosed with cancer between the years of 1986 and 1995 were linked to Carstairs 1995 
Categories, while those who were diagnosed with cancer between the years of 1996 and 
2000 were linked to 2004 SIMD scores. Like the group’s previous studies, five-year 
relative survival was computed and the “deprivation gap” was presented for all of the data 
which included a sub-cohort of 1,128 men with laryngeal cancer. This study demonstrated 
that the deprivation gap in five-year relative survival was at nearly 11% for men with 
cancer of the larynx in favour of those from the least deprived areas of Scotland and, in 
addition, was becoming approximately 3% wider every five years. However, the authors 
could not explain the reasoning behind the widening socioeconomic inequality for men 
with cancer of the larynx due to the limitations around cancer registry data which does not 
hold data such as stage, or health and behavioural information.  
Warnakulasuriya et al. (2007) examined the trends in crude survival for 12,791 people 
with cancer of the oral cavity and pharynx. Data were extracted from the Thames Cancer 
Registry between the years of 1995 and 2002, and the results between those who were 
less than 45 and those who were aged 45 and over were compared. As part of this 
analysis, the authors also investigated the association of stage, treatment, cancer network 
of residence, and socioeconomic status with survival. A total of 483 individuals who were 
younger than 45 years of age and 4,836 people who were older than 45 years were 
included in the analysis to explore the effect of socioeconomic status on relative survival, 
which was measured using IMD scores. Univariate unadjusted Cox proportional hazards 
models for all-cause mortality demonstrated a clear difference in survival for both the 
younger and older groups of people, with survival favouring those from less deprived 
regions. The authors reported that socioeconomic inequality attenuated following 
adjustment for disease stage and treatment modality, particularly for those who were 
younger than 45 years of age. However, this analysis was restricted to those who lived in 
South-East England, so is not necessarily generalisable to the rest of the UK. In addition, 
since this study investigated data from the Thames Cancer Registry, there were 
limitations in the availability of additional potential explanatory factors for socioeconomic 
inequality such as health and behavioural factors.   
A fourth small report produced by the LSHTM investigated survival of men with cancer of 
the larynx who were diagnosed between the years of 1986 and 1999 in England and 
Wales (Rachet et al., 2008). This study  used the same data sources and methods that 
were used in the groups’ earlier papers (Coleman et al., 2001; Coleman et al., 2004). 
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Rachet and colleagues took a deeper look at the 17% deprivation gap of males from the 
earlier article (Coleman et al., 2004) and reported that this gap had increased by 3.7% 
every five years, and that survival was consistently in favour of those from the least 
deprived areas. In addition, this paper investigated 10-year relative survival and 
discovered that the gap in 10-year relative survival for men diagnosed in the early 1990s 
was also wide at 11%, in favour of the people from the least deprived regions. The 
authors outlined that due to the widening socioeconomic inequality observed in this study, 
the gap between the most and least deprived males could continue to grow up to 20% or 
more in recent years. However, like the earlier papers, the underlying causes of 
socioeconomic inequality were not explored.  
A small study carried out by Anandan et al. (2008) included 556 people with cancer of the 
nasopharynx whose data were extracted from the Scottish Cancer Registry between the 
years of 1975 and 2001. The study investigated the effects of Carstairs 1991 Categories 
on one-year, three-year, and five-year relative survival, and overall survival. A difference 
between those from the least deprived and most deprived areas was discovered, with 
survival in favour of the people who resided in the areas that were least deprived. 
However, since this study was restricted to those with nasopharynx cancer, the sample 
size was small and therefore may not be generalisable to the whole population of people 
with head and neck cancer. In addition, due to the limitations of cancer registry data the 
explanations for socioeconomic inequality were not investigated.  
In a population-wide cohort study in Scotland including 1,909 people from the SAHNC 
who were diagnosed with head and neck cancer between the years of 1999 and 2001, 
Robertson et al. (2010) aimed to explain the effects of socioeconomic status on five-year 
overall survival and disease-specific survival. In this study, socioeconomic status was 
measured using 2001 Deprivation Category (DEPCAT) scores which were categorised 
into three groups – affluent, intermediate, and deprived. The authors reported that the 
people who were in the deprived group experienced a 33% (HR = 1.33, 95% CI = 1.06 to 
1.68) increased risk of all-cause mortality compared to those in the affluent group. 
However, in a multivariate Cox proportional hazards model, socioeconomic status was no 
longer an independent predictor of all-cause mortality or disease-specific mortality 
following the adjustment for other baseline covariates including WHO Performance Status, 
tumour stage, age at diagnosis, anatomical site of the tumour, smoking status, and 
alcohol consumption. This was the only UK-based study to investigate the underlying 
causes of socioeconomic inequality in survival of people with head and neck cancer. 
However, Robertson reports the limitations around the use of an area-based 
measurement of socioeconomic status and that the participants of the study may have 
under-reported their levels of smoking and alcohol consumption.  
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Ellis et al. (2012) undertook a fifth and more thorough study with the LSHTM involving 
men and women who had been diagnosed with laryngeal cancer. This more recent 
analysis reported socioeconomic inequalities in survival of 24,234 men and 5,186 women 
who were diagnosed with cancer of the larynx and recorded on the national cancer 
registries of England and Wales between the years of 1991 and 2006. The English and 
Welsh IMD scores were used and both one-year and five-year relative survival was 
reported along with the “deprivation gap” that was described earlier (Coleman et al., 2001; 
Coleman et al., 2004; Rachet et al., 2008). Ellis and colleagues reported that there was no 
difference in relative survival between the least deprived and most deprived groups of 
females with laryngeal cancer after one year and five years. However, the difference was 
much clearer for males, with a deprivation gap of 7% and 13% between the least deprived 
and most deprived males after one year and five years, respectively, in favour of the least 
deprived group. In addition, the authors outlined that there were differing results 
depending on the subsite of the laryngeal tumour, which included glottal and supraglottic 
tumours. These findings suggested that females with tumours of the glottis had a 
deprivation gap in favour of the least deprived group, while females with supraglottic 
tumours had a deprivation gap in favour of the most deprived group. However, similar to 
the group’s earlier studies, there were limitations around the use of data from cancer 
registry sources which did not allow further investigations into the explanations for 
socioeconomic inequality to be explored.  
Rylands et al. (2016) reported findings from a cohort of 523 people recorded with an SCC 
of the oral cavity in the University Hospital Aintree database between 2008 and 2012. The 
data were linked to 2010 IMD scores which grouped people into national quartiles, and 
two-year and five-year overall survival estimates were reported. Interestingly, the authors 
reported that there was not an obvious gradient in survival across the IMD quartiles, 
however there was a difference between binary groups of the most deprived compared to 
those from the least deprived group, in favour of the least deprived group, although this 
was minimal. This was a small study of people diagnosed at a single centre in the North of 
England and so these results are likely to be unreliable. In addition, the authors only 
investigated overall survival estimates and cause of death was not considered in a cause-
specific or relative survival setting.  
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1.4.5 Effect of socioeconomic status on survival of people with head and 
neck cancer in Europe 
1.4.5.1 Overview of studies in Europe 
Only five studies from Europe met the eligibility criteria for this literature review. Two of 
these articles included people from Turin, Italy (Rosso et al., 1996; Boffetta et al., 1997), 
one included people from The Netherlands (de Graeff et al., 2001), and the final two 
studies included individuals from Denmark (Andersen et al., 2008; Dalton et al., 2019). 
Four of these papers investigated survival of either all types of head and neck cancer or 
cancer of the mouth, pharynx, and larynx (Rosso et al., 1996; de Graeff et al., 2001; 
Andersen et al., 2008; Dalton et al., 2019), while the fifth study included people with 
cancer of the larynx (Boffetta et al., 1997). All five of the studies involved cancer registry 
data and contrastingly to the studies from the UK, all of the European studies used 
individual measures of socioeconomic status, and none of them used area-based 
measurements. Two articles investigated outcomes using overall survival (Boffetta et al., 
1997; de Graeff et al., 2001), two studies utilised relative survival (Andersen et al., 2008; 
Dalton et al., 2019), and the fifth paper used case fatality ratios (Rosso et al., 1996). Only 
one of the studies investigated the underlying causes of socioeconomic inequality in 
survival by education level (Boffetta et al., 1997). 
1.4.5.2 Studies in Europe 
The earliest European article was undertaken by Rosso et al. (1996) and examined social 
differences in cancer survival in Turin, Italy. This study used the Piedmont Cancer 
Registry which was linked to census data to provide measurements of socioeconomic 
status. The authors examined level of education status and estimated the case fatality 
ratios for all-cause mortality. People with cancer who were diagnosed between the years 
of 1985 and 1987 and followed-up to 1993 were included. A total of 11,653 people with 
cancer were eligible for the study, including 294 people with cancer of the mouth and 
pharynx and 274 individuals with cancer of the larynx. Case fatality ratios were displayed 
following adjustment for age, area of birth, sex, and housing tenure (owners or renters). 
No trend by education was apparent for individuals with cancer of the mouth and pharynx, 
and only a weak trend for those with cancer of the larynx was observed in favour of those 
with higher levels of education. However, the sample size for this study was small and 
only included data from one city in Italy and therefore, these results need to be interpreted 
with caution.  
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A second small cohort study of 355 people with cancer of the larynx from Turin, Italy was 
undertaken by Boffetta et al. (1997). Individuals were recruited between the years of 
1979 and 1982 and followed-up until 1994. The authors presented overall and relative 
survival with the aim of determining the prognostic factors of survival by exploring age, 
sex, tumour site, stage, smoking alcohol, nutrient intake, and two measurements for 
socioeconomic status including education level and occupation. Although statistically 
insignificant, the authors reported that there was an association between education level 
and survival following adjustment for tumour site, stage, and tobacco smoking, in favour of 
those with higher levels of education. However, the same limitations as those for the 
earlier European study also apply to this study since the sample size was small and the 
inclusion criteria was restricted to people in one city in Italy.  
A small cohort study by de Graeff et al. (2001) in the 1990s was conducted to evaluate 
the effects of sociodemographic factors on the survival of people with head and neck 
cancer. The study was carried out on 208 people in The Netherlands who were diagnosed 
with SCC of the oral cavity, oropharynx, hypopharynx, and larynx and recruited between 
the years of 1994 and 1996. The people were followed up either until progression of their 
cancer or death from their cancer. However, the length of follow-up was not defined. 
Although the study was primarily focussed on the association between quality of life and 
survival, de Graeff produced one univariate analysis which included family income and 
occupational level. This analysis reported no association between income and occupation 
and survival. However, there were several limitations to this study including the small 
sample size of people from a small area in The Netherlands and the number of events 
(including progression and deaths) were low.  
As part of a thorough analysis to examine the effects of socioeconomic inequality in 
incidence and survival of 3.22 million people registered with cancer on the Central 
Population Register in Denmark, Andersen et al. (2008) examined a sub-cohort of 3,058 
individuals with cancers of the mouth, pharynx, and larynx. People over the age of 30 in 
Denmark were diagnosed between the years of 1994 and 2003 for the occurrence of 
cancer and were followed-up until 2006. This was defined in a separate paper (Dalton et 
al., 2008) and was justified since people who were younger than 30 may still be in 
education and thus, have not yet established their socioeconomic position. Anderson and 
colleagues’ article assessed 3,058 people with cancers of the mouth or pharynx and 1,799 
people with cancer of the larynx. Socioeconomic status was measured using a variety of 
indicators including level of education, disposable income, affiliation to work market, social 
class, housing tenure, size of dwelling, and district type. For people with cancer of the 
mouth and pharynx, better survival was observed for both males and females if they had 
higher education, higher income, were homeowners, lived in dwellings of larger square 
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meter, or had better affiliation to the labour market. However, more disposable income 
was not associated with better survival outcomes for females. For males with cancer of 
the larynx, better survival was observed for those who were of higher education levels, 
higher levels of income, homeowners, had larger dwelling sizes, or who were of the 
creative core or creative professional social class. For females with cancer of the larynx, 
better survival was reported for those who had more income, were employed, 
homeowners, or lived in a larger dwelling. Interestingly, females with cancer of the larynx 
who had basic or high school levels of education had better survival after one-year than 
those with higher levels of education, however by five-years, this had reversed and the 
females who had obtained higher education levels had better survival. The population-
wide data from Denmark with multiple individual-level socioeconomic measures are 
strengths of this study. However, as per several other articles included in this literature 
review, the explanations of socioeconomic determinants and socioeconomic inequalities 
observed could not be assessed due to limitations of available data from a cancer registry.  
Dalton et al. (2019) explored the trends in socioeconomic inequality in cancer survival 
from 1987 to 2013. A total of 142,430 people with a diagnosis of cancer from Denmark 
were included in the study, which included a sub-cohort of 3,928 people with cancer of the 
head and neck. One-year and five-year relative survival was reported, and socioeconomic 
position was assessed by utilising the individuals’ disposable income in the year prior to 
their diagnosis. The authors reported that although relative survival improved over the 
period from 1987 to 2013, this improvement was more prominent in those who had higher 
income levels, particularly for those with cancer of the head and neck. Inequality in 
survival of people with head and cancer had increased over time. This was the only study 
discovered that investigated inequality utilising an individual measurement for levels of 
income.  
1.4.6 Effect of socioeconomic status on survival of people with head and 
neck cancer in the Americas 
1.4.6.1 Overview of studies in the Americas 
A total of 19 articles were found involving people with head and neck cancer in the 
Americas. This included 11 studies in the USA six studies in Canada and two studies in 
South America. Of the 11 papers from the USA, seven studies included people from 
across the entire USA (Konski et al., 2003; Chen and Halpern, 2007; Megwalu, 2017; Shin 
et al., 2017; Xu et al., 2017; Gaubatz et al., 2019; Stubbs et al., 2020), two papers 
included individuals from Florida (Molina et al., 2008; Guo et al., 2015), one study 
included individuals from California (Chu et al., 2011a), and one study included people 
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from Texas (Reitzel et al., 2012). Four articles utilised data from the National Cancer 
Database (Chen and Halpern, 2007; Shin et al., 2017; Gaubatz et al., 2019; Stubbs et al., 
2020), two studies utilised data from the SEER programme (Megwalu, 2017; Xu et al., 
2017), three involved extracts from local cancer registries (Molina et al., 2008; Chu et al., 
2011a; Guo et al., 2015), one involved data from a single-site cancer centre (Reitzel et al., 
2012), and the final paper used data which was collected as part of a randomised 
controlled trial (Konski et al., 2003). Of these articles, seven of them included all types of 
head and neck cancers (Konski et al., 2003; Molina et al., 2008; Chu et al., 2011a; Reitzel 
et al., 2012; Guo et al., 2015; Xu et al., 2017; Gaubatz et al., 2019), one included people 
with cancer of the pharynx (Shin et al., 2017), one included individuals with cancer of the 
oropharynx (Megwalu, 2017), and one included people with cancer of the larynx (Chen 
and Halpern, 2007). All of the studies reported overall survival or disease-specific survival. 
All of the papers used neighbourhood-level measurements of socioeconomic status.  
Of the six Canadian articles found, three studies included people in Ontario who were 
identified from the Ontario Cancer Registry (Mackillop et al., 1997; Groome et al., 2006; 
Booth et al., 2010), one study included people in Toronto diagnosed at the Toronto 
Princess Margaret Cancer Centre (Chu et al., 2016), one paper involved people from all of 
Canada diagnosed on the Canadian Cancer Registry (McDonald et al., 2014), and the 
final paper included people in British Columbia diagnosed on the British Columbia Cancer 
Registry (Auluck et al., 2016). Three of the articles included individuals with any type of 
head and neck cancer (Mackillop et al., 1997; McDonald et al., 2014; Chu et al., 2016), 
two included people with laryngeal cancer (Groome et al., 2006; Booth et al., 2010), and 
the final study included people with cancer of the oral cavity or oropharynx (Auluck et al., 
2016). All of the studies presented either overall survival or disease-specific survival, and 
only three articles presented results beyond five-years of follow-up (Mackillop et al., 1997; 
Groome et al., 2006; Chu et al., 2016). Four of the Canadian articles utilised a 
measurement of income to describe socioeconomic status (Mackillop et al., 1997; Groome 
et al., 2006; Booth et al., 2010; McDonald et al., 2014), while the other two studies used 
measurements of neighbourhood deprivation (Auluck et al., 2016; Chu et al., 2016).  
One South American study included people in Brazil with all types of head and neck 
cancer diagnosed from eight different hospitals (Lopez et al., 2011), while the second 
study included people from Argentina, Brazil, Columbia, and Uruguay. Both studies 
investigated all-cause mortality with at least three years of follow-up and education level 
was used as the measurement of socioeconomic status in both studies.  
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1.4.6.2 Studies in the USA 
Konski et al. (2003) investigated the effects of education on overall survival of 1,073 
people who had been recruited to a randomised controlled trial between the years of 1991 
and 1997. The trial aimed to evaluate radiotherapy fractionation schedules in participants 
with advanced stage SCC of the head and neck. In this article, the authors performed a 
nested cohort study from the trial data and analysed five-year overall survival from the 
time of randomisation. The paper evaluated the results of those who had attended college 
or technical school against those who had not attended school up to those who had 
graduated from high school or a general education diploma. There was a difference in 
overall survival up to five-years after randomisation – in a multivariate analysis adjusting 
for stage, site, and race, the people who attended college or technical school still had a 
substantially improved survival. However, this was a small study which only included 
people who had been included in a randomised controlled trial to investigate radiotherapy 
treatment, and therefore is not necessarily generalisable to the entire population of people 
with head and neck cancer.  
A large population-based study of people whose data had been collected by the National 
Cancer Database between the years of 1995 and 1998 was conducted by Chen and 
Halpern (2007). The study explored the predictive factors of survival for individuals who 
had been diagnosed with advanced SCC of the larynx between the years of 1995 and 
1998. A total of 7,019 people were included in the study and the authors utilised area-level 
characteristics as a measurement of socioeconomic status, including the percentage of 
high school graduates and median household income. The authors investigated Cox 
proportional hazards ratios for five-year all-cause mortality. This study did not confirm a 
difference for individuals who resided in areas with overall lower education or income 
levels following the adjustment for treatment, sex, race, hospital type, or insurance status. 
However, only those with advanced SCC of the larynx were included, and therefore these 
results are not necessarily applicable to the entire population of people with head and 
neck cancer.  
Molina et al. (2008) investigated the association of community poverty level with the 
survival of 20,915 people diagnosed with head and neck cancer in Florida between the 
years of 1998 and 2002. The authors investigated five-year overall survival using a variety 
of demographic, social, and clinical information, and recorded socioeconomic status using 
community poverty levels. This study reported that people from lower socioeconomic 
communities presented at a younger age, with tumours of higher stage, and with 
significantly lower median survival times compared to those who were from less deprived 
areas. The authors also discovered that area-based socioeconomic status was an 
independent predictor of survival in a stepwise multivariate Cox regression analysis which 
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included participant demographics (age, gender, race, ethnicity, tobacco use, and alcohol 
consumption), comorbidities, clinical characteristics (tumour grade, stage, and location of 
treatment), and treatment modality. This was one of the few studies from around the world 
that investigated the underlying causes of socioeconomic inequality in survival of people 
with head and neck cancer, however it only utilised an area-based measure and did not 
examine trends by the individual subsites of the head and neck.   
A large cohort study undertaken by Chu et al. (2011b) investigated the influence of 
socioeconomic status on the cancer-specific survival of Asians and Pacific Islanders. The 
study included a total of 53,544 people with head and neck cancer who were identified on 
the Californian Cancer Registry between the years of 1988 and 2007. Chu and colleagues 
utilised neighbourhood-level socioeconomic status in quintiles using education, income, 
occupation, and cost of living. The authors presented median survival of the cohort over 
the study period and produced multivariate Cox regression models for all-cause and 
disease-specific mortality. For all of the people included in the analysis, those who were of 
lower socioeconomic status were more at risk of cancer-specific deaths, and those with 
cancer of the oropharynx had the greatest difference in survival between the lowest and 
highest socioeconomic groups. This association continued to be significant after the 
adjustment for additional baseline covariates including stage, age, and year of diagnosis. 
For Asian and Pacific Islanders, the same differences were observed for males, however 
the number of female Asian and Pacific Islanders was too low to determine whether there 
was an association with socioeconomic status and cancer-specific survival. Due to the 
limitations of cancer registry data, further possible determinants of socioeconomic 
inequality in survival could not be investigated. Additionally, individual-level 
measurements of socioeconomic status were not available for this study.  
A smaller study conducted by Reitzel et al. (2012) investigated the effects of 
neighbourhood deprivation on the overall survival, disease-specific survival, and disease-
free survival results of a cohort of 1,151 people with head and neck cancer. The 
individuals were treated at the University of Texas MD Anderson Cancer Centre between 
the years of 1996 and 2009. The participants were linked to neighbourhood deprivation 
which considered education, employment status, and poverty. This study did not 
demonstrate an influence of neighbourhood deprivation on people with head and neck 
cancer, however when the results were stratified by the site of the head and neck, those 
with cancer of the oropharynx had differing results. For those with oropharyngeal cancer, 
a high level of neighbourhood deprivation was associated with poor overall survival even 
following the adjustment of additional covariates such as age, sex, stage, smoking status, 
and annual household income. This suggested that those with cancer of the oropharynx 
were at an increased risk of worse outcomes if they resided in areas of low education 
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level, low-income level, high levels of unemployment, single-parent households, and no 
vehicle availability.  
Guo et al. (2015) investigated the effects of neighbourhood-level poverty on overall 
survival and disease-specific survival of 25,157 people who were diagnosed with head 
and neck cancer. The data for the participants included in the study were extracted from 
the Florida Cancer Data System between the years of 1996 and 2010. Following 
adjustment for demographic and clinical information, socioeconomic inequality remained 
between those who resided in the poorer areas of Florida, who had a substantially higher 
risk of all-cause and disease-specific mortality. The authors also investigated the effect of 
individual smoking on socioeconomic inequality in survival and concluded that smoking 
accounted for a large part of the inequality observed. However, several potential 
explanatory factors for socioeconomic inequality were not available including alcohol 
consumption and comorbid conditions.  
Megwalu (2017) analysed data on 18,791 people with cancer of the oropharynx who were 
recorded on the SEER database between the years of 2004 and 2012. Megwalu 
conducted a thorough investigation of the effects of several neighbourhood-level 
socioeconomic factors on five-year overall survival and disease-specific survival, which 
included high school completion rate, bachelor’s degree completion rate, family poverty 
rate, median household income, unemployment rate, white collar occupation rate, and 
socioeconomic index (which were all categorised as “high” and “low”). The study reported 
that worse five-year overall survival and disease-specific survival was observed for people 
who were residing in areas with lower rates of high school completion, low bachelor’s 
degree completion rates, higher percentage of families living below the poverty line, high 
unemployment rates, low percentage of individuals working in white-collar professions, 
and low socioeconomic indices. In addition, Megwalu performed multivariate analyses 
which confirmed that this observation remained for people from low socioeconomic 
neighbourhoods following the adjustment for age, sex, race, marital status, year of 
diagnosis, cancer site, stage, and treatment.  
A study undertaken by Xu et al. (2017) also utilised the SEER database by extracting 
37,995 people with non-metastatic head and neck cancer diagnosed between the years of 
2007 and 2012. The authors presented five-year overall survival and disease-specific 
survival and investigated the effects of neighbourhood-level median household income, 
education level, unemployment rate, and residence status on survival. The median follow-
up time was 24 months. This study outlined that only those who resided in areas of lower 
median income had a lower overall survival and disease-specific survival in multivariate 
analyses following the adjustment for age, sex, race, marital status, insurance status, 
cancer subsite, stage, and treatment. However, this study did not include information on 
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behavioural data such as smoking and alcohol consumption and therefore, these could 
not be assessed for their association with socioeconomic inequality in survival.  
Shin et al. (2017) investigated the impact of socioeconomic status on the survival of 
people with head and neck cancer. Individuals were identified from the National Cancer 
Database if they were diagnosed between the years of 2004 and 2013. Five-year overall 
survival was evaluated with a median follow-up time of approximately 25 months. A total 
of 35,559 people with SCC of the pharynx were included, and socioeconomic status was 
determined using neighbourhood-level median household income and the proportion of 
participants who had attained a high school diploma. Shin and authors demonstrated a 
trend in survival across the median household income groups, suggesting that those who 
resided in areas of lower median household income had a substantially lower overall 
survival than those who live in areas of higher median household incomes. The same 
trend was also clear for those who resided in areas with a lower proportion high school 
diploma attainment. However, following the adjustment for insurance status, race, 
comorbidity, cancer site, and stage, the socioeconomic inequality no longer remained for 
either median household income or the proportion of people who attained a high school 
diploma.  
A study involving data from the National Cancer Database was undertaken by Gaubatz et 
al. (2019) to investigate the impact of neighbourhood-level income on the mortality of 
people with head and neck cancer in the USA. Data were utilised from the National 
Cancer Database on all people who had a diagnosis of head and neck cancer between 
the years of 2004 and 2014. The study consisted of 260,035 people and investigated the 
effects of neighbourhood-level median household income on 90-day all-cause mortality. 
The authors reported that the participants who resided in areas with lower median 
household income had poorer 90-day survival following adjustment for comorbidity, stage, 
tumour site, HPV status, facility type, waiting times for treatment, and treatment type. 
However, the follow-up period of this study was short and therefore conclusions around 
the socioeconomic inequality in long-term survival cannot be drawn from this article.  
1.4.6.3 Studies from Canada 
An early study involving people recorded on the Ontario Cancer Registry conducted by 
Mackillop et al. (1997) investigated the effects of income on the survival of people with 
one of eight different types of cancers, including nearly 16,000 people with head and neck 
cancer. The study included individuals who were diagnosed with cancer between the 
years of 1982 and 1991, and overall survival was reported for a period of seven years 
after diagnosis. Mackillop and colleagues linked information from the 1986 Canadian 
census to provide median household income as a measurement for socioeconomic status. 
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The study highlighted strong associations between income and overall survival for people 
with head and neck cancer, favouring those with higher levels of income. In addition, 
those who earned lower income also experienced higher rates of death from their head 
and neck cancer. Finally, the authors reported that the association between income and 
cancer survival was stronger for those with head and neck cancer than it was for any 
other cancer. However, these analyses were not adjusted for any confounding factors and 
therefore explanatory factors for socioeconomic inequality in survival were not 
investigated.  
A later study by Groome et al. (2006) investigated the effects of income on survival of 
people with cancer of the larynx. The study included 661 people with cancer of the glottis 
and 495 people with cancer of the supraglottis. Individuals were diagnosed on the Ontario 
Cancer Registry between the years of 1982 and 1995 and were followed-up for an 
average of 62 months. The authors reported cause-specific survival and discovered that 
those with cancer of the glottis who resided in areas of lower income had substantially 
worse survival than those who were from areas of higher income. However, this difference 
was not apparent for those with cancer of the supraglottic. This was a small study with 
limitations around access to information such as smoking and alcohol consumption due to 
the use of data from a national cancer registry. Therefore, the explanations for 
socioeconomic inequality in survival of people with cancer of the larynx could not be 
explored.  
A more recent study undertaken by Booth et al. (2010) investigated the impact of 
socioeconomic status on survival of people who were diagnosed with cancer on the 
Ontario Cancer Registry and at Regional Cancer Centres between the years of 2003 and 
2007, including a sub-cohort of 854 individuals with laryngeal cancer. The study 
investigated the effect of median household income on five-year overall survival and 
three-year disease-specific survival. The authors recorded a small difference across the 
median income groups for overall survival and disease-specific survival for those who 
were recorded in the Ontario Cancer Registry. Results did not demonstrate substantial 
differences in overall survival and disease-specific survival across the median household 
income groups. However, there were several limitations to this study including the use of 
cancer registry data which does not include information on behavioural data. In addition, 
the sample size of people with cancer of the larynx included in this analysis was small and 
therefore these results may not be reliable.  
McDonald et al. (2014) examined the relationship between average household income 
and survival of 30,228 people with cancer of the head and neck. Individuals were 
identified from the Canadian Cancer Registry between the years of 1992 and 2005 and 
were followed up to 2007 to provide two-year survival. McDonald and colleagues reported 
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that lower income was strongly associated with worse survival outcomes for those with 
head and neck cancer. In addition, time trends were also examined and the gap in 
survival increased over time for individuals with oropharyngeal cancer, but this trend was 
not observed for those with cancer of the oral cavity. However, the study did not contain 
additional information such as tumour stage or behavioural information, and therefore 
could not investigate explanatory factors of the observed socioeconomic inequality.  
Auluck et al. (2016) investigated the effects of neighbourhood deprivation on survival of 
people with SCC of the oral cavity and oropharynx. The participants were identified on the 
British Columbia Cancer Registry between the years of 1981 and 2009 and provided five-
year cancer-specific survival rates. The study included 2,059 people with cancer of the 
oropharynx and 4,319 people with cancer of the oral cavity. Auluck and colleagues 
reported significantly better disease-specific survival for men with cancer of the 
oropharynx who resided in affluent areas, however there was no difference for men with 
cancer of the oral cavity. Interestingly, women with cancer of the oropharynx and oral 
cavity did not exhibit the same difference as men with cancer of the oropharynx. The 
authors also presented trends in the deprivation gap and reported that there was an 
increase in the deprivation gap for men between 1981-1995 and 1996-2009. However, the 
reverse was observed for women. Finally, this study also investigated whether 
socioeconomic status was an independent predictor of survival and discovered that the 
association of socioeconomic status on survival remained following the adjustment for 
age, sex, stage, and time period.  
Chu et al. (2016) explored the prognostic importance of neighbourhood-level 
socioeconomic status on overall survival of 2,124 people with newly diagnosed head and 
neck cancer. The participants were diagnosed at the Toronto’s Princess Margaret Cancer 
Centre between the years of 2003 and 2010 and were followed-up for up to 8 years. Chu 
and colleagues reported that although low socioeconomic status was associated with 
poorer survival in a univariate model, it was no longer associated with poorer survival 
following the adjustment for other variables including age, gender, stage, comorbidity, 
smoking status, alcohol use, and HPV type 16 status. The authors outlined that those of 
lower socioeconomic status had comorbidities, tumours of higher stage, were smokers 
and alcohol users, and were often associated with HPV type 16 negative tumours.  
1.4.6.4 Studies form South America 
A small cohort study of people in Brazil was carried out by Lopez et al. (2011) which 
included 445 individuals with cancers of the oral cavity, oropharynx, larynx, and 
hypopharynx. Individuals were diagnosed between the years of 1998 and 2002 and 
followed up until 2005. Socioeconomic status was defined using the number of years the 
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participants had spent in education and a multivariate Cox proportional hazards 
regression model for disease-specific mortality was generated. The model was adjusted 
by age and sex, and the authors concluded that there were differing results for each 
subsite of the head and neck. For people with cancer of the oral cavity, oropharynx, and 
hypopharynx the risk of death from head and neck cancer increased as the number of 
years the participant spent in education increased. However, the results were contrasting 
for those with cancer of the larynx since these people had a lower risk of disease-specific 
mortality as the number of years in education increased. However, the hazard ratios were 
all non-significant and the sample sizes for each subgroup of the head and neck were 
very small, so these findings are unlikely to be reliable.  
Abrahão et al. (2020) investigated the predictors of survival in a cohort of 1,463 people 
diagnosed with SCC of the head and neck from Argentina, Brazil, Columbia, and Uruguay 
between the years of 2011 and 2017. Participants for the study were collected from the 
InterCHANGE study, a multicentre case-control study to investigate the risk factors and 
outcomes of people with SCC of the head and neck. Patients were followed up to 2018 
and the authors reported three-year overall survival and included the education level of 
the patients as an explanatory factor. In a univariate Cox proportional hazards model, 
those who were “illiterate” were 44% more at risk of all-cause mortality compared to those 
with “superior” education levels (HR = 1.44, 95% CI = 0.63 to 3.32). However, in a 
multivariate model including age, sex, rate, cancer stage, smoking history, alcohol 
consumption, and anatomical site, education level was no longer a predictor of survival.   
1.4.7 Effect of socioeconomic status on survival of people with head and 
neck cancer in other parts of the world 
1.4.7.1 Overview of studies from other parts of the world  
A total of six articles were found involving people with head and neck cancer in other parts 
of the world. This included five studies in Taiwan (Wong et al., 2006; Lee et al., 2012; 
Chang et al., 2013; Chien et al., 2018; Lai et al., 2018) and one study in Australia (Yu et 
al., 2008). Of the studies carried out in Taiwan, three of them utilised data from the 
National Health Insurance Research Database (NHIRD) (Lee et al., 2012; Chang et al., 
2013; Lai et al., 2018), one used Taiwan Cancer Registry data (Chien et al., 2018), and 
the final study used hospital-based records (Wong et al., 2006). Two papers included all 
types of head and neck cancers (Chien et al., 2018; Lai et al., 2018), two studies included 
people with oral cavity cancer (Wong et al., 2006; Lee et al., 2012), and the final study 
included individuals with cancer of the nasopharynx (Chang et al., 2013). Two articles 
examined overall survival (Wong et al., 2006; Lai et al., 2018), two studies investigated 
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cumulative survival (Lee et al., 2012; Chang et al., 2013), and one paper reported net 
survival estimates (Chien et al., 2018). Two-year follow-up was assessed in one of the 
studies (Lee et al., 2012), five-year follow-up was included in three of the studies (Wong et 
al., 2006; Chang et al., 2013; Chien et al., 2018), and one paper included up to 12.5 years 
of follow-up (Lai et al., 2018). Two studies investigated income as a measurement of 
socioeconomic status (Chien et al., 2018; Lai et al., 2018), one article assessed 
neighbourhood-level socioeconomic status (Chang et al., 2013), one study included both 
a neighbourhood-level of socioeconomic status and occupation (Lee et al., 2012), and the 
final study investigated both occupation and education as measurements for 
socioeconomic status (Wong et al., 2006). The Australian article used data from the New 
South Wales Central Cancer Registry and included people with cancer of the oral cavity, 
pharynx, and larynx. Additionally, the authors reported five-year relative survival 
proportions and defined socioeconomic status using an area-based measurement (Yu et 
al., 2008). 
1.4.7.2 Studies in Taiwan 
The earliest article in Taiwan written by Wong et al. (2006) investigated the impact of 
education on five-year survival of people with cancer of the oral cavity. This was a 
hospital-based study including 1,010 people treated at the Taichung Veterans General 
Hospital from 1995 to 2002 and followed-up to 2004. Interestingly, there was no observed 
difference in survival between those who had varying levels of education. However, this 
study was small and more than 78% of the cohort were junior high school graduates or 
below which suggests bias in the proportion of people who were selected across the 
education groups.  
A later study carried out by Lee et al. (2012) investigated the effects of individual and 
neighbourhood socioeconomic status on survival. This study used data from Taiwan’s 
NHIRD of people who were diagnosed between the years of 2005 and 2008 and included 
a total of 3,607 individuals with cancer of the oral cavity. The authors reported two-year 
cumulative survival and compared results by occupation and neighbourhood household 
income from the 2001 Taiwan Census. The authors recorded differences between the 
socioeconomically advantaged and disadvantaged groups, with survival favouring the 
advantaged groups. In addition, people of lower socioeconomic position remained at a 
higher risk of all-cause mortality following adjustment for age, gender, comorbidity, 
urbanisation, area of residence, treatment modality, hospital characteristics, and year of 
diagnosis. This was one of the few studies that explored the explanations for 
socioeconomic inequality in survival. However, the database did not include information 
on tumour stage or behavioural data such as smoking and alcohol consumption and 
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therefore, these risk-factors could not be explored for their association with socioeconomic 
inequality in survival.  
A further study was conducted by Chang et al. (2013) which investigated both individual 
and neighbourhood-level measurements of socioeconomic status and their effect with 
five-year cumulative survival. This study included 4,691 people who were diagnosed with 
nasopharyngeal cancer between the years of 2002 and 2006 on Taiwan’s NHIRD. The 
four-factor Hollingshead scale (Hollingshead AdB, 1975) was used which uses enrolee 
category as a proxy for individual-level socioeconomic status. From this, the participants 
of the study were grouped according to their occupational status. In addition, the authors 
also used neighbourhood household income averages from Taiwan’s 2001 Census as an 
area-based measurement for socioeconomic status. The authors reported that 
socioeconomic status remained a significant predictor of survival when adjusting by 
factors including age, gender, comorbidity, urbanisation, area of residence, treatment, and 
hospital characteristics. In addition, the authors suggested that those with worse 
socioeconomic status were treated in hospitals with lower healthcare resources, such as 
lower number of physicians per patient. However, similar to the previous study, the same 
limitations apply including the lack of staging and behavioural data to investigate their 
association with survival.  
Chien et al. (2018) investigated the impact of household income on five-year net survival 
which included data from the Taiwan NHIRD. A total of 5,307 people with cancer of the 
larynx and 65,624 people with cancer of oral cavity, oropharynx, and larynx diagnosed 
between the years of 1992 and 2011 were included in the study. The authors investigated 
five-year net survival proportions and reported that socioeconomic inequality existed for 
people with cancer of the larynx, oral cavity, and oropharynx. However, the underlying 
causes of socioeconomic inequalities were not explored in this study due to the limitations 
of these data around the collection of information such as stage and behavioural factors.  
A large population-based registry study conducted by Lai et al. (2018) explored the 
outcomes of 40,985 people with head and neck cancer. The individuals were recorded on 
the Taiwan NHIRD between the years of 2000 and 2013 and had only been treated with 
radiotherapy. The authors used income as a measurement of socioeconomic status and 
reported overall survival with an endpoint of December 2013. The authors reported that 
low income or living in residential areas of lower socioeconomic status had a detrimental 
effect on survival, regardless of the location in Taiwan that the person had lived. However, 
the underlying causes of socioeconomic inequality were not investigated as part of this 
study due to the limitations around data availability on cancer registry studies.  
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1.4.7.3 Studies in Australia 
Yu et al. (2008) investigated the impact of socioeconomic status on cancer survival for 
people diagnosed in Australia. People diagnosed on the New South Wales Central 
Cancer Registry between 1992 and 2000 were included in the study, along with a sub 
cohort of 6,331 people with head and neck cancer. The authors confirmed socioeconomic 
inequality in five-year relative survival for both men and women from an area-based 
measurement of socioeconomic status, in favour of those who lived in the least deprived 
regions. However, investigations into the potential determinants of socioeconomic 
inequality were not carried out as part of this study.  
1.4.8 Summary and gaps in the literature 
Collectively, the international and UK literature demonstrates consistent and clear findings 
of socioeconomic inequalities in the relationship between lower socioeconomic status and 
circumstances with poorer survival of people with head and neck cancer. Given the 
heterogeneity of the studies, their findings could not be formally pooled or combined to 
estimate the extent of socioeconomic inequalities, nor how it varied by global region, over 
time, or even by head and neck cancer subsite. It was not also possible to be assertive on 
or weigh the effects of differing possible explanatory factors. However, in the small 
number of studies which had modelled explanatory factors, the effect of socioeconomic 
status was fully explained or attenuated, with limited evidence available on an 
independent socioeconomic status effect on survival of people with head and neck cancer 
following consideration for potential underlying factors.  
Few studies investigated the underlying causes of inequality in survival of people with 
head and neck cancers. Of the studies that did investigate the explanatory factors of 
socioeconomic inequality, few included all of the potential confounders, and only two 
studies included tumour HPV status as a factor of interest. Additionally, few of the studies 
included in the literature review investigated the long-term impact of inequality on survival 
of people with head and neck cancer beyond five-years. Further investigations into the 
underlying causes of socioeconomic inequality need to be conducted with the aim to 
explain inequality in survival observed for people with head and neck cancer in the short-
term, middle-term, and long-term follow-up.  
In addition, of the studies that explored the underlying factors of inequality, there were no 
groupings of the factors that may explain socioeconomic inequalities in head and neck 
cancer survival. These have not been viewed through patient, tumour, or treatment factor 
groupings, and in particular, assessing the underlying determinants have not been 
grouped as per factors that might be more modifiable (for example, through behaviours 
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such as smoking and alcohol) compared with factors that might be more difficult to modify 
or control (for example, tumour site, stage, and treatment regimens).  
None of the studies included in this literature review from the UK explored socioeconomic 
inequality in survival of people with head and neck cancer using individual measurements 
of socioeconomic status such as household income or education level. Outside of the UK, 
all of the studies in Europe and only eight studies outside of Europe investigated 
socioeconomic inequality using either education level, household income, or type of 
occupation. This limitation to the UK-based literature provides a gap in the evidence of 
socioeconomic inequality in survival of people with head and neck cancer. No study 
formally analysed the extent of absolute and relative inequalities in survival using 
recommended metrics including relative index of inequality (RII) and slope index of 
inequality (SII) as per IARC 2019 suggestions. Moreover, the trends in survival inequality 
over calendar time had also not been reported in the literature.   
Despite the burden of both incidence and mortality of head and neck cancers being 
greatest in lower income countries, particularly in South East Asia (Ferlay et al., 2020), 
there is a lack of research on head and neck cancer survival or outcomes from this part of 
the world. This itself is an inequality, since inequalities between countries exist and are 
well recognised (International Agency for Research on Cancer, 2019), however, this is 
beyond the scope of this thesis. 
1.5 Aims and objectives of this thesis 
This thesis aims to inform patients, clinicians, policy makers, and the public in the UK that 
are involved with head and neck cancer on the magnitude of socioeconomic inequality 
observed in survival of people with head and neck cancer and what factors might explain 
these inequalities. This thesis has the potential to shine a light on the issue of 
socioeconomic inequality in survival of people with head and neck cancer. A series of 
epidemiological studies of multiple existing UK cohort studies will explore this topic from 
different angles. The findings could inform policy and practice in the further development 
and delivery of head and neck cancer services. 
The extent and nature of socioeconomic inequality in survival of people with head and 
neck cancer across the UK (and Scotland) is poorly understood and explanations for this 
inequality are yet to be thoroughly investigated by exploring potential underlying patient, 
tumour, and treatment explanatory factors. The overall aims of this thesis are to:  
1. Describe trends in socioeconomic determinants and socioeconomic inequalities in 
head and neck cancer survival over calendar time and follow-up time. 
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2. Understand socioeconomic inequality in survival of people with head and neck 
cancer. 
3. Explain the underlying determinants and explanations of socioeconomic inequality 
in survival of people with head and neck cancer. 
 
The individual aims and objectives of each chapter follow. 
1.5.1 Chapter 2 aims and objectives 
The aim of Chapter 2 is to describe the trends over time and follow-up time of the 
inequality in survival of people with head and neck cancer in Scotland by utilising the 
Scottish Cancer Registry. The objectives of this chapter are to:  
1. Determine the trends in inequality over calendar time from 1986 to 2015. 
2. Compare the patterns in inequality over follow-up time in one-year, five-year, and 
10-year survival.  
3. Examine these trends and patterns for all of the patients (and by sex), and across 
the three main subsites of head and neck cancer (oral cavity, oropharynx, and 
larynx).  
1.5.2 Chapter 3 aims and objectives 
The primary aim of Chapter 3 is to determine the factors that are independently 
associated with survival at three time points – one year, five years, and 12 years after a 
diagnosis of head and neck cancer by utilising the SAHNC cohort study of people with 
head and neck cancer who were diagnosed in Scotland between the years of 1999 and 
2001 (Scottish Audit of Head and Neck Cancers Steering Group, 2004). The secondary 
aim of this chapter is to compare several methods of measuring survival via the use of 
overall survival, disease-specific survival, and net survival estimates to provide an in-
depth and comprehensive picture of the factors that are associated with survival of people 
with head and neck cancer in Scotland. The objectives of this chapter are to: 
1. Explore the patient, tumour and treatment factors that are associated with one-
year, five-year, and 12-year overall survival and disease-specific survival. 
2. Compare the outcomes of three different survival metrics: overall survival, disease-
specific survival, and net survival estimates.  
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1.5.3 Chapter 4 aims and objectives 
Following on from the research of Chapter 3, and also using the SAHNC cohort, the aims 
of Chapter 4 are to explore the drivers of inequality in survival of people with head and 
neck cancer using an area-based measurement of socioeconomic status (Scottish Audit 
of Head and Neck Cancers Steering Group, 2004). This chapter explores socioeconomic 
inequality in Scotland one year, five years, and 12 years after a diagnosis of head and 
neck cancer. The objectives of this chapter are to: 
1. Explore the underlying patient, tumour and treatment factors that are associated 
with socioeconomic inequality in survival of people with head and neck cancer. 
2. Examine the differences in socioeconomic inequality in survival of people with 
head and neck cancer via overall survival, disease-specific survival, and net 
survival estimates. 
1.5.4 Chapter 5 aims and objectives 
The aim of Chapter 5 is to explore the underlying determinants of both area-based and 
individual measurements of socioeconomic status of people diagnosed with head and 
neck cancer by utilising the HN5000 cohort study (Ness et al., 2014; Ness et al., 2015). 
The objectives of this chapter are to: 
1. Explore the underlying demographic, health, behavioural, tumour, and treatment 
factors that are associated with socioeconomic inequality in survival of people with 
head and neck cancer. 
2. Compare socioeconomic inequality in both area-based and induvial measurements 
of socioeconomic status.  
1.5.5 Chapter 6 aims and objectives 
Chapter 6 begins with a summary of the collective thesis findings from the four studies 
that were conducted throughout this thesis in relation to the prior knowledge and gaps that 
were identified in the literature review. This chapter goes on to discuss the thesis 
strengths and limitations, and finally makes recommendations for policy, practice, and 
further research on socioeconomic inequalities in head and neck cancer outcomes and 
survival. Finally, the thesis will end with a conclusion section.    
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2 Trends over time in inequality in survival of 
people with head and neck cancer in 
Scotland: population-based cancer registry 
study  
2.1 Introduction  
This chapter investigates the trends over time in inequality in survival of people with head 
and neck cancer in Scotland. This study utilises data from the Scottish Cancer Registry of 
all of the head and neck cancer registrations between the years of 1986 and 2015.  
Cancer registration is the collection, maintenance, and management of data on new 
diagnoses of cancer that occur in a population (International Agency for Research on 
Cancer, 1991). The Scottish Cancer Registry is a member of the United Kingdom and 
Ireland Association of Cancer Registries (UKIACR), and has been collecting information 
on cancer incidence, mortality, and survival since 1958. The Scottish Cancer Registry 
database follows the international standards for cancer registration in order to maintain its’ 
quality and completeness of data (International Agency for Research on Cancer, 1991). 
The aim of the database is to improve cancer services by monitoring incidence, evaluating 
outcomes, and investigating the effectiveness of cancer prevention and screening 
programmes. The Scottish Cancer Registry is collected by the Information Service 
Division (ISD) of the NHS Scotland (now Public Health Scotland), with the aim to “collect, 
validate, analyse and store accurate, timely and comprehensive data on cancer” (ISD 
Scotland, 2010b). The database holds information such as personal and demographic 
data, and details on the tumour diagnosis, including the anatomical site of the tumour and 
its’ histology. In addition, the Scottish Cancer Registry holds geographical data including 
Carstairs and Morris Indices, SIMD, and data on the Scottish Cancer Network in which a 
person’s malignancy was diagnosed and treated. The database provides the opportunity 
to investigate the trends in socioeconomic inequality in survival of people with head and 
neck cancer, and to examine long-term survival after one year, five years, and 10 years of 
a diagnosis of head and neck cancer in Scotland. 
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2.1.1 Aims and objectives  
The aim of Chapter 2 is to describe the trends over time and follow-up time of the 
inequality in survival of people with head and neck cancer in Scotland by utilising the 
Scottish Cancer Registry. The objectives of this chapter are to:  
1. Determine the trends in inequality over calendar time from 1986 to 2015. 
2. Compare the patterns in inequality over follow-up time in one-year, five-year, and 
10-year survival.  
3. Examine these trends and patterns for all of the patients (and by sex), and across 
the three main subsites of head and neck cancer (oral cavity, oropharynx, and 
larynx).  
2.2 Methods  
2.2.1 Data extraction  
Data were requested and extracted from the Scottish Cancer Registry on all of the 
registrations who had had at least one head and neck malignancy diagnosed between 1st 
January 1986 and 31st December 2015.  
2.2.1.1 Measurement of Socioeconomic Status 
Socioeconomic status was obtained from the area-based Carstairs and Morris 1991 
Indices (Carstairs and Morris, 1989; McLoone, 2000). The index ranks the geographical 
areas of Scotland (from the person’s home postcode) into one of five groups using 1991 
Census data – group one represents the people who resided in the least deprived areas 
of Scotland and group five represents the people who resided in the most deprived areas 
of Scotland. The index categorises groups areas at the postcode level based on:  
(a) low social class, (b) lack of car ownership, (c) overcrowding, and (d) male 
unemployment.  
To standardise the results over time and compare trends over time, the Carstairs and 
Morris 1991 index was used in the primary analysis linked across all years of data from 
the cancer registry (as opposed to using the index with the most recent census data 
updates for different time periods and decades).  
However, two sensitivity analyses were conducted to compare various measurements of 
socioeconomic status. The first sensitivity analysis utilised the nearest Carstairs and 
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Morris Index that coincided with the date of the registrant’s diagnosis of head and neck 
cancer. Carstairs and Morris 1991 Categories were used for the people who were 
diagnosed between 1986 and 1995, Carstairs and Morris 2001 Categories (McLoone, 
2004) were used for the people who were diagnosed between 1996 and 2005, and 
Carstairs and Morris 2011 Categories (Brown et al., 2014) were used for the people who 
were diagnosed between 2006 and 2015. The second sensitivity analysis utilised the 
earliest defined SIMD category from 2004 census data (Public Health Scotland, 2020b). 
Due to the recency of SIMD in comparison to Carstairs and Morris 1991 Index, this 
sensitivity analysis only included individuals who were diagnosed from 2001 onwards (as 
it was not possible to link SIMD with more historic data). The SIMD 2004 is calculated 
using data from multiple sources in seven domains of deprivation: (a) income 
employment, (b) education, (c) housing, (d) health, (e) crime, and (f) geographical access 
(Scottish Executive, 2004). Like the Carstairs and Morris Index, SIMD is measured at the 
postcode level, however SIMD 2004 uses smaller geographical areas (“data zones”) than 
those used in the Carstairs and Morris Indices. 
2.2.1.2 Baseline characteristics 
Demographic data 
Data on sex and the age at which a person was diagnosed with cancer, along with 
information on their primary tumour (see section 2.2.5) that was recorded on the Scottish 
Cancer Registry were included.  
Tumour information 
Information was recorded on the anatomical site of the tumour which was determined 
using ICD-10 codes (World Health Organization, 2016). Data were requested on all of the 
registrations that had diagnoses of cancer(s) of the (a) lip (C00), (b) oral cavity (C02-C04, 
C05.0, C06), (c) oropharynx (C01, C05.1, C05. 2, C09, C10), (d) hypopharynx (C12, C13), 
(e) larynx (C32, C10.1), (f) major salivary glands (C07, C08), and (g) other sites of the 
head and neck (C14.0, C30.1, C41.1, C69.5). The pathology of the tumour was also 
recorded in the Scottish Cancer Registry, and for the purposes of this analysis was 
grouped as: (a) SCC, and (b) non-SCC.  
Treatment information 
The treatment modality that the people received for their cancer was only recorded on the 
Scottish Cancer Registry for those who were diagnosed from 1996 onwards. This was 
grouped as: (a) surgery only, (b) radiotherapy only, (c) surgery and radiotherapy,  
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(d) chemoradiotherapy only, (e) surgery and chemoradiotherapy, (f) chemotherapy with or 
without surgery, and (g) no treatment.  
2.2.2 Data verification  
The computer system that stores the Scottish Cancer Registry performs over 500 validity 
and feasibility checks to validate each record (ISD Scotland, 2010a). In addition, the 
quality of the data is verified by using “routine indicators, computer validation and ad hoc 
studies of data accuracy and case ascertainment” (ISD Scotland, 2010a). A study carried 
out by Brewster et al. (2002) generated a random sample of 3,500 registrations diagnosed 
between April and September 1997. Brewster confirmed that the quality of these data was 
high, with medical records available for 90.7% of registrations.  
2.2.3 Data linkage  
Scottish Cancer Registry data were linked to mortality records from the National Records 
of Scotland (NRS) which included death certification up to 31st December 2017. The 
records were linked using an established probability matching technique that was based 
on the Howard Newcombe principle (Newcombe et al., 1959). This method matches 
records to the mortality data using a unique Community Health Index (CHI) number that is 
assigned to every person who is registered with the NHS in Scotland.  
2.2.4 Information governance approvals 
The information governance and data linkage approvals for this study were obtained from 
the NHS Privacy Advisory Committee (now known as the Public Benefits and Privacy 
Panel (PBPP)) (Appendix 2.1). Amendments to the data linkage were requested in 2017, 
and this request was subsequently approved (Appendix 2.2).  
2.2.5 Eligible cases  
Scottish Cancer Registry data were provided on all of the individuals with at least one 
head and neck cancer, along with any other malignancy within or outside of the head and 
neck. All of the data provided contained people with diagnoses between 1st January 1986 
and 31st December 2015. Due to this, the following algorithm was developed and 
performed in order to identify a single record containing a person’s primary tumour: 
1. If a person had records containing a non-malignant tumour or duplicate skin 
cancer records, the records were removed. 
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2. If a person had duplicate records with the same ICD code and the same date of 
incidence, the duplicate records were removed, and a single entry was kept.  
3. If a person had both a head and neck tumour and a non-head and neck tumour 
diagnosed on the same date, the record containing the non-head and neck tumour 
was removed. 
4. If a person had multiple head and neck tumours diagnosed on the same date, the 
record containing the main subsite of the head and neck was kept (i.e., oral cavity 
over larynx, larynx over oropharynx, oropharynx over hypopharynx etc.). 
5. Following the above, the primary tumour of a person was identified from the 
earliest diagnosed tumour, and all of the future entries were removed.  
Following the removal of non-primary tumours, registrations were subsequently deleted if: 
1. Their primary tumour was found to not be a head and neck malignancy. 
2. They were younger than 18 years of age. 
3. They were missing Carstairs 1991 Category.   
2.2.6 Statistical analyses  
Frequency tables for each of the demographic data, tumour, and treatment information 
and socioeconomic status were produced along with the proportion of deaths that had 
occurred by 31st December 2017 for the whole cohort. In addition, frequency tables that 
displayed the cross-tabulation of socioeconomic status with the demographic data, and 
tumour, and treatment information were generated for the whole cohort and the 
proportions across each of the groups were compared using the Pearson’s chi-square 
test.  
One-year, five-year, and 10-year net survival with 95% CIs were calculated using the 
Pohar-Perme method (Pohar Perme et al., 2012; Pohar Perme et al., 2016) by using 
lifetables that were standardised by calendar year, age, sex, and Carstairs 1991 
Category. These lifetables were provided by the Cancer Survival Group at the LSHTM 
(Cancer Survival Group, 2019), and covered the period of 1991 to 2010. Therefore, the 
lifetables were extended back to 1986 using the data from 1991, and up to 2015 using the 
data from 2010. All of the net survival results were computed using the stns command in 
Stata, Version 16 (StataCorp., 2019). All of the survival estimates were generated for the 
whole cohort, for males and females, and for the three main anatomical sites of the head 
and neck (oral cavity, oropharynx, and larynx) separately. 
Overall survival and disease-specific survival were calculated using the Kaplan-Meier 
method with 95% confidence intervals (CIs). Disease-specific survival estimates were 
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generated by specifying the event indicator as those who had “died from head and neck 
cancer” which was extracted from the primary cause of death information on the person’s 
death certificate. Cause of death information for disease-specific survival was extracted 
from the data recorded on the person’s death certificate which was obtained from their 
NRS mortality data linkage. One-year, five-year, and 10-year overall survival and disease-
specific survival estimates were investigated for their relationship with inequality over time 
for all of the time periods. These results were produced in SAS Software, version 9.4.  
The SII and RII were calculated with 95% CIs for each of the survival estimates and Cox 
proportional hazards models. The SII is based on the linear regression of the mid-point of 
survival or mortality for each Carstairs 1991 Category (Regidor, 2004), while the RII can 
be estimated by dividing the SII by the population rate (Pamuk, 1985). These results were 
produced using SAS Software, version 9.4. 
2.3 Results  
2.3.1 Eligible cases  
A total of 43,579 registrations were included in the original database provided by the 
electronic Data Research and Innovation Service (eDRIS) at ISD, Scotland for diagnoses 
between the 1st January 1986 and 31st December 2015 (Figure 2.1). Following the defined 
algorithm in Section 2.2.5, 4,302 (9.4%) of the records were removed due to having 
tumours that were not malignant or duplicate skin cancer records. A total of 125 (0.3%) of 
the records were duplicate records and were removed, and 1,046 (0.9%) of the records 
were removed since these people had tumours both inside and outside of the head and 
neck, or multiple tumours within the head and neck diagnosed on the same day – the 
record containing the main site of the head and neck cancer was kept. A total of 9,290 
(24.2%) records were removed since these records were for people who had a tumour 
that was diagnosed at an earlier date. From the remaining registrations, those who did not 
have a head and neck cancer as their primary tumour (n = 3,974/8.6%) were removed. 
Records for people who had cancer of the thyroid or cancer of unknown primary (n = 
29/0.1%) were removed. Those who were younger than 18 years old (n = 57/0.1%), and 
people who were missing a Carstairs 1991 Category (n = 4) were also removed. The final 
database had a total of 24,778 individuals recorded with a primary head and neck cancer 
during the study period on the Scottish Cancer Registry. These results were compared 
with other publications of incident head and neck cancers and were found to be similar 
(Shack et al., 2007; Purkayastha et al., 2016). 
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Figure 2.1 – Flow chart of eligible cases included in the Scottish Cancer Registry study 
 
2.3.2 Baseline characteristics 
2.3.2.1 Whole cohort 
The numbers and proportions of the baseline characteristics are displayed in Table 2.1 on 
Page 63 for all of the people included in this study, along with the proportion of deaths that 
had occurred by 31st December 2017. The median age of the whole cohort was 63 years 
with an interquartile range of 55 to 72 years. There was a ratio of 2.4:1 of males to 
females, and people were more likely to have either a tumour of the oral cavity (n = 8,189; 
33.0%) or a tumour of the larynx (n = 7,706; 31.1%). A total of 21,403 (86.4%) individuals 
had tumours that were SCC. For those who had their treatment recorded from 1996, 
surgery only (n = 4,384; 26.5%) was the most common treatment modality used, while 
1,828 (11.1%) people received no treatment for their cancer. Over time, there was a rise 
in the number of individuals who had a primary diagnosis of head and neck cancer, which 
increased from 3,257 (13.1%) in 1986-1990 to 4,865 (19.6%) in 2011-2015. The highest 
proportion of the cohort were diagnosed in the West of Scotland Cancer Network (n = 
12,850; 51.9%). There was a trend in the proportion of people across the Carstairs 1991 
Categories with 3,623 (14.6%) individuals from the least deprived areas, and 6,594 
(26.6%) individuals from the most deprived areas.  
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2.3.2.2 Comparison between males and females 
The numbers and proportions of the baseline characteristics for males and females are 
displayed in Appendix 2.3 and Appendix 2.4, respectively, along with the proportion of 
deaths for males and females that had occurred by 31st December 2017. The median age 
of the male population was 63 years (IQR = 55 to 71), while females were slightly older 
with a median age of 66 years (IQR = 56 to 75). Males were more likely to have tumours 
of the larynx (n = 6,133/35.0%), while females were more likely to have tumours of the 
oral cavity (n = 3,027/41.6%). A total of 15,448 (88.2%) males had tumours that were 
SCC, while females had a slightly lower proportion of SCC tumours (n = 5,955/81.9%). Of 
the people who had their treatment recorded from 1996, males were less likely than 
females to have been treated by surgery only (males = 2,823/24.1%, and females = 
1,561/32.3%). From 1986, there was a rise in the number of both males and females who 
had a primary head and neck cancer from 2,280 (13.0%) in 1986-1990 to 3,445 (19.0%) in 
2011-2015 for males, and from 977 (13.2%) in 1886-1990 to 1,420 (19.5%) in 2011-2015 
for females. The highest proportion of both males and females were from the West of 
Scotland Cancer Network (males = 9,095/51.9%, females = 3,755/51.7%). There was a 
trend in the proportion of males across the Carstairs 1991 Categories with 2,506 (14.3%) 
males from the least deprived region, and 4,770 (27.2%) males from the most deprived 
region. There was also a trend in the proportions of females across the Carstairs 1991 
Categories, however compared to males, there was a slightly lower proportion of females 
in the most deprived region (n = 1,824/25.1%). 
2.3.2.3 Comparison between those with cancer of the oral cavity, oropharynx, and 
larynx 
The numbers and proportions of the baseline characteristics for people with cancer of the 
oral cavity, oropharynx, and larynx are displayed in Appendix 2.5 to Appendix 2.7, 
respectively, along with the proportion of deaths that had occurred by 31st December 
2017. The median age of those with cancer of the oral cavity, oropharynx, and larynx was 
63 years (IQR = 55 to 72), 59 years (IQR = 52 to 67), and 65 years (IQR = 57 to 72), 
respectively. People with cancer of the larynx were substantially more likely to be male 
with a ratio of 3.9:1 of males to females, which was much higher compared with people 
who were diagnosed with cancers of the oral cavity or oropharynx at 1.7:1 and 2.6:1 of 
males to females, respectively. Of those who had their treatment recorded from 1996 
onwards, people with cancer of the oral cavity were more likely to have been treated with 
surgery only (n = 2,327/41.1%), while people with cancer of the larynx were more likely to 
have been treated with radiotherapy only (n = 1,914/40.0%). Those who had cancer of the 
oropharynx were more likely to have been treated with chemoradiotherapy (n = 
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694/26.1%). Over time, there was a rise in the number of individuals who had a head and 
neck cancer, which for those with oral cavity and larynx cancer was from 954 (11.6%) and 
1,131 (14.7%) in 1986-1990, to 1,682 (20.5%) and 1,215 (15.8%) in 2011-2015, 
respectively. The most prominent difference over time was for individuals with cancer of 
the oropharynx which increased from 272 (8.0%) in 1896-1990 to 1,015 (30.0%) in 2011-
2015. People with cancer of the larynx were slightly more likely to have resided in the 
West of Scotland (n = 4,2274/54.9%) compared to people with cancer of the oral cavity (n 
= 4,208/51.4%), and oropharynx (n = 1,686/49.9%). People with cancer of the oral cavity 
or oropharynx had similar trends across the Carstairs 1991 Categories which increased 
from 1,278 (15.6%) and 511 (15.1%) in the least deprived category to 2,102 (25.7%) and 
873 (25.8%) in the most deprived category, respectively. The most prominent difference 
across the Carstairs 1991 Categories was for individuals with cancer of the larynx which 
increased from 938 (12.2%) individuals residing in the least deprived category to 2,311 
(30.0%) individuals residing the most deprived category.  
2.3.3 Death rates by December 2017  
2.3.3.1 Whole cohort 
A total of 18,322 (73.9%) deaths had occurred by 31st December 2017 when the Scottish 
Cancer Registry was linked to the mortality data from the NRS (Table 2.1, Page 63). 
People were more likely to die if they were older, had tumours of the hypopharynx, or 
were treated with chemotherapy with or without surgery. They were also more likely to die 
if they resided in the West of Scotland Cancer Network or were from the most deprived 
regions (79.4% versus 66.5%). There was a slightly higher proportion of deaths of males 
(n = 13,040; 74.5%) than females (n = 5,282; 72.5%), and a slightly higher proportion of 
death for those with cancer of SCC (n = 16,043; 75.0%) compared to those with non-SCC 
tumours (n = 2,279; 67.5%).  
2.3.3.2 Comparison between males and females 
For males and females, a total of 13,040 (74.5%) and 5,282 (72.7%) deaths, respectively, 
had occurred by 31st December 2017 when the Scottish Cancer Registry was linked to the 
mortality data from the NRS (Appendix 2.3 and Appendix 2.4). Males had a higher 
proportion of deaths compared to females if they were younger, had tumours of the 
salivary gland, or tumours that were non-SCC. There were no differences between the 
proportion of deaths for males and females by age, year of diagnosis, Scottish Cancer 
Network, or Carstairs 1991 Category.  
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2.3.3.3 Comparison between those with cancer of the oral cavity, oropharynx, and 
larynx 
For people who were diagnosed with tumours of the oral cavity, oropharynx, and larynx a 
total of 6,028 (73.6%), 2,204 (65.2%), and 5,854 (76.0%) deaths had occurred by 31st 
December 2017 when the Scottish Cancer Registry was linked to the mortality data from 
the NRS (Appendix 2.5 to Appendix 2.7). Females with tumours of the larynx had a higher 
proportion of deaths at 77.7% (n = 1,222) compared with females who had tumours of the 
oral cavity at 72.0% (n = 2,179). In addition, the proportion of deaths for those residing in 
the least deprived Carstairs 1991 Category was higher for people with cancer of the larynx 
at 79.5% (n = 1,838) compared to those with cancer of the oral cavity at 65.7% (n = 840), 
respectively. Individuals who had cancer of the oropharynx consistently had a lower 
proportion of deaths compared to people with cancer of the oral cavity or larynx. 
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Table 2.1 – Baseline characteristics and proportion of deaths for the whole cohort 
Variable Frequency 
(Column %) 
Died by 30th September 
2017 (Row %) 
Total 24,778 (100.0%) 18,322 (73.9%) 
Age at incidence   
   Less than 45 1,382 (5.6%) 541 (39.1%) 
   45 to 54 4,238 (17.1%) 2,553 (60.2%) 
   55 to 64 7,601 (30.7%) 5,418 (71.3%) 
   65 to 74 6,988 (28.2%) 5,663 (81.0%) 
   75 and over 4,569 (18.4%) 4,147 (90.8%) 
Sex   
   Male 17,508 (70.7%) 13,040 (74.5%) 
   Female 7,270 (29.3%) 5,282 (72.7%) 
ICD group   
   Oral cavity 8,189 (33.0%) 6,028 (73.6%) 
   Larynx 7,706 (31.1%) 5,854 (76.0%) 
   Oropharynx 3,379 (13.6%) 2,204 (65.2%) 
   Hypopharynx 1,586 (6.4%) 1,447 (91.2%) 
   Lip 1,379 (5.6%) 948 (68.7%) 
   Salivary gland 1,175 (4.7%) 720 (61.3%) 
   Other 1,364 (5.5%) 1,121 (82.2%) 
Pathology   
   SCC 21,403 (86.4%) 16,043 (75.0%) 
   Non-SCC 3,375 (13.6%) 2,279 (67.5%) 
Treatment   
   Surgery only 4,384 (17.7%) 2,278 (52.0%) 
   Radiotherapy only 3,096 (12.5%) 2,161 (69.8%) 
   Surgery and radiotherapy 2,762 (11.1%) 1,917 (69.4%) 
   Chemoradiotherapy 2,412 (9.7%) 1,430 (59.3%) 
   Surgery and chemoradiotherapy 1,502 (6.1%) 832 (55.4%) 
   Chemotherapy +/- surgery 552 (2.2%) 439 (79.5%) 
   No treatment 1,828 (7.4%) 1,727 (94.5%) 
   Unknown 8,242 (33.3%) 7,538 (91.5%) 
Year group   
   1986-1990 3,257 (13.1%) 3,033 (93.1%) 
   1991-1995 3,760 (15.2%) 3,446 (91.6%) 
   1996-2000 4,151 (16.8%) 3,551 (85.5%) 
   2001-2005 4,226 (17.1%) 3,212 (76.0%) 
   2006-2010 4,519 (18.2%) 2,875 (63.6%) 
   2011-2015 4,865 (19.6%) 2,205 (45.3%) 
Network of residence   
   West of Scotland (WoSCAN) 12,850 (51.9%) 9,834 (76.5%) 
   East of Scotland (SCAN) 6,154 (24.8%) 4,362 (70.9%) 
   North of Scotland (NOSCAN) 5,774 (23.3%) 4,126 (71.5%) 
Carstairs 1991 Category   
   1 – Least deprived 3,623 (14.6%) 2,408 (66.5%) 
   2 4,487 (18.1%) 3,180 (70.9%) 
   3 4,818 (19.4%) 3,550 (73.7%) 
   4 5,256 (21.2%) 3,950 (75.2%) 
   5 – Most deprived 6,594 (26.6%) 5,234 (79.4%) 
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2.3.4 Cross-tabulations of Carstairs 1991 Category by each baseline 
characteristic  
2.3.4.1 Whole cohort 
The cross-tabulations of each IMD Category with the baseline characteristics are 
displayed in Table 2.2. Compared to people who resided in the least deprived areas, 
those who resided in the most deprived regions were more likely to be younger, be males, 
and have cancer of the larynx that was SCC. From 1996 onwards, those who were in the 
most deprived category were also more likely to be treated with chemoradiotherapy or 
receive no treatment at all. Those who resided in the most deprived regions were also 
more likely to reside in the West of Scotland.  
2.3.4.2 Comparison between males and females 
The cross-tabulations of each IMD Category with the baseline characteristics are 
displayed in Appendix 2.8 and Appendix 2.9. The trends by the Carstairs 1991 Categories 
for both males and females coincided with the trends observed for the whole cohort. 
Males and females who resided in the most deprived areas were more likely to be 
between the ages of 45 and 64 and have cancer of the larynx that was SCC. From 1996 
onwards, both males and females who were in the most deprived categories were less 
likely to be treated with surgery only and were more likely to receive no treatment.  
2.3.4.3 Comparison between those with cancer of the oral cavity, oropharynx, and 
larynx 
The cross-tabulations of each IMD Category with the baseline characteristics are 
displayed in Appendix 2.10 and Appendix 2.12. People who resided in the most deprived 
regions were more likely to be between the ages of 45 and 54 if they had cancer of the 
oral cavity, between the ages of 45 and 64 if they had cancer of the oropharynx and be 
younger than 64 years of age if they had cancer of the larynx. The people who lived in the 
most deprived region and who had cancer of the oral cavity were more likely to be male, 
while those with cancer of the larynx were more likely to be female.  
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Table 2.2 – Cross-tabulation of Carstairs 1991 Category with baseline characteristics for the whole cohort 
Variable 
Carstairs 1991 Category (row %)  
1 – Least 
deprived 2 3 4 




Age at incidence      <0.001 
   Less than 45 232 (6.4%) 258 (5.7%) 265 (5.5%) 285 (5.4%) 342 (5.2%)  
   45 to 54 565 (15.6%) 705 (15.7%) 793 (16.5%) 896 (17.0%) 1,279 (19.4%)  
   55 to 64 977 (27.0%) 1,318 (29.4%) 1,480 (30.7%) 1,693 (32.2%) 2,133 (32.3%)  
   65 to 74 1,021 (28.2%) 1,278 (28.5%) 1,335 (27.7%) 1,496 (28.5%) 1,858 (28.2%)  
   75 and over 828 (22.9%) 928 (20.7%) 945 (19.6%) 886 (16.9%) 982 (14.9%)  
Sex      0.002 
   Male 2,506 (69.2%) 3,109 (69.3%) 3,403 (70.6%) 3,720 (70.8%) 4,770 (72.3%)  
   Female 1,117 (30.8%) 1,378 (30.7%) 1,415 (29.4%) 1,536 (29.2%) 1,824 (27.7%)  
ICD group      <0.001 
   Oral cavity 1,278 (35.3%) 1,520 (33.9%) 1,575 (32.7%) 1,714 (32.6%) 2,102 (31.9%)  
   Larynx 938 (25.9%) 1,245 (27.7%) 1,513 (31.4%) 1,699 (32.3%) 2,311 (35.0%)  
   Oropharynx 511 (14.1%) 647 (14.4%) 645 (13.4%) 703 (13.4%) 873 (13.2%)  
   Hypopharynx 200 (5.5%) 274 (6.1%) 274 (5.7%) 379 (7.2%) 459 (7.0%)  
   Lip 258 (7.1%) 324 (7.2%) 323 (6.7%) 262 (5.0%) 212 (3.2%)  
   Salivary gland 264 (7.3%) 246 (5.5%) 241 (5.0%) 209 (4.0%) 215 (3.3%)  
   Other 174 (4.8%) 231 (5.1%) 247 (5.1%) 290 (5.5%) 422 (6.4%)  
Pathology      <0.001 
   SCC 2,987 (82.4%) 3,826 (85.3%) 4,135 (85.8%) 4,619 (87.9%) 5,836 (88.5%)  
   Non-SCC 636 (17.6%) 661 (14.7%) 683 (14.2%) 637 (12.1%) 758 (11.5%)  
Treatment      <0.001 
   Surgery only 732 (20.2%) 873 (19.5%) 906 (18.8%) 914 (17.4%) 959 (14.5%)  
   Radiotherapy only 467 (12.9%) 512 (11.4%) 605 (12.6%) 672 (12.8%) 840 (12.7%)  
   Surgery and radiotherapy 441 (12.2%) 567 (12.6%) 554 (11.5%) 537 (10.2%) 663 (10.1%)  
   Chemoradiotherapy 295 (8.1%) 433 (9.7%) 455 (9.4%) 552 (10.5%) 677 (10.3%)  
   Surgery and chemoradiotherapy 262 (7.2%) 310 (6.9%) 290 (6.0%) 305 (5.8%) 335 (5.1%)  
   Chemotherapy +/- surgery 66 (1.8%) 78 (1.7%) 119 (2.5%) 114 (2.2%) 175 (2.7%)  
   No treatment 233 (6.4%) 288 (6.4%) 349 (7.2%) 380 (7.2%) 578 (8.8%)  
   Unknown 1,127 (31.1%) 1,426 (31.8%) 1,540 (32.0%) 1,782 (33.9%) 2,367 (35.9%)  
Network      <0.001 
   West of Scotland (WoSCAN) 1,222 (33.7%) 1,394 (31.1%) 1,930 (40.1%) 2,737 (52.1%) 5,567 (84.4%)  
   East of Scotland (SCAN) 1,008 (27.8%) 1,489 (33.2%) 1,531 (31.8%) 1,686 (32.1%) 440 (6.7%)  
   North of Scotland (NOSCAN) 1,393 (38.4%) 1,604 (35.7%) 1,357 (28.2%) 833 (15.8%) 587 (8.9%)  
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2.3.5 Follow-up time 
The median follow-up time for each of the whole cohort, males and females, and those 
with cancers of the oral cavity, oropharynx, and larynx are outlined below.  
Whole cohort: The median follow-up time was 8.4 years (IQR = 4.8 to 14.3 years) and 
2.0 years (IQR = 0.7 to 6.1 years) for those who were alive and for those who had died by 
the end of the follow-up period, respectively.  
Males: The median follow-up time was 8.3 years (IQR = 4.7 to 14.1 years) and 2.0 years 
(IQR = 0.7 to 6.0 years) for those who were alive and for those who had died by the end 
of the follow-up period, respectively.  
Females: The median follow-up time was 8.6 years (IQR = 5.0 to 14.8 years) and 1.9 
years (IQR = 0.6 to 6.4 years) for those who were alive and for those who had died by the 
end of the follow-up period, respectively.  
Oral cavity: The median follow-up time was 8.1 years (IQR = 4.6 to 13.3 years) and 1.8 
years (IQR = 0.6 to 5.4 years) for those who were alive and for those who had died by the 
end of the follow-up period, respectively.  
Larynx: The median follow-up time was 9.4 years (IQR = 5.3 to 15.3 years) and 3.1 years 
(IQR = 1.0 to 8.0 years) for those who were alive and for those who had died by the end 
of the follow-up period, respectively.  
Oropharynx: The median follow-up time was 6.6 years (IQR = 4.0 to 10.8 years) and 1.5 
years (IQR = 0.6 to 4.6 years) for those who were alive and for those who had died by the 
end of the follow-up period, respectively.  
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2.3.6 Survival results 
Net survival after one year, five years, and 10 years for each demographic are displayed 
in Table 2.3. Net survival after one year, five years, and 10 years was 77.8% (95% CI 
77.2% to 78.3%), 54.4% (95% CI 53.7% to 55.2%), and 43.9% (95% CI 42.8% to 45.0%), 
respectively. Similar trends and differences were observed for overall survival (Appendix 
2.13) and disease-specific survival (Appendix 2.14); however, the overall survival results 
were lower, with one-year, five-year, and 10-year overall survival at 75.1% (95% CI 74.6% 
to 75.7%), 47.0% (95% CI 46.4% to 47.6%), and 32.1% (95% CI 31.4% to 32.7%), 
respectively, while the disease-specific results were higher with one-year, five-year, and 
10-year disease-specific survival at 80.2% (95% CI 79.7% to 80.7%), 61.8% (95% CI 
61.1% to 62.4%), and 56.0% (55.3% to 56.7%), respectively. 
Net survival was the same between males and females, which after 10 years was 43.5% 
(95% CI 42.2% to 44.8%) and 44.7% (95% CI 42.6% to 46.7%), respectively. People with 
cancer of the lip had the highest net survival, which after 10 years was 82.6% (95 CI 
74.1% to 91.1%), while people with cancer of the hypopharynx had the lowest net 
survival, which after 10 years was 15.0% (95% CI 12.7% to 17.3%). Those who were 
treated with surgery only had the highest net survival, which after 10 years was 67.9% 
(95% CI 64.0% to 71.8%), while those who received chemotherapy with or without surgery 
had the lowest net survival, which after 10 years was 24.8% (95% CI 20.4% to 29.1%). 
The individuals who resided within the West of Scotland Cancer Network had the lowest 
net survival at all three time points, which after 10 years was 40.3% (95% CI 38.8% to 
41.8%). Over time, one-year net survival did not improve from the period of 1986-1990 at 
78.5% (95% CI 77.0% to 80.0%) to 2011-2015 at 78.8% (95% CI 77.6% to 80.0%). There 
was a slight improvement in five-year net survival which increased from 53.5% (95% CI 
51.3% to 55.7%) in 1986-1990 to 57.6% (95% CI 55.8% to 59.4%) in 2011-2015. 
However, there was also no improvement in 10-year net survival from the period of 1986-
1991 at 43.5% (95% CI 40.7% to 46.2%) to 2006-2010 at 44.6% (95% CI 42.1% to 
47.1%).  
There was a trend in net survival across the Carstairs 1991 Categories at all three time 
points. After 10 years, the people who were from the most deprived regions had a much 
lower net survival compared to the people who were from the least deprived areas at 
36.9% (95% CI 35.1% to 38.8%) and 48.8% (95% CI 45.9% to 51.7%), respectively.  
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Table 2.3 – Net survival by each baseline characteristic 
Variable 
One-year net 
survival (95% CI) 
Five-year net 
survival (95% CI) 
10-year net 
survival (95% CI) 
Total 77.8 (77.2, 78.3) 54.4 (53.7, 55.2) 43.9 (42.8, 45.0) 
Age at incidence    
   Less than 45 89.8 (88.2, 91.4) 73.8 (71.4, 76.2) 67.6 (64.9, 70.3) 
   45 to 54 84.6 (83.5, 85.7) 61.8 (60.3, 63.4) 51.9 (50.2, 53.7) 
   55 to 64 81.0 (80.1, 81.9) 55.5 (54.3, 56.8) 43.5 (42.1, 45.0) 
   65 to 74 75.7 (74.6, 76.8) 51.4 (49.9, 52.8) 39.2 (37.4, 41.0) 
   75 and over 65.3 (63.7, 66.9) 44.3 (42.0, 46.6) 36.6 (32.3, 40.9) 
Sex    
   Male 78.4 (77.7, 79.0) 53.9 (53.0, 54.8) 43.5 (42.2, 44.8) 
   Female 76.3 (75.2, 77.3) 55.6 (54.2, 57.0) 44.7 (42.6, 46.7) 
ICD group    
   Oral cavity 75.7 (74.7, 76.7) 51.5 (50.2, 52.8) 41.0 (39.2, 42.9) 
   Larynx 84.0 (83.1, 84.9) 61.5 (60.1, 62.8) 48.1 (46.2, 50.0) 
   Oropharynx 75.6 (74.1, 77.1) 52.0 (50.1, 53.9) 40.6 (38.2, 43.0) 
   Hypopharynx 55.1 (52.5, 57.6) 22.2 (19.9, 24.5) 15.0 (12.7, 17.3) 
   Lip 97.9 (96.4, 99.3) 89.6 (85.8, 93.4) 82.6 (74.1, 91.1) 
   Salivary gland 84.8 (82.5, 87.1) 62.8 (59.3, 66.2) 58.3 (53.5, 63.1) 
   Other 59.8 (57.1, 62.5) 31.9 (29.1, 34.6) 23.6 (20.6, 26.5) 
Treatment    
   Surgery only 91.5 (90.6, 92.5) 77.1 (75.3, 79.0) 67.9 (64.0, 71.8) 
   Radiotherapy only 81.6 (80.2, 83.1) 57.5 (55.3, 59.7) 44.2 (41.0, 47.3) 
   Surgery and radiotherapy 86.9 (85.5, 88.2) 57.6 (55.4, 59.8) 43.4 (40.6, 46.1) 
   Chemoradiotherapy 82.9 (81.3, 84.4) 53.3 (51.0, 55.6) 39.8 (36.9, 42.8) 
   Surgery and chemoradiotherapy 88.3 (86.6, 90.0) 57.5 (54.8, 60.3) 46.6 (43.2, 50.0) 
   Chemotherapy +/- surgery 57.8 (53.6, 62.0) 33.2 (28.9, 37.4) 24.8 (20.4, 29.1) 
   No treatment 18.6 (16.7, 20.4) 9.8 (8.2, 11.4) 7.6 (5.8, 9.4) 
   Unknown 76.6 (75.6, 77.6) 50.9 (49.6, 52.3) 40.8 (39.1, 42.5) 
Network of residence    
   West of Scotland (WoSCAN) 76.0 (75.2, 76.8) 51.8 (50.7, 52.8) 40.3 (38.8, 41.8) 
   East of Scotland (SCAN) 80.2 (79.1, 81.3) 58.7 (57.2, 60.3) 49.1 (46.7, 51.5) 
   North of Scotland (NOSCAN) 79.0 (77.9, 80.2) 55.7 (54.1, 57.2) 46.2 (44.0, 48.4) 
Year group    
   1986-1990 78.5 (77.0, 80.0) 53.5 (51.3, 55.7) 43.5 (40.7, 46.2) 
   1991-1995 75.6 (74.2, 77.1) 49.6 (47.6, 51.6) 39.8 (37.2, 42.3) 
   1996-2000 77.2 (75.8, 78.5) 54.4 (52.5, 56.2) 43.0 (40.3, 45.6) 
   2001-2005 78.2 (76.9, 79.5) 54.4 (52.6, 56.2) 44.8 (42.7, 46.9) 
   2006-2010 77.9 (76.7, 79.2) 55.9 (54.2, 57.6) 44.6 (42.1, 47.1) 
   2011-2015 78.8 (77.6, 80.0) 57.6 (55.8, 59.4) N/A 
Carstairs Category    
   1 – Least deprived 81.0 (79.7, 82.4) 60.2 (58.2, 62.2) 48.8 (45.9, 51.7) 
   2 79.6 (78.3, 80.8) 57.0 (55.2, 58.8) 48.1 (45.2, 51.0) 
   3 80.1 (78.9, 81.3) 55.9 (54.1, 57.6) 44.5 (41.8, 47.2) 
   4 76.5 (75.3, 77.7) 54.3 (52.7, 55.9) 44.9 (42.7, 47.1) 
   5 – Most deprived 74.0 (72.9, 75.1) 48.5 (47.0, 50.0) 36.9 (35.1, 38.8) 
SII (95% CI) 9.1 (3.7, 14.6) 13.7 (7.1, 20.2) 14.7 (3.8, 25.6) 
RII (95% CI) 0.12 (0.05, 0.19) 0.25 (0.13, 0.37) 0.34 (0.09, 0.58) 
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2.3.7 Trends over time in survival by Carstairs 1991 Category 
2.3.7.1 Whole cohort 
The trends over time in net survival by Carstairs 1991 Category for the whole cohort are 
displayed in Table 2.4. There was inequality in net survival for all of the people who were 
diagnosed with head and neck cancer between the years of 1986-1990 and 2011-2015 
after one year, five years, and 10 years. However, the inequality was stronger in more 
recent years, which was particularly noticeable after five years of follow-up. After five 
years, the people who were diagnosed in 1986-1990 and who were in the least deprived 
and most deprived groups had net survival estimates of 54.0% (95% CI 48.3% to 59.6%) 
and 49.2% (95% CI 45.2% to 53.3%), respectively. However, as the people in group three 
had the highest net survival estimate of 55.8% (95% CI 50.8% to 60.8%), the SII and RII 
did not display inequality at 6.6 (95% CI -6.0 to 19.3) and 0.12 (95% CI -0.11 to 0.36), 
respectively. However, inequality in five-year survival was much clearer for those who 
were diagnosed between the years of 2011-2015, and net survival for those who were in 
the least deprived and most deprived groups were 66.9% (95% CI 62.6% to 71.2%) and 
51.8% (95% CI 48.1% to 55.5%), respectively, with an SII and RII of 19.2 (95% CI 16.1 to 
22.3) and 0.32 (95% CI 0.27 to 0.37), respectively.  
By 10 years of follow-up, for the people who were in the least deprived and most deprived 
groups and who were diagnosed in 1986-1990, net survival estimates were 47.5% (95% 
CI 40.4% to 54.7%) and 39.0% (95% CI 34.2% to 43.9%), respectively, with an SII and RII 
of 8.4 (95% CI -4.2 to 20.9) and 0.19 (95% CI -0.10 to 0.48), respectively. These results 
were stronger than the SII and RII results after one year and five years of follow-up. 
Results for those who were diagnosed in 2011-2015 were similar but the inequality was 
substantially worse by five years than it was after one year of follow-up. After one year, 
the individuals in the least deprived and most deprived groups had net survival estimates 
of 82.8% (95% CI 80.0% to 85.6%) and 73.5% (95% CI 70.9% to 76.2%), respectively, 
with an SII and RII of 7.1 (95% CI 2.5 to 11.7) and 0.09 (95% CI 0.03 to 0.15), 
respectively. However, after five years for follow-up, the people who were diagnosed 
between the years of 2011-2015 and who were in the least deprived and most deprived 
groups had net survival estimates of 66.9% (95% CI 62.6% to 71.2%) and 51.8% (95% CI 
48.1% to 55.5%), respectively, with an SII and RII of 19.2 (95% CI 16.1 to 22.3) and 0.32 
(95% CI 0.27 to 0.37), respectively. The same trends were also observed for the results 
from overall survival (Appendix 2.15) and disease-specific survival (Appendix 2.21). 
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Table 2.4 – Net survival by Carstairs 1991 Category per year group of diagnosis for the whole cohort 
  Year group of diagnosis  
Carstairs 1991 Category 1986-1990 1991-1995 1996-2000 2001-2005 2006-2010 2011-2015 
One-year net  
survival (95% CI) 
      
   1 – Least deprived 81.0 (77.1, 84.9) 77.2 (73.3, 81.2) 82.4 (79.1, 85.6) 82.8 (79.6, 86.0) 79.3 (76.0, 82.6) 82.8 (80.0, 85.6) 
   2 79.1 (75.5, 82.8) 77.9 (74.5, 81.3) 81.3 (78.2, 84.5) 77.8 (74.7, 80.8) 78.4 (75.5, 81.4) 82.3 (79.7, 84.8) 
   3 81.3 (78.0, 84.8) 79.5 (76.3, 82.7) 80.0 (77.1, 83.0) 80.2 (77.3, 83.2) 80.2 (77.5, 83.0) 79.7 (77.0, 82.4) 
   4 75.2 (71.7, 78.6) 74.8 (71.6, 78.0) 73.0 (70.8, 77.0) 78.2 (75.3, 81.0) 78.6 (75.9, 81.3) 77.8 (75.0, 80.5) 
   5 – Most deprived 77.4 (74.4, 80.3) 71.6 (68.6, 74.5) 72.4 (69.6, 75.2) 74.8 (72.1, 77.6) 74.8 (72.2, 77.4) 73.5 (70.9, 76.2) 
SII (95% CI) 5.3 (-5.8, 16.4) 8.8 (-1.8, 19.4) 14.4 (5.3, 23.5) 7.7 (-1.6, 17.1) 5.3 (-3.3, 13.9) 7.1 (2.5, 11.7) 
RII (95% CI) 0.07 (-0.07, 0.21) 0.12 (-0.02, 0.26) 0.19 (0.07, 0.30) 0.10 (-0.02, 0.22) 0.07 (-0.04, 0.18) 0.09 (0.03, 0.15) 
Five-year net  
survival (95% CI) 
      
   1 – Least deprived 54.0 (48.3, 59.6) 54.7 (49.0, 60.4) 59.6 (54.8, 64.4) 62.0 (57.6, 66.5) 61.0 (56.7, 65.3) 66.9 (62.6, 71.2) 
   2 54.8 (49.4, 60.1) 51.0 (46.3, 55.8) 60.0 (55.5, 64.6) 54.2 (50.1, 58.2) 58.1 (54.0, 62.1) 62.8 (58.8, 66.7) 
   3 55.8 (50.8, 60.8) 52.1 (47.5, 56.7) 57.0 (52.8, 61.3) 56.2 (52.0, 60.4) 56.8 (53.0, 60.6) 57.1 (53.0, 61.1) 
   4 55.3 (50.6, 60.1) 51.4 (47.2, 55.6) 53.5 (49.5, 57.4) 54.6 (50.8, 58.4) 57.3 (53.7, 61.0) 52.6 (48.5, 56.7) 
   5 – Most deprived 49.2 (45.2, 53.3) 43.2 (39.4, 46.9) 46.9 (43.4, 50.4) 49.5 (45.9, 53.0) 50.2 (46.9, 53.5) 51.8 (48.1, 55.5) 
SII (95% CI) 6.6 (-6.0, 19.3) 12.7 (-0.8, 26.3) 17.5 (8.8, 26.3) 11.9 (-0.9, 24.7) 11.8 (1.5, 22.1) 19.2 (16.1, 22.3) 
RII (95% CI) 0.12 (-0.11, 0.36) 0.26 (-0.02, 0.53) 0.32 (0.16, 0.48) 0.22 (-0.02, 0.45) 0.21 (0.03, 0.39) 0.32 (0.27, 0.37) 
10-year net  
survival (95% CI) 
      
   1 – Least deprived 47.5 (40.4, 54.7) 41.2 (32.3, 50.1) 46.9 (40.9, 53.0) 51.6 (46.5, 56.7) 48.2 (41.7, 54.7) N/A 
   2 43.1 (36.7, 49.4) 45.3 (39.1, 51.4) 49.5 (40.5, 58.5) 47.0 (41.9, 52.1) 49.1 (43.7, 54.4) N/A 
   3 45.1 (38.5, 51.7) 38.7 (33.3, 44.0) 45.6 (39.5, 51.7) 48.4 (43.0, 53.8) 43.6 (36.5, 50.7) N/A 
   4 45.4 (39.2, 51.6) 42.7 (37.2, 48.2) 44.7 (39.6, 49.8) 44.9 (40.5, 49.3) 49.4 (44.5, 54.3) N/A 
   5 – Most deprived 39.0 (34.2, 43.9) 33.7 (29.4, 37.9) 33.9 (29.7, 38.1) 37.9 (33.9, 42.0) 38.9 (34.9, 43.0) N/A 
SII (95% CI) 8.4 (-4.2, 20.9) 11.1 (-7.9, 30.0) 18.2 (0.0, 36.3) 15.5 (4.1, 27.0) 10.4 (-10.1, 31.0) N/A 
RII (95% CI) 0.19 (-0.10, 0.48) 0.28 (-0.20, 0.76) 0.43 (0.00, 0.84) 0.34 (0.09, 0.60) 0.23 (-0.22, 0.68) N/A 
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2.3.7.2 Comparison between males and females  
The trends over time in net survival by Carstairs 1991 Category for males and females are 
displayed in Table 2.5 and Table 2.6, respectively. Net survival results for males and 
females after one year, five years, and 10 years between 1986-1990 to 2011-2015 were 
comparable to the results for the whole cohort by widening over calendar time and follow-
up time. For those who were diagnosed between the years of 1986-1990, inequality in 
five-year net survival was stronger for males than it was for females, with males exhibiting 
an SII and RII of 8.4 (95% CI 2.1 to 13.6) and 0.16 (95% CI 0.06 to 0.26), respectively, 
and females exhibiting an SII and RII of 1.5 (95% CI -27.8 to 30.8) and 0.03 (95% CI -0.50 
to 0.56), respectively. This difference in five-year net survival was also apparent for those 
who were diagnosed between the years of 2011-2015, with males exhibiting an SII and 
RII of 22.9 (95% CI 10.3 to 35.5) and 0.40 (95% CI 0.18 to 0.62), respectively and females 
exhibiting an SII and RII of 12.1 (95% CI% 4.1 to 20.1) and 0.21 (95% CI 0.07 to 0.34), 
respectively. However, this difference in inequality was not as clear by 10-years. The 
same trends were also observed for the results from overall survival (Appendix 2.16 and 
Appendix 2.17) and disease-specific survival (Appendix 2.22 and Appendix 2.23). 
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Table 2.5 – Net survival by Carstairs 1991 Category per year group of diagnosis for males 
  Year group of diagnosis  
Carstairs 1991 Category 1986-1990 1991-1995 1996-2000 2001-2005 2006-2010 2011-2015 
One-year net  
survival (95% CI) 
      
   1 – Least deprived 82.8 (78.2, 87.5) 77.5 (72.7, 82.3) 84.7 (81.1, 88.4) 81.9 (77.9, 85.9) 82.7 (79.0, 86.4) 81.6 (78.2, 85.0) 
   2 80.7 (76.4, 85.0) 80.7 (76.8, 84.7) 83.2 (79.5, 86.9) 76.9 (73.3, 80.6) 79.3 (75.8, 82.9) 85.2 (82.3, 88.1) 
   3 82.0 (78.0, 86.0) 82.5 (78.8, 86.1) 79.9 (76.4, 83.4) 80.5 (76.9, 84.1) 81.0 (77.7, 84.2) 79.7 (76.5, 82.9) 
   4 74.8 (70.6, 78.9) 75.8 (72.1, 79.6) 74.7 (71.1, 78.4) 77.7 (74.3, 81.1) 79.3 (76.1, 82.5) 77.4 (74.1, 80.6) 
   5 – Most deprived 78.3 (74.9, 81.8) 72.1 (68.7, 75.5) 72.6 (69.3, 75.9) 74.6 (71.3, 77.8) 74.6 (71.5, 77.7) 73.9 (70.9, 77.0) 
SII (95% CI) 6.6 (-7.3, 20.5) 10.7 (-5.8, 27.1) 16.5 (11.4, 21.6) 6.9 (-3.8, 17.7) 8.7 (-0.2, 17.6) 12.5 (1.1, 23.9) 
RII (95% CI) 0.08 (-0.09, 0.26) 0.14 (-0.08, 0.35) 0.21 (0.15, 0.28) 0.09 (-0.05, 0.23) 0.11 (0.0, 0.22) 0.16 (0.01, 0.30) 
Five-year net  
survival (95% CI) 
      
   1 – Least deprived 55.5 (48.4, 62.6) 54.7 (47.8, 61.6) 59.8 (54.1, 65.5) 60.9 (55.5, 66.3) 63.0 (57.9, 68.2) 67.7 (62.8, 72.7) 
   2 54.4 (47.7, 61.1) 52.2 (46.5, 58.0) 60.9 (55.5, 66.3) 53.0 (48.2, 57.8) 58.0 (53.1, 62.9) 63.8 (59.1, 68.4) 
   3 54.5 (48.4, 60.5) 53.1 (47.6, 58.5) 56.0 (51.0, 60.9) 56.7 (51.6, 61.8) 57.7 (53.2, 62.3) 57.3 (52.6, 62.0) 
   4 52.7 (47.0, 58.3) 50.5 (45.6, 55.5) 50.5 (45.7, 55.2) 53.3 (48.8, 57.9) 57.5 (53.2, 61.8) 50.6 (45.7, 55.5) 
   5 – Most deprived 49.0 (44.1, 53.8) 42.5 (38.2, 46.9) 47.7 (43.5, 51.8) 48.1 (43.9, 52.3) 48.5 (44.7, 52.4) 50.7 (46.2, 55.2) 
SII (95% CI) 8.4 (2.1, 13.6) 15.0 (2.5, 27.5) 17.9 (9.6, 26.2) 12.5 (-1.8, 26.8) 15.6 (2.1, 29.2) 22.9 (10.3, 35.5) 
RII (95% CI) 0.16 (0.06, 0.26) 0.30 (0.05, 0.56) 0.33 (0.18, 0.49) 0.23 (-0.03, 0.50) 0.28 (0.04, 0.52) 0.40 (0.18, 0.62) 
10-year net  
survival (95% CI) 
      
   1 – Least deprived 47.9 (38.7, 57.1) 38.2 (27.9, 48.5) 47.7 (40.4, 55.0) 50.8 (44.7, 56.8) 47.7 (39.3, 56.1) N/A 
   2 40.8 (33.1, 48.5) 47.3 (39.5, 55.2) 50.3 (43.1, 57.6) 47.4 (41.3, 53.6) 48.9 (42.4, 55.4) N/A 
   3 41.7 (33.6, 49.7) 40.6 (34.1, 47.1) 43.0 (35.7, 50.4) 47.6 (41.1, 54.2) 44.6 (35.2, 54.0) N/A 
   4 44.5 (37.0, 51.9) 45.3 (39.1, 51.5) 43.1 (37.4, 48.8) 46.4 (41.2, 51.6) 49.2 (43.6, 54.9) N/A 
   5 – Most deprived 37.8 (31.9, 43.7) 32.6 (27.7, 37.5) 34.2 (29.5, 39.0) 38.3 (33.3, 43.2) 37.6 (32.9, 42.3) N/A 
SII (95% CI) 8.4 (-7.4, 24.2) 11.4 (-18.7, 41.4) 18.8 (4.3, 33.3) 14.2 (2.0, 26.3) 12.0 (-9.3, 33.3) N/A 
RII (95% CI) 0.20 (-0.18, 0.58) 0.28 (-0.46, 1.03) 0.44 (0.10, 0.78) 0.31 (0.04, 0.58) 0.27 (-0.21, 0.74) N/A 
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Table 2.6 – Net survival by Carstairs 1991 Category per year group of diagnosis for females 
  Year group of diagnosis  
Carstairs 1991 Category 1986-1990 1991-1995 1996-2000 2001-2005 2006-2010 2011-2015 
One-year net  
survival (95% CI) 
      
   1 – Least deprived 77.3 (80.2, 84.4) 76.6 (69.4, 83.8) 76.4 (69.8, 83.0) 84.5 (79.2, 89.9) 71.4 (64.9, 77.9) 85.5 (80.6, 90.4) 
   2 75.6 (68.9, 82.4) 71.3 (64.8, 77.8) 77.2 (71.3, 83.2) 79.7 (74.2, 85.1) 76.3 (70.8, 81.8) 75.7 (70.6, 80.9) 
   3 79.7 (73.5, 86.0) 71.4 (64.6, 78.2) 80.3 (74.7, 85.9) 79.6 (74.4, 84.9) 78.5 (73.4, 83.6) 79.6 (74.5, 84.6) 
   4 76.0 (69.8, 82.3) 72.0 (65.8, 78.3) 72.2 (66.6, 77.8) 79.4 (74.2, 84.5) 76.9 (71.7, 82.1) 78.7 (73.6, 83.7) 
   5 – Most deprived 75.0 (69.3, 80.7) 69.9 (64.3, 75.6) 71.9 (66.7, 77.0) 75.5 (70.4, 80.7) 75.4 (70.4, 80.4) 72.5 (67.6, 77.5) 
SII (95% CI) 2.7 (-7.1, 12.5) 5.7 (-3.3, 14.6) 8.2 (-6.8, 23.2) 8.9 (1.1, 16.7) -2.8 (-16.0, 10.4) 11.1 (-7.5, 29.7) 
RII (95% CI) 0.03 (-0.09, 0.16) 0.08 (-0.05, 0.20) 0.11 (-0.09, 0.31) 0.11 (0.01, 0.21) -0.04 (-0.21, 0.14) 0.14 (-0.10, 0.38) 
Five-year net  
survival (95% CI) 
      
   1 – Least deprived 50.9 (41.6, 60.3) 54.7 (45.0, 64.4) 59.0 (50.3, 67.7) 64.2 (56.5, 72.0) 56.1 (48.4, 63.7) 65.1 (56.7, 73.4) 
   2 55.4 (46.6, 64.1) 48.3 (40.2, 56.5) 58.1 (50.0, 66.1) 56.8 (49.2, 64.3) 58.0 (50.8, 64.2) 60.6 (53.2, 68.0) 
   3 58.9 (50.4, 67.5) 49.6 (41.2, 58.0) 59.8 (51.6, 68.0) 55.1 (47.9, 62.3) 54.5 (47.7, 61.2) 56.8 (48.9, 64.6) 
   4 61.2 (52.8, 69.7) 53.4 (45.6, 61.3) 60.0 (52.7, 67.3) 57.8 (50.7, 64.8) 56.8 (50.1, 63.5) 57.4 (49.8, 65.0) 
   5 – Most deprived 49.9 (42.7, 57.2) 45.0 (37.6, 52.5) 44.9 (38.7, 51.1) 53.1 (46.6, 59.7) 54.8 (48.5, 61.0) 54.2 (47.5, 61.0) 
SII (95% CI) 1.5 (-27.8, 30.8) 7.5 (-11.3, 26.3) 16.7 (-11.6, 45.0) 9.8 (-4.9, 24.5) 2.1 (-5.5, 9.7) 12.1 (4.1, 20.1) 
RII (95% CI) 0.03 (-0.50, 0.56) 0.15 (-0.23, 0.53) 0.30 (-0.21, 0.81) 0.17 (-0.09, 0.43) 0.04 (-0.10, 0.17) 0.21 (0.07, 0.34) 
10-year net  
survival (95% CI) 
      
   1 – Least deprived 46.4 (35.6, 57.2) 48.6 (32.6, 64.5) 44.7 (34.4, 55.1) 53.2 (44.0, 62.4) 49.4 (40.3, 58.5) N/A 
   2 48.3 (37.5, 59.1) 40.5 (31.0, 50.0) 47.7 (26.6, 68.8) 45.7 (36.9, 54.6) 49.5 (40.2, 58.8) N/A 
   3 52.0 (41.6, 62.5) 32.7 (23.6, 41.8) 52.2 (41.5, 62.8) 49.8 (40.3, 59.2) 41.3 (32.9, 49.8) N/A 
   4 47.2 (36.5, 57.9) 36.1 (25.2, 47.0) 47.9 (37.7, 58.1) 41.1 (33.1, 49.1) 49.7 (40.1, 59.3) N/A 
   5 – Most deprived 42.2 (34.0, 50.5) 36.5 (28.6, 44.8) 32.9 (24.7, 41.2) 37.1 (30.0, 44.2) 42.6 (34.6, 50.6) N/A 
SII (95% CI) 6.8 (-11.0, 24.6) 11.6 (-12.3, 35.4) 16.7 (-18.5, 51.8) 18.5 (2.3, 34.7) 6.4 (-15.2, 28.1) N/A 
RII (95% CI) 0.15 (-0.23, 0.52) 0.30 (-0.32, 0.93) 0.38 (-0.42, 1.17) 0.41 (0.05, 0.78) 0.14 (-0.33, 0.61) N/A 
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2.3.7.3 Comparison between those with oral cavity, oropharynx, and cancer of the 
larynx 
The trends over time in net survival by Carstairs 1991 Category for people with cancer of 
the oral cavity, oropharynx, and larynx are displayed in Table 2.52 to Table 2.54, 
respectively. Net survival results for those with cancer of the oral cavity, oropharynx, and 
larynx after one year, five years, and 10 years between 1986-1990 to 2011-2015 were 
comparable to the results for the whole cohort by widening over calendar time and follow-
up time.  
For those who were diagnosed between the years of 1986-1990, there was no inequality 
in net survival after one year or five years for those diagnosed with cancer of the oral 
cavity, oropharynx, or larynx. However, results for those who were diagnosed between the 
years of 1986-1990 differed after 10 years of follow-up: for those with cancer of the oral 
cavity and larynx, there was no inequality present, however for those with cancer of the 
oropharynx, there was strong inequality with the least deprived and most deprived groups 
exhibiting 10-year net survival of 31.3% (95% CI 13.2% to 49.4%) and 15.7% (95% CI 
5.3% to 26.1%), respectively, and an SII and RII of 22.6 (95% CI 2.0 to 43.3) and 0.88 
(95% CI 0.08 to 1.68), respectively. However, for those who were diagnosed between the 
years of 2011-2015, inequality was present after one year and five years of follow-up. The 
same trends were also observed for the results from overall survival (Appendix 2.18 to 
Appendix 2.20) and disease-specific survival (Appendix 2.24 to Appendix 2.26). 
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Table 2.7 – Net survival by Carstairs 1991 Category per year group of diagnosis for people with cancer of the oral cavity 
  Year group of diagnosis  
Carstairs 1991 Category 1986-1990 1991-1995 1996-2000 2001-2005 2006-2010 2011-2015 
One-year net  
survival (95% CI) 
      
   1 – Least deprived 75.0 (66.9, 83.2) 75.1 (68.2, 81.9) 76.1 (69.9, 82.4) 84.9 (79.8, 89.9) 77.9 (72.5, 83.4) 83.1 (78.7, 87.5) 
   2 75.3 (68.3, 82.3) 72.9 (66.8, 78.9) 79.6 (74.0, 85.2) 72.4 (66.7, 78.1) 73.4 (68.1, 78.7) 83.4 (79.2, 87.6) 
   3 72.3 (65.3, 79.3) 76.0 (69.8, 82.1) 76.7 (71.2, 82.1) 78.1 (72.9, 83.2) 82.3 (77.9, 86.8) 77.5 (72.6, 82.3) 
   4 67.2 (60.3, 74.1) 71.9 (65.8, 77.9) 70.0 (64.1, 76.0) 77.2 (72.4, 82.0) 76.4 (71.7, 81.2) 78.9 (74.3, 83.5) 
   5 – Most deprived 73.3 (67.8, 78.9) 68.0 (62.5, 73.4) 71.9 (67.0, 76.7) 74.1 (69.3, 78.9) 73.8 (69.3, 78.4) 72.7 (68.0, 77.4) 
SII (95% CI) 3.8 (-13.6, 21.2) 8.5 (-2.5, 19.4) 9.2 (-5.2, 23.6) 7.3 (-14.7, 29.3) 3.4 (-16.9, 23.8) 13.1 (2.5, 23.7) 
RII (95% CI) 0.05 (-0.19, 0.29) 0.12 (-0.03, 0.27) 0.12 (-0.07, 0.32) 0.09 (-0.19, 0.38) 0.04 (-0.22, 0.31) 0.17 (0.03, 0.30) 
Five-year net  
survival (95% CI) 
      
   1 – Least deprived 39.7 (29.9, 49.5) 45.7 (36.5, 54.9) 54.1 (45.9, 62.2) 63.4 (56.1, 70.6) 59.7 (52.6, 66.7) 67.3 (60.4, 74.2) 
   2 43.9 (35.2, 52.6) 47.3 (39.5, 55.1) 52.8 (45.1, 60.5) 48.7 (41.8, 55.7) 55.6 (49.1, 62.2) 64.8 (58.3, 71.3) 
   3 47.6 (38.7, 56.4) 46.6 (38.3, 54.9) 51.7 (44.6, 58.8) 55.0 (48.1, 61.9) 63.4 (57.0, 69.8) 56.4 (49.3, 63.5) 
   4 49.6 (41.3, 57.9) 47.7 (40.1, 55.2) 46.9 (39.5, 54.3) 48.9 (42.6, 55.2) 54.2 (47.9, 60.5) 52.6 (45.5, 59.6) 
   5 – Most deprived 43.6 (36.3, 50.8) 39.2 (32.9, 45.6) 45.7 (39.7, 51.6) 45.6 (39.6, 51.5) 47.5 (42.0, 53.1) 48.2 (41.5, 54.8) 
SII (95% CI) -3.2 (-23.2, 16.7) 8.4 (-8.1, 24.9) 11.7 (6.3, 17.0) 16.6 (-7.4, 40.6) 14.6 (-10.4, 39.6) 25.4 (17.9, 32.9) 
RII (95% CI) -0.07 (-0.51, 0.37) 0.19 (-0.18, 0.55) 0.23 (0.13, 0.34) 0.32 (-0.14, 0.79) 0.26 (-0.19, 0.71) 0.44 (0.31, 0.57) 
10-year net  
survival (95% CI) 
      
   1 – Least deprived 32.9 (22.0, 43.7) 36.6 (25.6, 47.6) 41.0 (31.1, 50.8) 56.7 (48.1, 64.2) 41.9 (28.4, 55.3) N/A 
   2 30.3 (20.8, 39.8) 39.2 (30.6, 47.7) 38.4 (28.7, 48.0) 45.1 (37.2, 53.0) 46.5 (38.4, 54.7) N/A 
   3 35.8 (25.5, 46.2) 30.1 (21.6, 38.6) 49.1 (39.6, 58.7) 48.3 (39.5, 57.1) 44.6 (29.8, 59.5) N/A 
   4 38.2 (27.6, 48.7) 36.8 (26.4, 47.3) 33.1 (25.4, 40.7) 37.4 (30.5, 44.4) 50.1 (41.3, 58.9) N/A 
   5 – Most deprived 35.1 (27.1, 43.0) 32.8 (25.5, 40.0) 31.6 (23.2, 37.9) 33.9 (27.4, 40.5) 44.2 (37.6, 50.8) N/A 
SII (95% CI) -5.2 (-19.1, 8.6) 5.3 (-13.0, 23.6) 14.4 (-18.4, 47.2) 26.1 (7.5, 44.8) -2.7 (-19.4, 14.1) N/A 
RII (95% CI) -0.15 (-0.54, 0.25) 0.15 (-0.37, 0.68) 0.38 (-0.49, 1.24) 0.61 (0.18, 1.04) -0.06 (-0.43, 0.31) N/A 
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Table 2.8 – Net survival by Carstairs 1991 Category per year group of diagnosis for people with cancer of the oropharynx 
  Year group of diagnosis  
Carstairs 1991 Category 1986-1990 1991-1995 1996-2000 2001-2005 2006-2010 2011-2015 
One-year net  
survival (95% CI) 
      
   1 – Least deprived 72.2 (56.5, 87.9) 62.9 (48.1, 77.8) 87.7 (79.4, 95.9) 83.0 (74.8, 91.2) 77.4 (69.6, 85.2) 83.9 (78.1, 89.8) 
   2 71.5 (58.2, 84.8) 75.7 (64.6, 86.9) 71.3 (61.3, 81.4) 77.4 (69.3, 85.5) 82.5 (76.1, 88.9) 83.7 (78.5, 88.8) 
   3 79.4 (67.2, 91.7) 58.0 (45.3, 70.7) 78.5 (69.8, 87.2) 80.7 (73.1, 88.2) 81.8 (75.4, 88.3) 78.6, 72.6, 84.6) 
   4 55.9 (43.8, 68.0) 60.9 (49.2, 72.5) 71.5 (62.0, 81.0) 74.2 (65.7, 82.6) 80.1 (73.9, 86.4) 79.8 (73.9, 85.7) 
   5 – Most deprived 69.1 (58.1, 80.0) 65.0 (55.3, 74.8) 67.9 (59.4, 76.3) 67.4 (59.0, 75.8) 70.8 (64.1, 77.6) 74.4 (68.9, 79.9) 
SII (95% CI) 10.3 (-38.0, 58.7) 4.5 (-31.9, 40.9) 18.8 (-8.0, 45.7) 17.6 (1.7, 33.5) 10.3 (-12.0, 32.7) 12.2 (3.7, 20.7) 
RII (95% CI) 0.15 (0.56, 0.86) 0.07 (-0.50, 0.63) 0.25 (-0.11, 0.61) 0.23 (0.02, 0.44) 0.13 (-0.15, 0.42) 0.15 (0.05, 0.26) 
Five-year net  
survival (95% CI) 
      
   1 – Least deprived 35.5 (17.0, 54.0) 35.1 (20.1, 50.0) 56.0 (42.8, 69.1) 57.7 (46.6, 68.9) 55.0 (45.4, 64.7) 71.6 (63.4, 79.7) 
   2 42.0 (24.8, 59.3) 43.0 (29.6, 56.3) 39.1 (27.2, 51.0) 52.8 (42.7, 62.8) 66.4 (58.0, 74.8) 64.9 (56.9, 73.0) 
   3 34.0 (18.9, 49.1) 22.8 (11.4, 34.3) 57.4 (46.2, 68.7) 50.2 (40.2, 60.3) 56.5 (47.6, 65.3) 62.8 (54.9, 70.7) 
   4 34.4 (22.1, 46.7) 35.0 (22.6, 47.3) 44.2 (33.1, 55.3) 57.5 (47.3, 67.6) 56.6 (48.4, 64.8) 59.7 (51.1, 68.2) 
   5 – Most deprived 34.5 (22.5, 46.4) 36.6 (25.8, 47.4) 35.9 (26.9, 45.0) 47.8 (38.2, 57.4) 48.5 (40.7, 56.2) 56.3 (48.8, 63.8) 
SII (95% CI) 5.5 (-10.6, 21.7) 0.1 (-40.5, 40.7) 19.6 (-25.4, 64.5) 7.5 (-14.1, 29.1) 14.0 (-14.2, 42.1) 17.5 (10.5, 24.6) 
RII (95% CI) 0.15 (-0.30, 0.60) 0.00 (-1.17, 1.17) 0.43 (-0.56, 1.42) 0.14 (-0.26, 0.55) 0.25 (-0.25, 0.75) 0.28 (0.17, 0.39) 
10-year net  
survival (95% CI) 
      
   1 – Least deprived 31.3 (13.2, 49.4) 31.5 (16.1, 46.9) 42.4 (27.7, 57.1) 47.5 (35.8, 59.3) 53.8 (43.5, 64.2) N/A 
   2 35.9 (17.5, 54.3) 27.9 (15.2, 40.6) 32.2 (19.6, 44.8) 42.7 (31.6, 53.8) 57.1 (47.1, 67.1) N/A 
   3 25.2 (11.0, 39.4) 12.8 (1.9, 23.8) 46.2 (33.1, 59.4) 41.5 (30.0, 53.0) 48.7 (39.0, 58.4) N/A 
   4 26.7 (13.4, 40.0) 31.3 (17.3, 45.4) 37.4 (25.3, 49.5) 47.2 (36.2, 58.2) 49.6 (40.1, 59.1) N/A 
   5 – Most deprived 15.7 (5.3, 26.1) 14.9 (5.7, 24.1) 26.1 (17.2, 35.1) 31.7 (22.0, 41.4) 33.2 (24.4, 41.9) N/A 
SII (95% CI) 22.6 (2.0, 43.3) 15.4 (-29.8, 60.6) 16.9 (-21.2, 55.0) 14.4 (-13.7, 42.4) 26.8 (-0.4, 54.0) N/A 
RII (95% CI) 0.88 (0.08, 1.68) 0.68 (-1.32, 2.69) 0.47 (-0.59, 1.53) 0.35 (-0.33, 1.02) 0.57 (-0.01, 1.14) N/A 
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Table 2.9 – Net survival by Carstairs 1991 Category per year group of diagnosis for people with cancer of the larynx 
  Year group of diagnosis  
Carstairs 1991 Category 1986-1990 1991-1995 1996-2000 2001-2005 2006-2010 2011-2015 
One-year net  
survival (95% CI) 
      
   1 – Least deprived 84.5 (77.9, 91.1) 84.5 (77.9, 91.1) 86.3 (80.8, 91.8) 82.1 (75.6, 88.5) 86.9 (81.3, 92.6) 84.7 (78.6, 90.9) 
   2 87.7 (82.5, 93.0) 87.5 (82.5, 92.5) 87.0 (82.0, 92.0) 84.3 (79.3, 89.4) 83.1 (77.6, 88.6) 83.8 (78.2, 89.4) 
   3 88.5 (83.6, 93.5) 86.9 (82.3, 92.5) 87.9 (83.5, 92.3) 82.9 (77.8, 88.0) 84.6 (79.9, 89.3) 86.3 (81.7, 90.9) 
   4 83.8 (78.6, 89.1) 86.2 (81.8, 90.6) 81.4 (76.9, 86.0) 85.1 (80.5, 89.6) 85.1 (80.7, 89.6) 79.3 (74.2, 84.5) 
   5 – Most deprived 84.6 (80.5, 88.7) 82.1 (78.0, 86.3) 81.7 (77.5, 85.9) 83.9 (79.8, 87.9) 79.9 (75.5, 84.3) 78.3 (73.7, 82.8) 
SII (95% CI) 3.0 (-7.6, 13.7) 5.5 (-4.4, 15.3) 8.2 (-2.6, 19.1) -1.5 (-7.1, 4.1) 6.6 (-3.8, 17.0) 9.8 (2.0, 21.6) 
RII (95% CI) 0.04 (-0.09, 0.16) 0.06 (-0.05, 0.18) 0.10 (-0.03, 0.23) -0.02 (-0.08, 0.05) 0.08 (-0.05, 0.20) 0.12 (-0.02, 0.26) 
Five-year net  
survival (95% CI) 
      
   1 – Least deprived 58.6 (48.0, 69.2) 70.0 (58.7, 81.3) 68.6 (59.7, 77.5) 62.5 (53.7, 71.4) 74.1 (65.8, 82.4) 70.0 (59.7, 80.4) 
   2 65.3 (55.3, 75.3) 58.5 (50.4, 66.7) 70.6 (63.0, 78.1) 59.1 (51.6, 66.7) 60.5 (51.8, 69.1) 65.6 (56.5, 74.7) 
   3 61.0 (52.5, 69.5) 63.0 (55.7, 70.3) 66.1 (58.6, 73.5) 63.3 (55.8, 70.8) 56.9 (49.9, 64.0) 60.7 (52.5, 69.0) 
   4 64.8 (56.6, 72.9) 64.0 (57.1, 70.9) 60.9 (54.4, 67.4) 64. 3(57.6, 71.1) 66.3 (59.6, 73.0) 54.8 (46.5, 63.2) 
   5 – Most deprived 57.4 (51.0, 63.8) 55.9 (49.9, 61.9) 57.2 (51.0, 63.4) 56.7 (50.6, 62.8) 57.3 (51.3, 63.3) 56.5 (49.4, 63.6) 
SII (95% CI) 5.3 (-14.1, 24.6) 11.0 (-11.2, 33.2) 17.3 (9.0, 25.5) 6.6 (-7.6, 20.8) 10.6 (-22.1, 43.3) 16.3 (0.6, 31.9) 
RII (95% CI) 0.09 (-0.23, 0.40) 0.18 (-0.18, 0.54) 0.27 (0.14, 0.40) 0.11 (-0.12, 0.35) 0.17 (-0.36, 0.70) 0.27 (0.01, 0.53) 
10-year net  
survival (95% CI) 
      
   1 – Least deprived 45.2 (32.4, 58.0) 54.1 (33.7, 74.6) 50.3 (39.0, 61.6) 43.8 (33.9, 53.7) 63.2 (51.5, 74.9) N/A 
   2 47.7 (36.4, 59.0) 53.7 (42.7, 64.8) 61.1 (51.1, 71.1) 46.7 (37.7, 55.8) 49.2 (38.4, 59.9) N/A 
   3 43.7 (33.6, 53.8) 49.9 (41.0, 58.8) 44.1 (32.2, 56.0) 52.2 (42.1, 62.3) 43.1 (32.1, 54.1) N/A 
   4 50.9 (40.4, 61.4) 53.9 (45.5, 62.4) 52.7 (44.4, 61.1) 54.6 (46.6, 62.6) 53.2 (43.8, 62.6) N/A 
   5 – Most deprived 43.3 (35.5, 51.1) 45.8 (38.3, 53.3) 42.7 (35.2, 50.2) 40.5 (33.4, 47.6) 39.9 (32.4, 47.5) N/A 
SII (95% CI) 2.7 (-16.0, 21.5) 9.7 (-5.2, 24.5) 13.3 (-21.1, 47.7) 5.9 (-29.2, 40.9) 18.6 (-17.9, 54.9) N/A 
RII (95% CI) 0.06 (-0.35, 0.47) 0.19 (-0.10, 0.48) 0.27 (-0.43, 0.97) 0.12 (-0.62, 0.87) 0.39 (-0.37, 1.15) N/A 
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2.3.8 Sensitivity analyses 
Two sensitivity analyses were conducted using varying measurements of socioeconomic 
status. The first sensitivity analysis utilised the nearest Carstairs and Morris index to the 
date of the registrant’s diagnosis of head and neck cancer. Carstairs and Morris 1991 
Categories were used for the people who were diagnosed between 1986 and 1995, 
Carstairs and Morris 2001 Categories (McLoone, 2004) were used for the people who 
were diagnosed between 1996 and 2005, and Carstairs and Morris 2011 Categories 
(Brown et al., 2014) were used for the people who were diagnosed between 2006 and 
2015. The second sensitivity analysis utilised the earliest defined SIMD categories from 
2004 census data. Due to the recency of SIMD in comparison to Carstairs and Morris 
1991 Index, this sensitivity analysis only included individuals who were diagnosed in more 
recent years from 2001 onwards.  
2.3.8.1 Trends over time using the nearest Carstairs Category  
The trends over time in net survival by the nearest Carstairs Category for the whole cohort 
are displayed in Appendix 2.27. Since the same Carstairs 1991 Categories were used for 
those diagnosed between the years of 1986 and 1995, these results were the same as 
they were in the main analysis. For the remaining time periods, the results were also 
similar to the main analysis and inequality was present over the entire period. In addition, 
and in the same fashion as the main analysis, inequality became stronger over calendar 
time and over the follow-up period in the sensitivity analysis which used the nearest 
Carstairs Category by the year of the persons diagnosis. These results were also obtained 
for overall survival and disease-specific survival (Appendix 2.28 and Appendix 2.29).  
2.3.8.2 Trends over time using SIMD 2004 Categories  
The trends over time in net survival by SIMD 2004 Categories for those who were 
diagnosed from 2001 onwards are displayed in Appendix 2.30. Inequality remained 
present for the time periods between 2001 and 2015 when using SIMD 2004 Categories 
compared to Carstairs 2001 Categories. Inequality was strongest in the most recent time 
period of 2011-2015 in the same fashion as the trends that were observed in the main 
analysis. In addition, and similarly to the main analysis, inequality also became clearer 
over the follow-up period and was worse after five years and 10 years than it was after 
one year. These results were also obtained for overall survival and disease-specific 
survival (Appendix 2.31 and Appendix 2.32).   
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2.4 Discussion  
The aim of this chapter was to provide an overview of the time-trends in inequality in 
survival of people with head and neck cancer in Scotland. In addition to comparing trends 
over calendar time, the differences in inequality over follow-up time in one-year, five-year, 
and 10-year net survival were compared. These trends were examined for the whole 
cohort, by males and females, and across the three main subsites of head and neck 
cancer (oral cavity, oropharynx, and larynx). There are several key findings from this study 
which are outlined below.  
Survival of the whole cohort 
Net survival estimates after one year, five years, and 10 years were 77.8% (95% CI 
77.2% to 78.3%), 54.4% (95% CI 53.7% to 55.2%), and 43.9% (95% CI 42.8% to 45.0%), 
respectively (Table 2.3). Overall survival after one year, five years, and 10 years was 
75.1% (95% CI 74.6% to 75.7%), 47.0% (95% CI 46.4% to 47.6%), and 32.1% (95% CI 
31.4% to 32.7%), respectively (Appendix 2.13), while disease-specific survival was higher 
at 80.2% (95% CI 79.7% to 80.7%), 61.8% (95% CI 61.1% to 62.4%), and 56.0% (95% CI 
55.3% to 56.7%), respectively (Appendix 2.14). Over time, one-year net survival did not 
improve from the period of 1986-1990 at 78.5% (95% CI 77.0% to 80.0%) to 2011-2015 at 
78.8% (95% CI 77.6% to 80.0%). There was a slight improvement in five-year net survival 
which increased from 53.5% (95% CI 51.3% to 55.7%) in 1986-1990 to 57.6% (95% CI 
55.8% to 59.4%) in 2011-2015. However, there was also no improvement in 10-year net 
survival from the period of 1986-1991 at 43.5% (95% CI 40.7% to 46.2%) to 2006-2010 at 
44.6% (95% CI 42.1% to 47.1%).  
Trends in inequality in survival over calendar time 
Inequality in net survival estimates was evident for all of the time periods of diagnosis, 
however inequality observed in the period of 2011-2015 was higher than it was at any 
other time period before it. For this time period of diagnosis, the least deprived and most 
deprived groups had five-year net survival estimates of 66.9% (95% CI 62.6% to 71.2%) 
and 51.8% (95% CI 48.1% to 55.5%), respectively (Table 2.4). Additionally, the SII and RII 
for these results were 19.2 (95% CI 16.1 to 22.3) and 0.32 (95% CI 0.27 to 0.37), which 
was the highest of all of the models for net survival for those diagnosed between 2011-
2015 compared to those diagnosed during other time periods. The same pattern was 
observed for overall survival and disease-specific survival and for those with cancer of the 
oral cavity, oropharynx, and larynx, and for males and females individually (Appendix 2.15 
to Appendix 2.20, and Appendix 2.29). 
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Trends in inequality in survival over follow-up period 
In addition to inequality becoming worse over calendar time, inequality also became wider 
in the longer follow-up period since diagnosis. For example, for the people who were 
diagnosed in the period 2006-2010, the SIIs for net survival increased from 5.3 (95% CI -
5.8 to 16.4), to 6.6 (95% CI -6.0 to 19.3) and 8.4 (95% CI -4.2 to 20.9) after one year, five 
years, and 10 years, respectively (Table 2.23). This observation was apparent for net 
survival, disease-specific survival, and overall survival estimates for all of the cohort, for 
males and females individually and for those who had cancer of the oral cavity, 
oropharynx, and larynx (Appendix 2.15 to Appendix 2.20, and Appendix 2.29). 
Comparisons with previous studies 
Only two previous studies have utilised Scottish Cancer Registry data to investigate the 
inequality in survival of people with head and neck cancer. A sub cohort of men diagnosed 
with cancer of the larynx was included in a large study of people diagnosed on the 
Scottish Cancer Registry between the years of 1986 and 2000 and followed up to 2005 
(Shack et al., 2007). Shack et al (2007) utilised 1995 Carstairs Index to investigate five-
year relative survival. Similar to the present investigations, the study confirmed a 
deprivation gap in five-year relative survival for men with cancer of the larynx and in 
addition, concluded that inequality was widening by approximately 3% every five years. A 
second study investigated a cohort of registrations on the Scottish Cancer Registry with 
cancer of the nasopharynx diagnosed between the years of 1975 and 2001 (Anandan et 
al., 2008). This study also showed inequality in survival, but trends over time were not 
investigated.  
A study involving English and Welsh registry data investigated inequality utilising both 
Carstairs 1995 Index and the Index of Multiple Deprivation for men with cancer of the 
larynx diagnosed between 1996 and 1999 (Coleman et al., 2004). Coleman and 
colleagues investigated inequality in relative survival and confirmed that survival was 
improving for those who resided in areas of lower levels of deprivation, while those in the 
most deprived areas did not exhibit an improvement in survival over time. A further report 
on these data suggested that the gap between the least deprived and most deprived 
groups of England and wales could grow to up to 20% or more “in the near future” (Rachet 
et al., 2008).  
Limitations and strengths 
There are several limitations to this study. The main limitation is the accessibility of data. 
Since this study involved cancer registry data, there were no additional data available 
such as tumour stage or health and behavioural information, and therefore investigations 
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into the explanations of inequality in survival of people with head and neck cancer could 
not be explored. Secondly, socioeconomic status was measured using the area based 
Carstairs 1991 Index (Carstairs and Morris, 1990; McLoone, 2000), which is derived from 
the 1991 Census based on the proportion of male unemployment, social class, lack of car 
ownership, and overcrowding in a dwelling. This study involved cancer registry data, and 
therefore further data on individual measurements of socioeconomic status (including 
education level and amount of income) were not available. Additionally, Carstairs 1991 
Categories may not accurately represent rural and urban populations as it may be 
essential for people in these areas to own a car. However, as other indices such as 
education level or income were not available for this analysis, Carstairs 1991 Categories 
were the best measurement available. In addition, a further limitation of this study is the 
use of Carstairs 1991 Indices for the entire follow-up period, rather than the use of the 
Carstairs Categories at the nearest point in time (such as Carstairs 2001 and Carstairs 
2011 Indices). Carstairs 1991 Indices were deemed the most appropriate for this study to 
ensure a consistent and standardised comparison of the impact of socioeconomic status 
over time, since the more recent Carstairs Indices may re-allocate some areas into 
different socioeconomic groups. In addition, we performed a sensitivity analysis which 
utilised Carstairs 2001 and Carstairs 2011 Indices for people who were diagnosed from 
1996 onwards, and these results were the same as the results to the main analysis 
(Appendix 2.27). A second sensitivity analysis utilised data from the 2004 SIMD for people 
who were diagnosed from 2001 onwards. These results also demonstrated the same 
trends observed to those of the main analysis (Appendix 2.30).  
This study has several strengths. Firstly, the Scottish Cancer Registry is a reliable source 
of all of the head and neck cancer registrations in Scotland during the study period of 
1986 to 2015. Scottish Cancer Registry data is high quality data and well complete 
(Brewster et al., 1997; Brewster et al., 2002), and mortality (death record) linkage is 
thought to be highly accurate with detection of approximately 98.3% of the potential 
linkages (Newcombe et al., 1959; Kendrick and Clarke, 1993). Scottish Cancer Registry 
data were provided on all of the individuals with at least one head and neck cancer, along 
with any other malignancy within or outside of the head and neck that the person may also 
have had. All of the data that were provided included people with diagnoses between 1st 
January 1986 and 31st December 2015. We cross-checked these data (n = 43,578) with 
the published Head and Neck Cancer Statistics from ISD Scotland (ISD Scotland, 2018). 
However, for accurate comparisons of individual cases of people with a primary head and 
neck cancer, an algorithm was developed and performed in order to identify a single 
record containing a person’s primary tumour (Section 2.2.6). Following the execution of 
this algorithm, a total of 24,778 individual primary head and neck cancers were identified 
during the study period. These results were compared with other publications of incident 
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primary head and neck cancers and were found to be similar (Shack et al., 2007; 
Purkayastha et al., 2016). A further strength of this study is the large sample size of nearly 
25,000 people with a primary head and neck tumour diagnosed in Scotland between the 
years of 1986 and 2015. Due to the long time period of this analysis, this allowed 
investigations into long-term survival to be conducted, which is rarely examined for people 
with head and neck cancer. An additional strength of this analysis is the use of the 
Scottish Cancer Registry data to provide a comprehensive analysis to investigate 
inequality in survival of people with head and neck cancer from a wide range of 
perspectives based on the availability of the data. This included investigations of net 
survival, overall survival, and disease-specific survival after one year, five years, and 10 
years while also comparing survival over both follow-up time and calendar time for the 
whole cohort, and by sex and cancer subsites.  
2.4.1 Conclusion 
Inequalities in survival of people with head and neck cancer in Scotland are wide and 
have increased over time. This large population-based cancer registry analysis shows that 
those living in the most deprived areas have substantially worse survival prospects. This 
study demonstrates that inequality became worse over time for people with head and 
neck cancer and was at its widest in those diagnosed in the most recent period (2011-
2015). This study also confirms that inequality became worse in the longer follow-up 
period, particularly five years and 10 years after a diagnosis of head and neck cancer.  
These results demonstrate the public health and health service challenge of inequalities in 
survival of people with head and neck cancer over a period of nearly 30 years, the burden 
falling amongst those from the most deprived communities, and of a worsening picture of 
inequalities. This warrants further investigation into understanding the underlying causes 
of inequality in survival of people with head and neck cancer, with the aim of developing 
interventions, services, or policies to address this public health problem. 
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3 Determinants of survival in a population-
based cohort study of people with head 
and neck cancer in Scotland (SAHNC) 
3.1 Introduction  
The SAHNC is a prospective clinical cohort study of people with head and neck cancer. 
The SAHNC cohort study recruited individuals who were diagnosed in Scotland under the 
National Health Services (NHS) between September 1999 and August 2001. 
The SAHNC cohort study was set up by (what was previously known as) the Clinical 
Resource Audit Group (CRAG) which was part of the Scottish Executive Health 
Department (SEHD). The aim of the SEHD was to promote clinical effectiveness in 
Scotland and to facilitate and provide funding for projects such as prospective clinical 
cohort studies. A multidisciplinary National Steering Committee was convened to 
supervise the SAHNC cohort study. The group met on six occasions to organise, manage, 
and oversee the study over the two-year recruitment period. The aims of the study, as 
outlined in the Scottish Audit of Head and Neck Cancers: A Prospective Audit (Scottish 
Audit of Head and Neck Cancers Steering Group, 2004), were to: 
“1. Identify referral patterns for people with head and neck cancers from the 
primary care unit to the treatment units. 
2. Identify variations in clinical practice in the investigation and treatment of all 
types of head and neck cancers in Scotland from presentation to death. 
3. Identify good and inappropriate practice based on clinical outcomes and identify 
possible reasons for these. 
4. Identify areas which require further investigation/action. 
5. Establish a central core data set which will be the basis of ongoing quality 
assurance for the management of head and neck tumours. This is an essential 
feature of clinical governance. 
6. Set up recommendations for the development of national treatment protocols 
and head and neck treatment guidelines.” 
3.1.1 Aims and objectives  
In this thesis, the SAHNC cohort study provides a unique and valuable opportunity to 
explore the association of various patient, tumour, and treatment factors with survival of 
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people with head and neck cancer in Scotland. The primary aim of Chapter 3 is to 
determine the factors that are independently associated with survival at three time points 
– one year, five years, and 12 years after a diagnosis of head and neck cancer by utilising 
the SAHNC cohort study of people with head and neck cancer who were diagnosed in 
Scotland between the years of 1999 and 2001 (Scottish Audit of Head and Neck Cancers 
Steering Group, 2004). The secondary aim of this chapter is to compare methods of 
measuring survival via the use of overall, disease-specific, and net survival estimates to 
provide an in-depth and comprehensive picture of the factors that are associated with 
survival of people with head and neck cancer in Scotland. The objectives of this chapter 
are to: 
1. Explore the patient, tumour and treatment factors that are associated with one-
year, five-year, and 12-year overall survival and disease-specific survival. 
2. Compare the outcomes by the different survival metrics: overall survival, disease-
specific survival, and net survival estimates.  
3.2 Methods  
3.2.1 Data collection  
The baseline data collection for the SAHNC cohort study was undertaken between 1st 
September 1999 and 31st August 2001. A total of 61 hospitals contributed towards the 
study and were based in the health board areas of Argyll and Clyde, Ayrshire, Forth 
Valley, Grampian, Greater Glasgow, Highlands and Islands, Lanarkshire, Lothian, and 
Tayside.  
Data collection proformas were produced for the study by the multidisciplinary National 
Steering Committee with the aim to request information from clinicians and research 
nurses who were based at each of the contributing hospitals. Each hospital site was 
provided with the proformas at baseline and was asked to complete and return them to 
the appointed data manager within that region. The data collection proformas that were 
collected contained detailed information on various patient, tumour, and treatment factors 
which are outlined below.  
3.2.1.1 Patient factors  
The term “patient factors” has been used in this analysis as an overarching title for the 
factors under investigation which are not directly linked to any of the tumour or treatment 
factors (defined in detail below). The patient factors relate to all of the personal 
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information about the people who were recruited to the SAHNC cohort study, as well as 
socio-demographic information, behavioural history, and health status. The patient factors 
that were collected and included in this analysis included age at diagnosis, sex, 
socioeconomic status, smoking status, alcohol consumption, and WHO Performance 
Status.  
Socioeconomic status was obtained by linking the SAHNC data to the area-based 
Carstairs and Morris 2001 Categories using the patients’ home postcodes (Carstairs and 
Morris, 1989; Carstairs and Morris, 1990; McLoone, 2004). The categories rank the 
geographical areas of Scotland into one of five groups using 2001 Census data – group 
one represents the people from the least deprived areas and group five represents the 
people from the most deprived areas. The Carstairs and Morris 2001 Categories groups 
areas based on: (a) male unemployment rates, (b) lack of car ownership, (c) overcrowding 
in private households, and (d) low occupational social class.  
Smoking status and alcohol consumption were recorded at baseline and no further 
information was documented regarding the persons behaviour while they were undergoing 
their treatment. Smoking status was defined on the questionnaire as: (a) current smoker 
(up to time of diagnosis), (b) previous smoker, and (c) never smoked. There was no 
further information collected in addition to this, such as pack-years. Alcohol consumption 
was defined on the questionnaire as: (a) current (problem) drinker, (b) previous (problem) 
drinker, and (c) occasional drinker/never drank.  
WHO Performance Status was used to record the physical fitness of each patient at the 
time of their diagnosis and was defined as: (a) normal activity, (b) strenuous activity 
restricted, (c) up and about for more than 50% of their waking hours, (d) confined to a bed 
or a chair for more than 50% of their waking hours, and (e) confined to a bed or a chair for 
100% of their waking hours (Oken et al., 1982).  
3.2.1.2 Tumour factors  
The term “tumour factors” has been used in this analysis as an overarching title for the 
factors under investigation that are directly related to the person’s cancer diagnosis. The 
tumour factors that were collected included information on the specific anatomical site of 
the head and neck malignancy, the stage of the tumour, and the histological type of the 
tumour.  
The anatomical site of the head and neck tumour was determined using ICD-10 codes 
(World Health Organization, 2016). This included tumours of the (a) lip (C00); (b) oral 
cavity (C02-C04, C05.0, C06); (c) oropharynx (C01, C05.1, C05.2, C09, C10); (d) 
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hypopharynx (C12, C13); (e) larynx (C32, C10.1); (f) nasopharynx, nasal cavity, and 
sinuses (C11, C30.0, C31); (g) salivary glands (C07, C08); (h) and other ill-defined areas 
of the head and neck (C14, C30.1, C41, C44, C76, C77).   
The stage of each tumour was classified using the TNM Classification of Malignant 
Tumours from the UICC (Sobin and Wiettekind, 2002). The TNM Classification groups 
tumours into four categories from stage I to stage IV. Each anatomical site of the head 
and neck is staged individually according to the Tumour (T), Node (N) and Metastases (M) 
categorisation that was assigned by the treating clinician at the time of the patient’s 
diagnosis (as outlined in section 1.3.4). The histological type of the tumour was grouped 
as: (a) SCC and (b) non-SCC.  
3.2.1.3 Treatment factors  
The term “treatment factors” has been used in this analysis as an overarching title for the 
factors under investigation that are directly related to the patient’s cancer treatment. The 
treatment factors that were collected included information on the type of treatment 
modality the people received for their diagnosis of head and neck cancer, and also the 
geographical location of the treating hospital.  
The treatment modality groupings were decided in consultation with head and neck 
cancer clinicians in multidisciplinary meetings. For the purpose of this study, the treatment 
combinations were grouped into five categories: (a) surgery only; (b) radiotherapy only;  
(c) surgery combined with radiotherapy; (d) chemotherapy only, chemotherapy combined 
with surgery, chemotherapy combined with radiotherapy, and chemotherapy combined 
with both surgery and radiotherapy; or (e) no treatment.  
The geographical location of the treating hospital in which the patients received their care 
was based on the service that was delivered in the three Scottish Cancer Networks. 
These were located in one of three geographic regions: (a) West of Scotland Network 
(WoSCAN) (Ayrshire and Arran, Forth Valley, Greater Glasgow, Clyde, and Lanarkshire), 
(b) South East Scotland Cancer Network (SCAN) (Borders, Dumfries and Galloway, Fife, 
and Lothian), or (c) North of Scotland Cancer Network (NOSCAN) (Grampian, Highland, 
Orkney, Shetland, Tayside, and Western Isles). 
3.2.2 Data verification  
All of the data that were collected as part of the SAHNC cohort study were cross-checked 
against pathology forms and radiotherapy treatment lists. The data were also cross-
checked using SMR data which are routinely collected by hospital medical records 
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departments and logged with ISD Scotland. A quality assurance appraisal was also 
carried out on 10% of the data from the West of Scotland, and it was reported that the 
data were of “high quality”.  
3.2.3 Data linkage  
On 30th September 2013, the SAHNC data were linked to mortality records from the NRS. 
The records were linked using an established probability matching technique based on the 
Howard Newcombe principle (Newcombe et al., 1959). This method matches people to 
NRS mortality data using their unique CHI number registered with NHS, Scotland. 
Information governance and approval for the mortality linkage were obtained from the 
NHS Privacy Advisory Committee (now known as the Public Benefits and Privacy Panel) 
(Appendix 3.1). 
3.2.4 Cause of death  
The causes of death of those who had died in the SAHNC cohort study were extracted 
from the information recorded on their death certificates that were obtained from the NRS 
mortality data linkage. Primary and secondary causes of death were recorded using ICD-
10 codes and were grouped into three categories: (a) died from head and neck cancer,  
(b) died from another form of cancer, and (c) died from other non-cancer causes.  
3.2.5 Eligible cases 
Since this was a survival study, those unable to be matched to CHI numbers were 
excluded to enable successful data linkage of all of the patients included in this analysis to 
the NRS mortality records. For the successful computation of net survival, those who were 
unable to be matched to Carstairs 2001 Category due to invalid or missing postcode data 
were also excluded from the study. Due to the long-term follow-up of this study, people 
over the age of 85 were excluded since the life-expectancy for an 85 year old male and 
female in between the years of 2014 and 2016 was only 5.5 years and 6.4 years, 
respectively (National Records of Scotland, 2017).  
3.2.6 Statistical analyses  
Frequency tables of each of the patient, tumour, and treatment factors were produced 
along with the proportion of deaths that had occurred by September 2013. The primary 
and secondary causes of deaths for each of the patients who had died were examined via 
the use of frequency tables and graphically over time.  
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One-year, five-year, and 12-year overall survival and disease-specific survival estimates 
were calculated using the Kaplan-Meier method with 95% confidence intervals. Overall 
survival was computed using any cause of death as an event. Disease-specific survival 
was computed using an event for the people who had “died from head and neck cancer” 
which was recorded on their death certificate as their primary cause of death. In addition, 
Cox proportional hazards models with 95% confidence intervals that were minimally 
adjusted by age and sex for all-cause mortality and disease-specific mortality were 
produced to compare mortality across the groups of people by each patient, tumour, and 
treatment factor after one year, five years, and 12 years.  
Mutually adjusted forward stepwise multivariate Cox proportional hazards models were 
used to determine which variables had an independent association with all-cause mortality 
and disease-specific mortality after one year, five years, and 12 years. Age at diagnosis, 
tumour stage and treatment modality were forced into the mutually adjusted models due 
to their strong association with survival in the minimally adjusted models. As a precaution, 
these results were checked using a backwards stepwise routine to reduce dimensionality 
with the aim to find a core group of variables that explained mortality. In addition, two 
sensitivity analyses were performed by removing those who did not receive any treatment 
since these people were likely to have died soon after their diagnosis of head and neck 
cancer. In addition, a second sensitivity analysis was performed by removing those who 
had cancer of the oropharynx since we did not have access to HPV information for this 
study. 
Since this was a large study, many of the p-values were very small and therefore, chi-
square statistics were added to the analysis tables for overall survival, disease-specific 
survival, all-cause mortality, and disease-specific mortality as a way of visually ranking the 
importance of each determinant in the models. All overall survival, disease-specific 
survival results and Cox proportional hazards models were computed using SAS 
Software, Version 9.4. 
Additionally, net survival with 95% confidence intervals was calculated using the Pohar-
Perme method (Pohar Perme et al., 2012; Pohar Perme et al., 2016) by using lifetables 
that were standardised by calendar year, age, sex, and Carstairs 2001 Category. The 
lifetables were provided by the Cancer Survival Group at the LSHTM (Cancer Survival 
Group, 2019). All of the net survival results and the graphs for the estimated net survival 
function were computed using the stns command and the stns graph command in Stata, 
version 14 (Clerc-Urmes et al., 2014; StataCorp., 2017).  
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3.3 Results  
3.3.1 Eligible cases 
A total of 1,910 people with head and neck cancer who were diagnosed between 1st 
September 1999 and 31st August 2001 were recruited to the SAHNC cohort study. This 
accounted for 77% of all of the head and neck cancer cases that were diagnosed and 
recorded in the Scottish Cancer Registry during the same period (Scottish Audit of Head 
and Neck Cancers Steering Group, 2004).  
Figure 3.1 outlines the number of people that were excluded from the cohort for the 
purpose of this analysis. Of the 1,910 people who were recruited to the SAHNC cohort 
study, 1,985 were successfully linked to the NRS mortality data – 15 people were unable 
to be matched to the mortality data due to having an invalid CHI number. A further 15 
people were excluded as they were unable to be matched to the Carstairs 2001 Category 
due to having an invalid or a missing postcode. In addition, 60 patients over the age of 85 
were also excluded due to the low life expectancy of people of this age. The remaining 
1,820 patients were eligible to be included in this study.  
Figure 3.1 – Flow chart of eligible cases included in the SAHNC cohort study 
 
3.3.2 Baseline characteristics  
The numbers and proportions of the baseline patient, tumour, and treatment factors are 
displayed in Table 3.1 to Table 3.3, along with the proportions of deaths that had occurred 
by September 2013 per group within each variable. 
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3.3.2.1 Description of the patient factors  
The patients’ ages at diagnosis ranged from 13 to 85, with a median age of 63 years. 
There was a ratio of 2.5:1 of males to females, and a total of 937 (51.5%) individuals were 
from the two most deprived Carstairs 2001 Category in Scotland. There were 1,539 
(84.6%) people recorded as current or previous smokers at the time of their diagnosis, 
compared with only 221 (12.1%) recorded as never having smoked in their lifetime. A total 
of 708 (39.0%) patients were recorded as having had a current or previous problem with 
their levels of alcohol consumption compared with 891 (49.0%) who were recoded as 
either being an occasional drinker or never having drank alcohol. There were 825 (45.3%) 
people who had a normal WHO Performance Status at the time of their diagnosis, and 
none of the patients in the cohort were confined to a bed or a chair for 100% of their 
waking hours. 
Table 3.1 – Baseline characteristics and total number of deaths per determinant by 
September 2013 for each patient factor 
Variable 
Frequency 
N (Column %) 
Died by 
September 2013 
N (Row %) 
Total 1,820 (100.0%) 1,384 (76.0%) 
Age at diagnosis   
   Less than 45 99 (5.4%) 38 (38.4%) 
   45 to 54 288 (15.8%) 183 (63.5%) 
   55 to 64 592 (32.5%) 426 (72.0%) 
   65 to 74 551 (30.3%) 470 (85.3%) 
   75 and over 290 (15.9%) 267 (92.1%) 
Sex   
   Male 1,300 (71.4%) 1,000 (76.9%) 
   Female 520 (28.6%) 384 (73.9%) 
Carstairs 2001 Category   
   1 (Least deprived) 241 (13.2%) 183 (75.9%) 
   2 317 (17.4%) 226 (71.3%) 
   3 325 (17.9%) 248 (76.3%) 
   4 409 (22.5%) 311 (76.0%) 
   5 (Most deprived) 528 (29.0%) 416 (78.8%) 
Smoking behaviour    
   Never smoked 221 (12.1%) 133 (60.2%) 
   Previous smoker 405 (22.3%) 301 (74.3%) 
   Current smoker 1,134 (62.3%) 906 (79.9%) 
   Not recorded 60 (3.3%) 44 (73.3%) 
Alcohol consumption   
   Never/occasionally drank 891 (49.0%) 629 (70.6%) 
   Previous problem drinker 212 (11.7%) 180 (84.9%) 
   Current problem drinker 496 (27.3%) 410 (82.7%) 
   Not recorded 221 (12.1%) 165 (74.7%) 
WHO Performance Status   
   Normal activity 825 (45.3%) 511 (61.9%) 
   Strenuous activity restricted 465 (25.6%) 401 (86.2%) 
   Up and about >50% 137 (7.5%) 130 (94.9%) 
   Confined to bed/chair >50%  97 (5.3%) 96 (99.0%) 
   Not recorded 296 (16.3%) 246 (83.1%) 
3.3.2.2 Description of the tumour factors  
Those who had cancer of the larynx represented the largest group of patients with head 
and neck cancer at 32.1% (n = 584). This was followed by 28.8% (n = 506) of people with 
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cancer of the oral cavity, and the lowest prevalence of head and neck cancer was those 
with cancer of the nasal cavity (n = 85/4.7%) or lip (n = 85/4.7%). Most of the patients 
were diagnosed with stage IV tumours which represented 662 (36.4%) cases, and 1,585 
(87.0%) had a tumour which was of SCC histology. 
Table 3.2 – Baseline characteristics and total number of deaths per determinant by 
September 2013 for each tumour factor  
Variable 
Frequency 
N (Column %) 
Died by 
September 2013 
N (Row %) 
Anatomical site   
   Larynx 584 (32.1%) 427 (73.1%) 
   Oral cavity 506 (28.8%) 395 (78.1%) 
   Oropharynx 323 (17.8%) 261 (80.8%) 
   Hypopharynx 119 (6.5%) 112 (94.1%) 
   Nasal cavity 85 (4.7%) 64 (75.3%) 
   Lip 85 (4.7%) 40 (47.1%) 
   Other/salivary gland 118 (6.5%) 85 (72.0%) 
Tumour stage   
   I 383 (21.0%) 218 (56.9%) 
   II 369 (20.3%) 266 (72.1%) 
   III 273 (15.0%) 213 (78.0%) 
   IV 662 (36.4%) 586 (88.5%) 
   Unknown 133 (7.3%) 101 (75.9%) 
Histology   
   SCC 1,585 (87.1%) 1,209 (76.3%) 
   Non-SCC 235 (12.9%) 175 (74.5%) 
3.3.2.3 Description of the treatment factors  
The most common treatment modality received was “radiotherapy only,” by which a total 
507 (27.9%) patients were treated. This was followed by “surgery only,” by which 477 
(26.2%) people were treated, and a combination of surgery and radiotherapy, by which 
458 (25.2%) individuals were treated. A total of 1,001 (55.0%) people were treated within 
the West of Scotland (WoSCAN) cancer network, 440 (24.2%) were treated in the East of 
Scotland (SCAN) cancer network, and 379 (20.8%) were treated in the North of Scotland 
(NOSCAN) cancer network. 
Table 3.3 – Baseline characteristics and total number of deaths per determinant by 
September 2013 for each treatment factor  
Variable 
Frequency 
N (Column %) 
Died by 
September 2013 
N (Row %) 
Treatment modality   
   Surgery only 477 (26.2%) 164 (34.4%) 
   Radiotherapy only 507 (27.9%) 130 (25.6%) 
   Surgery and radiotherapy 458 (25.2%) 98 (21.4%) 
   Surgery, radiotherapy, and chemotherapy 65 (3.6%) 20 (4.6%) 
   Radiotherapy and chemotherapy 143 (7.9%) 21 (4.8%) 
   Chemotherapy +/- surgery 41 (2.3%) 1 (0.2%) 
   No treatment 129 (7.1%) 2 (1.6%) 
Network/region   
   WoSCAN (West of Scotland) 1,001 (55.0%) 787 (78.6%) 
   SCAN (East of Scotland) 440 (24.2%) 316 (71.8%) 
   NOSCAN (North of Scotland) 379 (20.8%) 281 (74.1%) 
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3.3.2.4 Death rates by September 2013 
A total of 1,384 (76.0%) deaths had occurred by September 2013 when the SAHNC data 
was linked to the NRS mortality data (Table 3.1). The patients were more likely to have 
died if they were older, from more deprived regions, were current or previous smokers, 
currently or previously drank alcohol to problematic levels, or had worse WHO 
Performance Status (Table 3.1). They were also more likely to die if they had cancers of 
the hypopharynx or oropharynx, had tumours of higher stage (Table 3.2), or were either 
treated with a treatment modality that was combined with chemotherapy or received no 
treatment at all (Table 3.3). There was a slight difference in the proportions of people who 
died across the three Scottish Cancer Networks, whereby those from the West of 
Scotland (WoSCAN) network had a higher rate of death (n = 787/78.6%) compared to 
those who were treated in the other two Scottish Cancer Networks (SCAN = 316/71.8%, 
NOSCAN = 281/74.1%). Interestingly, there was no substantial difference in the 
proportions of deaths between males and females by September 2013 (Table 3.1). 
3.3.3 Cause of death  
Table 3.4 displays a cross-tabulation of the primary and secondary causes of death of the 
1,384 (76.0%) patients who had died during the follow-up period to September 2013. A 
total of 677 (48.9%) primary causes of death were as a result of head and neck cancer. Of 
the 677 people whose primary cause of death was as a result of head and neck cancer, a 
total of 658 (97.2%) individuals also had “head and neck cancer” recorded as their 
secondary cause of death on their death certificates. The primary cause of 308 (22.3%) 
deaths was as a result of “other types of cancers”; however, 79 (25.6%) of these people 
had “head and neck cancer” recorded as their secondary cause of death, which suggests 
that the underlying cause of their death may have been as a result of head and neck 
cancer. The primary cause of 399 (38.8%) deaths was as a result of “other non-cancer” 
causes of death, however 83 (20.8%) of these individuals had “head and neck cancer” 
recorded as their secondary cause of death, which also suggests that the underlying 
cause of their death may have been as a result of head and neck cancer. Thus, a total of 
839 (60.6%) of deaths could have been in some way related to the patients’ head and 
neck cancer, but it was not recorded as a primary cause of death on their death certificate.  
Figure 3.2 displays the proportions of primary causes of death as a result of head and 
neck cancer, other types of cancer, and other types of deaths per year of follow-up until 
September 2013. Deaths resulting from head and neck cancer represented the highest 
proportion of deaths in the first two years after diagnosis. However, after four years, 
deaths from other causes, represented a higher proportion of deaths than those from 
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head and neck cancer. By September 2013, the most common cause of death was “death 
from other non-cancer causes”. 
Table 3.4 – Primary and secondary causes of death by September 2013 
 
Primary cause of death by September 2013 
N (Col. %) 
Secondary cause of death 
by September 2013 
Head and 
neck cancer 




    Head and neck cancer  658 (97.2%) 79 (25.6%) 83 (20.8%) 820 (59.2%) 
    Other types of cancer 1 (0.1%) 224 (72.7%) 13 (3.3%) 238 (17.2%) 
    Other non-cancer 18 (2.7%) 5 (1.6%) 303 (75.9%) 326 (23.6%) 
    Total, N (row %) 677 (48.9%) 308 (22.3%) 399 (28.8%) 1,384 (100.0%) 
 
Figure 3.2 – Proportions of deaths per year by head and neck cancer, other cancer, and 
other types of deaths  
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3.3.4 Overall survival, disease-specific survival, and net survival results 
Overall survival, disease-specific survival, and net survival estimates after one year, five 
years, and 12 years of diagnosis are displayed in Table 3.5 to Table 3.7 on Page 116 to 
Page 118. The Kaplan-Meier plots for the results of overall survival and disease-specific 
survival, and the graph for the estimated net survival function for the whole cohort are 
displayed in Figure 3.3 to Figure 3.5. Overall survival after one year, five years, and 12 
years was 76.0% (95% CI 74.0% to 77.9%), 46.1% (95% CI 43.8% to 48.4%), and 26.3% 
(95% CI 24.3% to 28.3%), respectively, while disease-specific survival was 82.3% (95% 
CI 80.4% to 84.0%), 64.1% (95% CI 61.7% to 66.4%), and 56.9% (95% CI 54.3% to 
59.4%), respectively. One-year, five-year, and 12-year net survival estimates were 78.3% 
(95% CI 76.2% to 80.3%), 53.8% (95% CI 51.1% to 56.5%), and 41.4% (95% CI 37.6% to 
45.1%), respectively. Results for disease-specific survival were higher than the overall 
survival results at all three time points. This observation would be expected since disease-
specific survival eliminates other causes of death that are not related to head and neck 
cancer. Over time, overall survival and disease-specific survival became further apart, 
which demonstrates the high proportion of deaths that were caused by disease-specific 
factors in the short-term follow-up, and the increase in other causes of death as the follow-
up period continued. The net survival results were also higher than those for overall 
survival after five years and 12 years but were lower than the results for disease-specific 
survival, suggesting that disease-specific survival does not fully capture all disease-
related deaths, particularly in the long-term.  
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Figure 3.3 – Kaplan-Meier plot for overall survival for the whole cohort 
 
Figure 3.4 – Kaplan-Meier plot for disease-specific survival for the whole cohort 
 
Figure 3.5 – Graph of the estimated net survival function for the whole cohort 
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3.3.4.1 Overall survival, disease-specific survival, and net survival by patient 
factors  
Age at diagnosis 
The Kaplan-Meier plots for overall survival and disease-specific survival, and the graph for 
the estimated net survival function for the age at diagnosis of the patients that were 
recruited to the SAHNC cohort are displayed in Figure 3.6 to Figure 3.8. As the age of the 
patients at diagnosis increased, the overall survival, disease-specific survival, and net 
survival results decreased. After 12 years, the survival between those who were less than 
45 years old and those who were aged 75 and over reduced from 62.6% (95% CI 52.3% 
to 71.3%) to 10.3% (95% CI 7.2% to 14.2%) for overall survival, from 72.1% (95% CI 
61.7% to 80.1%) to 45.3% (95% CI 37.9% to 52.4%) for disease-specific survival, and 
from 64.9% (95% CI 55.0% to 74.7%) to 43.2 (95% CI 28.0% to 58.4%) for net survival. 
The overall survival, disease-specific survival, and net survival results were similar for 
those who were less than 45 years old, suggesting that these people were more likely to 
have died as a result of their head and neck cancer. However, as the patients age 
increased, the differences between overall survival, disease-specific survival and net 
survival became clearer, suggesting that those who were older were more likely to die of 
other causes that were not related to their head and neck cancer. This was particularly 
noticeable between the survival results for people who were aged 75 and over, with 12-
year overall survival, disease-specific survival, and net survival results of 10.3% (95% CI 
14.9% to 21.3%), 54.2% (95% CI 49.1% to 59.1%), and 35.8% (95% CI 29.5% to 58.4%), 
respectively.  
  
Chapter 3: Determinants of survival 
96 
Figure 3.6 – Kaplan-Meier plot for overall survival by age group  
 
Figure 3.7 – Kaplan-Meier plot for disease-specific survival by age group  
 
Figure 3.8 – Graph of the estimated net survival function by age group 
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Sex 
The Kaplan-Meier plots for overall survival and disease-specific survival, and the graph for 
the estimated net survival function for the sex of the patients in the SAHNC cohort are 
displayed in Figure 3.9 to Figure 3.11. After one year, males and females had similar 
survival estimates at 76.2% (95% CI 73.7% to 78.4%) and 75.8% (95% CI 71.9% to 
79.2%) for overall survival, 82.0% (95% CI 79.8% to 84.1%) and 82.8% (95% CI 79.2% to 
85.9%) for disease-specific survival, and 78.5% (95% CI 76.1% to 80.9%) and 77.6% 
(95% CI 73.8% to 81.4%) for net survival, respectively. By five and 12 years, there were 
small differences between overall survival and disease-specific survival for males and 
females whereby after 12 years, males had a slightly lower overall survival of 24.9% (95% 
CI 22.6% to 27.3%) compared to females who had an overall survival of 29.6% (95% CI 
25.8% to 33.6%). Likewise, after 12 years the males also had a lower disease-specific 
survival of 55.3% (95% CI 52.2% to 58.3%) compared to the females who had a disease-
specific survival of 60.9% (95% CI 56.0% to 65.5%). However, 12-year net survival results 
for males and females were similar at 40.5% (95% CI 36.2% to 44.8%) and 43.0% (95% 
CI 36.1% to 49.8%), respectively.  
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Figure 3.9 – Kaplan-Meier plot for overall survival by sex  
 
Figure 3.10 – Kaplan-Meier plot for disease-specific survival by sex  
 
Figure 3.11 – Graph of the estimated net survival function by sex 
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Carstairs 2001 Category 
The Kaplan-Meier plots for overall survival and disease-specific survival, and the graph for 
the estimated net survival function for Carstairs 2001 Category are displayed in Figure 
3.12 to Figure 3.14. Compared to the individuals who were from the least deprived 
Carstairs 2001 Category, after one year, those from the most deprived group had a 
substantially lower overall survival, disease-specific survival, and net survival of 71.8% 
(95% CI 67.7%, to 75.4%), 79.1% (95% CI 75.2%, to 82.4%), and 73.7% (95% CI 69.7% 
to 77.6%), respectively. In contrast, the people who were in the least deprived group had 
overall survival, disease-specific survival, and net survival results of 83.4% (95% CI 
78.1% to 87.5%), 88.8% (95% CI 83.9% to 92.2%), and 86.1% (95% CI 81.3% to 91.0%), 
respectively. By five years and 12 years, the people from the most deprived area 
continued to have the lowest overall survival, disease-specific survival, and net survival, 
which after 12 years was 22.9% (95% CI 19.4% to 26.5%), 51.1% (95% CI 46.0% to 
55.9%), and 35.7% (95% CI 29.6% to 58.5%), respectively. The people in the second 
least deprived group had the highest overall survival and disease-specific survival results 
which after 12 years were 30.6% (95% CI 25.6% to 35.7%) and 65.6% (95% CI 59.6% to 
70.9%), respectively. However, the inequality by net survival after 12 years was not as 
well defined since those in the second most deprived group had the highest net survival 
result of 46.6% (95% CI 38.4% to 41.8%). 
 
Chapter 3: Determinants of survival 
100 
Figure 3.12 – Kaplan-Meier plot for overall survival by Carstairs 2001 Category  
 
Figure 3.13 – Kaplan-Meier plot for disease-specific survival by Carstairs 2001 Category 
 
Figure 3.14 – Graph of the estimated net survival function by Carstairs 2001 Category 
 
  
Chapter 3: Determinants of survival 
101 
Smoking behaviour 
The Kaplan-Meier plots for overall survival and disease-specific survival, and the graph for 
the estimated net survival function for the smoking behaviour that the patients had at the 
time of their diagnosis are displayed in Figure 3.15 to Figure 3.17. Those who had never 
smoked had 12-year overall survival, disease-specific survival, and net survival results of 
43.9% (95% CI 37.3% to 50.3%), 66.9% (95% CI 59.8% to 73.0%), and 70.6% (95% CI 
57.1% to 84.1%), respectively. The difference between these results suggests that the 
people who had never smoked were more likely to die of other causes that were not 
related to their head and neck cancer. In contrast, the individuals who were current 
smokers had a substantially lower overall survival, disease-specific survival, and net 
survival result at all three time points, which after 12 years was 22.3% (95% CI 19.9% to 
24.8%), 53.2% (95% CI 49.9% to 56.5%), and 32.4% (95% CI 28.6% to 36.2%), 
respectively. The substantial difference in overall survival and disease-specific survival, 
suggests that those who were current smokers may be dying as an indirect result of their 
head and neck cancer which is not being captured by the disease-specific results. 
Interestingly, the patients who were previous smokers had similar disease-specific 
survival and net survival results to those who were never smokers after one year and five 
years. After 12 years, the results for disease-specific survival remained similar to those 
after five years. However, the net survival results for those who had never smoked were 
substantially higher than that of the previous smokers at 70.6% (95% CI 57.1% to 84.1%) 
and 49.9% (95% CI 40.5% to 59.2%), respectively. This substantial difference suggests 
that in the long-term the patients who previously smoked are dying as an indirect result of 
their head and neck cancer, which is not being reflected on their cause of death 
certificates. 
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Figure 3.15 – Kaplan-Meier plot for overall survival by smoking behaviour  
 
Figure 3.16 – Kaplan-Meier plot for disease-specific survival by smoking behaviour  
 
Figure 3.17 – Graph of the estimated net survival function by smoking behaviour  
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Alcohol consumption 
The Kaplan-Meier plots for overall survival and disease-specific survival, and the graph for 
the estimated net survival function for the level of alcohol that the patients had consumed 
before their diagnosis are displayed in Figure 3.18 to Figure 3.20. The people who had a 
current problem with their levels of alcohol consumption obtained similar overall survival, 
disease-specific survival, and net survival results as those who were reported having had 
a previous problem with their alcohol consumption at all three time points. At 12 years, for 
those who had a current problem with their alcohol consumption and for those who had a 
previous problem with their alcohol consumption, their results were 18.2% (95% CI 14.9% 
to 21.7%) and 17.0% (95% CI 12.3% to 22.3%) for overall survival, respectively, 45.9% 
(95% CI 40.5% to 51.1%) and 49.7% (95% CI 42.1% to 56.9%) for disease-specific 
survival, respectively, and 23.5% (95% CI 18.6% to 28.4%) and 23.4% (95% CI 15.9% to 
30.9%) for net survival, respectively. The individuals who reported as never having drunk 
alcohol or who occasionally drank alcohol consistently had a substantially higher overall 
survival, disease-specific survival, and net survival results than those who drank to 
problematic levels at all three time points. These results were 32.3% (95% CI 29.3% to 
35.4%), 62.1% (95% CI 58.5% to 65.5%), and 70.6% (95% CI 57.1% to 84.1%) for overall 
survival, disease-specific survival, and net survival results after 12 years, respectively. 
The substantial difference between overall survival and disease-specific survival suggests 
that the patients who never or occasionally drank were likely to have died from other 
causes that were not related to their head and neck cancer. In addition, the results from 
the Kaplan-Meier plots indicate that those who did not report their levels of alcohol 
consumption could also have been never or occasional drinkers.  
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Figure 3.18 – Kaplan-Meier plot for overall survival by alcohol consumption  
 
Figure 3.19 – Kaplan-Meier plot for disease-specific survival by alcohol consumption  
 
Figure 3.20 – Graph of the estimated net survival function by alcohol consumption  
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WHO Performance Status 
The Kaplan-Meier plots for overall survival and disease-specific survival, and the graph for 
the estimated net survival function for the WHO Performance Status that the patients 
experienced at the time of their diagnosis are displayed in Figure 3.21 to Figure 3.23. 
There was a clear and prominent gradient observed by WHO Performance Status – as the 
patient’s WHO Performance Statuses decreased, the overall survival, disease-specific 
survival, and net survival also decreased at all three time points. This was particularly 
noticeable after 12 years by which time the people who had normal activity levels at 
diagnosis compared to those who had restricted strenuous activity levels at diagnosis had 
an overall survival estimate of 40.6% (95% CI 37.2% to 43.9%) and 16.1% (95% CI 13.0% 
to 19.6%), respectively. The results for the patients with normal activity levels at diagnosis 
compared to those who had restricted strenuous activity levels at diagnosis had disease-
specific survival and net survival results of 70.4% (95% CI 66.8% to 73.7%) and 49.7% 
(95% CI 44.1% to 55.0%), and 59.0% (95% CI 53.5% to 64.9%) and 33.1% (95% CI 
26.7% to 41.1%), respectively. These results suggest that a small amount of restriction to 
a person’s activity levels had a substantial negative effect on their outcome following a 
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Figure 3.21 – Kaplan-Meier plot for overall survival by WHO Performance Status  
 
Figure 3.22 – Kaplan-Meier plot for disease-specific survival by WHO Performance Status  
 
Figure 3.23 – Graph of the estimated net survival function by WHO Performance Status 
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3.3.4.2 Overall survival, disease-specific survival, and net survival by tumour 
factors  
Anatomical site 
The Kaplan-Meier plots for overall survival and disease-specific survival, and the graph for 
the estimated net survival function for the anatomical site of the patients’ tumour are 
displayed in Figure 3.24 to Figure 3.26. Clear variations in overall survival, disease-
specific survival, and net survival results were seen across the anatomical sites after one 
year, five years, and 12 years. The highest overall survival, disease-specific survival, and 
net survival was from people with cancers of the lip at 56.5% (95% CI 45.3% to 66.2%), 
91.3% (95% CI 81.5% to 96.0%), and 98.3% (95% CI 76.3% to 120.2%) after 12 years, 
respectively. The results for disease-specific and net survival for individuals with cancer of 
the lip were substantially higher than the results for overall survival, which suggests that 
very few deaths of those with cancer of the lip occur as a result of their disease. The 
lowest overall survival, disease-specific survival, and net survival was among people with 
cancers of the hypopharynx at 9.2% (95% CI 4.9% to 15.3%), 23.6% (95% CI 14.5% to 
33.9%), and 15.8% (95% CI 7.0% to 24.7%) at 12 years, respectively. The results for 
overall and net survival were similar, suggesting that these people are more likely to die 
as a result of their head and neck cancer. However, the disease-specific survival results 
were slightly higher, which suggests that disease-specific survival does not fully capture 
the deaths as a result of hypopharyngeal cancer. Individuals with cancer of the 
oropharynx did not demonstrate the obvious survival advantage that is usually seen in this 
cancer subgroup from HPV positivity and had a 12-year overall survival of 21.4% (95% CI 
17.1% to 26.0%), which was lower than the other two major head and neck groups of the 
oral cavity and larynx.  
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Figure 3.24 – Kaplan-Meier plot for overall survival by anatomical site  
 
Figure 3.25 – Kaplan-Meier plot for disease-specific survival by anatomical site  
 
Figure 3.26 – Graph of the estimated net survival function by anatomical site 
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Tumour stage 
The Kaplan-Meier plots for overall survival and disease-specific survival, and the graph for 
the estimated net survival function for the stage of the patient’s tumour are displayed in 
Figure 3.27 to Figure 3.29. As the tumour stage of the person’s cancer increased, the 
one-year, five-year, and 12-year overall survival, disease-specific survival, and net 
survival results also decreased at all three time points. Individuals who had stage I cancer 
had 12-year overall survival, disease-specific survival, and net survival of 46.0% (95% CI 
40.9% to 50.9%), 84.0% (95% CI 79.4% to 87.8%), and 72.2% (95% CI 62.7% to 81.6%), 
respectively. However, those who had stage IV cancer had 12-year overall survival, 
disease-specific survival, and net survival results of 13.9% (95% CI 11.4% to 16.7%), 
35.3% (95% CI 31.0% to 39.6%), and 21.6% (95% CI 17.1% to 26.0%), respectively. The 
disease-specific and net survival results after five years were substantially higher than the 
results for overall survival for those with stage I or stage II tumours. This suggests that the 
people who were diagnosed with early staged tumours were more likely to have died from 
other causes that were not related to their head and neck cancer.  
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Figure 3.27 – Kaplan-Meier plot for overall survival by tumour stage  
 
Figure 3.28 – Kaplan-Meier plot for disease-specific survival by tumour stage  
 
Figure 3.29 – Graph of the estimated net survival function by tumour stage 
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3.3.4.3 Overall survival, disease-specific survival, and net survival by treatment 
factors  
Treatment modality 
The Kaplan-Meier plots for overall survival and disease-specific survival, and the graph for 
the estimated net survival function for the treatment modality that the patients received are 
displayed in Figure 3.30 to Figure 3.32. Those who were treated with chemotherapy with 
or without surgery, or who received no treatment had the worst overall survival, disease-
specific survival, and net survival results at all three time points, which after just one year 
was 9.8% (95% CI 3.1% to 21.0%) and 10.9% (95% CI 6.2% to 16.9%); 17.2% (95% CI 
5.6% to 34.0%) and 18.1% (95% CI 10.7% to 26.9%); and 10.0% (95% CI 1.3% to 18.7%) 
and 11.2% (95% CI 6.8% to 16.7%), respectively. Those who were treated with surgery 
only had the highest overall survival, disease-specific survival, and net survival results, 
which after one year was 88.9% (95% CI 85.7% to 91.4%), 93.5% (95% CI 90.8% to 
95.4%) and 91.7% (95% CI 88.8% to 94.6%), respectively. The substantial difference 
between overall survival, and disease-specific survival and net survival results suggest 
that in the long-term, those who were treated with surgery only were more likely to die as 
a result of other causes of death that are not related to their head and neck cancer. The 
overall survival, disease-specific survival, and net survival results for the individuals who 
were treated with surgery only were followed by those who were treated with either 
radiotherapy only or surgery and radiotherapy, the results of which were similar at 82.1% 
(95% CI 78.4% to 85.1%) and 83.0% (95% CI 79.2% to 86.1%); 87.0% (95% CI 83.7% to 
89.7%) and 86.5% (95% CI 82.9% to 89.3%); and 84.8% (95% CI 81.3% to 88.2%) and 
84.9% (95% CI 81.4% to 88.5%), respectively, after one year.   
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Figure 3.30 – Kaplan-Meier plot for overall survival by treatment modality  
 
Figure 3.31 – Kaplan-Meier plot for disease-specific survival by treatment modality  
 
Figure 3.32 – Graph of the estimated net survival function by treatment modality 
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Scottish Cancer Network 
The Kaplan-Meier plots for overall survival and disease-specific survival, and the graph for 
the estimated net survival function for the Scottish Cancer Network that the people were 
treated in are displayed in Figure 3.33 to Figure 3.35. One-year overall survival was 
similar across the three Scottish Cancer Networks at 77.6% (95% CI 73.0% to 81.5%) for 
NOSCAN, 76.4% (95% CI 72.1% to 80.1%) for SCAN and 75.3% (95% CI 72.5% to 
77.9%) for WoSCAN. However, the results varied slightly at 12 years, by which time 
WoSCAN had the lowest overall survival of 24.0% (95% CI 21.4% to 26.7%) compared to 
SCAN at 30.0% (95% CI 25.8% to 34.3%). Like the results for overall survival, one-year 
disease-specific survival was similar across the three Scottish Cancer Networks at 82.5% 
(95% CI 79.9% to 84.8%) for WoSCAN, 82.0% (95% CI 78.0% to 85.4%) for the SCAN 
and 81.9% (95% CI 77.6% to 85.5%) for NOSCAN. However, the results varied slightly at 
12 years by which time WoSCAN had the lowest disease-specific survival at 54.8% (95% 
CI 51.1% to 58.3%) compared to the SCAN at 60.0% (95% CI 54.8% to 64.8%). One-year 
and five-year net survival results were similar across the three Scottish Cancer Networks, 
however the results varied slightly at 12 years when WoSCAN obtained lower net survival 
of 36.9% (95% CI 32.0% to 41.7%), and SCAN obtained 12-year net survival of 50.0% 
(95% CI 42.0% to 58.1%).  
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Figure 3.33 – Kaplan-Meier plot for overall survival by Scottish Cancer Network 
 
Figure 3.34 – Kaplan-Meier plot for disease-specific survival by Scottish Cancer Network  
 
Figure 3.35 – Graph of the estimated net survival function by Scottish Cancer Network 
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Table 3.5 – One-year overall survival, disease-specific survival, and net survival results for 








%, (95% CI) 
One-year net 
survival  
%, (95% CI) 
Whole cohort 76.0 (74.0, 77.9) 82.3 (80.4, 84.0) 78.3 (76.2, 80.3) 
Age at diagnosis    
   Less than 45 90.9 (83.3, 95.2) 94.8 (88.0, 97.8) 91.1 (85.5, 96.8) 
   45 to 54 83.7 (78.9, 87.5) 86.5 (81.9, 90.0) 84.2 (80.0, 88.6) 
   55 to 64 78.4 (74.8, 81.5) 83.1 (79.7, 85.9) 79.6 (76.2, 83.0) 
   65 to 74 73.1 (69.2, 76.6) 81.7 (78.1, 84.8) 75.9 (72.1, 79.8) 
   75 and over 64.1 (58.3, 69.4) 72.9 (67.2, 77.8) 69.1 (63.2, 75.0) 
Sex    
   Male 76.2 (73.7, 78.4) 82.0 (79.8, 84.1) 78.5 (76.1, 80.9) 
   Female 75.8 (71.9, 79.2) 82.8 (79.2, 85.9) 77.6 (73.8, 81.4) 
Carstairs 2001 Category    
   1 (Least deprived) 83.4 (78.1, 87.5) 88.8 (83.9, 92.2) 86.1 (81.3, 91.0) 
   2 78.6 (73.6, 82.7) 83.2 (78.5, 86.9) 80.9 (76.2, 85.5) 
   3 76.3 (71.3, 80.6) 82.2 (77.5, 86.1) 78.6 (73.8, 83.3) 
   4 75.1 (70.6, 79.0) 81.8 (77.5, 85.3) 77.2 (72.8, 81.5) 
   5 (Most deprived) 71.8 (67.7, 75.4) 79.1 (75.2, 82.4) 73.7 (69.7, 77.6) 
Smoking behaviour    
   Never smoked 85.5 (80.2, 89.5) 89.3 (84.4, 92.8) 87.9 (83.1, 92.7) 
   Previous smoker 80.3 (76.0, 83.8) 87.0 (83.2, 90.0) 83.3 (79.2, 87.3) 
   Current smoker 72.8 (70.1, 75.2) 79.0 (76.4, 81.3) 74.6 (71.9, 77.2) 
   Not recorded 75.0 (62.0, 84.1) 86.0 (73.9, 92.7) 77.6 (66.2, 88.9) 
Alcohol consumption    
   Never/occasionally drank 79.2 (76.4, 81.8) 85.0 (82.4, 87.2) 81.7 (78.9, 84.4) 
   Previous problem drinker 72.2 (65.6, 77.7) 76.6 (70.2, 81.8) 74.0 (67.9, 80.2) 
   Current problem drinker 70.8 (66.6, 74.6) 77.8 (73.7, 81.3) 72.4 (68.3, 76.5) 
   Not recorded 78.7 (72.7, 83.6) 86.7 (81.2, 90.6) 81.3 (75.7, 86.9) 
WHO Performance Status    
   Normal activity 88.1 (85.7, 90.2) 91.9 (89.8, 92.6) 90.2 (88.0, 92.5) 
   Strenuous activity restricted 72.3 (68.0, 76.1) 79.1 (74.9, 82.6) 74.6 (70.5, 78.9) 
   Up and about >50%  50.4 (41.7, 58.4) 62.0 (52.7, 70.0) 52.2 (44.2, 61.6) 
   Confined to bed/chair >50%  34.0 (24.8, 43.4) 44.8 (33.7, 55.2) 35.6 (27.0, 46.8) 
   Not recorded 74.0 (68.6, 78.6) 79.2 (74.0, 83.5) 76.5 (71.5, 81.8) 
Anatomical site    
   Larynx 81.9 (78.5, 84.8) 85.9 (82.8, 88.5) 84.4 (81.1, 87.6) 
   Oral cavity 76.9 (67.2, 85.1) 82.1 (78.4, 85.3) 79.1 (75.3, 82.9) 
   Oropharynx 65.3 (59.9, 70.2) 73.8 (68.5, 78.4) 66.7 (61.4, 72.0) 
   Hypopharynx 55.5 (46.1, 63.9) 68.4 (58.5, 76.4) 57.0 (47.9, 66.2) 
   Nasal cavity 77.7 (67.2, 85.1) 82.8 (72.6, 89.4) 79.5 (70.4, 88.5) 
   Lip 94.1 (86.4, 97.5) 97.6 (90.8, 99.4) 97.7 (92.4, 100.3) 
   Other/salivary gland 79.7 (71.2, 85.9) 87.7 (80.2, 92.6) 81.6 (74.1, 89.0) 
Tumour stage    
   I 97.1 (94.9, 98.4) 98.7 (96.9, 99.5) 99.9 (98.2, 101.7) 
   II 89.2 (85.5, 91.9) 93.3 (90.2, 95.5) 91.9 (88.6, 95.2) 
   III 74.7 (69.1, 79.5) 81.7 (76.4, 85.9) 76.6 (71.3, 81.9) 
   IV 57.6 (53.7, 61.2) 66.2 (62.4, 69.8) 59.1 (55.2, 63.0) 
   Unknown 73.7 (65.3, 80.3) 80.3 (72.2, 86.2) 76.2 (68.5, 83.9) 
Treatment modality     
   Surgery only 88.9 (85.7, 91.4) 93.5 (90.8, 95.4) 91.7 (88.8, 94.6) 
   Radiotherapy only 82.1 (78.4, 85.1) 87.0 (83.7, 89.7) 84.8 (81.3, 88.2) 
   Surgery and radiotherapy 83.0 (79.2, 86.1) 86.4 (82.9, 89.3) 84.9 (81.4, 88.5) 
   Surgery, radiotherapy and chemotherapy 69.2 (56.5, 78.9) 70.7 (58.0, 80.2) 70.5 (59.2, 81.9) 
   Radiotherapy and chemotherapy 70.6 (62.4, 77.4) 77.5 (69.6, 83.6) 72.0 (64.4, 79.6) 
   Chemotherapy +/- surgery 9.8 (3.1, 21.0) 17.2 (5.6, 34.0) 10.0 (1.3, 18.7) 
   No treatment 10.9 (6.2, 16.9) 18.1 (10.7, 26.9) 11.2 (6.8, 16.7) 
Network/region    
   WoSCAN (West Scotland) 75.3 (72.5, 77.9) 82.5 (79.9, 84.8) 77.4 (74.7, 80.2) 
   SCAN (East Scotland) 76.4 (72.1, 80.1) 82.0 (78.0, 85.4) 78.7 (74.6, 82.8) 
   NOSCAN (North Scotland) 77.6 (73.0, 81.5) 81.9 (77.6, 85.5) 79.7 (75.4, 84.0) 
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Table 3.6 – Five-year overall survival, disease-specific survival, and net survival results for 








%, (95% CI) 
Five-year net 
survival  
%, (95% CI) 
Whole cohort 46.1 (43.8, 48.4) 64.1 (61.7, 66.4) 53.8 (51.1, 56.5) 
Age at diagnosis    
   Less than 45 76.8 (67.1, 83.9) 82.1 (72.8, 88.5) 77.5 (69.2, 85.9) 
   45 to 54 56.6 (50.7, 62.1) 68.8 (62.9, 74.0) 58.9 (53.0, 64.9) 
   55 to 64 48.5 (44.4, 52.4) 65.7 (61.5, 69.6) 52.8 (48.4, 57.2) 
   65 to 74 39.6 (35.5, 43.6) 61.1 (56.4, 65.4) 49.1 (44.0, 54.1) 
   75 and over 32.8 (27.4, 38.2) 54.0 (47.6, 60.0) 51.3 (42.8, 59.9) 
Sex    
   Male 45.2 (42.5, 47.9) 62.6 (59.7, 65.3) 53.5 (50.3, 56.8) 
   Female 48.3 (43.9, 52.5) 67.8 (63.3, 71.9) 54.3 (49.3, 59.3) 
Carstairs 2001 Category    
   1 (Least deprived) 49.8 (43.3, 55.9) 69.6 (62.9, 75.3) 58.1 (50.4, 65.8) 
   2 50.1 (46.4, 57.4) 69.8 (64.2, 74.8) 58.8 (52.5, 65.2) 
   3 44.6 (39.2, 49.9) 61.0 (55.1, 66.4) 51.8 (45.5, 58.1) 
   4 47.7 (42.8, 52.4) 64.4 (59.2, 69.1) 55.9 (50.1, 61.6) 
   5 (Most deprived) 40.5 (36.3, 44.7) 59.6 (54.9, 63.9) 48.1 (43.0, 53.2) 
Smoking behaviour    
   Never smoked 59.7 (52.9, 65.9) 72.5 (65.8, 78.0) 68.3 (60.4, 76.2) 
   Previous smoker 50.9 (45.9, 55.6) 68.1 (63.0, 72.7) 63.1 (57.0, 69.2) 
   Current smoker 41.6 (38.7, 44.5) 60.6 (57.4, 63.5) 47.4 (44.0, 50.7) 
   Not recorded 48.3 (35.3, 60.2) 71.2 (56.6, 81.7) 56.9 (41.5, 72.4) 
Alcohol consumption    
   Never/occasionally drank 51.6 (48.3, 54.9) 68.0 (64.6, 71.1) 60.4 (56.4, 64.4) 
   Previous problem drinker 37.3 (30.8, 43.7) 54.9 (47.4, 61.7) 42.8 (35.3, 50.3) 
   Current problem drinker 37.1 (32.9, 41.3) 57.1 (52.2, 61.7) 42.5 (37.6, 47.4) 
   Not recorded 52.5 (45.7, 58.8) 72.1 (65.2, 77.9) 62.2 (54.2, 70.3) 
WHO Performance Status    
   Normal activity 64.0 (60.6, 67.2) 78.3 (75.2, 81.1) 73.0 (69.3, 76.9) 
   Strenuous activity restricted 35.9 (31.6, 40.3) 57.5 (52.5, 62.2) 43.2 (38.1, 48.9) 
   Up and about >50%  13.9 (8.7, 20.2) 30.3 (21.2, 40.0) 16.7 (10.9, 25.6) 
   Confined to bed/chair >50%  5.2 (1.9, 10.8) 15.1 (7.1, 26.0) 6.8 (3.1, 15.0) 
   Not recorded 40.5 (34.9, 46.1) 58.5 (52.2, 64.3) 49.0 (42.6, 56.4) 
Anatomical site    
   Larynx 54.6 (50.5, 58.6) 71.4 (67.4, 75.1) 65.2 (60.3, 70.1) 
   Oral cavity 45.7 (41.3, 49.9) 64.3 (59.6, 68.5) 53.2 (48.0, 58.4) 
   Oropharynx 35.0 (29.8, 40.2) 49.9 (43.8, 55.7) 38.3 (32.5, 44.1) 
   Hypopharynx 18.5 (12.1, 25.9) 32.6 (23.0, 42.4) 21.2 (13.1, 29.2) 
   Nasal cavity 45.9 (35.1, 56.0) 60.0 (48.2, 70.0) 52.3 (40.3, 64.3) 
   Lip 77.6 (67.2, 85.1) 97.6 (90.8, 99.4) 93.7 (81.6, 105.7) 
   Other/salivary gland 41.5 (32.6, 50.2) 67.4 (56.8, 75.9) 46.5 (36.1, 56.9) 
Tumour stage    
   I 76.8 (72.2, 80.7) 91.0 (87.5, 93.6) 89.7 (84.5, 94.9) 
   II 54.2 (49.0, 59.1) 75.6 (70.6, 79.9) 63.5 (57.3, 69.7) 
   III 43.6 (37.6, 49.4) 63.9 (57.3, 69.7) 50.3 (43.5, 57.2) 
   IV 25.4 (22.1, 28.7) 40.2 (36.0, 44.3) 29.4 (25.5, 33.3) 
   Unknown 43.6 (35.1, 51.8) 60.5 (51.0, 68.8) 51.4 (41.2, 61.6) 
Treatment modality     
   Surgery only 60.2 (55.6, 64.4) 79.6 (75.5, 83.1) 70.9 (65.5, 76.3) 
   Radiotherapy only 54.0 (49.6, 58.3) 72.3 (68.0, 76.2) 64.4 (59.1, 69.7) 
   Surgery and radiotherapy 43.0 (38.4, 47.5) 61.7 (56.7, 66.3) 49.1 (43.9, 54.3) 
   Surgery, radiotherapy and chemotherapy 44.6 (32.3, 56.2) 53.1 (40.1, 64.4) 48.9 (35.3, 62.4) 
   Radiotherapy and chemotherapy 34.3 (26.6, 42.0) 44.6 (35.7, 53.0) 37.5 (29.0, 46.1) 
   Chemotherapy +/- surgery 2.4 (0.2, 11.0) 4.3 (0.3, 17.9) 2.6 (1.5, 6.8) 
   No treatment 1.6 (0.3, 5.0) 5.6 (1.7, 13.1) 1.7 (0.4, 3.9) 
Network/region    
   WoSCAN (West Scotland) 44.5 (41.4, 47.5) 64.1 (60.8, 67.2) 51.9 (48.3, 55.6) 
   SCAN (East Scotland) 47.5 (42.8, 52.1) 64.2 (59.3, 68.7) 56.0 (50.4, 61.7) 
   NOSCAN (North Scotland) 48.8 (43.7, 53.7) 63.7 (58.4, 68.6) 55.6 (49.8, 61.5) 
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Table 3.7 – 12-year overall survival, disease-specific survival, and net survival results for 




%, (95% CI) 
12-year disease-
specific survival 
%, (95% CI) 
12-year net 
survival  
%, (95% CI) 
Whole cohort 26.3 (24.3, 28.3) 56.9 (54.3, 59.4) 41.4 (37.6, 45.1) 
Age at diagnosis    
   Less than 45 62.6 (52.3, 71.3) 72.1 (61.7, 80.1) 64.9 (55.0, 74.7) 
   45 to 54 37.5 (31.9, 43.0) 60.2 (53.8, 66.0) 42.2 (35.9, 48.5) 
   55 to 64 30.2 (26.6, 34.0) 60.0 (55.5, 64.2) 38.8 (34.0, 43.7) 
   65 to 74 18.0 (14.9, 21.3) 54.2 (49.1, 59.1) 35.8 (29.5, 42.2) 
   75 and over 10.3 (7.2, 14.2) 45.3 (37.9, 52.4) 43.2 (28.0, 58.4) 
Sex    
   Male 24.9 (22.6, 27.3) 55.3 (52.2, 58.3) 40.5 (36.2, 44.8) 
   Female 29.6 (25.8, 33.6) 60.9 (56.0, 65.5) 43.0 (36.1, 49.8) 
Carstairs 2001 Category    
   1 (Least deprived) 27.0 (21.5, 32.7) 61.8 (54.4, 68.4) 40.4 (30.7, 50.0) 
   2 30.6 (25.6, 35.7) 65.6 (59.6, 70.9) 43.8 (35.0, 52.6) 
   3 26.2 (21.5, 31.0) 55.5 (49.2, 61.3) 40.7 (31.5, 49.9) 
   4 26.9 (22.7, 31.3) 55.5 (49.9, 60.8) 46.6 (38.4, 54.7) 
   5 (Most deprived) 22.9 (19.4, 26.5) 51.1 (46.0, 55.9) 35.7 (29.6, 41.8) 
Smoking behaviour    
   Never smoked 43.9 (37.3, 50.3) 66.9 (59.8, 73.0) 70.6 (57.1, 84.1) 
   Previous smoker 27.4 (23.2, 31.8) 59.8 (54.1, 65.0) 49.9 (40.5, 59.2) 
   Current smoker 22.3 (19.9, 24.8) 53.2 (49.9, 56.5) 32.4 (28.6, 36.2) 
   Not recorded 28.3 (17.6, 40.0) 67.3 (51.2, 79.1) 40.3 (22.2, 58.5) 
Alcohol consumption    
   Never/occasionally drank 32.3 (29.3, 35.4) 62.1 (58.5, 65.5) 54.1 (48.0, 60.1) 
   Previous problem drinker 17.0 (12.3, 22.3) 49.7 (42.1, 56.9) 23.4 (15.9, 30.9) 
   Current problem drinker 18.2 (14.9, 21.7) 45.9 (40.5, 51.1) 23.5 (18.6, 28.4) 
   Not recorded 29.0 (23.1, 35.0) 65.4 (57.6, 72.1) 43.9 (33.8, 54.0) 
WHO Performance Status    
   Normal activity 40.6 (37.2, 43.9) 70.4 (66.8, 73.7) 59.0 (53.5, 64.9) 
   Strenuous activity restricted 16.1 (13.0, 19.6) 49.7 (44.1, 55.0) 33.1 (26.7, 41.1) 
   Up and about >50%  7.3 (3.7, 12.5) 30.3 (21.2, 40.0) 11.6 (5.9, 22.9) 
   Confined to bed/chair >50%  1.0 (0.1, 5.0) 10.1 (2.8, 23.1) 1.5 (0.3, 9.0) 
   Not recorded 19.3 (15.0, 23.9) 50.2 (43.4, 56.7) 31.2 (23.7, 41.1) 
Anatomical site    
   Larynx 29.5 (25.8, 33.2) 63.8 (59.2, 67.9) 50.5 (43.4, 57.7) 
   Oral cavity 23.7 (20.1, 27.5) 55.4 (50.3, 60.3) 36.8 (30.1, 43.6) 
   Oropharynx 21.4 (17.1, 26.0) 45.8 (39.6, 51.8) 25.7 (19.7, 31.8) 
   Hypopharynx 9.2 (4.9, 15.3) 23.6 (14.5, 33.9) 15.8 (7.0, 24.7) 
   Nasal cavity 25.9 (17.1, 35.5) 52.6 (40.2, 63.6) 31.9 (19.5, 44.4) 
   Lip 56.5 (45.3, 66.2) 91.3 (81.5, 96.0) 98.3 (76.3, 120.2) 
   Other/salivary gland 30.5 (22.5, 38.9) 62.3 (51.0, 71.7) 44.8 (29.9, 59.7) 
Tumour stage    
   I 46.0 (40.9, 50.9) 84.0 (79.4, 87.8) 72.2 (62.7, 81.6) 
   II 30.4 (25.7, 35.1) 65.6 (59.6, 70.9) 51.8 (42.8, 60.9) 
   III 23.8 (18.9, 29.0) 53.4 (46.2, 60.0) 32.7 (24.4, 41.0) 
   IV 13.9 (11.4, 16.7) 35.3 (31.0, 39.6) 21.6 (17.1, 26.0) 
   Unknown 24.8 (17.9, 32.4) 55.4 (45.4, 64.3) 36.8 (24.5, 49.1) 
Treatment modality     
   Surgery only 36.7 (32.4, 41.0) 72.8 (68.1, 77.0) 61.7 (53.1, 70.2) 
   Radiotherapy only 27.6 (23.8, 31.6) 63.1 (58.1, 67.7) 44.3 (37.0, 51.5) 
   Surgery and radiotherapy 24.9 (21.0, 28.9) 54.2 (48.8, 59.3) 36.2 (29.7, 42.6) 
   Surgery, radiotherapy and chemotherapy 32.3 (21.4, 43.7) 47.3 (34.3, 59.2) 39.4 (23.4, 55.5) 
   Radiotherapy and chemotherapy 17.5 (11.8, 23.1) 37.3 (28.3, 46.3) 22.3 (13.8, 30.8) 
   Chemotherapy +/- surgery 2.4 (0.2, 11.0) 4.3 (0.3, 17.9) 2.6 (1.5, 6.8) 
   No treatment 1.6 (0.3, 5.0) 5.6 (1.7, 13.1) 1.7 (0.4, 3.9) 
Network/region    
   WoSCAN (West Scotland) 24.0 (21.4, 26.7) 54.8 (51.1, 58.3) 36.9 (32.0, 41.7) 
   SCAN (East Scotland) 30.0 (25.8, 34.3) 60.0 (54.8, 64.8) 50.0 (42.0, 58.1) 
   NOSCAN (North Scotland) 28.0 (23.5, 32.6) 58.6 (52.9, 63.8) 41.9 (34.7, 49.2) 
  
Chapter 3: Determinants of survival 
118 
3.3.5 Minimally adjusted Cox proportional hazards models for all-cause 
mortality and disease-specific mortality  
The Cox proportional hazards models that were minimally adjusted for age and sex for 
one-year, five-year, and 12-year all-cause mortality and disease-specific mortality are 
displayed in Table 3.8 to Table 3.13 on Page 124 to Page 129.  
3.3.5.1 Minimally adjusted Cox proportional hazards models for all-cause mortality 
and disease-specific mortality for the patient factors  
Carstairs 2001 Category 
Following adjustment for age and sex, the patients in the most deprived group were 96% 
(HR = 1.96, 95% CI 1.38 to 2.77) and 43% (HR = 1.43, 95% CI 1.15 to 1.76) more at risk 
of all-cause mortality after one year and five years, respectively, compared to those who 
were from the least deprived group. However, by 12 years, the people in the most 
deprived category only had a 27% (HR = 1.27, 95% CI 1.06 to 1.52) higher risk of all-
cause mortality compared to those who were from the least deprived group. Following 
adjustment for age and sex, the individuals in the most deprived group were two-fold (HR 
= 2.09, 95% CI 1.36 to 3.22), 55% (HR = 1.55, 95% CI 1.17 to 2.06), and 51% (HR = 1.51, 
95% CI 1.16 to 1.96) more at risk of disease-specific mortality compared to those from the 
least deprived groups after one year, five years, and 12 years, respectively. The results 
for disease-specific mortality following age and sex adjustment were substantially higher 
than the results from the models for all-cause mortality after 12-years, suggesting that the 
patients from the most deprived regions were more at risk of disease-specific mortality 
than they were of all-cause mortality.  
Smoking behaviour 
The patients who were reported as current smokers at the time of their diagnosis were at 
a substantially higher risk of all-cause mortality than those who were reported as never 
having smoked in their lifetime at all three time points following adjustment for age and 
sex. The individuals who were reported as current smokers were 88% (HR = 1.88, 95% CI 
1.56 to 2.27) more at risk of all-cause mortality at 12 years compared to those who were 
reported as never having smoked in their lifetime. Interestingly, the people who were 
reported as being previous smokers at the time of their diagnosis had a smaller excess 
risk of all-cause mortality compared to those who were reported as never having smoked 
in their lifetime (one-year HR = 1.21, 95% CI 0.87 to 1.67; five-year HR = 1.13, 95% CI 
0.88 to 1.45, 12-year HR = 1.20, 95% CI 0.98 to 1.48) following adjustment for age and 
sex. Like the results for all-cause mortality, the patients who were reported as current 
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smokers at the time of their diagnosis had a substantially higher risk of disease-specific 
mortality than those who were reported as never having smoked in their lifetime at all 
three time points following adjustment for age and sex. The individuals who were reported 
as current smokers were 70% (HR = 1.70, 95% CI 1.30 to 2.22) more at risk of disease-
specific mortality at 12 years compared to those who were reported as never having 
smoked. Similar to the results for all-cause mortality, the people who were reported as 
being previous smokers at the time of their diagnosis had no excess risk of disease-
specific mortality compared to those who were reported as never having smoked in their 
lifetime (one-year HR = 0.99, 95% CI 0.68 to 1.44; five-year HR = 1.04, 95% CI 0.75 to 
1.44; 12-year HR = 1.07, 95% CI 0.79 to 1.45) following adjustment for age and sex.  
Alcohol consumption 
Patients who were reported as having a current problem with their levels of alcohol 
consumption at the time of their diagnosis were at a substantially higher risk of all-cause 
mortality than those who were reported as never having drank or who occasionally drank 
at diagnosis at all three time points following adjustment for age and sex. Those who were 
reported as having a current problem with alcohol consumption were 77% (HR = 1.77, 
95% CI 1.55 to 2.02) more at risk of all-cause mortality after 12 years compared to the 
individuals who were reported as never having drank or who occasionally drank before 
their diagnosis. The people who were reported as having a previous problem with their 
alcohol consumption were at a lower risk of all-cause mortality than those who were 
reported as having a current problem with their alcohol consumption after one year, five 
years, and 12 years following adjustment for age and sex. After 12 years, those who were 
reported as having a previous problem with their alcohol consumption were 63% (HR = 
1.63, 95% CI 1.38 to 1.93) more at risk of all-cause mortality than the people who were 
reported as never having drank or who occasionally drank following adjustment for age 
and sex, which was noticeably lower than those who were reported as having a current 
problem with their levels of alcohol consumption.  
Following adjustment for age and sex, the individuals who were reported as having a 
current problem with their consumption of alcohol were at a higher risk of disease-specific 
mortality than those who were reported as never having drank or who occasionally drank. 
The patients who were reported as having a current problem with alcohol were 73% (HR = 
1.73, 95% CI 1.43 to 2.08) more at risk of disease-specific mortality after 12 years 
compared to those who were reported as never having drank or who occasionally drank 
before their diagnosis. Like the results for all-cause mortality, those who were reported as 
having a previous problem with their alcohol consumption were at a lower risk of disease-
specific mortality than those who were reported as having a current problem with their 
alcohol consumption after one year, five years, and 12 years following adjustment for age 
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and sex. After 12 years, the people who were reported as having a previous problem with 
their alcohol consumption were 63% (HR = 1.63, 95% CI 1.29 to 2.08) more at risk of 
disease-specific mortality than the people who were reported as never having drank or 
who occasionally drank following adjustment for age and sex, which was noticeably lower 
than those who were reported as having a previous problem with their alcohol 
consumption.  
WHO Performance Status 
The patients who had a worse WHO Performance Status were at a considerably higher 
risk of all-cause mortality following adjustment for age and sex at all three time points. The 
individuals who were reported as being confined to a bed or a chair for more than 50% of 
their waking hours were at a more than seven-fold (HR = 7.08, 95% CI 5.34 to 9.40) 
higher risk of all-cause mortality after one year. By 12 years, this risk had reduced, but 
those who were reported as being confined to a bed or a chair for more than 50% of their 
waking hours remained at a near six-fold (HR = 5.74, 95% CI 4.56 to 7.22) increased risk 
of all-cause mortality compared to the people who were of a normal WHO Performance 
Status following adjustment for age and sex. Like the results for all-cause mortality, the 
people who had worse WHO Performance Status continued to be at a substantially higher 
risk of disease-specific mortality following adjustment for age and sex at all three time 
points. Those who were reported as being confined to a bed or a chair for more than 50% 
of their waking hours had a more than seven-fold increased risk of disease-specific 
mortality after one year, five years, and 12 years (one-year HR = 7.86, 95% CI 5.61 to 
11.03; five-year HR = 7.64, 95% CI 5.66 to 10.31; 12-year HR = 7.25, 95% CI 5.40 to 
9.71). However, unlike the results for all-cause mortality, the results for disease-specific 
mortality by WHO Performance Status did not attenuate over time. 
3.3.5.2 Minimally adjusted Cox proportional hazards models for all-cause mortality 
and disease-specific mortality for the tumour factors  
Anatomical site 
Following adjustment for age and sex, the patients with cancer of the lip had a 77% (HR = 
0.23, 95% CI 0.17 to 0.33) lower risk of all-cause mortality after 12 years compared to 
those with cancer of the oropharynx. However, the individuals with cancer of the 
hypopharynx had a 42% (HR = 1.42, 95% CI 1.14 to 1.78) higher risk of all-cause 
mortality after 12 years compared to those with cancer of the oropharynx following 
adjustment for age and sex. The same differences were observed following adjustment for 
age and sex whereby people with cancer of the lip had a 92% (HR = 0.08, 95% CI 0.03 to 
0.17) lower risk of disease-specific mortality after 12 years compared to those with cancer 
Chapter 3: Determinants of survival 
121 
of the oropharynx. However, people with cancer of the hypopharynx had a 50% (HR = 
1.50, 95% CI 1.13 to 1.99) higher risk of disease-specific mortality after 12 years 
compared to those with cancer of the oropharynx.  
Tumour stage 
The patients who were diagnosed with cancers that were stage IV were substantially more 
at risk of all-cause mortality than those who were diagnosed with cancers that were stage 
I. This was particularly apparent after one year, by which time the individuals who had 
stage IV tumours were 10 times (HR = 10.24, 95% CI 7.17 to 14.63) more at risk of all-
cause mortality than those who were diagnosed with stage I tumours. By 12 years, the 
people who had stage IV tumours remained at an increased risk of all-cause mortality 
compared to those who had stage I tumours, however this risk had reduced to 3.5-fold 
(HR = 3.51, 95% CI 3.00 to 4.11). The increase in the risk of individuals with stage IV 
tumours was stronger for disease-specific mortality, and those who were diagnosed with 
stage IV tumours were more than 20 times (HR = 20.52, 95% CI 11.51 to 36.59) more at 
risk of disease-specific survival after one year compared to those who were diagnosed 
with stage I tumours following adjustment for age and sex. A similar pattern to the results 
for all-cause mortality was observed over time for disease-specific mortality, whereby 
those who were diagnosed with stage IV tumours had a reduction in the excess risk of 
disease-specific mortality after 12 years, but remained nearly 8 times (HR = 7.80, 95% CI 
5.83 to 10.45) more at risk.  
3.3.5.3 Minimally adjusted Cox proportional hazards models for all-cause mortality 
and disease-specific mortality for the treatment factors  
Treatment modality 
Following adjustment for age and sex, the patients who were treated with radiotherapy 
only were 24% (HR = 1.24, 95% CI 1.06 to 1.44) more at risk of all-cause mortality than 
those who were treated with surgery only after 12 years. Despite having similar survival 
results to those who were treated with radiotherapy, the people who were treated with a 
combination of surgery and radiotherapy were 57% (HR = 1.57, 95% CI 1.35 to 1.83) 
more at risk of all-cause mortality compared to those who were treated with surgery only 
after 12 years following adjustment for age and sex. The individuals who received 
chemotherapy with or without surgery, or who received no treatment were substantially 
more at risk of all-cause mortality than those who were treated with surgery only after 12 
years following age and sex adjustment (chemotherapy group HR = 10.48, 95% CI 7.47 to 
14.71; no treatment HR = 12.17, 95% CI 9.77 to 15.16). Like the results for all-cause 
mortality, the people who were treated with radiotherapy only were at a 45% (HR = 1.45, 
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95% CI 1.14 to 1.86) higher risk of disease-specific mortality compared to those who were 
treated with surgery only following adjustment for age and sex. Also like the results for all-
cause mortality, even though the survival results for those who were treated with 
radiotherapy only or with surgery and radiotherapy were similar, the people who were 
treated with surgery and radiotherapy had a higher risk of disease-specific mortality of 
two-fold (HR = 2.08, 95% CI 1.64 to 2.64) after 12 years following adjustment for age and 
sex. The patients who were treated with chemotherapy with or without surgery, or who 
received no treatment were considerably more at risk of disease-specific survival than 
those who were treated with surgery only (chemotherapy group HR = 15.26, 95% CI 9.90 
to 23.53; no treatment HR = 18.98, 95% CI 14.13 to 25.50) 
Scottish Cancer Network 
Following adjustment for age and sex, there was no excess risk in all-cause or disease-
specific mortality for any of the three Scottish Cancer Networks at one year or five years. 
However, by 12 years, the patients who were treated in the West of Scotland were 22% 
(HR = 1.22, 95% CI 1.07 to 1.39) more at risk than those who were treated in the East of 
Scotland. This difference was not reflected in the results for disease-specific mortality, 
since the people who were treated in the West of Scotland had no increased risk of 
disease-specific mortality than those who were treated in the East of Scotland (HR = 1.15, 
95% CI 0.95 to 1.39).  
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Table 3.8 – Minimally adjusted* hazard ratios for all-cause mortality after one year for each 




   
HR (95% CI) HR p-value p-value Chi-sq. 
Carstairs 2001 Category   <0.001 19.61 
  1 (Least deprived) 1.00 (Ref.) -   
  2 1.35 (0.92, 2.00) 0.402   
  3 1.53 (1.05, 2.25) 0.009   
  4 1.62 (1.12, 2.33) 0.096   
  5 (Most deprived) 1.96 (1.38, 2.77) <0.001   
Smoking behaviour   <0.001 43.51 
  Never smoked 1.00 (Ref.) -   
  Previous smoker 1.21 (0.87, 1.67) 0.253   
  Current smoker 2.02 (1.51, 2.71) <0.001   
  Not recorded 1.08 (0.62, 1.86) 0.787   
Alcohol consumption   <0.001 46.79 
  Never/occasionally drank 1.00 (Ref.) -   
  Previous problem drinker 1.51 (1.19, 1.93) <0.001   
  Current problem drinker 1.81 (1.50, 2.18) <0.001   
  Not recorded 0.89 (0.68, 1.17) 0.416   
WHO Performance Status   <0.001 243.60 
  Normal activity 1.00 (Ref.) -   
  Strenuous restricted 2.37 (1.93, 2.91) <0.001   
  Up and about >50%  4.81 (3.72, 6.22) <0.001   
  Confined to bed/chair >50%  7.08 (5.34, 9.40) <0.001   
  Not recorded 2.17 (1.71, 2.74) <0.001   
Anatomical site   <0.001 115.13 
  Larynx 0.44 (0.35, 0.55) <0.001   
  Oral cavity 0.61 (0.49, 0.75) <0.001   
  Oropharynx 1.00 (Ref.) -   
  Hypopharynx 1.36 (1.03, 1.79) 0.031   
  Nasal cavity 0.69 (0.47, 1.01) 0.056   
  Lip 0.12 (0.06, 0.24) <0.001   
  Other/salivary gland 0.74 (0.54, 1.03) 0.073   
Tumour stage   <0.001 244.59 
   I 1.00 (Ref.) -   
   II 3.16 (2.13, 4.71) <0.001   
   III 5.39 (3.64, 7.99) <0.001   
   IV 10.24 (7.17, 14.63) <0.001   
   Unknown 5.69 (3.68, 8.82) <0.001   
Treatment modality    <0.001 670.50 
   Surgery only 1.00 (Ref.) -   
   Radiotherapy only 1.58 (1.22, 2.04) <0.001   
   Surgery and radiotherapy 1.81 (1.40, 2.34) <0.001   
   Surgery, radiotherapy and chemotherapy 2.94 (1.92, 4.50) <0.001   
   Radiotherapy and chemotherapy 3.46 (2.54, 4.71) <0.001   
   Chemotherapy +/- surgery 16.78 (11.40, 24.70) <0.001   
   No treatment 19.58 (14.83, 25.85) <0.001   
Network/region   0.360 2.04 
  WoSCAN (West Scotland) 1.14 (0.94, 1.37) 0.181   
  SCAN (East Scotland) 1.00 (Ref.) -   
  NOSCAN (North Scotland) 1.04 (0.83, 1.32) 0.711   
*Adjusted by age and tumour sex 
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Table 3.9 – Minimally adjusted* hazard ratios for all-cause mortality after five years for each 




   
HR (95% CI) HR p-value p-value Chi-sq. 
Carstairs 2001 Category   <0.001 20.58 
  1 (Least deprived) 1.00 (Ref.) -   
  2 0.99 (0.78, 1.26) 0.776   
  3 1.22 (0.97, 1.54) 0.110   
  4 1.14 (0.91, 1.43) 0.266   
  5 (Most deprived) 1.43 (1.15, 1.76) 0.001   
Smoking behaviour   <0.001 59.68 
  Never smoked 1.00 (Ref.) -   
  Previous smoker 1.13 (0.88, 1.45) 0.341   
  Current smoker 1.86 (1.49, 2.32) <0.001   
  Not recorded 1.20 (0.80, 1.80) 0.368   
Alcohol consumption   <0.001 74.87 
  Never/occasionally drank 1.00 (Ref.) -   
  Previous problem drinker 1.58 (1.30, 1.91) <0.001   
  Current problem drinker 1.83 (1.58, 2.13) <0.001   
  Not recorded 0.96 (0.79, 1.18) 0.728   
WHO Performance Status   <0.001 319.64 
  Normal activity 1.00 (Ref.) -   
  Strenuous restricted 2.12 (1.81, 2.48) <0.001   
  Up and about >50%  4.07 (3.28, 5.04) <0.001   
  Confined to bed/chair >50%  6.60 (5.19, 8.38) <0.001   
  Not recorded 1.96 (1.63, 2.34) <0.001   
Anatomical site   <0.001 158.98 
  Larynx 0.47 (0.40, 0.57) <0.001   
  Oral cavity 0.66 (0.55, 0.78) <0.001   
  Oropharynx 1.00 (Ref.) -   
  Hypopharynx 1.43 (1.13, 1.82) 0.003   
  Nasal cavity 0.75 (0.55, 1.01) 0.062   
  Lip 0.18 (0.11, 0.28) <0.001   
  Other/salivary gland 0.75 (0.58, 0.99) 0.040   
Tumour stage   <0.001 299.14 
   I 1.00 (Ref.) -   
   II 2.14 (1.69, 2.72) <0.001   
   III 3.22 (2.53, 4.11) <0.001   
   IV 5.36 (4.34, 6.61) <0.001   
   Unknown 3.04 (2.27, 4.07) <0.001   
Treatment modality    <0.001 684.14 
   Surgery only 1.00 (Ref.) -   
   Radiotherapy only 1.24 (1.04, 1.50) 0.020   
   Surgery and radiotherapy 1.69 (1.41, 2.03) <0.001   
   Surgery, radiotherapy and chemotherapy 2.02 (1.42, 2.87) <0.001   
   Radiotherapy and chemotherapy 2.60 (2.04, 3.31) <0.001   
   Chemotherapy +/- surgery 12.63 (8.90, 17.90) <0.001   
   No treatment 14.39 (11.39, 18.18) <0.001   
Network/region   0.161 3.65 
  WoSCAN (West Scotland) 1.13 (0.97, 1.31) 0.106   
  SCAN (East Scotland) 1.00 (Ref.) -   
  NOSCAN (North Scotland) 1.01 (0.84, 1.21) 0.931   
*Adjusted by age and tumour sex 
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Table 3.10 – Minimally adjusted* hazard ratios for all-cause mortality after 12 years for each 




   
HR (95% CI) HR p-value p-value Chi-sq. 
Carstairs 2001 Category   0.005 15.10 
  1 (Least deprived) 1.00 (Ref.) -   
  2 0.94 (0.77, 1.15) 0.441   
  3 1.09 (0.89, 1.32) 0.479   
  4 1.08 (0.89, 1.30) 0.406   
  5 (Most deprived) 1.27 (1.06, 1.52) 0.012   
Smoking behaviour   <0.001 72.33 
  Never smoked 1.00 (Ref.) -   
  Previous smoker 1.20 (0.98, 1.48) 0.081   
  Current smoker 1.88 (1.56, 2.27) <0.001   
  Not recorded 1.27 (0.90, 1.79) 0.170   
Alcohol consumption   <0.001 86.53 
  Never/occasionally drank 1.00 (Ref.) -   
  Previous problem drinker 1.63 (1.38, 1.93) <0.001   
  Current problem drinker 1.77 (1.55, 2.02) <0.001   
  Not recorded 1.02 (0.86, 1.22) 0.796   
WHO Performance Status   <0.001 320.45 
  Normal activity 1.00 (Ref.) -   
  Strenuous restricted 1.94 (1.70, 2.22) <0.001   
  Up and about >50%  3.49 (2.86, 4.25) <0.001   
  Confined to bed/chair >50%  5.74 (4.56, 7.22) <0.001   
  Not recorded 1.81 (1.55, 2.11) <0.001   
Anatomical site   <0.001 156.92 
  Larynx 0.54 (0.46, 0.64) <0.001   
  Oral cavity 0.71 (0.60, 0.83) <0.001   
  Oropharynx 1.00 (Ref.) -   
  Hypopharynx 1.42 (1.14, 1.78) 0.002   
  Nasal cavity 0.77 (0.59, 1.02) 0.066   
  Lip 0.23 (0.17, 0.33) <0.001   
  Other/salivary gland 0.72 (0.56, 0.92) 0.009   
Tumour stage   <0.001 282.10 
   I 1.00 (Ref.) -   
   II 1.60 (1.33, 1.91) <0.001   
   III 2.22 (1.84, 2.69) <0.001   
   IV 3.51 (3.00, 4.11) <0.001   
   Unknown 2.10 (1.65, 2.66) <0.001   
Treatment modality    <0.001 650.19 
   Surgery only 1.00 (Ref.) -   
   Radiotherapy only 1.24 (1.06, 1.44) 0.006   
   Surgery and radiotherapy 1.57 (1.35, 1.83) <0.001   
   Surgery, radiotherapy and chemotherapy 1.68 (1.23, 2.31) 0.001   
   Radiotherapy and chemotherapy 2.38 (1.92, 2.94) <0.001   
   Chemotherapy +/- surgery 10.48 (7.47, 14.71) <0.001   
   No treatment 12.17 (9.77, 15.16) <0.001   
Network/region   0.007 10.02 
  WoSCAN (West Scotland) 1.22 (1.07, 1.39) 0.003   
  SCAN (East Scotland) 1.00 (Ref.) -   
  NOSCAN (North Scotland) 1.08 (0.92, 1.26) 0.377   
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Table 3.11 – Minimally adjusted* hazard ratios for disease-specific mortality after one year 




   
HR (95% CI) HR p-value p-value Chi-sq. 
Carstairs 2001 Category   0.028 10.87 
  1 (Least deprived) 1.00 (Ref.) -   
  2 1.59 (0.99, 2.54) 0.284   
  3 1.69 (1.06, 2.69) 0.017   
  4 1.72 (1.10, 2.69) 0.004   
  5 (Most deprived) 2.09 (1.36, 3.22) <0.001   
Smoking behaviour   <0.001 27.25 
  Never smoked 1.00 (Ref.) -   
  Previous smoker 0.99 (0.68, 1.44) 0.950   
  Current smoker 1.69 (1.21, 2.35) 0.001   
  Not recorded 0.72 (0.35, 1.48) 0.375   
Alcohol consumption   <0.001 32.15 
  Never/occasionally drank 1.00 (Ref.) -   
  Previous problem drinker 1.60 (1.21, 2.13) 0.001   
  Current problem drinker 1.70 (1.35, 2.13) <0.001   
  Not recorded 0.77 (0.55, 1.09) 0.137   
WHO Performance Status   <0.001 180.91 
  Normal activity 1.00 (Ref.) -   
  Strenuous restricted 2.48 (1.93, 3.18) <0.001   
  Up and about >50%  4.97 (3.63, 6.81) <0.001   
  Confined to bed/chair >50%  7.86 (5.61, 11.03) <0.001   
  Not recorded 2.17 (1.63, 2.88) <0.001   
Anatomical site   <0.001 74.84 
  Larynx 0.44 (0.34, 0.58) <0.001   
  Oral cavity 0.60 (0.46, 0.77) <0.001   
  Oropharynx 1.00 (Ref.) -   
  Hypopharynx 1.27 (0.90, 1.78) 0.174   
  Nasal cavity 0.72 (0.46, 1.13) 0.149   
  Lip 0.04 (0.01, 0.17) <0.001   
  Other/salivary gland 0.53 (0.34, 0.83) 0.005   
Tumour stage   <0.001 183.62 
   I 1.00 (Ref.) -   
   II 5.68 (3.06, 10.55) <0.001   
   III 9.57 (5.17, 17.72) <0.001   
   IV 20.52 (11.51, 36.59) <0.001   
   Unknown 10.66 (5.53, 20.55) <0.001   
Treatment modality    <0.001 495.41 
   Surgery only 1.00 (Ref.) -   
   Radiotherapy only 1.72 (1.24, 2.39) 0.001   
   Surgery and radiotherapy 2.12 (1.53, 2.94) <0.001   
   Surgery, radiotherapy and chemotherapy 4.45 (2.78, 7.12) <0.001   
   Radiotherapy and chemotherapy 4.33 (2.98, 6.31) <0.001   
   Chemotherapy +/- surgery 18.33 (11.32, 29.70) <0.001   
   No treatment 24.15 (17.07, 34.19) <0.001   
Network/region   0.905 0.20 
  WoSCAN (West Scotland) 1.03 (0.82, 1.29) 0.804   
  SCAN (East Scotland) 1.00 (Ref.) -   
  NOSCAN (North Scotland) 1.06 (0.81, 1.40) 0.656   
*Adjusted by age and tumour sex 
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Table 3.12 – Minimally adjusted* hazard ratios for disease-specific mortality after five years 




   
HR (95% CI) HR p-value p-value Chi-sq. 
Carstairs 2001 Category   0.005 15.00 
  1 (Least deprived) 1.00 (Ref.) -   
  2 1.06 (0.77, 1.46) 0.693   
  3 1.41 (1.04, 1.92) 0.029   
  4 1.28 (0.95, 1.72) 0.107   
  5 (Most deprived) 1.55 (1.17, 2.06) 0.002   
Smoking behaviour   <0.001 32.40 
  Never smoked 1.00 (Ref.) -   
  Previous smoker 1.04 (0.75, 1.44) 0.801   
  Current smoker 1.72 (1.29, 2.29) <0.001   
  Not recorded 0.93 (0.53, 1.65) 0.804   
Alcohol consumption   <0.001 40.96 
  Never/occasionally drank 1.00 (Ref.) -   
  Previous problem drinker 1.64 (1.29, 2.09) <0.001   
  Current problem drinker 1.65 (1.36, 2.01) <0.001   
  Not recorded 0.79 (0.59, 1.06) 0.116   
WHO Performance Status   <0.001 224.53 
  Normal activity 1.00 (Ref.) -   
  Strenuous restricted 2.20 (1.78, 2.72) <0.001   
  Up and about >50%  4.56 (3.46, 6.00) <0.001   
  Confined to bed/chair >50%  7.64 (5.66, 10.31) <0.001   
  Not recorded 2.11 (1.66, 2.68) <0.001   
Anatomical site   <0.001 116.65 
  Larynx 0.42 (0.33, 0.53) <0.001   
  Oral cavity 0.58 (0.46, 0.72) <0.001   
  Oropharynx 1.00 (Ref.) -   
  Hypopharynx 1.36 (1.01, 1.83) 0.041   
  Nasal cavity 0.73 (0.50, 1.07) 0.106   
  Lip 0.04 (0.01, 0.13) <0.001   
  Other/salivary gland 0.52 (0.36, 0.77) 0.001   
Tumour stage   <0.001 248.49 
   I 1.00 (Ref.) -   
   II 2.93 (1.98, 4.34) <0.001   
   III 5.11 (3.46, 7.54) <0.001   
   IV 10.12 (7.14, 14.35) <0.001   
   Unknown 5.33 (3.44, 8.27) <0.001   
Treatment modality    <0.001 525.25 
   Surgery only 1.00 (Ref.) -   
   Radiotherapy only 1.47 (1.13, 1.91) 0.005   
   Surgery and radiotherapy 2.07 (1.60, 2.68) <0.001   
   Surgery, radiotherapy and chemotherapy 3.50 (2.32, 5.28) <0.001   
   Radiotherapy and chemotherapy 3.82 (2.80, 5.23) <0.001   
   Chemotherapy +/- surgery 16.17 (10.41, 25.13) <0.001   
   No treatment 19.93 (14.68, 27.05) <0.001   
Network/region   0.858 0.31 
  WoSCAN (West Scotland) 1.06 (0.87, 1.28) 0.580   
  SCAN (East Scotland) 1.00 (Ref.) -   
  NOSCAN (North Scotland) 1.04 (0.82, 1.32) 0.748   
*Adjusted by age and tumour sex 
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Table 3.13 – Minimally adjusted* hazard ratios for disease-specific mortality after 12 years 






HR (95% CI) HR p-value p-value Chi-sq. 
Carstairs 2001 Category   0.002 17.19 
  1 (Least deprived) 1.00 (Ref.) -   
  2 0.98 (0.73, 1.33) 0.892   
  3 1.32 (0.99, 1.75) 0.053   
  4 1.27 (0.97, 1.68) 0.073   
  5 (Most deprived) 1.51 (1.16, 1.96) 0.002   
Smoking behaviour   <0.001 32.91 
  Never smoked 1.00 (Ref.) -   
  Previous smoker 1.07 (0.79, 1.45) 0.644   
  Current smoker 1.70 (1.30, 2.22) <0.001   
  Not recorded 0.94 (0.55, 1.61) 0.835   
Alcohol consumption   <0.001 47.75 
  Never/occasionally drank 1.00 (Ref.) -   
  Previous problem drinker 1.63 (1.29, 2.06) <0.001   
  Current problem drinker 1.73 (1.43, 2.08) <0.001   
  Not recorded 0.83 (0.64, 1.09) 0.184   
WHO Performance Status   <0.001 222.87 
  Normal activity 1.00 (Ref.) -   
  Strenuous restricted 2.12 (1.74, 2.59) <0.001   
  Up and about >50%  4.13 (3.16, 5.40) <0.001   
  Confined to bed/chair >50%  7.25 (5.40, 9.72) <0.001   
  Not recorded 2.04 (1.63, 2.54) <0.001   
Anatomical site   <0.001 123.79 
  Larynx 0.46 (0.37, 0.57) <0.001   
  Oral cavity 0.63 (0.50, 0.78) <0.001   
  Oropharynx 1.00 (Ref.) -   
  Hypopharynx 1.50 (1.13, 1.99) 0.006   
  Nasal cavity 0.78 (0.54, 1.13) 0.184   
  Lip 0.08 (0.03, 0.17) <0.001   
  Other/salivary gland 0.56 (0.39, 0.80) 0.002   
Tumour stage   <0.001 258.81 
   I 1.00 (Ref.) -   
   II 2.47 (1.77, 3.45) <0.001   
   III 4.10 (2.94, 5.71) <0.001   
   IV 7.80 (5.83, 10.45) <0.001   
   Unknown 4.11 (2.79, 6.05) <0.001   
Treatment modality    <0.001 527.92 
   Surgery only 1.00 (Ref.) -   
   Radiotherapy only 1.45 (1.14, 1.86) 0.003   
   Surgery and radiotherapy 2.08 (1.64, 2.64) <0.001   
   Surgery, radiotherapy and chemotherapy 3.14 (2.12, 4.65) <0.001   
   Radiotherapy and chemotherapy 3.74 (2.79, 5.02) <0.001   
   Chemotherapy +/- surgery 15.26 (9.90, 23.53) <0.001   
   No treatment 18.98 (14.13, 25.50) <0.001   
Network/region   0.326 2.24 
  WoSCAN (West Scotland) 1.15 (0.95, 1.39) 0.143   
  SCAN (East Scotland) 1.00 (Ref.) -   
  NOSCAN (North Scotland) 1.07 (0.85, 1.35) 0.551   
*Adjusted by age and tumour sex 
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3.3.6 Mutually adjusted multivariate Cox proportional hazards model for 
all-cause mortality 
Results for the mutually adjusted Cox proportional hazards model for one-year, five-year, 
and 12-year all-cause mortality are displayed in Table 3.14 to Table 3.16 on Page 133 to 
Page 135. 
3.3.6.1 Determinants with an independent association with all-cause mortality – 
summary of findings 
In the order that they were entered into the model, the determinants that had an 
independent association with all-cause mortality following the forced inclusion of age at 
diagnosis, tumour stage and treatment modality in the forward stepwise mutually adjusted 
Cox proportional hazards models after one year, five years, and 12 years were WHO 
Performance Status, alcohol consumption, anatomical site, and smoking behaviour. A 
description of these effects is outlined below.  
3.3.6.2 Patient factors with an independent association with all-cause mortality  
Age at diagnosis 
Following mutual adjustment, the patients who were older continued to have a greater risk 
of all-cause mortality following mutual adjustment, particularly after 12 years, by which 
time the people who were 75 years and older had a near 2.5-fold (HR = 2.44, 95% CI 1.97 
to 3.01) increase in the risk of all-cause mortality compared to those who were aged 
between the years of 45 and 54.  
Smoking behaviour 
Following mutual adjustment, the patients who were reported as having been current 
smokers at the time of their head and neck cancer diagnosis were at a greater risk of all-
cause mortality compared to those who were reported as having been previous smokers 
or who had never smoked at the time of their diagnosis. After one year, five years, and 12 
years, the people who were current smokers were 42% (HR = 1.42, 95% CI 1.04 to 1.94), 
39% (H = 1.39, 95% CI 1.10 to 1.76), and 45% (HR = 1.45, 95% CI 1.19 to 1.77) more at 
risk of all-cause mortality than those who had never smoked, respectively. However, after 
one year, five years, and 12 years, the individuals who were previous smokers were not at 
an increased risk of all-cause mortality compared to those who never smoked following 
mutual adjustment (one-year HR = 1.12, 95% CI 0.80 to 1.56; five-year HR = 1.04, 95% 
CI 0.81 to 1.35; 12-year HR = 1.08, 95% CI 0.87 to 1.34).  
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Alcohol consumption 
Following mutual adjustment, the patients who were reported as having a current problem 
with their consumption of alcohol were 32% (HR = 1.32, 95% CI 1.08 to 1.61) more at risk 
of one-year all-cause mortality than those who were reported as never having drank or 
who occasionally drank alcohol. Over time, the risk of all-cause mortality became greater 
for those who had a current problem with their alcohol consumption at diagnosis, and after 
12 years these people were 51% (HR = 1.51, 95% CI 1.31 to 1.73) more at risk of all-
cause mortality than those who never drank or who occasionally drank alcohol. A similar 
pattern was observed for the individuals who were reported as having a previous problem 
with their alcohol consumption at diagnosis, and after one year these people had no 
excess risk of all-cause mortality than those who were reported as never having drank or 
who occasionally drank alcohol (HR = 1.19, 95% CI 0.93 to 1.53). However, by five years 
this risk had increased to 29% (HR = 1.29, 95% CI 1.06 to 1.57) and after 12 years the 
risk was higher at 36% (HR = 1.36, 95% CI 1.15 to 1.62) for those who had a previous 
problem with their alcohol consumption compared to those who never drank or who 
occasionally drank alcohol following mutual adjustment.  
WHO Performance Status 
The patients who had worse WHO Performance Status at the time of their diagnosis were 
at a significantly increased risk of all-cause mortality following mutual adjustment at all 
three time points. Those who were reported as being confined to a bed or a chair for more 
than 50% of their waking hours were at a more than two-fold increased risk of all-cause 
mortality after one year, five years, and 12 years (one-year HR = 2.38, 95% CI 1.74 to 
3.27; five-year HR = 2.80, 95% CI 2.15 to 3.65; 12-year HR = 2.61, 95% CI 2.03 to 3.36) 
following mutual adjustment.  
3.3.6.3 Tumour factors with an independent association with all-cause mortality  
Anatomical site 
Following mutual adjustment, the patients with cancer of the lip had a 50% (HR = 0.50, 
95% CI 0.35 to 0.73) lower risk of all-cause mortality after 12 years compared to those 
with cancer of the oropharynx. People with cancer of the larynx also had a reduced risk of 
all-cause mortality by 26% (HR = 0.74, 95% CI 0.63 to 0.88) after 12 years compared to 
those who were diagnosed with cancer of the oropharynx. However, interestingly there 
were no differences in overall survival between the patients who had cancers of the 
oropharynx, hypopharynx, nasal cavity, or other tumours of the head and neck cancer 
after one year, five years, and 12 years following mutual adjustment.  
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Tumour stage 
As the tumour stage of the patients’ cancer increased, the one-year, five-year, and 12-
year risk of all-cause mortality increased at all three time points following mutual 
adjustment. Individuals who had stage IV cancer had a near six-fold (HR = 5.89, 95% CI 
3.98 to 8.71) increased risk of all-cause mortality compared to those who were diagnosed 
with stage I cancer after one year. Over time, the difference in risk across the cancer 
stages attenuated, however after 12 years the people who were diagnosed with stage IV 
cancer still had a more than two-fold (HR = 2.38, 95% CI 1.97 to 2.88) increased risk of 
all-cause mortality than those who were diagnosed with a tumour stage I tumour following 
mutual adjustment.  
3.3.6.4 Treatment factors with an independent association with all-cause mortality  
Treatment modality 
Following mutual adjustment, the patients who were treated with a combination of surgery 
and radiotherapy had no excess risk of all-cause mortality compared to those who were 
treated with surgery only after one year (HR = 0.97, 95% CI 0.73 to 1.29), five years (HR 
= 1.01, 95% CI 0.82 to 1.24), and 12 years (HR = 1.02, 95% CI 0.86 to 1.22). After one 
year, the people who were treated with radiotherapy only were 62% (HR = 1.62, 95% CI 
1.22 to 2.16) more at risk of all-cause mortality following mutual adjustment compared to 
those who received surgery only. However, by five years and 12 years this excess risk 
had reduced to around 30% for those who received radiotherapy only compared to those 
who received surgery only following adjustment for age and tumour stage (five-year HR = 
1.32, 95% CI 1.07 to 1.63; 12-year HR = 1.31, 95% CI 1.09 to 1.57).  
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Table 3.14 – Mutually adjusted hazard ratios for all-cause mortality after one year for each 




   
HR (95% CI) HR p-value p-value Chi-sq. 
Age at diagnosis   <0.001 22.23 
  Less than 45 0.71 (0.42, 1.21) 0.208   
  45 to 54 1.00 (Ref.) -   
  55 to 64 1.00 (0.77, 1.29) 0.991   
  65 to 74 1.37 (1.05, 1.79) 0.019   
  75 and over 1.60 (1.18, 2.18) 0.002   
Smoking behaviour   0.024 9.40 
  Never smoked 1.00 (Ref.) -   
  Previous smoker 1.12 (0.80, 1.56) 0.520   
  Current smoker 1.42 (1.04, 1.94) 0.026   
  Not recorded 0.94 (0.51, 1.73) 0.835   
Alcohol consumption   0.023 10.82 
  Never/occasionally drank 1.00 (Ref.) -   
  Previous problem drinker 1.19 (0.93, 1.53) 0.169   
  Current problem drinker 1.32 (1.08, 1.61) 0.006   
  Not recorded 0.86 (0.63, 1.16) 0.323   
WHO Performance Status   <0.001 41.46 
  Normal activity 1.00 (Ref.) -   
  Strenuous restricted 1.52 (1.23, 1.89) <0.001   
  Up and about >50%  2.19 (1.66, 2.90) <0.001   
  Confined to bed/chair >50%  2.38 (1.74, 3.27) <0.001   
  Not recorded 1.45 (1.13, 1.85) 0.003   
Anatomical site   0.006 18.33 
  Larynx 0.72 (0.57, 0.91) 0.007   
  Oral cavity 1.00 (0.79, 1.27) 0.991   
  Oropharynx 1.00 (Ref.) -   
  Hypopharynx 0.99 (0.74, 1.31) 0.926   
  Nasal cavity 0.80 (0.54, 1.20) 0.279   
  Lip 0.48 (0.23, 1.03) 0.058   
  Other/salivary gland 1.25 (0.88, 1.77) 0.210   
Tumour stage   <0.001 88.70 
  I 1.00 (Ref.) -   
  II 2.71 (1.81, 4.05) <0.001   
  III 4.17 (2.77, 6.27) <0.001   
  IV 5.89 (3.98, 8.71) <0.001   
  Unknown 4.36 (2.74, 6.95) <0.001   
Treatment modality    <0.001 285.18 
   Surgery only 1.00 (Ref.) -   
   Radiotherapy only 1.62 (1.22, 2.16) <0.001   
   Surgery and radiotherapy 0.97 (0.73, 1.29) 0.828   
   Surgery, radiotherapy and chemotherapy 1.39 (0.88, 2.19) 0.154   
   Radiotherapy and chemotherapy 1.70 (1.21, 2.40) 0.002   
   Chemotherapy +/- surgery 7.25 (4.77, 11.02) <0.001   
   No treatment 7.78 (5.68, 10.66) <0.001   
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Table 3.15 – Mutually adjusted hazard ratios for all-cause mortality after five years for each 




   
HR (95% CI) HR p-value p-value Chi-sq. 
Age at diagnosis   <0.001 69.51 
  Less than 45 0.56 (0.36, 0.87) 0.010   
  45 to 54 1.00 (Ref.) -   
  55 to 64 1.11 (0.91, 1.36) 0.306   
  65 to 74 1.65 (1.34, 2.03) <0.001   
  75 and over 2.01 (1.58, 2.56) <0.001   
Smoking behaviour   0.001 16.08 
  Never smoked 1.00 (Ref.) -   
  Previous smoker 1.04 (0.81, 1.35) 0.745   
  Current smoker 1.39 (1.10, 1.76) 0.006   
  Not recorded 1.14 (0.72, 1.79) 0.574   
Alcohol consumption   <0.001 29.35 
  Never/occasionally drank 1.00 (Ref.) -   
  Previous problem drinker 1.29 (1.06, 1.57) 0.012   
  Current problem drinker 1.50 (1.28, 1.75) <0.001   
  Not recorded 0.95 (0.76, 1.20) 0.688   
WHO Performance Status   <0.001 79.64 
  Normal activity 1.00 (Ref.) -   
  Strenuous restricted 1.51 (1.28, 1.77) <0.001   
  Up and about >50%  2.27 (1.81, 2.86) <0.001   
  Confined to bed/chair >50%  2.80 (2.15, 3.65) <0.001   
  Not recorded 1.44 (1.19, 1.73) <0.001   
Anatomical site   <0.001 29.90 
  Larynx 0.70 (0.57, 0.85) <0.001   
  Oral cavity 0.95 (0.78, 1.15) 0.570   
  Oropharynx 1.00 (Ref.) -   
  Hypopharynx 1.05 (0.82, 1.34) 0.708   
  Nasal cavity 0.83 (0.60, 1.14) 0.243   
  Lip 0.48 (0.30, 0.78) 0.003   
  Other/salivary gland 1.12 (0.84, 1.48) 0.457   
Tumour stage   <0.001 96.36 
  I 1.00 (Ref.) -   
  II 1.91 (1.50, 2.43) <0.001   
  III 2.46 (1.90, 3.18) <0.001   
  IV 3.33 (2.61, 4.26) <0.001   
  Unknown 2.61 (1.91, 3.58) <0.001   
Treatment modality    <0.001 277.35 
   Surgery only 1.00 (Ref.) -   
   Radiotherapy only 1.32 (1.07, 1.63) 0.011   
   Surgery and radiotherapy 1.01 (0.82, 1.24) 0.917   
   Surgery, radiotherapy and chemotherapy 1.08 (0.74, 1.57) 0.682   
   Radiotherapy and chemotherapy 1.39 (1.06, 1.83) 0.017   
   Chemotherapy +/- surgery 6.24 (4.29, 9.06) <0.001   
   No treatment 6.22 (4.77, 8.10) <0.001   
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Table 3.16 – Mutually adjusted hazard ratios for all-cause mortality after 12 years for each 




   
HR (95% CI) HR p-value p-value Chi-sq. 
Age at diagnosis   <0.001 139.21 
  Less than 45 0.59 (0.42, 0.84) 0.004   
  45 to 54 1.00 (Ref.) -   
  55 to 64 1.17 (0.98, 1.40) 0.077   
  65 to 74 1.94 (1.62, 2.32) <0.001   
  75 and over 2.44 (1.97, 3.01) <0.001   
Smoking behaviour   <0.001 24.62 
  Never smoked 1.00 (Ref.) -   
  Previous smoker 1.08 (0.87, 1.34) 0.488   
  Current smoker 1.45 (1.19, 1.77) <0.001   
  Not recorded 1.22 (0.83, 1.80) 0.304   
Alcohol consumption   <0.001 38.81 
  Never/occasionally drank 1.00 (Ref.) -   
  Previous problem drinker 1.36 (1.15, 1.62) <0.001   
  Current problem drinker 1.51 (1.31, 1.73) <0.001   
  Not recorded 1.01 (0.83, 1.23) 0.900   
WHO Performance Status   <0.001 84.55 
  Normal activity 1.00 (Ref.) -   
  Strenuous restricted 1.46 (1.27, 1.68) <0.001   
  Up and about >50%  2.13 (1.73, 2.63) <0.001   
  Confined to bed/chair >50%  2.61 (2.03, 3.36) <0.001   
  Not recorded 1.42 (1.21, 1.66) <0.001   
Anatomical site   <0.001 32.79 
  Larynx 0.74 (0.63, 0.88) <0.001   
  Oral cavity 0.98 (0.82, 1.16) 0.790   
  Oropharynx 1.00 (Ref.) -   
  Hypopharynx 1.06 (0.84, 1.33) 0.624   
  Nasal cavity 0.78 (0.59, 1.04) 0.087   
  Lip 0.50 (0.35, 0.73) <0.001   
  Other/salivary gland 1.02 (0.79, 1.33) 0.881   
Tumour stage   <0.001 83.57 
  I 1.00 (Ref.) -   
  II 1.44 (1.20, 1.73) <0.001   
  III 1.77 (1.45, 2.17) <0.001   
  IV 2.38 (1.97, 2.88) <0.001   
  Unknown 1.97 (1.52, 2.56) <0.001   
Treatment modality    <0.001 283.86 
   Surgery only 1.00 (Ref.) -   
   Radiotherapy only 1.31 (1.09, 1.57) 0.004   
   Surgery and radiotherapy 1.02 (0.86, 1.22) 0.810   
   Surgery, radiotherapy and chemotherapy 1.00 (0.72, 1.39) 0.984   
   Radiotherapy and chemotherapy 1.40 (1.10, 1.78) 0.006   
   Chemotherapy +/- surgery 6.01 (4.19, 8.62) <0.001   
   No treatment 5.99 (4.67, 7.69) <0.001   
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3.3.6.5 Sensitivity analysis 1 – excluding people who received no treatment in the 
models for all-cause mortality  
The results for the forward stepwise models which excluded the people who received no 
treatment after one year, five years, and 12 years are displayed in Table 3.17 to Table 
3.19. Following the exclusion of the people who received no treatment, a total of 1,691 
people remained in this sensitivity analysis. When a forward stepwise multivariate Cox 
proportional hazards model was performed, the determinants with an independent 
association with all-cause mortality following the forced inclusion of age at diagnosis, 
tumour stage, and treatment modality after one year, five years, and 12 years were WHO 
Performance Status, alcohol consumption, anatomical site, and smoking behaviour. This 
displayed the same results as the main cohort.  
3.3.6.6 Sensitivity analysis 2 – excluding people with oropharynx cancer in the 
models for all-cause mortality  
The results for the forward stepwise models which excluded the people who had cancer of 
the oropharynx after one year, five years, and 12 years are displayed in Table 3.20 to 
Table 3.22. Following the exclusion of the people who had cancer of the oropharynx, a 
total of 1,497 people remained in this sensitivity analysis. The determinants with an 
independent association with all-cause mortality in a mutually adjusted Cox proportional 
hazards model following the forced inclusion of age at diagnosis, tumour stage, and 
treatment modality were WHO Performance Status, alcohol consumption, anatomical site, 
and smoking behaviour after five years and 12 years. These results were the same as the 
results for the main cohort of people at both five years and 12 years. However, the results 
differed slightly after one year and the determinants with an independent association with 
all-cause mortality after one year included age at diagnosis, tumour stage, treatment 
modality, WHO Performance Status, alcohol consumption, anatomical site, and Scottish 
Cancer Network.   
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Table 3.17 – Mutually adjusted hazard ratios for all-cause mortality after one year for each 
patient, tumour, and treatment factor following the exclusion of people who received no 
treatment (n = 1,691) 
Variable 
One-year    
HR (95% CI) HR p-value p-value Chi-sq. 
Age at diagnosis   <0.001 19.22 
  Less than 45 0.80 (0.47, 1.39) 0.434   
  45 to 54 1.00 (Ref.) -   
  55 to 64 1.09 (0.83, 1.43) 0.522   
  65 to 74 1.52 (1.15, 2.01) 0.003   
  75 and over 1.69 (1.21, 2.37) 0.002   
Smoking status    0.015 10.47 
  Never smoked 1.00 (Ref.) -   
  Previous smoker 1.10 (0.77, 1.57) 0.588   
  Current smoker 1.45 (1.05, 2.01) 0.025   
  Unknown 0.74 (0.35, 1.59) 0.442   
Alcohol consumption   0.006 12.59 
  Never/occasionally drank 1.00 (Ref.) -   
  Previous problem drinker 1.14 (0.87, 1.51) 0.348   
  Current problem drinker 1.41 (1.14, 1.74) 0.002   
  Not recorded 0.83 (0.58, 1.20) 0.316   
WHO Performance Status   <0.001 42.81 
  Normal activity 1.00 (Ref.) -   
  Strenuous restricted 1.52 (1.22, 1.91) 0.001   
  Up and about >50%  2.59 (1.92, 3.48) <0.001   
  Confined to bed/chair >50%  1.98 (1.32, 2.97) 0.001   
  Not recorded 1.47 (1.14, 1.89) 0.003   
Anatomical site   <0.001 31.07 
  Larynx 0.67 (0.52, 0.88) 0.001   
  Oral cavity 1.18 (0.90, 1.54) 0.003   
  Oropharynx 1.00 (Ref.)    
  Hypopharynx 1.30 (0.95, 1.78) 0.105   
  Nasal cavity 0.90 (0.58, 1.41) 0.657   
  Lip 0.60 (0.28, 1.30) 0.195   
  Other/salivary gland 1.38 (0.95, 2.00) 0.093   
Stage   <0.001 102.05 
  I 1.00 (Ref.) -   
  II 2.55 (1.68, 3.86) <0.001   
  III 4.09 (2.68, 6.24) <0.001   
  IV 6.72 (4.48, 10.08) <0.001   
  Unknown 3.76 (2.25, 6.29) <0.001   
Treatment modality    <0.001 129.61 
   Surgery only 1.00 (Ref.) -   
   Radiotherapy only 1.74 (1.31, 2.32) 0.001   
   Surgery and radiotherapy 0.91 (0.68, 1.22) 0.533   
   Surgery, radiotherapy and chemotherapy 1.28 (0.81, 2.03) 0.294   
   Radiotherapy and chemotherapy 1.58 (1.11, 2.25) 0.011   
   Chemotherapy +/- surgery 7.96 (5.17, 12.26) <0.001   
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Table 3.18 – Mutually adjusted hazard ratios for all-cause mortality after five years for each 
patient, tumour, and treatment factor study following the exclusion of people who received 
no treatment (n = 1,691) 
Variable 
Five-year    
HR (95% CI) HR p-value p-value Chi-sq. 
Age at diagnosis   <0.001 65.73 
  Less than 45 0.59 (0.38, 0.93) 0.022   
  45 to 54 1.00 (Ref.) -   
  55 to 64 1.18 (0.96, 1.46) 0.125   
  65 to 74 1.76 (1.42, 2.18) <0.001   
  75 and over 2.09 (1.62, 2.07) <0.001   
Smoking status    <0.001 18.30 
  Never smoked 1.00 (Ref.) -   
  Previous smoker 1.02 (0.78, 1.32) 0.904   
  Current smoker 1.42 (1.11, 1.81) 0.005   
  Unknown 1.08 (0.65, 1.79) 0.771   
Alcohol consumption   <0.001 28.58 
  Never/occasionally drank 1.00 (Ref.) -   
  Previous problem drinker 1.24 (1.00, 1.53) 0.050   
  Current problem drinker 1.53 (1.30, 1.80) <0.001   
  Not recorded 0.94 (0.72, 1.21) 0.622   
WHO Performance Status   <0.001 80.83 
  Normal activity 1.00 (Ref.) -   
  Strenuous restricted 1.49 (1.26, 1.76) <0.001   
  Up and about >50%  2.60 (2.04, 3.31) <0.001   
  Confined to bed/chair >50%  2.69 (1.96, 3.68) <0.001   
  Not recorded 1.47 (1.21, 1.78) <0.001   
Anatomical site   <0.001 44.09 
  Larynx 0.67 (0.54, 0.82) <0.001   
  Oral cavity 1.03 (0.84, 1.27) 0.764   
  Oropharynx 1.00 (Ref.) -   
  Hypopharynx 1.34 (1.03, 1.74) 0.030   
  Nasal cavity 0.96 (0.68, 1.35) 0.799   
  Lip 0.56 (0.34, 0.91) 0.020   
  Other/salivary gland 1.17 (0.87, 1.58) 0.297   
Stage   <0.001 106.27 
  I 1.00 (Ref.) -   
  II 1.87 (1.46, 2.40) <0.001   
  III 2.44 (1.88, 3.18) <0.001   
  IV 3.63 (2.82, 4.66) <0.001   
  Unknown 2.33 (1.65, 3.30) <0.001   
Treatment modality    <0.001 118.70 
   Surgery only 1.00 (Ref.) -   
   Radiotherapy only 1.38 (1.12, 1.71) 0.003   
   Surgery and radiotherapy 0.98 (0.79, 1.21) 0.831   
   Surgery, radiotherapy and chemotherapy 1.03 (0.71, 1.50) 0.880   
   Radiotherapy and chemotherapy 1.31 (1.00, 1.73) 0.053   
   Chemotherapy +/- surgery 6.76 (4.62, 9.88) <0.001   
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Table 3.19 – Mutually adjusted hazard ratios for all-cause mortality after 12 years for each 
patient, tumour, and treatment factor following the exclusion of people who received no 
treatment (n = 1,691) 
Variable 
12-year    
HR (95% CI) HR p-value p-value Chi-sq. 
Age at diagnosis   <0.001 133.95 
  Less than 45 0.61 (0.43, 0.88) 0.008   
  45 to 54 1.00 (Ref.) -   
  55 to 64 1.23 (1.03, 1.47) 0.024   
  65 to 74 2.03 (1.69, 2.44) <0.001   
  75 and over 2.53 (2.03, 3.15) <0.001   
Smoking status    <0.001 27.03 
  Never smoked 1.00 (Ref.) -   
  Previous smoker 1.06 (0.85, 1.32) 0.591   
  Current smoker 1.47 (1.20, 1.81) <0.001   
  Unknown 1.20 (0.79, 1.81) 0.397   
Alcohol consumption   <0.001 36.01 
  Never/occasionally drank 1.00 (Ref.) -   
  Previous problem drinker 1.32 (1.10, 1.58) 0.003   
  Current problem drinker 1.52 (1.32, 1.75) <0.001   
  Not recorded 1.00 (0.81, 1.23) 0.972   
WHO Performance Status   <0.001 83.17 
  Normal activity 1.00 (Ref.) -   
  Strenuous restricted 1.43 (1.24, 1.65) <0.001   
  Up and about >50%  2.34 (1.87, 2.92) <0.001   
  Confined to bed/chair >50%  2.50 (1.85, 3.38) <0.001   
  Not recorded 1.46 (1.24, 1.72) <0.001   
Anatomical site   <0.001 41.43 
  Larynx 0.73 (0.61, 0.87) <0.001   
  Oral cavity 1.05 (0.88, 1.26) 0.586   
  Oropharynx 1.00 (Ref.) -   
  Hypopharynx 1.29 (1.01, 1.64) 0.043   
  Nasal cavity 0.93 (0.69, 1.26) 0.645   
  Lip 0.58 (0.40, 0.84) 0.004   
  Other/salivary gland 1.06 (0.81, 1.39) 0.675   
Stage   <0.001 91.03 
  I 1.00 (Ref.) -   
  II 1.41 (1.17, 1.70) <0.001   
  III 1.75 (1.42, 2.15) <0.001   
  IV 2.52 (2.08, 3.06) <0.001   
  Unknown 1.75 (1.32, 2.32) <0.001   
Treatment modality    <0.001 121.10 
   Surgery only 1.00 (Ref.) -   
   Radiotherapy only 1.37 (1.14, 1.64) <0.001   
   Surgery and radiotherapy 1.00 (0.84, 1.20) 0.981   
   Surgery, radiotherapy and chemotherapy 0.97 (0.69, 1.36) 0.855   
   Radiotherapy and chemotherapy 1.35 (1.05, 1.72) 0.017   
   Chemotherapy +/- surgery 6.58 (4.57, 9.47) <0.001   
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Table 3.20 – Mutually adjusted hazard ratios for all-cause mortality after one year for each 
patient, tumour, and treatment factor following the  exclusion of people who had 
oropharynx cancer (n = 1,497) 
Variable 
One-year    
HR (95% CI) HR p-value p-value Chi-sq. 
Age at diagnosis   0.015 12.31 
  Less than 45 0.55 (0.29, 1.05) 0.070   
  45 to 54 1.00 (Ref.) -   
  55 to 64 0.82 (0.61, 1.11) 0.197   
  65 to 74 1.07 (0.80, 1.44) 0.640   
  75 and over 1.23 (0.88, 1.71) 0.232   
Alcohol consumption   0.006 12.34 
  Never/occasionally drank 1.00 (Ref.) -   
  Previous problem drinker 1.40 (1.05, 1.86) 0.020   
  Current problem drinker 1.38 (1.11, 1.72) 0.004   
  Not recorded 0.94 (0.70, 1.27) 0.681   
WHO Performance Status   <0.001 42.56 
  Normal activity 1.00 (Ref.) -   
  Strenuous restricted 1.45 (1.13, 1.85) 0.003   
  Up and about >50%  2.67 (1.95, 3.66) <0.001   
  Confined to bed/chair >50%  2.30 (1.59, 3.32) <0.001   
  Not recorded 1.40 (1.06, 1.85) 0.018   
Anatomical site   0.007 16.14 
  Larynx 1.00 (Ref.)    
  Oral cavity 1.38 (1.09, 1.75) 0.008   
  Hypopharynx 1.34 (0.99, 1.79) 0.055   
  Nasal cavity 1.03 (0.68, 1.56) 0.879   
  Lip 0.68 (0.32, 1.45) 0.315   
  Other/salivary gland 1.67 (1.17, 2.36) 0.004   
Stage   <0.001 82.36 
  I 1.00 (Ref.) -   
  II 2.99 (1.94, 4.61) <0.001   
  III 4.34 (2.77, 6.79) <0.001   
  IV 6.57 (4.29, 10.06) <0.001   
  Unknown 4.24 (2.56, 7.01) <0.001   
Treatment modality    <0.001 200.22 
   Surgery only 1.00 (Ref.) -   
   Radiotherapy only 1.63 (1.19, 2.22) 0.002   
   Surgery and radiotherapy 1.01 (0.74, 1.38) 0.966   
   Surgery, radiotherapy and chemotherapy 1.26 (0.71, 2.25) 0.423   
   Radiotherapy and chemotherapy 2.26 (1.53, 3.34) <0.001   
   Chemotherapy +/- surgery 5.78 (3.45, 9.68) <0.001   
   No treatment 7.77 (5.47, 11.04) <0.001   
Network/region   0.040 6.45 
  WoSCAN (West Scotland) 1.15 (0.91, 1.46) 0.235   
  SCAN (East Scotland) 1.00 (Ref.) -   
  NOSCAN (North Scotland) 1.43 (1.08, 1.89) 0.012   
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Table 3.21 – Mutually adjusted hazard ratios for all-cause mortality after five years for each 
patient, tumour, and treatment factor following the exclusion of people who had oropharynx 
cancer (n = 1,497) 
Variable 
Five-year    
HR (95% CI) HR p-value p-value Chi-sq. 
Age at diagnosis   <0.001 49.06 
  Less than 45 0.42 (0.25, 0.73) 0.002   
  45 to 54 1.00 (Ref.) -   
  55 to 64 0.98 (0.78, 1.24) 0.882   
  65 to 74 1.40 (1.11, 1.77) 0.004   
  75 and over 1.75 (1.35, 2.28) <0.001   
Smoking status    0.013 10.84 
  Never smoked 1.00 (Ref.) -   
  Previous smoker 0.90 (0.68, 1.19) 0.462   
  Current smoker 1.21 (0.93, 1.56) 0.153   
  Unknown 0.95 (0.59, 1.54) 0.840   
Alcohol consumption   <0.001 23.07 
  Never/occasionally drank 1.00 (Ref.) -   
  Previous problem drinker 1.48 (1.18, 1.85) <0.001   
  Current problem drinker 1.46 (1.23, 1.74) <0.001   
  Not recorded 1.04 (0.81, 1.34) 0.766   
WHO Performance Status   <0.001 75.91 
  Normal activity 1.00 (Ref.) -   
  Strenuous restricted 1.41 (1.18, 1.70) <0.001   
  Up and about >50%  2.69 (2.08, 3.48) <0.001   
  Confined to bed/chair >50%  2.77 (2.05, 3.73) <0.001   
  Not recorded 1.42 (1.15, 1.75) 0.00   
Anatomical site   <0.001 26.45 
  Larynx 1.00 (Ref.) -   
  Oral cavity 1.37 (1.13, 1.66) 0.001   
  Hypopharynx 1.51 (1.18, 1.94) 0.001   
  Nasal cavity 1.17 (0.85, 1.62) 0.335   
  Lip 0.71 (0.44, 1.14) 0.156   
  Other/salivary gland 1.60 (1.20, 2.13) 0.001   
Stage   <0.001 86.43 
  I 1.00 (Ref.) -   
  II 2.07 (1.60, 2.69) <0.001   
  III 2.54 (1.92, 3.35) <0.001   
  IV 3.48 (2.67, 4.54) <0.001   
  Unknown 2.71 (1.94, 3.77) <0.001   
Treatment modality    <0.001 180.84 
   Surgery only 1.00 (Ref.) -   
   Radiotherapy only 1.31 (1.04, 1.65) 0.023   
   Surgery and radiotherapy 1.04 (0.83, 1.30) 0.732   
   Surgery, radiotherapy and chemotherapy 1.11 (0.70, 1.75) 0.663   
   Radiotherapy and chemotherapy 1.67 (1.22, 2.28) 0.001   
   Chemotherapy +/- surgery 5.19 (3.26, 8.28) <0.001   
   No treatment 5.73 (4.26, 7.70) <0.001   
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Table 3.22 – Mutually adjusted hazard ratios for all-cause mortality after 12 years for each 
patient, tumour, and treatment factor following the exclusion of people who had oropharynx 
cancer (n = 1,497) 
Variable 
12-year    
HR (95% CI) HR p-value p-value Chi-sq. 
Age at diagnosis   <0.001 101.06 
  Less than 45 0.52 (0.34, 0.78) 0.002   
  45 to 54 1.00 (Ref.) -   
  55 to 64 1.03 (0.84, 1.25) 0.805   
  65 to 74 1.67 (1.37, 2.04) <0.001   
  75 and over 2.13 (1.69, 2.68) <0.001   
Smoking status    <0.001 16.89 
  Never smoked 1.00 (Ref.) -   
  Previous smoker 0.95 (0.75, 1.19) 0.644   
  Current smoker 1.28 (1.03, 1.59) 0.026   
  Unknown 1.04 (0.69, 1.57) 0.840   
Alcohol consumption   <0.001 32.23 
  Never/occasionally drank 1.00 (Ref.) -   
  Previous problem drinker 1.55 (1.28, 1.89) <0.001   
  Current problem drinker 1.46 (1.25, 1.70) <0.001   
  Not recorded 1.10 (0.89, 1.35) 0.389   
WHO Performance Status   <0.001 79.91 
  Normal activity 1.00 (Ref.) -   
  Strenuous restricted 1.37 (1.17, 1.60) <0.001   
  Up and about >50%  2.54 (2.00, 3.21) <0.001   
  Confined to bed/chair >50%  2.56 (1.93, 3.39) <0.001   
  Not recorded 1.39 (1.17, 1.66) <0.001   
Anatomical site   <0.001 29.88 
  Larynx 1.00 (Ref.) -   
  Oral cavity 1.33 (1.13, 1.57) <0.001   
  Hypopharynx 1.44 (1.15, 1.81) 0.002   
  Nasal cavity 1.05 (0.78, 1.39) 0.764   
  Lip 0.69 (0.48, 0.99) 0.043   
  Other/salivary gland 1.35 (1.04, 1.76) 0.023   
Stage   <0.001 84.62 
  I 1.00 (Ref.) -   
  II 1.56 (1.28, 1.90) <0.001   
  III 1.83 (1.47, 2.28) <0.001   
  IV 2.58 (2.10, 3.17) <0.001   
  Unknown 2.14 (1.63, 2.80) <0.001   
Treatment modality    <0.001 181.88 
   Surgery only 1.00 (Ref.) -   
   Radiotherapy only 1.34 (1.09, 1.63) 0.004   
   Surgery and radiotherapy 1.02 (0.84, 1.23) 0.839   
   Surgery, radiotherapy and chemotherapy 1.12 (0.75, 1.66) 0.583   
   Radiotherapy and chemotherapy 1.56 (1.18, 2.07) 0.002   
   Chemotherapy +/- surgery 4.72 (3.00, 7.43) <0.001   
   No treatment 5.41 (4.09, 7.16) <0.001   
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3.3.7 Mutually adjusted multivariate Cox proportional hazards model for 
disease-specific mortality  
Results for the mutually adjusted Cox proportional hazards model for one-year, five-year, 
and 12-year disease-specific mortality are displayed in Table 3.23 to Table 3.25 on Page 
146 to Page 148.  
3.3.7.1 Determinants with an independent association with disease-specific 
mortality – summary of findings 
In the order that they entered the model, the determinants that had an independent 
association with disease-specific mortality following mutual adjustment and after the 
forced inclusion of age at diagnosis, tumour stage, and treatment modality after one year 
were WHO Performance Status, alcohol consumption, and network; and at five years and 
12 years included WHO Performance Status, alcohol consumption, and anatomical site. 
These results were similar to the results for all-cause mortality. However, after one year 
anatomical site was not an independent predictor of disease-specific mortality, but 
Scottish Cancer Network was an independent predictor of disease-specific mortality. 
Interestingly, and unlike the results for all-cause mortality, smoking behaviour was also 
not an independent predictor in any of the models for one-year, five-year or 12-year 
disease-specific mortality. A description of these effects is outlined below. 
3.3.7.2 Patient factors with an independent association with disease-specific 
mortality  
Age at diagnosis 
Patients who were older continued to have a greater risk of disease-specific mortality 
following mutual adjustment, particularly after 12 years by which time those who were 75 
years and older had a 58% (HR = 1.58, 95% CI 1.18 to 2.11) increased risk of disease-
specific mortality compared to those who were aged between the years of 45 and 54.  
Alcohol consumption 
The patients who were reported as having a current problem with their consumption of 
alcohol were more than 40% more at risk of disease-specific mortality than those who 
were reported as never having drank or who occasionally drank alcohol following mutual 
adjustment after one and five years (one-year HR = 1.42, 95% CI 1.13 to 1.78; five-year 
HR = 1.45, 95% CI 1.19 to 1.76). Similar to the results for all-cause mortality, over time, 
the risk of disease-specific mortality became greater for those who had a current problem 
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with their alcohol consumption at diagnosis, and after 12 years these people were 54% 
(HR = 1.54, 95% CI 1.28 to 1.86) more at risk of disease-specific mortality than those who 
never drank or who occasionally drank alcohol. 
WHO Performance Status 
Patients who had a worse WHO Performance Status at diagnosis were at a substantially 
increased risk of disease-specific mortality following mutual adjustment at all three time 
points. Individuals who were reported as being confined to a bed or a chair for more than 
50% of their waking hours were at a more than 2.5-fold increased risk of disease-specific 
mortality after one year, five years, and 12 years (one-year HR = 2.51, 95% CI 1.72 to 
3.66; five-year HR = 2.72, 95% CI 1.95 to 3.80; 12-year HR = 2.66, 95% CI 1.92 to 3.68) 
following mutual adjustment. These results were comparable to the results for all-cause 
mortality following mutual adjustment.  
3.3.7.3 Tumour factors with an independent association with disease-specific 
mortality  
Anatomical site 
Anatomical site was an independent predictor of five-year and 12-year disease-specific 
mortality, but not one-year disease-specific mortality. Following mutual adjustment, the 
patients with cancer of the lip had a 75% (HR = 0.25, 95% CI 0.11 to 0.58) lower risk of 
disease-specific mortality after 12 years compared to those with cancer of the oropharynx. 
People with cancer of the larynx also had a reduced risk of disease-specific mortality by 
22% (HR = 0.78, 95% CI 0.61 to 0.99) after 12 years compared to those who were 
diagnosed with cancer of the oropharynx. However, interestingly there were no 
differences between the outcomes for individuals with oropharynx, hypopharynx, nasal 
cavity, and other tumours of the head and neck after one year, five years, and 12 years 
following mutual adjustment.  
Tumour stage 
As the stage of the patients’ tumour increased, the risk of one-year, five-year, and 12-year 
disease-specific mortality increased at all three time points following mutual adjustment. 
Individuals who had stage IV cancer had more than a 12-fold (HR = 12.42, 95% CI 6.77 to 
22.83) increased risk of disease-specific mortality compared to those who were diagnosed 
with stage I cancer after one year. This was substantially higher than the results for all-
cause mortality, suggesting that people with stage IV cancers are highly likely to have 
died from their cancer. Over time, the difference in risk across the tumour stages 
attenuated in the same way that it did for all-cause mortality, however after 12 years the 
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patients who were diagnosed with stage IV cancer were still nearly five times (HR = 4.86, 
95% CI 3.49 to 6.77) more at risk of disease-specific mortality than the people who were 
diagnosed with a stage I tumour following mutual adjustment. 
3.3.7.4 Treatment factors with an independent association with disease-specific 
mortality  
Treatment modality 
Following mutual adjustment, the patients who were treated with a combination of surgery 
and radiotherapy had no excess risk of disease-specific mortality compared to those who 
were treated with surgery only after one year (HR = 1.12, 95% CI 0.79 to 1.59), five years 
(HR = 1.07, 95% CI 0.81 to 1.43), or 12 years (HR = 1.14, 95% CI 0.88 to 1.49), which 
was the same as the results for all-cause mortality. After one year, the individuals who 
were treated with radiotherapy only were 70% (HR = 1.70, 95% CI 1.21 to 1.59) more at 
risk of disease-specific mortality following mutual adjustment compared to those who 
received surgery only. However, by five years and 12 years this excess risk had reduced 
slightly to 54% for those who received radiotherapy only compared to those who received 
surgery only following adjustment for age and tumour stage (five-year HR = 1.54, 95% CI 
1.15 to 2.06; 12-year HR = 1.54, 95% CI 1.17 to 2.03). These results were comparable to 
the results for all-cause mortality. 
Network 
Scottish Cancer Network was an independent predictor of one-year disease-specific 
mortality, but not for five-year or 12-year disease-specific mortality. These results were not 
observed in the mutually adjusted models for all-cause mortality. Patients who were 
diagnosed in the North of Scotland Cancer Network were 30% (HR = 1.30, 95% CI 0.98 to 
1.73) more at risk of disease-specific mortality than those who were in the East of 
Scotland Cancer Network. Those who were treated in the West of Scotland Cancer 
Network were not at an increased risk of disease-specific mortality than those who were 
treated in the East of Scotland Cancer Network (HR = 0.95, 95% CI 0.74 to 1.20).  
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Table 3.23 – Mutually adjusted hazard ratios for disease-specific mortality after one year for 




   
HR (95% CI) HR p-value p-value Chi-sq. 
Age at diagnosis   0.018 11.93 
  Less than 45 0.70 (0.38, 1.27) 0.236   
  45 to 54 1.00 (Ref.) -   
  55 to 64 0.89 (0.66, 1.20) 0.432   
  65 to 74 1.03 (0.76, 1.40) 0.856   
  75 and over 1.41 (1.00, 2.00) 0.053   
Alcohol consumption   <0.001 19.33 
  Never/occasionally drank 1.00 (Ref.) -   
  Previous problem drinker 1.35 (1.01, 1.80) 0.041   
  Current problem drinker 1.42 (1.13, 1.78) 0.002   
  Not recorded 0.69 (0.48, 0.97) 0.035   
WHO Performance Status   <0.001 31.61 
  Normal activity 1.00 (Ref.) -   
  Strenuous restricted 1.60 (1.23, 2.09) <0.001   
  Up and about >50%  2.25 (1.60, 3.15) <0.001   
  Confined to bed/chair >50%  2.51 (1.72, 3.66) <0.001   
  Not recorded 1.51 (1.11, 2.04) 0.008   
Tumour stage   <0.001 84.00 
  I 1.00 (Ref.) -   
  II 4.89 (2.62, 9.12) <0.001   
  III 7.23 (3.85, 13.57) <0.001   
  IV 12.42 (6.77, 22.83)  <0.001   
  Unknown 7.86 (3.99, 15.51) <0.001   
Treatment modality    <0.001 233.82 
   Surgery only 1.00 (Ref.) -   
   Radiotherapy only 1.70 (1.21, 2.38) 0.002   
   Surgery and radiotherapy 1.12 (0.79, 1.59) 0.532   
   Surgery, radiotherapy and chemotherapy 2.08 (1.26, 3.42) 0.004   
   Radiotherapy and chemotherapy 2.13 (1.42, 3.19) <0.001   
   Chemotherapy +/- surgery 7.27 (4.41, 12.00) <0.001   
   No treatment 10.15 (6.93, 14.87) <0.001   
Network/region   0.043 6.29 
  WoSCAN (West Scotland) 0.95 (0.74, 1.20) 0.649   
  SCAN (East Scotland) 1.00 (Ref.) -   
  NOSCAN (North Scotland) 1.30 (0.98, 1.73) 0.071   
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Table 3.24 – Mutually adjusted hazard ratios for disease-specific mortality after five years 




   
HR (95% CI) HR p-value p-value Chi-sq. 
Age at diagnosis   <0.001 19.77 
  Less than 45 0.66 (0.40, 1.11) 0.118   
  45 to 54 1.00 (Ref.) -   
  55 to 64 0.95 (0.74, 1.23) 0.721   
  65 to 74 1.24 (0.95, 1.62) 0.112   
  75 and over 1.55 (1.14, 2.10) 0.005   
Alcohol consumption   <0.001 24.63 
  Never/occasionally drank 1.00 (Ref.) -   
  Previous problem drinker 1.41 (1.10, 1.81) 0.006   
  Current problem drinker 1.45 (1.19, 1.76) <0.001   
  Not recorded 0.76 (0.57, 1.03) 0.073   
WHO Performance Status   <0.001 43.61 
  Normal activity 1.00 (Ref.) -   
  Strenuous restricted 1.43 (1.15, 1.78) 0.002   
  Up and about >50%  2.15 (1.60, 2.89) <0.001   
  Confined to bed/chair >50%  2.72 (1.95, 3.80) <0.001   
  Not recorded 1.45 (1.13, 1.86) 0.003   
Anatomical site   0.007 17.81 
  Larynx 0.73 (0.57, 0.93) 0.011   
  Oral cavity 0.91 (0.71, 1.17) 0.465   
  Oropharynx 1.00 (Ref.) -   
  Hypopharynx 0.98 (0.73, 1.33) 0.900   
  Nasal cavity 0.79 (0.53, 1.17) 0.242   
  Lip 0.15 (0.05, 0.47) 0.001   
  Other/salivary gland 0.76 (0.51, 1.13) 0.177   
Tumour stage   <0.001 99.58 
  I 1.00 (Ref.) -   
  II 2.48 (1.67, 3.69) <0.001   
  III 3.71 (2.47, 5.56) <0.001   
  IV 6.14 (4.17, 9.03) <0.001   
  Unknown 4.83 (3.02, 7.74) <0.001   
Treatment modality    <0.001 201.83 
   Surgery only 1.00 (Ref.) -   
   Radiotherapy only 1.54 (1.15, 2.06) 0.004   
   Surgery and radiotherapy 1.07 (0.81, 1.43) 0.635   
   Surgery, radiotherapy and chemotherapy 1.51 (0.98, 2.35) 0.064   
   Radiotherapy and chemotherapy 1.68 (1.19, 2.38) 0.003   
   Chemotherapy +/- surgery 6.31 (3.96, 10.05) <0.001   
   No treatment 7.53 (5.36, 10.59) <0.001   
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Table 3.25 – Mutually adjusted hazard ratios for disease-specific mortality after 12 years for 




   
HR (95% CI) HR p-value p-value Chi-sq. 
Age at diagnosis   <0.001 22.85 
  Less than 45 0.78 (0.51, 1.21) 0.267   
  45 to 54 1.00 (Ref.) -   
  55 to 64 0.94 (0.74, 1.19) 0.607   
  65 to 74 1.28 (0.99, 1.64) 0.056   
  75 and over 1.58 (1.18, 2.11) 0.002   
Alcohol consumption   <0.001 30.95 
  Never/occasionally drank 1.00 (Ref.) -   
  Previous problem drinker 1.42 (1.12, 1.80) 0.004   
  Current problem drinker 1.54 (1.28, 1.86) <0.001   
  Not recorded 0.81 (1.15, 1.07) 0.131   
WHO Performance Status   <0.001 43.93 
  Normal activity 1.00 (Ref.) -   
  Strenuous restricted 1.41 (1.15, 1.73) 0.001   
  Up and about >50%  2.06 (1.55, 2.74) <0.001   
  Confined to bed/chair >50%  2.66 (1.92, 3.68) <0.001   
  Not recorded 1.46 (1.16, 1.84) 0.001   
Anatomical site   0.005 18.47 
  Larynx 0.78 (0.61, 0.99) 0.037   
  Oral cavity 0.98 (0.78, 1.25) 0.885   
  Oropharynx 1.00 (Ref.) -   
  Hypopharynx 1.10 (0.82, 1.47) 0.531   
  Nasal cavity 0.82 (0.56, 1.20) 0.314   
  Lip 0.25 (0.11, 0.58) 0.001   
  Other/salivary gland 0.80 (0.54, 1.18) 0.259   
Tumour stage   <0.001 98.22 
  I 1.00 (Ref.) -   
  II 2.13 (1.52, 2.98) <0.001   
  III 3.03 (2.14, 4.29) <0.001   
  IV 4.86 (3.49, 6.77) <0.001   
  Unknown 3.83 (2.52, 5.83) <0.001   
Treatment modality    <0.001 205.62 
   Surgery only 1.00 (Ref.) -   
   Radiotherapy only 1.54 (1.17, 2.03) 0.002   
   Surgery and radiotherapy 1.14 (0.88, 1.49) 0.325   
   Surgery, radiotherapy and chemotherapy 1.45 (0.95, 2.21) 0.084   
   Radiotherapy and chemotherapy 1.77 (1.28, 2.45) <0.001   
   Chemotherapy +/- surgery 6.49 (4.10, 10.26) <0.001   
   No treatment 7.71 (5.54, 10.73) <0.001   
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3.3.7.5 Sensitivity analyses 1 – excluding people who received no treatment  
The results for the forward stepwise models for disease-specific mortality which excluded 
the people who received no treatment after one year, five years, and 12 years are 
displayed in Table 3.26 to Table 3.28. Following the exclusion of the people who received 
no treatment, a total of 1,691 people remained in the first sensitivity analysis. After one 
year, when a forward stepwise multivariate Cox proportional hazards model was 
performed, the determinants with an independent association with disease-specific 
mortality following the forced inclusion of age at diagnosis, tumour stage, and treatment 
modality was WHO Performance Status, alcohol consumption, and anatomical site. The 
determinants after five and 12 years were WHO Performance Status, alcohol 
consumption, anatomical site, and smoking status. These results were similar to the 
results for the main cohort of people for disease-specific mortality; however smoking 
status was also an independent determinant of disease-specific mortality after five and 12 
years following the exclusion of the people who received no treatment.  
3.3.7.6 Sensitivity analyses 2 – excluding people with oropharynx cancer  
The results for the forward stepwise models for disease-specific mortality which excluded 
the people who had oropharynx cancer after one year, five years, and 12 years are 
displayed in Table 3.29 to Table 3.31. Following the exclusion of the people who had 
cancer of the oropharynx, a total of 1,497 patients were remaining in this sensitivity 
analysis. The determinants with an independent association with one-year disease-
specific mortality in a mutually adjusted Cox proportional hazards model following the 
forced inclusion of age at diagnosis, tumour stage, and treatment modality were WHO 
Performance Status, alcohol consumption, and Scottish Cancer Network. These results 
were similar to the results for the main cohort of people after one year. The determinants 
with an independent association with disease-specific mortality in a mutually adjusted Cox 
proportional hazards model following the forced inclusion of age at diagnosis, tumour 
stage, and treatment modality were WHO Performance Status, alcohol consumption, and 
anatomical site after five and 12 years with the addition of Scottish Cancer Network. 
These results were similar to the results for the main cohort of people at both five years 
and 12 years.  
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Table 3.26 – Mutually adjusted hazard ratios for disease-specific mortality after one year for 
each patient, tumour, and treatment factor following the exclusion of people who received 
no treatment (n = 1,691) 
Variable 
One-year    
HR (95% CI) HR p-value p-value Chi-sq. 
Age at diagnosis   0.315 4.74 
  Less than 45 0.81 (0.44, 1.48) 0.488   
  45 to 54 1.00 (Ref.) -   
  55 to 64 0.95 (0.70, 1.30) 0.760   
  65 to 74 1.12 (0.80, 1.55) 0.513   
  75 and over 1.33 (0.90, 1.96) 0.151   
Alcohol consumption   0.001 15.74 
  Never/occasionally drank 1.00 (Ref.) -   
  Previous problem drinker 1.28 (0.93, 1.76) 0.135   
  Current problem drinker 1.40 (1.09, 1.80) 0.008   
  Not recorded 0.60 (0.39, 0.94) 0.024   
WHO Performance Status   <0.001 28.92 
  Normal activity 1.00 (Ref.) -   
  Strenuous restricted 1.52 (1.16, 2.00) 0.003   
  Up and about >50%  2.52 (1.76, 3.61) <0.001   
  Confined to bed/chair >50%  2.13 (1.32, 3.44) 0.002   
  Not recorded 1.48 (1.08, 2.01) 0.015   
Anatomical site   0.011 16.55 
  Larynx 0.81 (0.59, 1.12) 0.202   
  Oral cavity 1.32 (0.96, 1.81) 0.091   
  Oropharynx 1.00 (Ref.)    
  Hypopharynx 1.31 (0.90, 1.92) 0.162   
  Nasal cavity 1.02 (0.61, 1.70) 0.931   
  Lip 0.27 (0.07, 1.16) 0.078   
  Other/salivary gland 0.91 (0.55, 1.52) 0.717   
Stage   <0.001 87.30 
  I 1.00 (Ref.) -   
  II 5.24 (2.67, 10.29) <0.001   
  III 8.01 (4.05, 15.86) <0.001   
  IV 15.29 (7.86, 29.74) <0.001   
  Unknown 8.47 (3.90, 18.42) <0.001   
Treatment modality    <0.001 81.23 
   Surgery only 1.00 (Ref.) -   
   Radiotherapy only 1.88 (1.31, 2.70) <0.001   
   Surgery and radiotherapy 1.00 (0.70, 1.44) 0.994   
   Surgery, radiotherapy and chemotherapy 1.73 (1.04, 2.89) 0.036   
   Radiotherapy and chemotherapy 1.78 (1.16, 2.72) 0.008   
   Chemotherapy +/- surgery 7.58 (4.49, 12.82) <0.001   
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Table 3.27 – Mutually adjusted hazard ratios for disease-specific mortality after five years 
for each patient, tumour, and treatment factor following the exclusion of people who 
received no treatment (n = 1,691) 
Variable 
Five-year    
HR (95% CI) HR p-value p-value Chi-sq. 
Age at diagnosis   0.002 17.18 
  Less than 45 0.75 (0.44, 1.25) 0.269   
  45 to 54 1.00 (Ref.) -   
  55 to 64 1.00 (0.77, 1.31) 0.977   
  65 to 74 1.35 (1.03, 1.79) 0.033   
  75 and over 1.64 (1.17, 2.29) 0.004   
Smoking status    0.037 8.47 
  Never smoked 1.00 (Ref.) -   
  Previous smoker 0.92 (0.65, 1.30) 0.618   
  Current smoker 1.27 (0.92, 1.74) 0.141   
  Unknown 0.88 (0.41, 1.89) 0.741   
Alcohol consumption   0.005 12.84 
  Never/occasionally drank 1.00 (Ref.) -   
  Previous problem drinker 1.29 (0.99, 1.70) 0.064   
  Current problem drinker 1.36 (1.09, 1.69) 0.007   
  Not recorded 0.74 (0.51, 1.10) 0.133   
WHO Performance Status   <0.001 46.40 
  Normal activity 1.00 (Ref.) -   
  Strenuous restricted 1.38 (1.10, 1.73) 0.006   
  Up and about >50%  2.53 (1.86, 3.45) <0.001   
  Confined to bed/chair >50%  2.66 (1.78, 3.98) <0.001   
  Not recorded 1.51 (1.17, 1.96) 0.002   
Anatomical site   <0.001 29.53 
  Larynx 0.70 (0.53, 0.92) 0.010   
  Oral cavity 1.08 (0.83, 1.42) 0.571   
  Oropharynx 1.00 (Ref.) -   
  Hypopharynx 1.39 (1.00, 1.91) 0.048   
  Nasal cavity 1.01 (0.66, 1.55) 0.962   
  Lip 0.18 (0.06, 0.59) 0.004   
  Other/salivary gland 0.81 (0.52, 1.25) 0.334   
Stage   <0.001 102.84 
  I 1.00 (Ref.) -   
  II 2.55 (1.69, 3.85) <0.001   
  III 3.79 (2.49, 5.77) <0.001   
  IV 6.77 (4.52, 10.13) <0.001   
  Unknown 4.42 (2.63, 7.43) <0.001   
Treatment modality    <0.001 80.91 
   Surgery only 1.00 (Ref.) -   
   Radiotherapy only 1.62 (1.20, 2.18) 0.001   
   Surgery and radiotherapy 1.03 (0.77, 1.38) 0.829   
   Surgery, radiotherapy and chemotherapy 1.52 (0.97, 2.37) 0.068   
   Radiotherapy and chemotherapy 1.62 (1.13, 2.31) 0.008   
   Chemotherapy +/- surgery 7.03 (4.35, 11.36) <0.001   
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Table 3.28 – Mutually adjusted hazard ratios for disease-specific mortality after 12 years for 
each patient, tumour, and treatment factor following the exclusion of people who received 
no treatment (n = 1,691) 
Variable 
12-year    
HR (95% CI) HR p-value p-value Chi-sq. 
Age at diagnosis   <0.001 20.33 
  Less than 45 0.85 (0.55, 1.33) 0.480   
  45 to 54 1.00 (Ref.) -   
  55 to 64 0.99 (0.77, 1.26) 0.909   
  65 to 74 1.38 (1.06, 1.78) 0.016   
  75 and over 1.66 (1.22, 2.28) 0.002   
Smoking status    0.046 7.99 
  Never smoked 1.00 (Ref.) -   
  Previous smoker 0.93 (0.67, 1.28) 0.650   
  Current smoker 1.24 (0.93, 1.67) 0.144   
  Unknown 0.88 (0.44, 1.77) 0.727   
Alcohol consumption   <0.001 17.81 
  Never/occasionally drank 1.00 (Ref.) -   
  Previous problem drinker 1.30 (1.00, 1.69) 0.047   
  Current problem drinker 1.45 (1.18, 1.78) <0.001   
  Not recorded 0.80 (0.56, 1.13) 0.197   
WHO Performance Status   <0.001 45.05 
  Normal activity 1.00 (Ref.) -   
  Strenuous restricted 1.36 (1.10, 1.68) 0.005   
  Up and about >50%  2.36 (1.75, 3.19) <0.001   
  Confined to bed/chair >50%  2.59 (1.74, 3.85) <0.001   
  Not recorded 1.53 (1.20, 1.94) <0.001   
Anatomical site   <0.001 32.31 
  Larynx 0.77 (0.59, 0.99) 0.043   
  Oral cavity 1.16 (0.90, 1.50) 0.253   
  Oropharynx 1.00 (Ref.) -   
  Hypopharynx 1.53 (1.12, 2.08) 0.008   
  Nasal cavity 1.09 (0.73, 1.63) 0.678   
  Lip 0.31 (0.13, 0.72) 0.007   
  Other/salivary gland 0.87 (0.58, 1.30) 0.489   
Stage   <0.001 101.33 
  I 1.00 (Ref.) -   
  II 2.16 (1.53, 3.05) <0.001   
  III 3.05 (2.13, 4.37) <0.001   
  IV 5.24 (3.72, 7.38) <0.001   
  Unknown 3.41 (2.15, 5.41) <0.001   
Treatment modality    <0.001 82.17 
   Surgery only 1.00 (Ref.) -   
   Radiotherapy only 1.63 (1.23, 2.16) <0.001   
   Surgery and radiotherapy 1.11 (0.85, 1.45) 0.456   
   Surgery, radiotherapy and chemotherapy 1.47 (0.96, 2.26) 0.079   
   Radiotherapy and chemotherapy 1.71 (1.22, 2.39) 0.002   
   Chemotherapy +/- surgery 7.28 (4.55, 11.65) <0.001   
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Table 3.29 – Mutually adjusted hazard ratios for disease-specific mortality after one year for 
each patient, tumour, and treatment factor following the exclusion of people who had 
oropharynx cancer (n = 1,497) 
Variable 
One-year    
HR (95% CI) HR p-value p-value Chi-sq. 
Age at diagnosis   0.019 11.81 
  Less than 45 0.59 (0.29, 1.23) 0.160   
  45 to 54 1.00 (Ref.) -   
  55 to 64 0.78 (0.55, 1.10) 0.157   
  65 to 74 0.87 (0.61, 1.24) 0.450   
  75 and over 1.30 (0.87, 1.93) 0.202   
Smoking status    0.054 7.65 
  Never smoked 1.00 (Ref.) -   
  Previous smoker 0.67 (0.44, 1.03) 0.066   
  Current smoker 0.86 (0.58, 1.28) 0.459   
  Unknown 0.35 (0.13, 0.91) 0.031   
Alcohol consumption   0.012 11.05 
  Never/occasionally drank 1.00 (Ref.) -   
  Previous problem drinker 1.61 (1.14, 2.25) 0.006   
  Current problem drinker 1.38 (1.05, 1.81) 0.023   
  Not recorded 0.89 (0.58, 1.37) 0.596   
WHO Performance Status   <0.001 29.48 
  Normal activity 1.00 (Ref.) -   
  Strenuous restricted 1.43 (1.06, 1.94) 0.021   
  Up and about >50%  2.48 (1.69, 3.65) <0.001   
  Confined to bed/chair >50%  2.62 (1.70, 4.05) <0.001   
  Not recorded 1.48 (1.06, 2.09) 0.0234   
Stage   <0.001 65.94 
  I 1.00 (Ref.) -   
  II 5.48 (2.78, 10.81) <0.001   
  III 7.43 (3.71, 14.87) <0.001   
  IV 12.84 (6.57, 25.10) <0.001   
  Unknown 7.62 (3.62, 16.01) <0.001   
Treatment modality    <0.001 170.84 
   Surgery only 1.00 (Ref.) -   
   Radiotherapy only 1.59 (1.09, 2.30) 0.015   
   Surgery and radiotherapy 1.10 (0.75, 1.61) 0.630   
   Surgery, radiotherapy and chemotherapy 2.00 (1.07, 3.71) 0.029   
   Radiotherapy and chemotherapy 2.97 (1.89, 4.66) <0.001   
   Chemotherapy +/- surgery 8.28 (4.65, 14.74) <0.001   
   No treatment 9.10 (5.92, 13.98) <0.001   
Network/region   0.007 9.84 
  WoSCAN (West Scotland) 1.04 (0.78, 1.40) 0.770   
  SCAN (East Scotland) 1.00 (Ref.) -   
  NOSCAN (North Scotland) 1.60 (1.14, 2.24) 0.006   
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Table 3.30 – Mutually adjusted hazard ratios for disease-specific mortality after five years 
for each patient, tumour, and treatment factor following the exclusion of people who had 
oropharynx cancer (n = 1,497) 
Variable 
Five-year    
HR (95% CI) HR p-value p-value Chi-sq. 
Age at diagnosis   0.011 12.98 
  Less than 45 0.54 (0.28, 1.04) 0.065   
  45 to 54 1.00 (Ref.) -   
  55 to 64 0.85 (0.63, 1.15) 0.297   
  65 to 74 0.99 (0.73, 1.35) 0.961   
  75 and over 1.33 (0.94, 1.87) 0.106   
Alcohol consumption   <0.001 19.50 
  Never/occasionally drank 1.00 (Ref.) -   
  Previous problem drinker 1.57 (1.18, 2.09) 0.002   
  Current problem drinker 1.36 (1.08, 1.70) 0.009   
  Not recorded 0.74 (0.52, 1.03) 0.077   
WHO Performance Status   <0.001 46.04 
  Normal activity 1.00 (Ref.) -   
  Strenuous restricted 1.33 (1.03, 1.71) 0.031   
  Up and about >50%  2.63 (1.87, 3.68) <0.001   
  Confined to bed/chair >50%  2.88 (1.97, 4.22) <0.001   
  Not recorded 1.51 (1.14, 2.01) 0.005   
Anatomical site   0.013 14.37 
  Larynx 1.00 (Ref.) -   
  Oral cavity 1.27 (0.99, 1.63) 0.058   
  Hypopharynx 1.29 (0.94, 1.76) 0.117   
  Nasal cavity 0.98 (0.65, 1.49) 0.934   
  Lip 0.20 (0.06, 0.66) 0.008   
  Other/salivary gland 1.04 (0.70, 1.56) 0.840   
Stage   <0.001 86.15 
  I 1.00 (Ref.) -   
  II 2.66 (1.72, 4.11) <0.001   
  III 3.77 (2.41, 5.91) <0.001   
  IV 6.64 (4.34, 10.17) <0.001   
  Unknown 4.51 (2.70, 7.55) <0.001   
Treatment modality    <0.001 144.38 
   Surgery only 1.00 (Ref.) -   
   Radiotherapy only 1.42 (1.03, 1.97) 0.032   
   Surgery and radiotherapy 1.03 (0.75, 1.42) 0.834   
   Surgery, radiotherapy and chemotherapy 1.59 (0.91, 2.76) 0.103   
   Radiotherapy and chemotherapy 2.43 (1.63, 3.61) <0.001   
   Chemotherapy +/- surgery 6.68 (3.94, 11.33) <0.001   
   No treatment 6.71 (4.55, 9.90) <0.001   
Network/region   0.019 7.97 
  WoSCAN (West Scotland) 1.05 (0.82, 1.34) 0.712   
  SCAN (East Scotland) 1.00 (Ref.) -   
  NOSCAN (North Scotland) 1.45 (1.09, 1.93) 0.012   
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Table 3.31 – Mutually adjusted hazard ratios for disease-specific mortality after 12 years for 
each patient, tumour, and treatment factor following the exclusion of people who had 
oropharynx cancer (n = 1,497) 
Variable 
12-year    
HR (95% CI) HR p-value p-value Chi-sq. 
Age at diagnosis   0.005 15.01 
  Less than 45 0.71 (0.42, 1.19) 0.194   
  45 to 54 1.00 (Ref.) -   
  55 to 64 0.86 (0.65, 1.13) 0.281   
  65 to 74 1.06 (0.80, 1.40) 0.694   
  75 and over 1.41 (1.02, 1.94) 0.035   
Alcohol consumption   <0.001 23.77 
  Never/occasionally drank 1.00 (Ref.) -   
  Previous problem drinker 1.58 (1.20, 2.07) 0.001   
  Current problem drinker 1.46 (1.18, 1.81) <0.001   
  Not recorded 0.79 (0.58, 1.08) 0.135   
WHO Performance Status   <0.001 45.09 
  Normal activity 1.00 (Ref.) -   
  Strenuous restricted 1.28 (1.01, 1.62) 0.041   
  Up and about >50%  2.44 (1.76, 3.38) <0.001   
  Confined to bed/chair >50%  2.80 (1.94, 4.04) <0.001   
  Not recorded 1.45 (1.11, 1.88) 0.006   
Anatomical site   0.004 17.34 
  Larynx 1.00 (Ref.) -   
  Oral cavity 1.27 (1.00, 1.60) 0.046   
  Hypopharynx 1.37 (1.01, 1.85) 0.041   
  Nasal cavity 0.96 (0.65, 1.42) 0.825   
  Lip 0.32 (0.14, 0.74) 0.008   
  Other/salivary gland 1.02 (0.70, 1.50) 0.904   
Stage   <0.001 90.20 
  I 1.00 (Ref.) -   
  II 2.27 (1.58, 3.28) <0.001   
  III 3.19 (2.18, 4.68) <0.001   
  IV 5.40 (3.76, 7.76) <0.001   
  Unknown 3.74 (2.37, 5.90) <0.001   
Treatment modality    <0.001 90.20 
   Surgery only 1.00 (Ref.) -   
   Radiotherapy only 1.45 (1.07, 1.96) 0.017   
   Surgery and radiotherapy 1.07 (0.80, 1.44) 0.632   
   Surgery, radiotherapy and chemotherapy 1.51 (0.90, 2.55) 0.119   
   Radiotherapy and chemotherapy 2.31 (1.59, 3.36) <0.001   
   Chemotherapy +/- surgery 6.59 (3.92, 11.08) <0.001   
   No treatment 6.57 (4.51, 9.58) <0.001   
Network/region   0.049 6.03 
  WoSCAN (West Scotland) 1.13 (0.89, 1.42) 0.312   
  SCAN (East Scotland) 1.00 (Ref.) -   
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3.4 Discussion  
Overall survival estimates after one year, five years, and 12 years were 76.0% (95% CI 
74.0% to 77.9%), 46.1% (95% CI 43.8% to 48.4%), and 26.3% (95% CI 24.3% to 28.3%), 
respectively, while disease-specific survival was higher at all three time points at 82.3% 
(95% CI 80.4% to 84.0%), 64.1% (95% CI 61.7% to 66.4%), and 56.9% (95% CI 54.3% to 
59.4%), respectively. Net survival estimates after one year, five years, and 12 years were 
78.3% (95% CI 76.2% to 80.3%), 53.8% (95% CI 51.1% to 56.5%), and 41.4% (95% CI 
37.6% to 45.1%), respectively.  
Poor overall survival, disease-specific survival, and net survival estimates were strongly 
associated with older age, but interestingly, there was not an obvious difference in survival 
between males and females. Poor survival was also associated with residing in areas of 
lower deprivation status, current or previous smoking, current or previous levels of alcohol 
consumption, and worse WHO Performance Status. In addition, patients who were 
diagnosed with tumours of the hypopharynx, or tumours of higher stage experienced 
poorer survival outcomes. People who were treated with a form of therapy which involved 
chemotherapy were also more likely to have worse survival outcomes. There was no 
obvious difference between the survival results across the three Scottish Cancer 
Networks.  
Following minimal adjustment for age and sex, the patients who were from the least 
deprived regions still had a higher risk of mortality, particularly for disease-specific 
mortality in the short-term. Individuals who were reported as being current or previous 
smokers or alcohol drinkers at the time of their diagnosis also exhibited a higher risk of all-
cause mortality and disease-specific mortality. Following minimal adjustment for age and 
sex, WHO Performance Status remained associated with all-cause mortality and disease-
specific mortality, with a substantial difference in the excess risk of mortality between the 
people who presented with a normal WHO Performance Status and those who were 
restricted in their levels of strenuous activity at the time of their diagnosis. Minimal 
adjustment by age and sex did not explain the differences that were observed between 
the people with tumours in different anatomical sites of the head and neck, nor did it 
explain the difference exhibited between the those with cancer of higher tumour stages. 
Following minimal adjustment for age and sex, patients who were treated with surgery 
only continued to have the lowest risk of all-cause mortality and disease-specific mortality, 
while those who were treated with any form of therapy that involved chemotherapy had 
the highest risk of mortality, along with those who did not receive any treatment. 
Interestingly, there was no obvious difference across the three Scottish Cancer Networks 
following adjustment for age and sex, until 12 years by which time those who were being 
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treated in the WoSCAN region had a slightly higher risk of all-cause mortality than those in 
other regions. However, these results were not reflected in the minimally adjusted models 
for disease-specific mortality, suggesting that the people in the WoSCAN area were more 
likely to have died as a result of other causes of death in the long-term.  
In the mutually adjusted models, the patient, tumour, and treatment factors that were 
independently associated with one-year, five-year, and 12-year all-cause mortality 
following the forced inclusion of age at diagnosis, tumour stage, and treatment modality, 
included WHO Performance Status, alcohol consumption, anatomical site, and smoking 
status. The results for the mutually adjusted models for disease-specific mortality differed 
slightly, in that after one year the factors with an independent association with disease-
specific mortality after the forced inclusion of age at diagnosis, tumour stage, and 
treatment modality included WHO Performance Status, alcohol consumption, and Scottish 
Cancer Network. However, by five years and 12 years, the factors that had an 
independent association with disease-specific mortality after the forced inclusion of age at 
diagnosis, tumour stage, and treatment modality included WHO Performance Status, 
alcohol consumption, and anatomical site, which was the same as the results for all-cause 
mortality.  
The strong association of patients with higher tumour stage and survival reflects the high 
prevalence of disease-specific deaths in this population. Likewise, the relationship 
between WHO Performance Status and survival could be an indicator of the severity of 
their cancer, or additionally, WHO Performance Status could be a representation of the 
person’s comorbidities, which have been previously described to have a negative impact 
on survival of people with head and neck cancer (Piccirillo, 2000). Similarly, the 
association of prior smoking and alcohol consumption are likely to be linked to other 
comorbidities such as chronic obstructive pulmonary disease, heart disease, liver disease 
and other cancers (Boje et al., 2013). The strong relationship between the differing 
treatment modalities and survival is likely to be a reflection for the people who received 
palliative or supportive care as opposed to curative treatment. This would particularly be 
the case for those who received no treatment for their cancer, however in a sensitivity 
analysis excluding these people, the same results were observed. There was a significant 
variance in survival of people by anatomical site, which is likely to be influenced by the 
inclusion of people with cancer of the lip, who had a considerably higher overall survival, 
disease-specific survival, and net survival results compared to the people with tumours 
that were in other sites of the head and neck.   
There was a substantial difference between overall survival, disease-specific survival, and 
net survival estimates in this study, particularly in the long-term follow-up period. This 
study demonstrates that overall survival overestimates death as a result of head and neck 
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cancer since the specific cause of the patients’ death is not considered in this 
measurement of survival. Contrary to this, disease-specific survival may also be an 
unreliable estimate in long-term follow-up studies because the measurement relies on 
cause of death information from a death certificate, which is often not accurate. The 
difference between the overall and the disease-specific results in this study suggest that 
people are dying of other head and neck cancer related causes that are not a direct result 
of the person’s head and neck cancer and are therefore not documented clearly on their 
death certificates.  
Net survival estimates survival using the background mortality of a group of people with 
the same demographics as the patient in the study (in this case, calendar year, age, sex, 
and Carstairs 2001 Category), and calculates the excess death that has occurred as a 
result of the patients’ disease. There is no need to use death certificates to compute net 
survival and as thus there is little inaccuracy as to the survival of the SAHNC cohort from 
head and neck cancer. Therefore, we feel that the use of net survival provides a good 
compromise to the traditional method of overall and disease-specific survival in long-term 
studies to estimate the true burden of head and neck cancer deaths.  
One limitation of this study is the absence of HPV status of the people in the cohort. Over 
the last two decades, there has been an increase in the association in the rising incidence 
of head and neck cancer with HPV (Junor et al., 2010; Chaturvedi et al., 2013; 
Purkayastha et al., 2016). This trend is particularly common for people with cancer of the 
oropharynx for whom around one to two thirds of tumours may be HPV-driven (Kreimer et 
al., 2005). People with HPV-positive tumours have a considerably better prognosis than 
people with HPV-negative tumours, even following adjustment for other baseline 
covariates (Ragin and Taioli, 2007; Wang et al., 2015). However, the primary focus of this 
analysis with the SAHNC cohort was to investigate the long-term survival of people with 
head and neck cancer in Scotland diagnosed between the years of 1999 and 2001. As a 
result, the baseline data collection for this study was ahead of the discovery of the 
association of HPV with head and neck cancer (D'Souza et al., 2007) and therefore HPV 
data were not routinely collected or available. However, aside from patients with cancer of 
the oropharynx, the majority of head and neck cancers that are diagnosed today are HPV-
negative and it is likely that these tumours are associated with tobacco and alcohol 
consumption (Herrero et al., 2003; Hashibe et al., 2009). Previous studies have suggested 
that smoking status, alcohol consumption, and HPV status are three independent risk 
factors of incidence and survival of people with head and neck cancer (Gillison et al., 
2008; Smith et al., 2012). Furthermore, the oropharyngeal patients in this study did not 
exhibit the well-documented survival advantage that is usually observed for HPV-
associated oropharyngeal cancer (Wang et al., 2015). A sensitivity analysis involving the 
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exclusion of people with oropharynx cancer for this study demonstrated similar results to 
the whole cohort. Therefore, the SAHNC patients’ cancers are likely to be predominantly 
related to smoking and alcohol behaviours and as a result, we propose that our findings 
remain relevant to clinicians, researchers, and other health professionals in gaining an 
understanding of the long-term prognosis of people with non-HPV driven head and neck 
cancer, particularly since the prevalence of smoking and problem alcohol consumption 
was very high in this study.  
The SAHNC cohort also pre-dates the use of organ preservation strategies that were 
introduced in Scotland in 2006 (Scottish Intercollegiate Guidelines Network, 2001-2014). 
However, studies following the introduction of these practices outline the importance of 
ensuring clear margins in surgery in the treatment of head and neck cancer (Gourin and 
Johnson, 2009; Hormann and Sadick, 2013). Therefore, due to the high proportion of 
people being treated with surgery in the SAHNC cohort, this study also remains relevant, 
and this study may be used in treatment planning decisions for people with head and neck 
cancer. Moreover, these analyses were based on historical cases (1999 to 2001), which is 
a prerequisite for estimating long-term follow-up, and so could be argued as a strength of 
the SAHNC cohort. 
The SAHNC cohort represented 77% of all head and neck cancer cases that were 
recorded on the Scottish Cancer Registry over the two-year study period and therefore, 
was representative of head and neck cancer cases in Scotland. This study adds to the 
worldwide literature on the long-term survival of people with head and neck cancer, and 
provides an in-depth analysis of overall survival, disease-specific survival, and net survival 
of people with head and neck cancer using a national clinical cohort. This study also 
supports the use of net survival, particularly in analyses with long-term follow-up.   
3.4.1 Conclusion 
Overall survival estimates after one year, five years, and 12 years were 76.0% (95% CI 
74.0% to 77.9%), 46.1% (95% CI 43.8% to 48.4%), and 26.3% (95% CI 24.3% to 28.3%), 
respectively, while disease-specific survival was higher at all three time points at 82.3% 
(95% CI 80.4% to 84.0%), 64.1% (95% CI 61.7% to 66.4%), and 56.9% (95% CI 54.3% to 
59.4%), respectively. Net survival estimates after one year, five years, and 12 years were 
78.3% (95% CI 76.2% to 80.3%), 53.8% (95% CI 51.1% to 56.5%), and 41.4% (95% CI 
37.6% to 45.1%), respectively. Following mutual adjustment, overall and disease-specific 
survival for people with head and neck cancer was associated with age at diagnosis, 
cancer stage, treatment modality, WHO Performance Status, alcohol consumption, 
anatomical site, smoking status, and cancer network.  
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The substantial difference between overall survival, disease-specific survival and net 
survival demonstrates the overestimation of deaths that are specific to head and neck 
cancer when using overall survival, and the underestimation of disease-specific mortality 
when using death certificates where people have died only from head and neck cancer. 
These results suggest that people are dying of other causes that are related to their head 
and neck cancer but are not as a direct result of their cancer. Therefore, the use of net 
survival seems to provide a good compromise to traditional methods to estimate the true 
burden of head and neck cancer in long-term follow-up studies.
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4 Inequality in survival of a population-based 
cohort study of people with head and neck 
cancer in Scotland (SAHNC) 
4.1 Introduction  
Chapter 3 investigated which patient, tumour, and treatment factors had an independent 
association with one-year, five-year, and 12-year survival for the SAHNC cohort. It was 
observed that there was inequality in survival by Carstairs 2001 Category, however when 
a forward-stepwise multivariate Cox proportional hazards model was performed, 
socioeconomic status was no longer a predictor of one-year, five-year, or 12-year all-
cause mortality or disease-specific mortality.  
4.1.1 Aims and objectives 
Following on from the research of Chapter 3, and by also using the SAHNC cohort, the 
aims of Chapter 4 are to explore the drivers of inequality in survival of people with head 
and neck cancer by using an area-based measurement of socioeconomic status (Scottish 
Audit of Head and Neck Cancers Steering Group, 2004). This chapter explores 
socioeconomic inequality in Scotland one year, five years, and 12 years after a diagnosis 
of head and neck cancer. The objectives of this chapter are to: 
1. Explore the underlying patient, tumour and treatment factors that are associated 
with socioeconomic inequality in survival of people with head and neck cancer. 
2. Examine the differences in socioeconomic inequality in survival of people with 
head and neck cancer via the use of overall survival, disease-specific survival, and 
net survival estimates. 
4.2 Methods  
4.2.1 Data included  
This chapter utilises the same data that was used in the study that investigated the 
determinants of survival using the SAHNC cohort, including the number of patients, and 
all of the patient, tumour, and treatment factors that were defined in Chapter 3.  
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4.2.2 Statistical analyses  
The statistical methods used throughout this chapter were the same as the methods that 
were used throughout Chapter 3 for determining overall survival, disease-specific survival, 
and net survival and the same statistical software programmed that were used in Chapter 
3 were also used in this chapter. In addition to the analyses performed in Chapter 3, 
frequency tables that displayed cross-tabulations of each of the patient, tumour, and 
treatment factors with Carstairs 2001 Category were generated, and the proportions 
across each of the groups were compared using the Pearson’s chi-square test. The 
primary and secondary causes of deaths of the participants within each of the Carstairs 
2001 Category were also investigated.  
Cox proportional hazards models for all-cause mortality and disease-specific mortality 
were used to determine the magnitude of and the explanations for socioeconomic 
inequality observed. Several models were produced by adjusting for: (a) age and sex;  
(b) age, sex, and smoking status; (c) age, sex, and alcohol consumption; (d) age, sex, and 
WHO Performance Status; (e) age, sex, and anatomical site; (f) age, sex, and tumour 
stage; (g) age, sex, and treatment modality; (h) age, sex, and Scottish Cancer Network;  
(i) age, sex, and all participant factors (including smoking status, alcohol consumption, 
and WHO Performance Status); (j) age, sex, and all tumour and treatment factors 
(including anatomical site, tumour stage, treatment modality, and Scottish Cancer 
Network); and (k) age, sex, and all patient, tumour, and treatment (full adjustment). A 
sensitivity analysis was performed which excluded WHO Performance Status from all of 
the models since it was such a strong predictor of survival in Chapter 3. Therefore, WHO 
Performance Status may be an indicator of death and as thus, including it in models to 
estimate mortality may be an over-adjustment.   
In addition, the SII was also calculated for each of the models that were produced to 
compare inequality over time. The SII is based on the regression of the mid-point of 
survival or mortality for each Carstairs 2001 Category (Regidor, 2004). 
4.3 Results  
4.3.1 Cross-tabulations of Carstairs 1991 Category by each baseline 
characteristic 
The numbers and proportions of all of the patient, tumour, and treatment factors that were 
cross-tabulated with Carstairs 2001 Category are displayed in Table 4.1 to Table 4.3 on 
Page 165 to Page 167. 
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4.3.1.1 Description of the participant factors by Carstairs 2001 Category  
A total of 528 (29.0%) participants of the SAHNC cohort resided in areas that were of the 
most deprived in Scotland (group five), whereas only 241 (13.2%) of the participants 
resided in the least deprived areas of Scotland (group one). There were no obvious 
differences across the Carstairs 2001 Category by age or sex, however there was a 
slightly higher proportion of males who were from the most deprived regions compared to 
those from the least deprived regions (n = 387 (73.3%) compared with n = 161 (66.8%)). 
As the deprivation category increased from group one (least deprived) to group five (most 
deprived) the proportion of current smokers increased from 49.0% (n = 118) to 75.0% (n = 
396). However, it can be observed that even among the least deprived groups, the 
prevalence of smoking was high, which is not surprising for a cohort of people with head 
and neck cancer. The increase in proportions across the Carstairs 2001 Category could 
also be observed for alcohol consumption where a proportion of 31.6% (n = 76) of 
participants were current or previous problem drinkers within the least deprived group, 
compared to a proportion of 45.8% (n = 242) in the most deprived group. The levels of 
normal WHO Performance Status decreased across the Carstairs 2001 Category from 
56.9% (n = 137) in the least deprived group to 38.8% (n = 205) in the most deprived 
group. 
4.3.1.2 Description of the tumour factors by Carstairs 2001 Category  
There were no obvious differences in the proportions of the anatomical site of the patients’ 
tumours across the Carstairs 2001 Category. However, the participants who resided in the 
most deprived areas were more likely to have tumours that were stage IV at 40.0% (n = 
211) compared to the participants who resided in the least deprived areas at 32.8% (n = 
79). Similarly, the participants who were in the least deprived group had a greater 
proportion of stage I cancers at 24.1% (n = 58) compared to the participants who were in 
the most deprived group at 17.4% (n = 92). There were no clear differences across the 
Carstairs 2001 Category by the histology of the participants’ tumours. 
4.3.1.3 Description of the treatment factors by Carstairs 2001 Category  
The participants who lived in the least deprived areas were more likely to be treated using 
single modality treatments such as surgery only or radiotherapy only at 29.9% (n = 72) 
and 30.7% (n = 74), respectively, compared to the participants who  lived in the most 
deprived regions at 24.6% (n = 130) and 22.5% (n = 119), respectively. The participants 
who resided in the most deprived regions of Scotland were more likely to have been 
treated with a combination of chemotherapy, radiotherapy, and surgery at 16.7% (n = 88) 
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compared to the participants who resided in the least deprived areas at 9.5% (n = 23). 
The participants who were in the most deprived group also had a higher proportion of 
participants who received no treatment at 9.1% (n = 48) compared to the participants who 
were in the least deprived group at 5.4% (n = 13). However, these differences are more 
likely to reflect the stage of the patients’ tumours, given the higher proportion of people 
from the most deprived regions with a stage IV tumour. The people from the most 
deprived area were more likely to have been treated in the West of Scotland Cancer 
Network at 78.2% (n = 413) while those from the least deprived area were more likely to 
be treated in either the East of Scotland Cancer Network or the North of Scotland Cancer 
Network at 34.4% (n = 83) and 30.3% (n = 73). 
Chapter 4: Inequality in survival in Scotland 
164 
Table 4.1 – Baseline characteristics by Carstairs 2001 Category for each participant factor 
Variable 
Frequencies of Carstairs 2001 Category (Col. %) Chi-
square 
p-value 
1 – Least 
deprived  
2 3 4 5 – Most 
deprived 
Whole cohort (Row %) 241 (13.2%) 317 (17.4%) 325 (17.9%) 409 (22.5%) 528 (29.0%) - 
Age at diagnosis      0.470 
   Less than 45 16 (6.6%) 23 (7.3%) 16 (4.9%) 21 (5.1%) 23 (4.4%)  
   45 to 54 35 (14.5%) 44 (13.9%) 45 (13.9%) 68 (16.6%) 96 (18.2%)  
   55 to 64 70 (29.1%) 105 (33.1%) 108 (33.2%) 140 (34.2%) 169 (32.0%)  
   65 to 74 72 (29.9%) 90 (28.4%) 111 (34.2%) 108 (26.4%) 170 (32.2%)  
   75 and over 48 (19.9%) 55 (17.4%) 45 (13.9%) 72 (17.6%) 70 (13.3%)  
Sex      0.440 
   Male 161 (66.8%) 227 (71.6%) 236 (72.6%) 289 (70.7%) 387 (73.3%)  
   Female 80 (33.2%) 90 (28.4%) 89 (27.4%) 120 (29.3%) 141 (26.7%)  
Smoking status      <0.001 
   Current smoker 118 (49.0%) 173 (54.6%) 191 (58.8%) 256 (62.6%) 396 (75.0%)  
   Previous smoker 60 (24.9%) 86 (27.1%) 68 (20.9%) 100 (24.5%) 91 (17.2%)  
   Never smoked 56 (23.2%) 45 (14.2%) 50 (15.4%) 41 (10.0%) 29 (5.5%)  
   Not recorded 7 (2.9%) 13 (4.1%) 16 (4.9%) 12 (2.9%) 12 (2.3%)  
Alcohol consumption      <0.001 
   Current (problem) drinker 51 (21.2%) 77 (24.3%) 80 (24.6%) 108 (26.4%) 180 (34.1%)  
   Previous (problem) drinker 25 (10.4%) 29 (9.2%) 49 (15.1%) 47 (11.5%) 62 (11.7%)  
   Occasional/never drank 138 (57.3%) 164 (51.7%) 150 (46.2%) 198 (48.4%) 241 (45.6%)  
   Not recorded 27 (11.2%) 47 (14.8%) 46 (14.2%) 56 (13.7%) 45 (8.5%)  
WHO Performance Status      0.003 
   Normal activity 137 (56.9%) 169 (53.3%) 137 (42.3%) 177 (43.3%) 205 (38.8%)  
   Strenuous activity restricted 54 (22.4%) 66 (20.8%) 94 (28.9%) 102 (24.9%) 149 (28.2%)  
   Up and about > 50%  18 (7.5%) 23 (7.3%) 17 (5.2%) 33 (8.1%) 46 (8.7%)  
   Confined to bed/chair >50%  8 (3.3%) 18 (5.7%) 22 (6.8%) 26 (6.4%) 23 (4.4%)  
   Not recorded 24 (10.0%) 41 (12.9%) 55 (16.9%) 71 (17.4%) 105 (19.9%)  
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Table 4.2 – Baseline characteristics by Carstairs 2001 Category for each tumour factor  
Variable 
Frequencies of Carstairs 2001 Category (Col. %) Chi-
square 
p-value 
1 – Least 
deprived  
2 3 4 5 – Most 
deprived 
Anatomical site      0.470 
   Lip 11 (4.6%) 17 (5.4%) 18 (5.5%) 23 (5.6%) 16 (3.0%)  
   Larynx 71 (29.5%) 102 (32.2%) 103 (31.7%) 143 (35.0%) 165 (31.3%)  
   Nasal cavity 12 (5.0%) 14 (4.4%) 22 (6.8%) 15 (3.7%) 22 (4.2%)  
   Oral cavity 76 (31.5%) 93 (29.3%) 78 (24.0%) 97 (23.7%) 162 (30.7%)  
   Oropharynx 40 (16.6%) 53 (16.7%) 63 (19.4%) 69 (16.9%) 98 (18.6%)  
   Hypopharynx 12 (5.0%) 19 (6.0%) 20 (6.2%) 35 (8.6%) 33 (6.3%)  
   Other/salivary gland 19 (7.9%) 19 (6.0%) 21 (6.5%) 27 (6.6%) 32 (6.1%)  
Stage      0.023 
   I 58 (24.1%) 85 (26.8%) 75 (23.1%) 73 (17.9%) 92 (17.4%)  
   II 48 (19.9%) 62 (19.6%) 65 (20.0%) 88 (21.5%) 106 (20.1%)  
   III 37 (15.4%) 42 (13.3%) 40 (12.3%) 80 (19.6%) 74 (14.0%)  
   IV 79 (32.8%) 102 (32.2%) 125 (38.5%) 145 (35.5%) 211 (40.0%)  
   Unknown 19 (7.9%) 26 (8.2%) 20 (6.2%) 23 (5.6%) 45 (8.5%)  
Histology      0.621 
   SCC 211 (87.6%) 269 (84.9%) 282 (86.8%) 355 (86.8%) 468 (88.6%)  
   Non-SCC 30 (12.5%) 48 (15.1%) 43 (13.2%) 54 (13.2%) 60 (11.4%)  
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Table 4.3 – Baseline characteristics by Carstairs 2001 Category for each treatment factor  
Variable 
Frequencies of Carstairs 2001 Category (Col. %) Chi-
square 
p-value 
1 – Least 
deprived  
2 3 4 5 – Most 
deprived 
Treatment modality      0.064 
   Surgery only 72 (29.9%) 83 (26.2%) 86 (26.5%) 106 (25.9%) 130 (24.6%)  
   Radiotherapy only 74 (30.7%) 99 (31.2%) 98 (30.2%) 117 (28.6%) 119 (22.5%)  
   Surgery + radiotherapy 59 (24.5%) 82 (25.9%) 73 (22.5%) 101 (24.7%) 143 (27.1%)  
   Chemo +/- radio +/- surgery 23 (9.5%) 34 (10.7%) 48 (14.8%) 56 (13.7%) 88 (16.7%)  
   No treatment 13 (5.4%) 19 (6.0%) 20 (6.2%) 29 (7.1%) 48 (9.1%)  
Network      <0.001 
   WoSCAN (West Scotland) 85 (35.3%) 110 (34.7%) 149 (45.9%) 244 (59.7%) 413 (78.2%)  
   SCAN (East Scotland) 83 (34.4%) 85 (26.8%) 108 (33.2%) 108 (26.4%) 56 (10.6%)  
   NOSCAN (North Scotland) 73 (30.3%) 122 (38.5%) 68 (20.9%) 68 (20.9%) 59 (11.2%)  
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4.3.1.4 Death rates by September 2013 by Carstairs 2001 Category 
The number and proportions of deaths by Carstairs 2001 Category are displayed in Table 
4.4. As the Carstairs 2001 Category increased from group one (least deprived) to five 
(most deprived), the proportion of patients dying as a result of head and neck cancer as 
their primary cause of death increased from 42.6% (n = 78) to 51.9% (n = 216). This trend 
was also observed for the patients’ secondary causes of death which increased from 
51.9% (n = 95) to 61.5% (n = 256) for those head and neck cancer deaths.  
4.3.2 Cause of death by Carstairs 2001 Category 
The proportions of head and neck cancer related deaths during each time period following 
diagnosis are also displayed in Table 4.4. Compared to the participants who were in the 
least deprived group, the participants who were in the most deprived group had a higher 
proportion of head and neck cancer deaths in the first year after their diagnosis (33.3% 
versus 48.1%, respectively). However, the patients who were in the second Carstairs 
2001 Category had the highest proportion of head and neck cancer deaths after the first 
year of diagnosis at 52.5%. After one year and before five years, the participants who 
were in the least deprived Carstairs 2001 Category had the highest proportion of head 
and neck cancer deaths at 51.3%, which was followed by the participants who were in 
Carstairs 2001 Category three at 46.5%. After five years, there were no differences in the 
proportions of head and neck cancer deaths across the Carstairs 2001 Category. 
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Table 4.4 – Primary and secondary cause of death by September 2013 by Carstairs 2001 Category 
 Frequencies of Carstairs 2001 Category (Col. %)  
 
1 – Least 
deprived  




Primary cause of death      0.080 
   Cancer – Head and neck 78 (42.6%) 99 (43.8%) 127 (51.4%) 157 (50.5%) 216 (51.9%)  
   Cancer – Other 46 (25.1%) 54 (23.9%) 61 (24.7%) 73 (23.5%) 74 (17.8%)  
   Other 59 (32.2%) 73 (32.3%) 59 (23.9%) 81 (26.1%) 126 (30.3%)  
Secondary cause of death      0.066 
   Cancer – Head and neck 95 (51.9%) 127 (56.2%) 152 (61.5%) 190 (61.1%) 256 (61.5%)  
   Cancer – Other 40 (21.9%) 35 (15.5%) 46 (18.6%) 59 (19.0%) 58 (13.9%)  
   Other 48 (26.2%) 64 (28.3%) 49 (19.8%) 62 (19.9%) 102 (24.5%)  
Head and Neck cancer deaths      0.240 
   Up to one year 26 (33.3%) 52 (52.5%) 55 (43.3%) 71 (45.2%) 104 (48.1%)  
   Between one and five years 40 (51.3%) 37 (37.4%) 59 (46.5%) 61 (38.9%) 85 (39.4%)  
   More than five years 12 (15.4%) 10 (10.1%) 13 (10.2%) 25 (15.9%) 27 (12.5%)  
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4.3.3 Overall survival, disease-specific survival, and net survival results by 
Carstairs 2001 Category  
One-year, five-year, and 12-year overall survival, disease-specific survival, and net 
survival results by each Carstairs 2001 Category along with the SII for each measurement 
are displayed in Table 4.5. These estimates are the same as the figures that are outlined 
in Table 3.5 to Table 3.7 on Page 116 to Page 118 of Chapter 3. However, this chapter 
provides a more detailed review, including comparisons of the SII estimates.  
There was clear inequality in overall survival, disease-specific survival, and net survival 
across Carstairs 2001 Category after one year of follow-up. One-year overall survival for 
the participants who resided in the least deprived areas was 83.4% (95% CI 78.1% to 
87.5%), whereas the participants who resided in the most deprived areas had a 
considerably lower one-year overall survival of 71.8% (95% CI 67.7% to 75.4%). Similarly, 
one-year disease-specific survival was also substantially lower for the participants who 
were from the most deprived regions at 71.9% (95% CI 75.2% to 82.4%), compared to 
88.8% (95% CI 83.9% to 92.9%) for the participants who were from the least deprived 
regions. One-year net survival also demonstrated the same difference, and the 
participants who were in the least deprived group had one-year net survival of 86.1% 
(95% CI 81.3% to 91.0%), while the participants who were in the most deprived group had 
a considerably lower one-year net survival result of 73.7% (95% CI 69.7% to 77.6%). One 
year after the patient’s diagnosis of head and neck cancer, the SII across Carstairs 2001 
Category was highest for net survival at 13.6 (95% CI 7.1 to 20.1), and lowest for disease-
specific survival at 9.5 (95% CI 1.4 to 17.7). This result for the SII suggests that within the 
first year after their diagnosis the participants who are from more deprived regions are 
more likely to die as a result of underlying causes of their head and neck cancer that may 
not necessarily be considered in disease-specific survival.  
After five years, the inequality by overall survival, disease-specific survival, and net 
survival remained and those who were from the least deprived and most deprived areas 
had five-year overall survival of 49.8% (95% CI 43.3% to 55.9%) and 40.5% (95% CI 
36.3% to 44.7%), respectively. Similarly, the participants who were from the least deprived 
regions still had a considerably higher disease-specific and net survival result of 69.6% 
(95% CI 62.9% to 75.3%) and 58.1% (95% CI 50.4% to 65.8%), respectively, compared to 
the participants who were from the most deprived regions at 59.6% (95% CI 54.9% to 
63.9%) and 46.6% (95% CI 41.7% to 51.5%), respectively. Similar to the results for one-
year survival, the SII was the strongest for net survival at 16.1 (95% CI -1.0 to 33.3), and 
inequality had increased for all three measurements of survival. However, the results were 
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not clear cut since the confidence intervals for all three of the SIIs were crossing over 
zero.  
After 12 years, inequality in overall survival by Carstairs 2001 Category had attenuated, 
and patients who were from the least deprived and most deprived regions had 12-year 
overall survival of 27.0% (95% CI 21.5% to 32.7%) and 22.9% (95% CI 19.4% to 26.6%), 
respectively. This attenuation can also be demonstrated by the lower SII of 7.4 (95% CI -
2.7 to 17.5) after 12 years for overall survival. Similar results were observed for net 
survival, and the participants who were from the least deprived and most deprived areas 
had 12-year net survival of 40.4% (95% CI 30.7% to 50.0%) and 35.7% (95% CI 29.6% to 
41.8%), respectively, with an SII of 6.6 (95% CI -17.2 to 30.3). Contrastingly, the 
inequality by disease-specific survival was at its strongest after 12 years with an SII of 
16.5 (95% CI 1.5 to 31.5). The participants who were from the least deprived and most 
deprived regions had 12-year disease-specific survival of 61.8% (95% CI 54.4% to 68.4%) 
and 51.1% (95% CI 46.0% to 55.9%), respectively.  
Table 4.5 – One-year, five-year, and 12-year overall survival, disease-specific survival, and 
net survival results for each Carstairs 2001 Category  
Carstairs 2001 Category 
Overall  
survival %  
(95% CI) 
Disease-specific 
survival %  
(95% CI) 
Net  
survival %  
(95% CI) 
One-year    
  1 (Least deprived) 83.4 (78.1, 87.5) 88.8 (83.9, 92.2) 86.1 (81.3, 91.0) 
  2 78.6 (73.6, 82.7) 83.2 (78.5, 86.9) 80.9 (76.2, 85.5) 
  3 76.3 (71.3, 80.6) 82.2 (77.5, 86.1) 78.6 (73.8, 83.3) 
  4 75.1 (70.6, 79.0) 81.8 (77.5, 85.3) 77.2 (72.8, 81.5) 
  5 (Most deprived) 71.8 (67.7, 75.4) 79.1 (75.2, 82.4) 73.7 (69.7, 77.6) 
SII (95% CI) 12.7 (6.7, 18.8) 9.5 (1.4, 17.7) 13.6 (7.1, 20.1) 
Five-year    
  1 (Least deprived) 49.8 (43.3, 55.9) 69.6 (62.9, 75.3) 58.1 (50.4, 65.8) 
  2 52.1 (46.4, 57.4) 69.8 (64.2, 74.8) 61.0 (54.4, 67.6) 
  3 44.6 (39.2, 49.9) 61.0 (55.1, 66.4) 52.9 (46.4, 59.3) 
  4 47.7 (42.8, 52.4) 64.4 (59.2, 69.1) 55.8 (50.1, 61.6) 
  5 (Most deprived) 40.5 (36.3, 44.7) 59.6 (54.9, 63.9) 46.6 (41.7, 51.5) 
SII (95% CI) 12.9 (-1.8, 27.5) 12.5 (-1.8, 26.9) 16.1 (-1.0, 33.3) 
12-year    
  1 (Least deprived) 27.0 (21.5, 32.7) 61.8 (54.4, 68.4) 40.4 (30.7, 50.0) 
  2 30.6 (25.6, 35.7) 65.6 (59.6, 70.9) 43.8 (35.0, 52.6) 
  3 26.2 (21.5, 31.0) 55.5 (49.2, 61.3) 40.7 (31.5, 49.9) 
  4 26.9 (22.7, 31.3) 55.5 (49.9, 60.8) 46.6 (38.4, 54.7) 
  5 (Most deprived) 22.9 (19.4, 26.6) 51.1 (46.0, 55.9) 35.7 (29.6, 41.8) 
SII (95% CI) 7.4 (-2.7, 17.5) 16.5 (1.5, 31.5) 6.6 (-17.2, 30.3) 
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4.3.4 Adjusted Cox proportional hazards models for all-cause mortality by 
Carstairs 2001 Category  
The adjusted Cox Proportional hazards models for all-cause mortality by Carstairs 2001 
Category along with the SIIs for each model are displayed in Table 4.6 to Table 4.9 on 
Page 175 to Page 178. 
4.3.4.1 Adjusted Cox proportional hazards models by age and sex for all-cause 
mortality by Carstairs 2001 Category  
Trends were observed following minimal adjustment for age and sex in the models for all-
cause mortality at all three time points (Table 4.6). After one year, five years, and 12 
years, the participants who resided in the most deprived areas of Scotland were 96% (HR 
= 1.96, 95% CI 1.38 to 2.77), 43% (HR = 1.43, 95% CI 1.15 to 1.76) and 27% (HR = 1.27, 
95% CI 1.06 to 1.52) more at risk of all-cause mortality following adjustment for age and 
sex, respectively. Inequality in survival following adjustment for age and sex was strongest 
after one year of follow-up and attenuated over time. This can be demonstrated from both 
the reduction in the hazard ratios for those in the most deprived group, and the reduction 
in the SIIs from 1.1 (95% CI 0.7 to 1.5) after one year to 0.4 (95% CI 0.1 to 0.7) after 12 
years.  
4.3.4.2 Adjusted Cox proportional hazards models by individual patient, tumour, 
and treatment factors for all-cause mortality by Carstairs 2001 Category 
In minimally adjusted models that were adjusted by each of the individual patient, tumour, 
and treatment factors (Table 4.6 and Table 4.7), there were no variables that fully 
explained the inequality in all-cause mortality after one or five years. Although inequality 
remained strong, there was a slight attenuation across Carstairs 2001 Category after one 
year following adjustment for WHO Performance Status, smoking status, tumour stage, 
and treatment modality, which can be observed by the reduction in the SII and the 
attenuation of the hazard ratios. Similarly, after 12 years, the people from the most 
deprived areas continued to be at an increased risk of all-cause mortality compared to the 
people from the least deprived area in each of the minimally adjusted models that were 
adjusted by the individual patient, tumour, and treatment factors. However, smoking status 
fully explained the inequality in all-cause mortality observed across Carstairs 2001 
Category after 12 years, which can be demonstrated in the attenuation of the hazard 
ratios and the reduction in the SII to 0.2 (95% CI -0.1 to 0.4).  
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4.3.4.3 Adjusted Cox proportional hazards models by all patient, tumour, and 
treatment factors for all-cause mortality by Carstairs 2001 Category  
Following adjustment for age, sex and, a) all participant factors, b) all tumour factors, and 
c) all treatment factors, inequality had reduced, but remained clear after one year in all of 
the models (Table 4.8). However, after five years and 12 years, inequality was no longer 
apparent following adjustment for age, sex, and participant factors, which can be 
demonstrated by the attenuation in the hazard ratios and the reduction of the SIIs to 0.2 
(95% CI -0.2 to 0.6) and 0.1 (95% CI -0.3 to 0.4), respectively. Inequality remained after 
five years following adjustment for age, sex, and a) tumour factors, and  
b) treatment factors. However, after 12 years, there was no longer inequality when 
adjusting by these factors. Interestingly, following adjustment for age, sex, tumour, and 
treatment factors combined, there was no longer a difference between the participants 
who were most deprived and the participants in other Carstairs 2001 Category at any time 
point.   
4.3.4.4 Fully adjusted Cox proportional hazards models for all-cause mortality by 
Carstairs 2001 Category  
Following full adjustment for age, sex, patient, tumour, and treatment factors, there was 
no longer inequality across the Carstairs 2001 Category (one-year HR = 1.16, 95% CI 
0.80 to 1.68, five-year HR = 0.97, 95% CI 0.78 to 1.22, 12-year HR = 0.87, 95% CI 0.72 to 
1.05) (Table 4.8). The attenuation of inequality was also demonstrated by the SIIs which 
had reduced from 1.1 (95% CI 0.7 to 1.5) to 0.2 (95% CI -0.4 to 0.7) after one-year, 0.6 
(95% CI 0.1 to 1.0) to 0.03 (95% CI -0.6 to 0.6) after five-years, and 0.4 (95% CI 0.1 to 
0.7) to -0.1 (95% CI -0.5 to 0.4) after 12-years in the minimally adjusted models by age 
and sex and the fully adjusted models, respectively.  
4.3.4.5 Fully adjusted Cox proportional hazards models for all-cause mortality by 
Carstairs 2001 Category by removing WHO Performance Status 
In a sensitivity analysis which excluded WHO Performance Status as an adjustment 
variable, the results were similar to the models that included WHO Performance Status as 
an adjustment variable (Table 4.9). Following adjustment for age, sex and participant 
factors, inequality in survival was stronger after one and five years. After one year, the 
participants who were from the most deprived areas were 66% (HR = 1.66, 95% CI 1.17 
to 2.37) more at risk of all-cause mortality than the people who were from the least 
deprived areas, compared to 46% (HR = 1.46, 95% CI 1.02 to 2.09) more at risk in the 
model which included WHO Performance Status too. However, after five years, the 
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participants who were from the most deprived regions were 25% (HR = 1.25, 95% CI 1.01 
to 1.55) more at risk of all-cause mortality than the participants who were from the least 
deprived regions, compared to no excess risk (HR = 1.11, 95% CI 0.89 to 1.38) in the 
model which include WHO Performance Status. When WHO Performance Status was 
removed as an adjustment variable in the model that was fully adjusted by age, sex, 
patient, tumour, and treatment factors, the results were the same, and the participants 
who were from the most deprived areas were at no extra risk than those who were from 
the least deprived areas. 
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Table 4.6 – Minimally adjusted hazard ratios by participant factors for all-cause mortality (ACM) after one year, five years, and 12 years for Carstairs 2001 
Category  
 Adjusted by age and sex Adjusted by WHO* Adjusted by Smoking^ Adjusted by Alcohol+ 
Variable HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value 
One-year ACM  <0.001  0.003  0.003  <0.001 
1 (Least deprived) 1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  
2 1.35 (0.92, 2.00)  1.22 (0.83, 1.81)  1.31 (0.88, 1.93)  1.36 (0.92, 2.01)  
3 1.53 (1.05, 2.25)  1.38 (0.94, 2.03)  1.47 (1.00, 2.15)  1.51 (1.03, 2.22)  
4 1.62 (1.12, 2.33)  1.37 (0.95, 1.98)  1.49 (1.03, 2.15)  1.57 (1.09, 2.27)  
5 (Most deprived) 1.96 (1.38, 2.77)  1.66 (1.16, 2.35)  1.68 (1.18, 2.40)  1.85 (1.30, 2.63)  
SII (95% CI) 1.1 (0.7, 1.5)  0.7 (0.3, 1.1)  0.7 (0.2, 1.2)  0.9 (0.4, 1.4)  
Five-year ACM  <0.001  0.008  0.012  0.001 
1 (Least deprived) 1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  
2 0.99 (0.78, 1.26)  0.90 (0.71, 1.14)  0.97 (0.76, 1.23)  1.00 (0.79, 1.27)  
3 1.22 (0.97, 1.54)  1.12 (0.89, 1.41)  1.19 (0.94, 1.49)  1.21 (0.96, 1.52)  
4 1.14 (0.91, 1.43)  1.00 (0.80, 1.25)  1.07 (0.85, 1.34)  1.10 (0.88, 1.38)  
5 (Most deprived) 1.43 (1.15, 1.76)  1.24 (1.00, 1.53)  1.26 (1.02, 1.56)  1.35 (1.09, 1.67)  
SII (95% CI) 0.6 (0.1, 1.0)  0.3 (-0.2, 0.9)  0.3 (-0.1, 0.8)  0.4 (0.0, 0.9)  
12-year ACM  <0.001  0.029  0.102  0.009 
1 (Least deprived) 1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  
2 0.94 (0.77, 1.15)  0.87 (0.71, 1.06)  0.92 (0.75, 1.12)  0.95 (0.78, 1.16)  
3 1.09 (0.89, 1.32)  1.01 (0.83, 1.23)  1.05 (0.87, 1.28)  1.06 (0.88, 1.29)  
4 1.08 (0.89, 1.30)  0.96 (0.79, 1.16)  1.00 (0.83, 1.20)  1.04 (0.86, 1.25)  
5 (Most deprived) 1.27 (1.06, 1.52)  1.13 (0.94, 1.35)  1.10 (0.92, 1.32)  1.20 (1.01, 1.44)  
SII (95% CI) 0.4 (0.1, 0.7)  0.2 (-0.2, 0.6)  0.2 (-0.1, 0.4)  0.3 (0.0, 0.6)  
*Adjusted by age, sex and WHO Performance Status 
^Adjusted by age, sex and smoking status 
+Adjusted by age, sex and alcohol consumption 
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Table 4.7 – Minimally adjusted hazard ratios by tumour and treatment factors for all-cause mortality (ACM) after one year, five years, and 12 years for Carstairs 
2001 Category  
 Adjusted by Site* Adjusted by Stage^ Adjusted by Treatment+ Adjusted by Network& 
Variable HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value 
One-year ACM  <0.001  0.002  0.007  <0.001 
  1 (Least deprived) 1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  
  2 1.38 (0.93, 2.03)  1.32 (1.89, 1.95)  1.21 (0.81, 1.78)  1.36 (0.92, 2.01)  
  3 1.54 (1.05, 2.25)  1.51 (1.03, 2.21)  1.53 (1.04, 2.25)  1.53 (1.04, 2.25)  
  4 1.63 (1.13, 2.35)  1.52 (1.05, 2.20)  1.48 (1.03, 2.14)  1.61 (1.12, 2.33)  
  5 (Most deprived) 1.91 (1.35, 2.71)  1.73 (1.22, 2.46)  1.58 (1.11, 2.25)  1.96 (1.37, 2.80)  
SII (95% CI) 1.0 (0.5, 1.5)  0.8 (0.3, 1.3)  0.6 (0.0, 1.3)  1.7 (0.6, 1.5)  
Five-year ACM  <0.001  0.004  0.005  <0.001 
  1 (Least deprived) 1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  
  2 1.03 (0.81, 1.31)  1.00 (0.79, 1.27)  0.91 (0.72, 1.16)  0.99 (0.78, 1.26)  
  3 1.28 (1.02, 1.61)  1.25 (0.99, 1.57)  1.23 (0.97, 1.55)  1.22 (0.96, 1.53)  
  4 1.19 (0.95, 1.49)  1.10 (0.88, 1.37)  1.12 (0.89, 1.40)  1.13 (0.90, 1.42)  
  5 (Most deprived) 1.41 (1.15, 1.75)  1.32 (1.07, 1.63)  1.24 (1.00, 1.53)  1.40 (1.13, 1.74)  
SII (95% CI) 0.5 (0.1, 0.9)  0.4 (-0.1, 0.9)  0.3 (-0.2, 0.9)  0.5 (0.1, 1.0)  
12-year ACM  0.001  0.012  0.010  0.006 
  1 (Least deprived) 1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  
  2 0.96 (0.79, 1.18)  0.94 (0.77, 1.15)  0.88 (0.72, 1.07)  0.93 (0.77, 1.14)  
  3 1.14 (0.94, 1.39)  1.09 (0.90, 1.33)  1.10 (0.90, 1.33)  1.08 (0.89, 1.31)  
  4 1.12 (0.93, 1.35)  1.04 (0.86, 1.25)  1.07 (0.89, 1.29)  1.05 (1.05, 1.27)  
  5 (Most deprived) 1.25 (1.05, 1.50)  1.19 (1.00, 1.42)  1.14 (0.96, 1.37)  1.22 (1.02, 1.47)  
SII (95% CI) 0.3 (0.1, 0.6)  0.3 (0.0, 0.6)  0.3 (-0.1, 0.6)  0.3 (0.0, 0.6)  
*Adjusted by age, sex and anatomical site 
^Adjusted by age, sex and tumour stage 
+Adjusted by age, sex and treatment modality 
&Adjusted by age, sex and Scottish Cancer Network 
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Table 4.8 – Adjusted hazard ratios by a combination of patient, tumour, and treatment factors for all-cause mortality (ACM) after one year, five years, and 12 
years for Carstairs 2001 Category  
 Adjusted by all participant 
factors* Adjusted by all tumour factors^ 
Adjusted by all treatment 
factors+ 
Adjusted by tumour and 
treatment factors 
combined& 
Adjusted by all patient, 
tumour, and treatment 
factors combined% 
Variable HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value 
One-year ACM  0.037  0.002  0.006  0.113  0.351 
  1 (Least deprived) 1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  
  2 1.20 (0.81, 1.78)  1.32 (0.89, 2.95)  1.18 (0.79, 1.74)  1.09 (0.74, 1.62)  0.99 (0.67, 1.47)  
  3 1.31 (0.89, 1.92)  1.53 (1.04, 2.25)  1.55 (1.06, 2.29)  1.42 (0.96, 2.09)  1.28 (0.86, 1.89)  
  4 1.30 (0.90, 1.89)  1.53 (1.06, 2.21)  1.51 (1.04, 2.18)  1.29 (0.89, 1.88)  1.16 (0.79, 1.69)  
  5 (Most deprived) 1.46 (1.02, 2.09)  1.73 (1.22, 2.46)  1.59 (1.11, 2.29)  1.32 (0.92, 1.91)  1.16 (0.80, 1.68)  
SII (95% CI) 0.5 (0.2, 0.8)  0.8 (0.2, 1.3)  0.7 (0.0, 1.4)  0.3 (-0.3, 1.0)  0.2 (-0.4, 0.7)  
Five-year ACM  0.157  0.004  0.003  0.065  0.715 
  1 (Least deprived) 1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  
  2 0.89 (0.70, 1.13)  1.03 (0.81, 1.31)  0.90 (0.71, 1.15)  0.91 (0.72, 1.16)  0.80 (0.63, 1.02)  
  3 1.07 (0.85, 1.35)  1.32 (1.04, 1.66)  1.24 (0.98, 1.57)  1.29 (1.02, 1.63)  1.11 (0.88, 1.41)  
  4 0.95 (0.76, 1.19)  1.13 (0.90, 1.42)  1.14 (0.91, 1.43)  1.07 (0.85, 1.34)  0.90 (0.72, 1.14)  
  5 (Most deprived) 1.11 (0.89, 1.38)  1.33 (1.08, 1.65)  1.28 (1.03, 1.59)  1.17 (0.94, 1.46)  0.97 (0.78, 1.22)  
SII (95% CI) 0.2 (-0.2, 0.6)  0.4 (-0.2, 0.9)  0.4 (-0.1, 1.0)  0.2 (-0.5, 0.9)  0.03 (-0.6, 0.6)  
12-year ACM  0.624  0.015  0.015  0.197  0.465 
  1 (Least deprived) 1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  
  2 0.86 (0.70, 1.04)  0.95 (0.78, 1.16)  0.87 (0.71, 1.06)  0.87 (0.71, 1.06)  0.79 (0.64, 0.96)  
  3 0.95 (0.78, 1.16)  1.15 (0.94, 1.40)  1.10 (0.91, 1.34)  1.14 (0.94, 1.39)  0.99 (0.81, 1.21)  
  4 0.89 (0.74, 1.08)  1.07 (0.88, 1.29)  1.07 (0.89, 1.30)  1.02 (0.84, 1.23)  0.86 (0.71, 1.05)  
  5 (Most deprived) 0.99 (0.82, 1.19)  1.19 (0.99, 1.42)  1.14 (0.95, 1.37)  1.06 (0.88, 1.27)  0.87 (0.72, 1.05)  
SII (95% CI) 0.1 (-0.3, 0.4)  0.3 (-0.1, 0.6)  0.3 (-0.1, 0.6)  0.1 (-0.4, 0.6)  -0.1 (-0.5, 0.4)  
*Adjusted by age, sex and all participant factors including smoking status, alcohol consumption and WHO Performance Status  
^Adjusted by age, sex and all tumour factors including anatomical site and tumour stage 
+Adjusted by age, sex and all treatment modality and network 
&Adjusted by age, sex and both tumour and treatment factors including stage, anatomical site, treatment modality and network of treatment 
%Adjusted by all factors including age, sex, smoking status, alcohol consumption, WHO Performance status, stage, anatomical site, treatment modality and network of treatment 
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Table 4.9 – Sensitivity analysis - adjusted hazard ratios by a combination of patient, tumour, 
and treatment factors for all-cause mortality (ACM) after one year, five years, and 12 years 
for Carstairs 2001 Category excluding WHO Performance Status 
 
Adjusted by all 
participant factors 
excluding WHO* 
Adjusted by all patient, 
tumour, and treatment 
factors combined 
excluding WHO^ 
Variable HR (95% CI) 
p-
value 
HR (95% CI) 
p-
value 
One-year ACM  0.005  0.222 
  1 (Least deprived) 1.00 (Ref.)  1.00 (Ref.)  
  2 1.32 (0.89, 1.95)  1.16 (0.78, 1.73)  
  3 1.46 (1.00, 2.14)  1.37 (0.93, 2.02)  
  4 1.49 (1.03, 2.15)  1.28 (0.88, 1.85)  
  5 (Most deprived) 1.66 (1.17, 2.37)  1.29 (0.89, 1.89)  
SII (95% CI) 0.7 (0.2, 1.2)  0.3 (-0.3, 0.8)  
Five-year ACM  0.021  0.428 
  1 (Least deprived) 1.00 (Ref.)  1.00 (Ref.)  
  2 0.98 (0.77, 1.25)  0.95 (0.75, 1.21)  
  3 1.18 (0.94, 1.49)  1.21 (0.96, 1.53)  
  4 1.06 (0.84, 1.33)  1.01 (0.80, 1.27)  
  5 (Most deprived) 1.25 (1.01, 1.55)  1.09 (0.87, 1.36)  
SII (95% CI) 0.3 (-0.1, 0.7)  0.1 (-0.4, 0.6)  
12-year ACM  0.160  0.752 
  1 (Least deprived) 1.00 (Ref.)  1.00 (Ref.)  
  2 0.93 (0.76, 1.14)  0.91 (0.74, 1.11)  
  3 1.04 (0.86, 1.27)  1.07 (0.88, 1.31)  
  4 0.99 (0.82, 1.19)  0.95 (0.79, 1.16)  
  5 (Most deprived) 1.10 (0.91, 1.31)  0.95 (0.79, 1.15)  
SII (95% CI) 0.2 (-0.1, 0.4)  0.0 (-0.4, 0.3)  
*Adjusted by age, sex and all participant factors including smoking status and alcohol consumption  
^Adjusted by all factors including age, sex, smoking status, alcohol consumption, WHO Performance status, stage, 
anatomical site, treatment modality and network of treatment 
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4.3.5 Adjusted Cox proportional hazards models for disease-specific 
mortality by Carstairs 2001 Category  
Minimally adjusted Cox Proportional hazards models for disease-specific mortality by 
Carstairs 2001 Category along with the SII for each model are displayed in Table 4.10 to 
Table 4.13 on Page 182 to Page 185. 
4.3.5.1 Adjusted Cox proportional hazards models by age and sex for disease-
specific mortality by Carstairs 2001 Category  
Similar to the models for all-cause mortality, there was clear inequality by disease-specific 
mortality following minimal adjustment by age and sex at all three time points. (Table 
4.10). After one year, five years, and 12 years the participants who resided in the most 
deprived areas of Scotland were two-fold (HR = 2.09, 95% CI 1.36 to 3.22), 55% (HR = 
1.55, 95% CI 1.17 to 2.06) and 51% (HR = 1.51, 95% CI 1.16 to 1.96) more at risk of 
disease-specific mortality following adjustment for age and sex, respectively. Inequality in 
survival following adjustment for age and sex was strongest after one-year of follow-up 
and attenuated over time which can be demonstrated in the reduction in the SII from 1.1 
(95% CI 0.2 to 1.9) at one-year to 0.7 (95% CI 0.2 to 1.2) at 12-years. In addition, the 
magnitude of the inequality by disease-specific mortality was stronger than it was for all-
cause mortality at all three time points.  
4.3.5.2 Adjusted Cox proportional hazards models by individual patient, tumour, 
and treatment factors for disease-specific mortality by Carstairs 2001 
Category  
In the minimally adjusted models by each individual patient, tumour, and treatment factor 
(Table 4.10 and Table 4.11), there was no adjustment variable that fully explained the 
inequality in disease-specific mortality after one year, five years, or 12 years. However, 
when the models were adjusted by age, sex and, a) WHO Performance Status,  
b) smoking status, c) tumour stage, or e) treatment modality, inequality attenuated which 
can be demonstrated by the reduction in the hazard ratios and the reduction in the SIIs.  
4.3.5.3 Fully adjusted Cox proportional hazards models for disease-specific 
mortality by Carstairs 2001 Category  
In contrast to the model for all-cause mortality, following adjustment for age, sex, and 
participant factors, there was no longer a difference between the participants who were 
from the most deprived regions and the participants in other Carstairs 2001 Categories 
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(one-year HR = 1.51, 95% CI 0.97 to 2.34, five-year HR = 1.21, 95% CI 0.91 to 1.62, 12-
year HR = 1.18, 95% CI 0.90 to 1.55) (Table 4.12). The reduction in the inequality 
following adjustment for age, sex, and participant factors could also be observed from the 
SIIs which were 0.7 (95% CI -0.1 to 3.5), 0.3 (95% CI -0.3 to 0.8) and 0.3 (95% CI -0.2 to 
0.7) after one year, five years, and 12 years, respectively.  
Similar to the models for all-cause mortality, in the models adjusting for age, sex, and 
tumour factors, inequality by disease-specific survival remained strong after one year and 
five years, and the participants who were from the most deprived areas were 85% (HR = 
1.85, 95% CI 1.20 to 2.86) and 42% (HR = 1.42, 95% CI 1.07 to 1.88) more at risk of 
disease-specific mortality compared to the participants who were from the least deprived 
areas (Table 4.12). However, unlike the model for all-cause mortality, after 12 years the 
participants in the most deprived group remained 38% (HR = 1.38, 95% CI 1.06 to 1.79) 
more at risk of disease-specific mortality compared to the participants who were least 
deprived. Interestingly, the SII did not display inequality in disease-specific survival 
following adjustment by age, sex, and tumour factors at one, five or 12 years at 0.8 (95% 
CI -0.1 to 1.7), 0.4 (95% CI -0.4 to 1.3), and 0.5 (95% CI -0.2 to 1.1) respectively.  
Following adjustment for age, sex, and treatment factors, similar results were observed to 
the models for all-cause mortality (Table 4.12). After one year, the participants in the most 
deprived group were 79% (HR = 1.79, 95% CI 1.15 to 2.80) more at risk of disease-
specific mortality compared to the participants who were in the least deprived group. 
Inequality had attenuated slightly by five-years and the participants who were from the 
most deprived areas were 46% (HR = 1.46, 95% CI 1.09 to 1.95) more at risk of disease-
specific mortality than the participants who were from the least deprived areas. However, 
unlike the results for all-cause mortality, after 12 years, the participants who lived in the 
most deprived regions were 38% (HR = 1.38, 95% CI 1.05 to 1.82) more at risk of 
disease-specific mortality. Similar to the model adjusting by age, sex, and tumour factors, 
the SII did not display the inequality in disease-specific survival following adjustment by 
age, sex, and treatment factors after one year, five years or 12 years at 1.1 (95% CI -0.2 
to 2.4), 0.6 (95% CI -0.2 to 1.4), and 0.6 (95% CI -0.2 to 1.3) respectively. 
Similar to the results for all-cause mortality, following adjustment for age, sex, tumour, and 
treatment factors, there was no longer a difference between the participants who were 
from the most deprived regions and the participants in other Carstairs 2001 Categories 
(one-year HR = 1.45, 95% CI 0.92 to 2.29, five-year HR = 1.27, 95% CI 0.95 to 1.71, 12-
year HR = 1.22, 95% CI 0.92 to 1.60) for disease-specific mortality (Table 4.12). The 
reduction in inequality following adjustment for age, sex, tumour, and treatment factors 
could also be observed from the SIIs which were 0.4 (95% CI -0.4 to 1.3), 0.3 (95% CI -
0.7 to 1.4) and 0.3 (95% CI -0.6 to 1.2) at one-year, five-year, and 12-years, respectively.  
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Similar to the results for all-cause mortality, following full adjustment for age, sex, patient, 
tumour, and treatment factors, there was also no longer a clear inequality across Carstairs 
2001 Category, suggesting that the participants who were from the most deprived areas 
were no longer at an increased risk of disease-specific mortality (one-year HR = 1.23, 
95% CI 0.78 to 1.96, five-year HR = 1.07, 95% CI 0.79 to 1.45, 12-year HR = 1.02, 95% 
CI 0.77 to 1.35) (Table 4.11). The attenuation of inequality was also demonstrated by the 
SIIs which had reduced from 1.1 (95% CI 0.2 to 1.9) to 0.2 (95% CI -0.5 to 0.9) after one 
year, 0.7 (95% CI 0.1 to 1.2) to 0.1 (95% CI -0.7 to 1.0) after five years, and 0.7 (95% CI 
0.2 to 1.2) to 0.1 (95% CI -0.7 to 0.9) after 12 years in the minimally adjusted models by 
age and sex and the fully adjusted models, respectively.  
4.3.5.4 Fully adjusted Cox proportional hazards models for disease-specific 
mortality by Carstairs 2001 Category by removing WHO Performance Status 
In a sensitivity analysis which excluded WHO Performance Status as an adjustment 
variable, the results were similar to the models that included WHO Performance Status as 
an adjustment variable (Table 4.13). Following adjustment for age, sex, and participant 
factors, inequality in survival was stronger after one year, five years, and 12 years. When 
WHO Performance Status was removed as an adjustment variable in the model that was 
fully adjusted by age, sex, patient, tumour, and treatment factors, the results were the 
same, and the participants who were from the most deprived areas were at no extra risk 
than those who were from the least deprived areas.
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Table 4.10 – Minimally adjusted hazard ratios by participant factors for disease-specific mortality (DSM) after one year, five years, and 12 years for Carstairs 
2001 Category  
 Adjusted by age and sex Adjusted by WHO* Adjusted by Smoking^ Adjusted by Alcohol+ 
Variable HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value 
One-year DSM  0.001  0.025  0.026  0.005 
  1 (Least deprived) 1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  
  2 1.59 (0.99, 2.54)  1.42 (0.88, 2.28)  1.54 (0.96, 2.47)  1.60 (1.00, 2.56)  
  3 1.69 (1.06, 2.69)  1.50 (0.94, 2.39)  1.62 (1.01, 2.59)  1.67 (1.05, 2.67)  
  4 1.72 (1.10, 2.69)  1.43 (0.91, 2.25)  1.59 (1.01, 2.49)  1.67 (1.07, 2.62)  
  5 (Most deprived) 2.09 (1.36, 3.22)  1.73 (1.12, 2.67)  1.78 (1.15, 2.75)  1.98 (1.28, 3.05)  
SII (95% CI) 1.1 (0.2, 1.9)  0.7 (0.0, 1.4)  0.7 (-0.2, 1.6)  0.9 (0.0, 1.8)  
Five-year DSM  <0.001  0.018  0.012  0.003 
  1 (Least deprived) 1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  
  2 1.06 (0.77, 1.46)  0.96 (0.69, 1.32)  1.05 (0.76, 1.44)  1.08 (0.78, 1.48)  
  3 1.41 (1.04, 1.92)  1.28 (0.95, 1.74)  1.38 (1.02, 1.87)  1.40 (1.03, 1.90)  
  4 1.28 (0.95, 1.72)  1.11 (0.82, 1.50)  1.21 (0.90, 1.63)  1.25 (0.93, 1.68)  
  5 (Most deprived) 1.55 (1.17, 2.06)  1.32 (1.00, 1.76)  1.39 (1.05, 1.85)  1.48 (1.11, 1.96)  
SII (95% CI) 0.7 (0.1, 1.2)  0.4 (-0.2, 1.0)  0.4 (-0.2, 1.0)  0.5 (0.0, 1.1)  
12-year DSM  <0.001  0.005  0.005  0.001 
  1 (Least deprived) 1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  
  2 0.98 (0.73, 1.33)  0.89 (0.66, 1.20)  0.97 (0.72, 1.30)  1.00 (0.74, 1.35)  
  3 1.32 (0.99, 1.75)  1.21 (0.91, 1.60)  1.29 (0.97, 1.72)  1.30 (0.98, 1.73)  
  4 1.27 (0.97, 1.68)  1.11 (0.84, 1.46)  1.20 (0.91, 1.58)  1.23 (0.94, 1.62)  
  5 (Most deprived) 1.51 (1.16, 1.96)  1.30 (1.00, 1.70)  1.35 (1.03, 1.76)  1.43 (1.10, 1.86)  
SII (95% CI) 0.7 (0.2, 1.2)  0.4 (-0.1, 1.0)  0.3 (-0.2, 0.9)  0.6 (0.1, 1.0)  
*Adjusted by age, sex and WHO Performance Status 
^Adjusted by age, sex and smoking status 
+Adjusted by age, sex and alcohol consumption 
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Table 4.11 – Minimally adjusted hazard ratios by tumour and treatment factors for disease-specific mortality (DSM) after one year, five years, and 12 years for 
Carstairs 2001 Category  
 Adjusted by Site* Adjusted by Stage^ Adjusted by Treatment+ Adjusted by Network& 
Variable HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value 
One-year DSM  0.002  0.012  0.039  <0.001 
  1 (Least deprived) 1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  
  2 1.61 (1.01, 2.59)  1.55 (0.97, 2.49)  1.42 (0.88, 2.27)  1.58 (0.98, 2.53)  
  3 1.69 (1.06, 2.70)  1.68 (1.05, 2.69)  1.73 (1.08, 2.77)  1.71 (1.07, 2.72)  
  4 1.74 (1.11, 2.72)  1.63 (1.04, 2.56)  1.60 (1.02, 2.51)  1.77 (1.13, 2.79)  
  5 (Most deprived) 2.05 (1.33, 3.15)  1.86 (1.21, 2.87)  1.68 (1.08, 2.59)  2.21 (1.42, 3.44)  
SII (95% CI) 1.0 (0.2, 1.9)  0.8 (-0.1, 1.7)  0.6 (-0.4, 1.6)  1.3 (0.5, 2.1)  
Five-year DSM  0.002  0.010  0.019  <0.001 
  1 (Least deprived) 1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  
  2 1.12 (0.81, 1.54)  1.08 (0.78, 1.49)  0.98 (0.71, 1.35)  1.06 (0.77, 1.45)  
  3 1.48 (1.09, 2.01)  1.46 (1.08, 1.98)  1.44 (1.06, 1.95)  1.43 (1.05, 1.94)  
  4 1.33 (0.99, 1.78)  1.24 (0.92, 1.66)  1.25 (0.93, 1.69)  1.31 (0.97, 1.77)  
  5 (Most deprived) 1.53 (1.15, 2.03)  1.42 (1.07, 1.89)  1.31 (0.99, 1.74)  1.61 (1.20, 2.15)  
SII (95% CI) 0.6 (-0.1, 1.2)  0.5 (-0.3, 1.2)  0.4 (-0.4, 1.2)  0.7 (0.1, 1.3)  
12-year DSM  <0.001  0.003  0.005  <0.001 
  1 (Least deprived) 1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  
  2 1.02 (0.76, 1.38)  1.00 (0.74, 1.35)  0.91 (0.67, 1.23)  0.98 (0.72, 1.32)  
  3 1.39 (1.04, 1.85)  1.35 (1.02, 1.80)  1.34 (1.01, 1.78)  1.32 (1.00, 1.76)  
  4 1.32 (1.00, 1.73)  1.23 (0.93, 1.62)  1.26 (0.96, 1.66)  1.28 (0.97, 1.69)  
  5 (Most deprived) 1.48 (1.14, 1.92)  1.39 (1.07, 1.81)  1.30 (1.00, 1.69)  1.51 (1.16, 1.98)  
SII (95% CI) 0.6 (0.1, 1.2)  0.5 (-0.1, 1.0)  0.4 (-0.3, 1.1)  0.7 (0.2, 1.1)  
*Adjusted by age, sex and anatomical site 
^Adjusted by age, sex and tumour stage 
+Adjusted by age, sex and treatment modality 
&Adjusted by age, sex and Scottish Cancer Network 
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Table 4.12 – Adjusted hazard ratios by a combination of patient, tumour, and treatment factors for disease-specific mortality (DSM) after one year, five years, 
and 12 years for Carstairs 2001 Category  
 
Adjusted by all participant 
factors* 
Adjusted by all tumour 
factors^ 
Adjusted by all treatment 
factors+ 
Adjusted by tumour and 
treatment factors 
combined& 
Adjusted by all patient, 
tumour, and treatment 
factors combined% 
Variable HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value 
One-year DSM  0.162  0.013  0.012  0.129  0.431 
  1 (Least deprived) 1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  
  2 1.41 (0.88, 2.27)  1.54 (0.96, 2.48)  1.36 (0.85, 2.18)  1.23 (0.76, 1.97)  1.11 (0.69, 1.80)  
  3 1.42 (0.88, 2.27)  1.69 (1.06, 2.71)  1.77 (1.11, 2.84)  1.57 (0.98, 2.52)  1.40 (0.87, 2.26)  
  4 1.37 (0.87, 2.16)  1.64 (1.04, 2.58)  1.67 (1.06, 2.63)  1.42 (0.90, 2.25)  1.24 (0.78, 1.98)  
  5 (Most deprived) 1.51 (0.97, 2.34)  1.85 (1.20, 2.86)  1.79 (1.15, 2.80)  1.45 (0.92, 2.29)  1.23 (0.78, 1.96)  
SII (95% CI) 0.7 (-0.1, 3.5)  0.8 (-0.1, 1.7)  1.1 (-0.2, 2.4)  0.4 (-0.4, 1.3)  0.2 (-0.5, 0.9)  
Five-year DSM  0.117  0.014  0.001  0.046  0.343 
  1 (Least deprived) 1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  
  2 0.96 (0.70, 1.33)  1.10 (0.80, 1.51)  0.96 (0.69, 1.32)  0.94 (0.68, 1.29)  0.82 (0.59, 1.14)  
  3 1.24 (0.91, 1.68)  1.52 (1.12, 2.06)  1.47 (1.09, 2.02)  1.49 (1.10, 2.03)  1.29 (0.95, 1.77)  
  4 1.07 (0.79, 1.45)  1.26 (0.93, 1.70)  1.34 (0.99, 1.80)  1.21 (0.89, 1.63)  1.03 (0.75, 1.40)  
  5 (Most deprived) 1.21 (0.91, 1.62)  1.42 (1.07, 1.88)  1.46 (1.09, 1.95)  1.27 (0.95, 1.71)  1.07 (0.79, 1.45)  
SII (95% CI) 0.3 (-0.3, 0.8)  0.4 (-0.4, 1.3)  0.6 (-0.2, 1.4)  0.3 (-0.7, 1.4)  0.1 (-0.7, 1.0)  
12-year DSM  0.066  0.005  <0.001  0.036  0.359 
  1 (Least deprived) 1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  1.00 (Ref.)  
  2 0.89 (0.66, 1.20)  1.01 (0.75, 1.36)  0.89 (0.66, 1.21)  0.88 (0.65, 1.19)  0.78 (0.58, 1.06)  
  3 1.16 (0.87, 1.54)  1.40 (1.05, 1.87)  1.37 (1.03, 1.83)  1.38 (1.04, 1.85)  1.20 (0.90, 1.61)  
  4 1.06 (0.80, 1.40)  1.25 (0.94, 1.64)  1.32 (1.00, 1.74)  1.19 (0.90, 1.58)  1.02 (0.77, 1.35)  
  5 (Most deprived) 1.18 (0.90, 1.55)  1.38 (1.06, 1.79)  1.38 (1.05, 1.82)  1.22 (0.92, 1.60)  1.02 (0.77, 1.35)  
SII (95% CI) 0.3 (-0.2, 0.7)  0.5 (-0.2, 1.1)  0.6 (-0.2, 1.3)  0.3 (-0.6, 1.2)  0.1 (-0.7, 0.9)  
*Adjusted by age, sex and all participant factors including smoking status, alcohol consumption and WHO Performance Status  
^Adjusted by age, sex and all tumour factors including anatomical site and tumour stage 
+Adjusted by age, sex and all treatment modality and network 
&Adjusted by age, sex and both tumour and treatment factors including stage, anatomical site, treatment modality and network of treatment 
%Adjusted by all factors including age, sex, smoking status, alcohol consumption, WHO Performance status, stage, anatomical site, treatment modality and network of treatment 
Chapter 4: Inequality in survival in Scotland 
184 
Table 4.13 – Sensitivity analysis - adjusted hazard ratios by a combination of patient, 
tumour, and treatment factors for disease-specific mortality (DSM) after one year, five years, 
and 12 years for Carstairs 2001 Category excluding WHO Performance Status 
 
Adjusted by all 
participant factors* 
Adjusted by all patient, 
tumour, and treatment 
factors combined^ 
Variable HR (95% CI) 
p-
value 
HR (95% CI) 
p-
value 
One-year DSM  0.032  0.274 
  1 (Least deprived) 1.00 (Ref.)  1.00 (Ref.)  
  2 1.57 (0.98, 2.52)  1.33 (0.82, 2.15)  
  3 1.62 (1.01, 2.59)  1.53 (0.95, 2.47)  
  4 1.59 (1.01, 2.50)  1.40 (0.88, 2.21)  
  5 (Most deprived) 1.77 (1.14, 2.73)  1.41 (0.89, 2.23)  
SII (95% CI) 0.7 (-0.3, 1.6)  0.3 (-0.5, 1.1)  
Five-year DSM  0.018  0.163 
  1 (Least deprived) 1.00 (Ref.)  1.00 (Ref.)  
  2 1.07 (0.78, 1.47)  1.01 (0.73, 1.39)  
  3 1.38 (1.02, 1.87)  1.41 (1.04, 1.92)  
  4 1.21 (0.90, 1.63)  1.18 (0.87, 1.60)  
  5 (Most deprived) 1.38 (1.04, 1.84)  1.22 (0.90, 1.65)  
SII (95% CI) 0.4 (-0.2, 1.0)  0.2 (-0.6, 1.0)  
12-year DSM  0.009   
  1 (Least deprived) 1.00 (Ref.)  1.00 (Ref.) 0.174 
  2 0.99 (0.73, 1.33)  0.95 (0.70, 1.28)  
  3 1.28 (0.96, 1.70)  1.31 (0.98, 1.75)  
  4 1.19 (0.90, 1.57)  1.16 (0.88, 1.54)  
  5 (Most deprived) 1.33 (1.02, 1.74)  1.15 (0.87, 1.53)  
SII (95% CI) 0.4 (0.0, 0.9)  0.2 (-0.5, 0.9)  
*Adjusted by age, sex and all participant factors including smoking status and alcohol consumption  
^Adjusted by all factors including age, sex, smoking status, alcohol consumption, WHO Performance status, stage, 
anatomical site, treatment modality and network of treatment 
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4.4 Discussion  
This study demonstrates that there was a clear gradient across Carstairs 2001 Category 
for overall survival and disease-specific survival after one year, five years, and 12 years 
for people with a diagnosis of head and neck cancer between the years of 1999 and 2001 
in Scotland. Inequality in disease-specific survival became worse over the follow-up time 
from one years, five years, and 12 years after diagnosis, but the same trend was not 
apparent for overall survival and net survival estimates. However, following adjustment for 
age and sex, this trend for disease-specific survival was no longer apparent. In addition, 
the results for the net survival analysis demonstrated a gradient across the Carstairs 2001 
Categories after one year and five years, but this gradient disappeared by 12 years, 
suggesting that some of the inequality in long-term survival was partly attributable to 
background mortality. 
Following full adjustment after one year, five years, and 12 years, inequality was no longer 
apparent, suggesting that inequality in survival of patients with head and neck cancer can 
be explained by multiple patient, tumour, and treatment factors. Following multiple 
individual adjustments of various participants, tumour, and treatment factors, none of the 
models were fully explained which suggests that inequality in survival of participants with 
head and neck cancer is not straightforward, and that many factors play a combined effect 
in the role of the explanation of inequality in head and neck cancer survival. In addition, 
the results for the net survival analysis demonstrated a gradient across the Carstairs 2001 
Category after one year and five years, but this gradient disappears by 12 years, 
suggesting that some of the inequality in long-term survival is partly attributable to 
background mortality, and since this cohort has such long follow-up, influence from 
background mortality is to be expected. 
There are limitations to this study, several of which were discussed in Chapter 3. In 
addition to these, socioeconomic status was measured using the area based Carstairs 
2001 Index (Carstairs and Morris, 1989; McLoone, 2000), which is derived from the 2001 
Census and considers the proportion of male unemployment, those in social classes IV 
and V, lack of car ownership, and overcrowding in a dwelling. Since this was a clinical 
cohort study, further data on socioeconomic status indexes (including education level and 
levels of income) was not collected as part of this study. The Carstairs 2001 Category 
may not accurately represent rural and urban populations as it may be essential for 
people in these areas to own a car (Valentova, 2011), and as other indices such as 
education level of income were not available for this analysis, Carstairs 2001 Category 
was the best measurement available. 
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4.4.1 Conclusion  
This study adds to the understanding of inequality in survival for people with head and 
neck cancer. The SAHNC cohort represented 77% of all head and neck cancer cases on 
the Scottish Cancer Registry over a two-year period and is therefore a good 
representation of head and neck cancer in Scotland. In unadjusted models, a clear 
gradient across Carstairs 2001 Category for overall survival, disease-specific survival, and 
net survival was observed after one year, five years, and 12 years for this cohort of people 
with head and neck cancer. Following adjustment for multiple patient, tumour, and 
treatment factors, inequality was no longer present for all-cause mortality and disease-
specific mortality. This study concludes that explanations for inequality in survival of 
participants with head and neck cancer are not straightforward, and that many factors 
including various patient, tumour, and treatment factors play a part in inequality in survival 
of participants with head and neck cancer. 
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5 Inequality in survival of people with head 
and neck cancer in England: Results from 
the Head and Neck 5000 prospective 
clinical cohort study (HN5000) 
5.1 Introduction  
This chapter aims to undertake an in-depth exploration into the nature and extent of 
socioeconomic inequality in survival of people with head and neck cancer by considering 
both area-based and individual dimensions of socioeconomic circumstances. The 
explanations for inequality will be explored via multiple demographic data, health status, 
behavioural factors, tumour factors, and treatment factors. 
The HN5000 is a population-based prospective clinical cohort study of people with head 
and neck cancer. Those with a new primary head and neck tumour who had been 
diagnosed on the NHS in England, Scotland, or Wales were eligible to be recruited to the 
study between April 2011 and December 2014 (Ness et al., 2014). The study was funded 
by the National Institute of Health Research (NIHR) and was conducted by the University 
of Bristol. Full ethical approval was granted by the National Research Ethics Committee 
(South West Frenchay Ethics Committee, reference 10/H0107/57, 5 th November 2010) 
and the study was approved by the Research and Development departments for the 
participating NHS trusts. The primary aim of the HN5000 was to “evaluate the impact of 
centralisation of care for people with head and neck cancer” (Ness et al., 2014). However, 
in addition to this, the study team aimed to develop a “well-phenotyped clinical cohort that 
will provide a biomedical resource for translational and prognostic research in head and 
neck cancer” and welcomed collaboration from other head and neck cancer researchers 
(Ness et al., 2014). 
Previous studies have relied on either area-based or individual measurements of 
socioeconomic status to document and explain potential explanatory factors of inequality 
in survival of people with head and neck cancer. No prior study has investigated both 
forms of measurements of socioeconomic status. In this thesis, the HN5000 provides the 
unique opportunity to thoroughly explore inequality in survival of people with head and 
neck cancer via the use of both area-based and individual measurements of 
socioeconomic status, which were not both available in any of the previous chapters 
throughout this thesis. Although this study does not contain long-term follow-up data due 
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to the recency of the recruitment of the cohort, the database contains detailed information 
on patient demographics, health status, behavioural data, tumour factors, and treatment 
information to explore as potential confounders for inequality in survival of people with 
head and neck cancer. 
5.1.1 Aims and objectives 
The aim of Chapter 5 is to explore the underlying determinants of both area-based and 
individual measurements of socioeconomic status of people diagnosed with head and 
neck cancer on the HN5000 cohort study (Ness et al., 2014; Ness et al., 2015). The 
objectives of this chapter are to: 
1. Explore the underlying demographic, health, behavioural, tumour, and treatment 
factors that are associated with socioeconomic inequality in survival of people with 
head and neck cancer. 
2. Compare socioeconomic inequality in both area-based and induvial measurements 
of socioeconomic status.  
5.2 Methods  
5.2.1 Data collection  
The HN5000 baseline data collection was undertaken between 1st April 2011 and 31st 
December 2014. A total of 76 UK centres contributed to the study throughout England, 
Scotland, and Wales. Information was gathered from clinical records using data capture 
forms which were completed by research nurses on the participants’ diagnosis of head 
and neck cancer and the treatment modality that they received. In addition, the 
participants were asked to self-complete three questionnaires at baseline prior to the start 
of treatment, at four months after their diagnosis, and at 12 months after their diagnosis. 
At each time point, the cohort was asked about their demographics, general health, 
behaviours, and a variety of information relating to their socioeconomic position 
(described in detail below). In addition, there were also separate questionnaire sheets 
enquiring about the participants’ outlook and feelings, and about their sexual behaviours, 
however these results will not be used as part of this study.  
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5.2.1.1 SES factors  
Area-based measurement of socioeconomic status 
Due to the nature of this work and the need to utilise an area-based measurement of 
socioeconomic status to compare with individual measurements of socioeconomic status, 
only those recruited from England were included in this study. Therefore, the area-based 
measurement of socioeconomic status was derived from the English IMD 2010 score 
(English Indices of Deprivation, 2011) which were linked to the HN5000 using the 
participants’ home postcodes and Lower Layer Super Output Area (LLSOA) codes (NHS, 
2019). The IMD 2010 categorises geographical areas in England using information from 
seven domains: (a) Income Deprivation, (b) Employment Deprivation, (c) Health 
Deprivation and Disability, (d) Education Skills and Training Deprivation, (e) Barriers to 
Housing and Services, (f) Living Environment Deprivation, and (g) Crime. The IMD 2010 
score has five categories – group one represents the people from the most deprived areas 
and group five represents the people from the least deprived areas.  
Individual measurements of socioeconomic status 
The individual measurements of socioeconomic status were obtained from the 
participants’ questionnaire responses at baseline prior to the start of treatment. This 
included: highest education level attained, number of years spent in full-time education, 
total annual household income, proportion of income from benefits, and whether the 
participants had any financial concerns of living with or after cancer. The highest 
education level that the participants had attained was grouped as: (a) up to secondary 
school (primary school or secondary school, which usually includes students up to the age 
of 16), (b) further education (school/college sixth form or further education college, which 
usually includes students between the ages of 16 to 18), and (c) higher education or 
university (which usually includes students aged 18 and over). The number of years that 
the participants had spent in education was categorised as: a) less than £11,999 a year, 
b) between £12,000 (approximately 18,826 US$ in August 2012) and £28,999 a year, or 
c) more than £29,000 a year (approximately 45,497 US$ in August 2012). Note that in the 
financial year 2012/2013 the median disposable income in the UK was approximately 
£24,200. The total proportion of a patient’s income that they received from benefits was 
recorded on the questionnaire as: (a) all, (b) about three quarters, (c) about half, (d) about 
a quarter, (e) very little, and (f) none, but for the purpose of this analysis, this was grouped 
as: (a) all, (b) some (groups b to e), and (c) none. Whether the participants had any 
financial concerns of living with or after cancer or not was recorded as: (a) yes, or (b) no.  
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5.2.1.2 Demographic data  
The participants’ demographic data were recorded on the age of the participants when 
they provided informed consent to the study and the participants’ sex which was obtained 
from the baseline data capture form. Marital status was recorded on the baseline 
questionnaire as: (a) single, (b) widowed, (c) separated, (d) married, (e) divorced, and  
(f) living with a partner, and for the purpose of this analysis, this was grouped as: 
(a) single; (b) married or living with a partner; and (c) separated, divorced, or widowed.  
5.2.1.3 Health status data  
The health status of the participants was recorded via comorbidity and WHO Performance 
Status (Oken et al., 1982) from the baseline data prior to the start of the participants’ 
treatment. Comorbidity was recorded on the baseline data capture form using the Adult 
Comorbidity Evaluation (ACE-27) (Piccirillo and Feinstein, 1996), which categorises 
people as having: (a) no comorbidity, (b) mild comorbidity, c) moderate comorbidity, and 
(d) severe comorbidity. For the purpose of this analysis the two worst comorbidities were 
grouped into a “moderate/severe” category due to low numbers. WHO Performance 
Status was measured on the participants’ baseline questionnaire and was recorded as:  
(a) normal activity, (b) strenuous activity restricted, (c) up and about for more than 50% of 
their waking hours, (d) confined to a bed or chair for more than 50%, and (e) confined to a 
bed or chair for 100% of their waking hours. Due to small numbers, the worst two WHO 
Performance Status categories were combined into a “confined to a bed or chair for more 
than 50% of their waking hours” category.  
5.2.1.4 Behavioural factor data  
The participants’ behavioural data were recorded on smoking status and alcohol 
consumption. Smoking status was recorded on the baseline questionnaire and was 
defined as: (a) current smoker, (b) previous smoker, and (c) never smoked. The number 
of units of alcohol per week that the participants drank was calculated from the baseline 
questionnaire responses to how many days per week they drank alcohol, and how many 
bottles of wine, spirits, or pints of beers/lager/cider they drank each week before they 
were diagnosed with cancer. Using the responses to these questions, the participants’ 
alcohol consumption was calculated in units and subsequently grouped as: (a) none,  
(b) moderate (more than zero and less than 14 units per week for men and women),  
(c) hazardous (between 14 and 50 units per week for men, and between 14 and 35 units 
per week for women), and (d) harmful (more than 50 units per week for men, and more 
than 35 units per week for women) (NICE, 2011b). 
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5.2.1.5 Tumour factors  
The tumour factors were recorded on the anatomical site of the tumour, tumour stage, and 
HPV status. Anatomical site was determined using ICD-10 codes (World Health 
Organization, 2016). Tumours of the (a) lip and oral cavity (C00, C02-C04, C05.0, C06), 
(b) oropharynx (C01, C05.1, C05.2, C09, C10), (c) nasopharynx (C11), (d) hypopharynx 
(C12, C13), (e) larynx (C32, C10.1), (f) nasal cavity (C30.0), (g) sinuses (C31), (h) major 
salivary glands (C07, C08), (i) minor salivary glands (any ICD-10 code with histology 
recorded as “salivary gland”), and (j) other sites of the head and neck (C14.0, C30.1, 
C41.1, C69.5) were included. Due to small numbers, the participants with cancers of the 
nasopharynx, nasal cavity, sinuses, and other sites of the head and neck were combined 
into one group for this study which has been labelled as “Other”. Tumour stage was 
classified using the TNM Classification of Malignant Tumours from the UICC, Seventh 
Edition, which divides tumours into four categories from stage I to stage IV (Sobin et al., 
2009). HPV status was determined by the German Cancer Research Center (DKFZ) in 
Heidelberg. An HPV-positive result was determined from a serological response to HPV16 
E6 antibodies using a glutathione S-transferase multiplex assay with a cut-off value of 
more than 1000 Median Fluorescence Intensity (MFI) units (Waterboer et al., 2005). 
5.2.1.6 Treatment factors  
The treatment modality that the participants received was extracted from the data capture 
forms at four-months and was grouped as: (a) surgery only; (b) chemoradiotherapy only, 
(c) radiotherapy only, (d) surgery combined with chemotherapy, chemoradiotherapy or 
radiotherapy; (e) chemotherapy only; and (f) no treatment. 
5.2.2 Data verification  
The HN5000 data was entered onto a central database which contained automatic range 
and logic checks with the aim of reducing data entry issues. In addition, missing, 
inconsistent and text fields were identified and checked against pathology reports, 
particularly for the tumour diagnosis and the stage of the tumour. Where data were not 
clear, the HN5000 study team at the University of Bristol contacted the study centres for 
additional information. Finally, double data entry was complete on a random sample of 
10% of the questionnaire data to determine an error rate and to highlight sections within 
the questionnaires that may require double data entry for the whole cohort of people.  
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5.2.3 Data linkage  
On 11th October 2018, the cohort was linked to mortality data by the National Office of 
Statistics from the UK Health and Social Care Information Centre. The number of days 
between the date of consent and the date of death or the most recent follow-up date was 
calculated. 
5.2.4 Eligible cases 
All of these analyses were performed using the HN5000 data release V2.4 (October 
2018). Participants were excluded from the HN5000 if they had withdrawn or were found 
to be ineligible because a biopsy result confirmed that they did not have head and neck 
cancer or had a carcinoma in situ. In addition, for this analysis, people who had thyroid 
cancer, cancer of unknown primary (CUP), or did not live in England (and therefore could 
not be linked to IMD data) were also excluded. Participants were also removed if they had 
not returned any of their questionnaire pack. 
5.2.5 Statistical analyses  
Frequency tables of each of the participant, demographic, health, behavioural, tumour, 
treatment, and socioeconomic status factors are displayed along with the proportion of 
deaths that had occurred by October 2018. Frequency tables that displayed the cross-
tabulation of the socioeconomic status factors with each participant, demographic, health, 
behavioural, tumour, and treatment factors were generated without the “unknown” 
categories and the proportions across each of the groups were compared using the 
Pearson’s chi-square test.  
Three-year overall survival was determined using the Kaplan-Meier method with 95% 
confidence intervals. The differences between the results of the Kaplan-Meier curves were 
determined using the long-rank test. 
Adjusted Cox Proportional Hazard models for all-cause mortality were displayed to identify 
the potential explanatory factors of the inequality in survival. Hazard ratios (HR) with 
confidence intervals (CI) and p-values for each socioeconomic status variable were 
produced to measure the differences in all-cause mortality between various groups of 
people. To explore the potential explanatory factors of inequality, these models were 
adjusted by: (a) age and sex; (b) age, sex, and each individual factor separately (including 
comorbidity, smoking status, alcohol consumption, anatomical site, stage, HPV status, 
and treatment modality); (c) age, sex, and health and behavioural factors combined 
(including comorbidity, smoking status, and alcohol consumption); (d) age, sex, tumour, 
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and treatment factors combined (including anatomical site, stage, HPV status and 
treatment modality); or (e) age, sex, and all of the potential explanatory factors combined 
(including  comorbidity, smoking status, alcohol consumption, anatomical site, stage, HPV 
status, and treatment modality).  
All of the statistical analyses were performed using Stata Version 16.0 (StataCorp., 2019). 
5.2.6 Missing data  
Patterns of missing data were checked and reviewed for the whole cohorts’ data. The risk 
of bias from levels of missing data was investigated by cross-tabulating the data from the 
participants who did and did not return their questionnaire with each of the demographic, 
health, behavioural, tumour, treatment, and socioeconomic status factors. 
5.2.6.1 Multiple imputation 
As a result of the high levels of missing data in the HN5000 cohort, multiple imputation 
(MI) was performed to impute values for missing data (Little and Rubin, 2019). The ICE 
package for the multiple Imputation of Chained Equations in Stata 16.0 was used 
(Royston, 2009). Twenty imputed datasets were generated using a model which included 
the event indicator for death, the Nelson-Aalen estimator of the cumulative hazard (White 
and Royston, 2009), all of the socioeconomic status variables, and all of the potential 
explanatory factors. The results of the minimally and mutually adjusted Cox Proportional 
Hazards models following multiple imputation were computed using the mim command in 
Stata 16.0 (Galati et al., 2007), which combines the results from each imputed dataset 
using Rubin’s Rules (Rubin, 1987). 
5.3 Results  
5.3.1 Eligible cases  
A total of 5,511 participants were recruited for the HN5000, however 107 (1.9%) 
participants were excluded from the cohort due to either withdrawing, being ineligible due 
to not having a primary head and neck cancer, not consenting to the study, or having a 
tumour of stage 0 (Figure 5.1). In addition, a total of 1,964 (36.3%) participants were 
excluded from this analysis due to having thyroid cancer, CUP, residing in Scotland or 
Wales, or for not returning their baseline questionnaire pack. Thus, a total of 3,440 were 
eligible for this analysis – 62.4% of the original 5,511 people that were recruited.   
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Figure 5.1 – Flow chart of eligible cases included in the HN5000 cohort study 
 
5.3.2 Missing data  
Following the exclusion of the participants who did not return their questionnaire, data 
were still missing for marital status (n = 44/1.3%), comorbidity (n = 75/2.2%), WHO 
Performance Status (n = 162/4.7%), smoking status (n = 173/5.0%) and alcohol 
consumption (n = 111/3.2%). In addition, some data were also missing for tumour stage  
(n = 31/0.9%) and HPV status (n = 459/13.3%). For the socioeconomic status factors, 
some data were missing for IMD Category (n = 85/2.5%), highest education level obtained 
(n = n = 208/6.0%), time spent in education (n = 329/9.6%), total annual household 
income (n = 517/15.0%), proportion of income from benefits (n = 214/6.2%), and whether 
the people were having financial concerns of living with or after cancer (n = 208/6.0%). 
5.3.3 Baseline characteristics  
The numbers and proportions of the participant characteristics, demographic factors, 
health status, behavioural factors, tumour and treatment factors, and socioeconomic 
factors along with the proportion of deaths observed by October 2018 for each variable 
are displayed in Table 5.1 and Table 5.2. 
The age at date of consent of the participants ranged from 22 to 95 (median = 62 years), 
and nearly three quarters (n = 2,526/73.4%) of the cohort was male. Most of the people 
were either married or living with a partner (n = 2,283/66.4%). More than a half  
(n = 1,881/54.7%) of the participants had at least a mild comorbidity, however 52.3%  
(n = 1,799) of the cohort were of normal WHO Performance Status at the time of their 
diagnosis. Approximately three quarters (n = 2,527/73.5%) of the cohort were either 
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current or former smokers, and 70.3% (n = 2,418) of the participants were moderate to 
harmful drinkers. A proportion of 38.8% (n = 1,334) of people had tumours of the 
oropharynx, while 45.2% (n = 1,555) of the cohort had stage IV tumours, and 61.5%  
(n = 2,114) of the participants were diagnosed with HPV negative tumours. The 
participants were most likely to be treated with chemoradiotherapy or a combination of 
surgery and chemoradiotherapy (n = 1,936/56.2%). There was an even spread of 
participants across the IMD Categories ranging from 17.9% (n = 616) to 21.7% (n = 746). 
Nearly half (n = 1,556/45.2%) of the cohort had attained an education level of up to 
secondary school, and nearly one third (n = 1,007/29.3%) of participants had spent 10 
years or less in full-time education. More than half (n = 1,988/57.8%) of the cohort earned 
less than £29,000 per year, one third (n = 1,100/32.0%) earned at least some of their 
income from benefits, and 34.3% (n = 1,181) of people had financial concerns of living 
with cancer. 
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Table 5.1 – Frequency and number of people who had died by October 2018 for the 
participant characteristics, demographic factors, health and behavioural factors, and 
tumour and treatment factors 
Variable 
Frequency Died by October 2018  
(col. %) (row %) 
Whole cohort 3,440  1,068 (31.1%) 
Age group   
   Less than 44 210 (6.1%) 37 (17.6%) 
   45 to 54 676 (19.7%) 156 (23.1%) 
   55 to 64 1,192 (34.7%) 356 (29.9%) 
   65 to 74 940 (27.3%) 313 (33.3%) 
   75 and over 422 (12.3%) 206 (48.8%) 
Sex   
   Male 2,526 (73.4%) 820 (32.5%) 
   Female 914 (26.6%) 248 (27.1%) 
Marital status   
   Single 427 (12.4%) 153 (35.8%) 
   Separated/divorced/widowed 686 (19.9%) 280 (40.8%) 
   Married/living with partner 2,283 (66.4%) 620 (27.2%) 
   Unknown 44 (1.3%) 15 (34.1%) 
Comorbidity   
   No comorbidity 1,484 (43.1%) 321 (21.6%) 
   Mild comorbidity 1,149 (33.4%) 372 (32.4%) 
   Moderate/severe comorbidity 732 (21.3%) 352 (48.1%) 
   Unknown 75 (2.2%) 23 (30.7%) 
WHO Performance Status   
   Normal activity 1,799 (52.3%) 377 (21.0%) 
   Strenuous activity restricted 843 (24.5%) 306 (36.3%) 
   Up and about > 50%  470 (13.7%) 207 (44.0%) 
   Confined > 50% or 100% 166 (4.8%) 105 (63.3%) 
   Unknown 162 (4.7%) 73 (45.1%) 
Smoking status   
   Current smoker 664 (19.3%) 301 (45.3%) 
   Former smoker 1,863 (54.2%) 573 (30.8%) 
   Never smoked 740 (21.5%) 150 (20.3%) 
   Unknown 173 (5.0%) 44 (25.4%) 
Alcohol consumption   
   Non-drinker 911 (26.5%) 297 (32.6%) 
   Moderate 729 (21.2%) 179 (24.6%) 
   Hazardous 1,210 (35.2%) 359 (29.7%) 
   Harmful 479 (13.9%) 182 (38.0%) 
   Unknown 111 (3.2%) 51 (46.0%) 
Anatomical Site   
   Oropharynx 1,334 (38.8%) 332 (24.9%) 
   Lip and oral cavity 900 (26.2%) 318 (35.3%) 
   Larynx 728 (21.2%) 214 (29.4%) 
   Hypopharynx 160 (4.7%) 96 (60.0%) 
   Salivary glands 147 (4.3%) 34 (23.1%) 
   Other 171 (5.0%) 74 (43.3%) 
Stage   
   I 788 (22.9%) 131 (16.6%) 
   II 593 (17.2%) 176 (29.7%) 
   III 473 (13.8%) 155 (32.8%) 
   IV 1,555 (45.2%) 590 (37.9%) 
   Unknown 31 (0.9%) 16 (51.6%) 
HPV status   
   Negative 2,114 (61.5%) 760 (36.0%) 
   Positive 867 (25.2%) 150 (17.3%) 
   Unknown 459 (13.3%) 158 (34.4%) 
Treatment   
   Surgery only 765 (22.2%) 167 (21.8%) 
   Chemoradiotherapy only 1,064 (30.9%) 311 (29.2%) 
   Radiotherapy only 702 (20.4%) 255 (36.3%) 
   Surgery and chemo/radio 872 (25.3%) 302 (34.6%) 
   Chemotherapy only 15 (0.4%) 14 (93.3%) 
   No treatment 22 (0.6%) 19 (86.4%) 
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Table 5.2 – Frequency and number of people who had died by October 2018 for all of the 
socioeconomic status factors 
Variable 
Frequency Died by October 2018  
(col. %) (row %) 
IMD Category   
   1 – Most deprived 674 (19.6%) 257 (38.1%) 
   2 616 (17.9%) 188 (30.5%) 
   3 746 (21.7%) 227 (30.4%) 
   4 664 (19.3%) 186 (28.0%) 
   5 – Least deprived 655 (19.0%) 182 (27.8%) 
   Unknown 85 (2.5%) 28 (32.9%) 
Highest education level   
   Up to secondary school 1,556 (45.2%) 535 (34.4%) 
   Further education 827 (24.0%) 229 (27.7%) 
   Higher education/degree 849 (24.7%) 229 (27.0%) 
   Unknown 208 (6.0%) 75 (36.1%) 
Time in education   
   10 years or less 1,007 (29.3%) 358 (35.6%) 
   11 to 13 years 1,200 (34.9%) 334 (27.8%) 
   14 years or more 904 (26.3%) 263 (29.1%) 
   Unknown 329 (9.6%) 113 (34.4%) 
Household income   
   £11,999 or less 884 (25.7%) 344 (38.9%) 
   £12,000 to £28,999 1,104 (32.1%) 336 (30.4%) 
   £29,000 or more 935 (27.2%) 187 (20.0%) 
   Unknown 517 (15.0%) 201 (38.9%) 
Income from benefits   
   All 487 (14.2%) 213 (43.7%) 
   Some 613 (17.8%) 231 (27.7%) 
   None 2,126 (61.8%) 548 (25.8%) 
   Unknown 214 (6.2%) 76 (35.5%) 
Financial concerns    
   Yes 1,181 (34.3%) 358 (30.3%) 
   No 2,051 (59.6%) 631 (30.8%) 
   Unknown 208 (6.0%) 79 (38.0%) 
5.3.4 Cross-tabulations of each of the socioeconomic status factors with 
the potential explanatory factors  
5.3.4.1 Cross-tabulation of IMD Category with potential explanatory factors 
The cross-tabulation of each IMD Category with all of the potential explanatory factors is 
displayed in Table 5.3 to Table 5.5. In addition, the cross-tabulation of each IMD Category 
with the individual measurements of socioeconomic status is displayed in Table 5.6. 
People who resided in areas of the least deprived IMD Category were more likely to be 
younger, have moderate or severe comorbidities, have worse WHO Performance Status 
and be current smokers or be harmful drinkers. In addition, the participants from the most 
deprived regions were slightly more likely to be males and were increasingly more likely to 
be single, separated, divorced, or widowed. Those who were from the least deprived 
areas were also more likely to have tumours of the larynx, tumours that were HPV 
negative, and be treated with radiotherapy only. There was no difference across the IMD 
Categories by tumour stage. People who resided in the most deprived areas were more 
likely to have obtained an education level of up to secondary school, have spent less time 
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in education, earn £11,999 or less per year, earn all of their income from benefits, or have 
financial concerns of living with or after cancer. 
5.3.4.2 Cross-tabulation of highest education level with potential explanatory 
factors 
The cross-tabulation of highest education level attained with all of the potential 
explanatory factors for inequality is displayed in Table 5.7. The participants who had 
attained an education level of up to secondary school were more likely to be older, have 
moderate or severe comorbidities, have worse WHO Performance Status, and be current 
or former smokers. Interestingly, these people were also more likely to be married or living 
with a partner, be non-drinkers of alcohol, and there was a slightly higher proportion of 
females who had attained an education level of up to secondary school. In addition, those 
who had attained an education level of up to secondary school were more likely to have 
tumours of the larynx, tumours that were HPV negative, and be treated with radiotherapy 
only. There was no difference between the tumour staging across the groups for the 
highest level of education the participants had attained. 
5.3.4.3 Cross-tabulation of the number of years spent in education with potential 
explanatory factors 
The cross-tabulation of the number of years spent in education with all of the potential 
explanatory factors is displayed in Table 5.8. The participants who had spent 10 years or 
less in education were more likely to be older and male. In addition, these people were 
also more likely to have mild to severe comorbidities, have worse WHO Performance 
Status, and be current or former smokers. Those who had spent 10 years or less in 
education were also more likely to have tumours of the larynx, tumours that were HPV 
negative, and be treated with radiotherapy only. There was no difference between the 
proportion of participants across the groups for the number of years the people spent in 
education by marital status, alcohol consumption, or tumour stage. 
5.3.4.4 Cross-tabulation of annual household income with potential explanatory 
factors 
The cross-tabulation of annual household income with all of the potential explanatory 
factors is displayed in Table 5.9. The participants who had earned £11,000 or less per 
year were more likely to be older, male, and be single, separated, divorced, or widowed. 
In addition, these people were also more likely to have mild to severe comorbidities, have 
worse WHO Performance Status, or be current smokers and non-drinkers. Those who 
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had spent 10 years or less in education were also more likely to have tumours of the lip 
and oral cavity or the larynx, have tumours that were stage II, be HPV negative, and have 
treatment with surgery only or radiotherapy only.  
5.3.4.5 Cross-tabulation of proportion of income from benefits with potential 
explanatory factors 
The cross-tabulation of proportion of income from benefits with all of the potential 
explanatory factors is displayed in Table 5.10. The participants who earned all of their 
income from benefits were more likely to be between the ages of 45 and 64 and be male, 
single, separated, divorced, or widowed. In addition, these people were also more likely to 
have mild to severe comorbidities, have worse WHO Performance Status, be current 
smokers and be either non-drinkers or harmful drinkers. Those who earned all of their 
income from benefits were also more likely to have tumours of the larynx, have tumours 
that were stage II, be HPV negative, and be treated with radiotherapy only.  
5.3.4.6 Cross-tabulation of proportion of financial concerns with potential 
explanatory factors 
The cross-tabulation of the proportion of income from benefits that the participants 
received with all of the potential explanatory factors is displayed in Table 5.11. The 
participants who were having financial concerns of living with or after cancer were more 
likely to be younger and male, single, separated, divorced, or widowed. In addition, these 
people were also more likely have worse WHO Performance Status, be current smokers 
and be harmful drinkers. Those who earned all of their income from benefits were also 
more likely to have tumours of the oropharynx, have tumours that were stage IV, be HPV 
positive, and be treated with chemoradiotherapy only or surgery combined with 
chemoradiotherapy.  
5.3.4.7 Summary of findings from cross-tabulations of socioeconomic status 
factors with potential explanatory factors 
Generally, those with lower socioeconomic status were more likely to have comorbidities, 
worse WHO Performance Status, be current or former smokers, and have tumours of the 
larynx and be HPV negative. There were no clear similarities across the socioeconomic 
status factors by age, sex, marital status, alcohol consumption, tumour stage or the 
treatment modality the participants received.
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Table 5.3 – Cross-tabulation of IMD Category with participant characteristics and demographic factors 
Variable 
IMD Category  
1 – Most 
deprived 2 3 4 
5 – Least 
deprived p-value 
Age group      <0.001 
   Less than 44 44 (6.5%) 39 (6.3%) 37 (5.0%) 46 (6.9%) 41 (6.3%)  
   45 to 54 160 (23.7%) 136 (22.1%) 150 (20.1%) 114 (17.2%) 101 (15.4%)  
   55 to 64 252 (37.4%) 198 (32.1%) 262 (35.1%) 216 (32.5%) 232 (35.4%)  
   65 to 74 158 (23.4%) 175 (28.4%) 209 (28.0%) 177 (26.7%) 197 (30.1%)  
   75 and over 60 (8.9%) 68 (11.0%) 88 (11.8%) 111 (16.7%) 84 (12.8%)  
Sex      0.047 
   Male 515 (76.4%) 432 (70.1%) 549 (73.6%) 502 (75.6%) 467 (71.3%)  
   Female 159 (23.6%) 184 (29.9%) 197 (26.4%) 162 (24.4%) 188 (28.7%)  
Marital status      <0.001 
   Single 144 (21.8%) 73 (12.0%) 113 (15.3%) 49 (7.4%) 39 (6.0%)  
   Separated, divorced, or widowed. 167 (25.3%) 149 (24.5%) 148 (20.1%) 101 (15.3%) 99 (15.3%)  
   Married or living with partner 349 (52.9%) 387 (63.5%) 476 (64.6%) 511 (77.3%) 507 (78.6%)  
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Table 5.4 – Cross-tabulation of IMD Category with all of the health and behavioural factors 
Variable 
IMD Category  
1 – Most 
deprived 2 3 4 
5 – Least 
deprived p-value 
Comorbidity      <0.001 
   No comorbidity 252 (38.0%) 255 (42.9%) 334 (45.8%) 298 (45.6%) 315 (49.2%)  
   Mild comorbidity 220 (33.2%) 210 (35.3%) 234 (32.1%) 228 (34.9%) 222 (34.7%)  
   Moderate/severe comorbidity 191 (28.8%) 130 (21.8%) 161 (22.1%) 127 (19.4%) 103 (16.1%)  
WHO Performance Status      <0.001 
   Normal activity 246 (39.7%) 293 (50.3%) 384 (53.6%) 418 (64.6%) 410 (65.3%)  
   Strenuous activity restricted 173 (27.9%) 165 (28.3%) 191 (26.7%) 149 (23.0%) 146 (23.2%)  
   Up and about > 50%  131 (21.2%) 107 (18.4%) 98 (13.7%) 64 (9.9%) 54 (8.6%)  
   Confined > 50% or 100% 69 (11.1%) 18 (3.1%) 43 (6.0%) 16 (2.5%) 18 (2.9%)  
Smoking status      <0.001 
   Current smoker 218 (34.4%) 141 (23.9%) 126 (17.8%) 99 (15.5%) 61 (9.8%)  
   Former smoker 349 (55.1%) 339 (57.5%) 418 (59.2%) 360 (56.5%) 347 (56.0%)  
   Never smoked 66 (10.4%) 110 (18.6%) 162 (22.9%) 178 (27.9%) 212 (34.2%)  
Alcohol consumption      <0.001 
   Non-drinker 182 (28.4%) 187 (31.2%) 190 (26.3%) 174 (27.0%) 154 (24.0%)  
   Moderate 111 (17.3%) 120 (20.0%) 173 (24.0%) 149 (23.1%) 166 (25.9%)  
   Hazardous 219 (34.2%) 209 (34.9%) 255 (35.3%) 239 (37.1%) 259 (40.3%)  
   Harmful 129 (20.1%) 83 (13.9%) 104 (14.4%) 83 (12.9%) 63 (9.8%)  
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Table 5.5 – Cross-tabulation of IMD Category with all of the tumour and treatment factors 
 IMD Category  
Variable 
1 – Most 
deprived 2 3 4 
5 – Least 
deprived p-value 
Anatomical Site      <0.001 
   Oropharynx 208 (30.9%) 259 (42.0%) 300 (40.2%) 282 (42.5%) 252 (38.5%)  
   Lip and oral cavity 191 (28.3%) 133 (21.6%) 190 (25.5%) 168 (25.3%) 195 (29.8%)  
   Larynx 171 (25.4%) 142 (23.1%) 148 (19.8%) 133 (20.0%) 116 (17.7%)  
   Hypopharynx 44 (6.5%) 29 (4.7%) 37 (5.0%) 20 (3.0%) 26 (4.0%)  
   Salivary glands 17 (2.5%) 23 (3.7%) 40 (5.4%) 31 (4.7%) 32 (4.9%)  
   Other 43 (6.4%) 30 (4.9%) 31 (4.2%) 30 (4.5%) 34 (5.2%)  
Stage      0.25 
   I 153 (22.9%) 135 (22.1%) 176 (23.8%) 148 (22.6%) 160 (24.6%)  
   II 139 (20.8%) 109 (17.8%) 122 (16.5%) 110 (16.8%) 98 (15.1%)  
   III 100 (15.0%) 79 (12.9%) 113 (15.3%) 84 (12.8%) 87 (13.4%)  
   IV 276 (41.3%) 289 (47.2%) 329 (44.5%) 312 (47.7%) 305 (46.9%)  
HPV status      0.003 
   Negative 446 (77.6%) 375 (69.7%) 451 (69.9%) 395 (68.9%) 398 (68.4%)  
   Positive 129 (22.4%) 163 (30.3%) 194 (30.1%) 178 (31.1%) 184 (31.6%)  
Treatment      0.014 
   Surgery only 148 (22.0%) 118 (19.2%) 159 (21.3%) 144 (21.7%) 180 (27.5%)  
   Chemoradiotherapy only 197 (29.2%) 191 (31.0%) 235 (31.5%) 219 (33.0%) 194 (29.6%)  
   Radiotherapy only 167 (24.8%) 133 (21.6%) 154 (20.6%) 128 (19.3%) 102 (15.6%)  
   Surgery and chemo/radio 152 (22.6%) 167 (27.1%) 190 (25.5%) 168 (25.3%) 174 (26.6%)  
   Chemotherapy only 5 (0.7%) 2 (0.3%) 5 (0.7%) 1 (0.2%) 2 (0.3%)  
   No treatment 5 (0.7%) 5 (0.8%) 3 (0.4%) 4 (0.6%) 3 (0.5%)  
 
  
Chapter 5: Inequality in survival in England 
203 
 
Table 5.6 – Cross-tabulation of IMD Category with all of the other socioeconomic status factors 
Variable 
IMD Category  
1 – Most 
deprived 2 3 4 
5 – Least 
deprived 
p-value 
Highest education level      <0.001 
   Up to secondary school 395 (64.5%) 334 (57.1%) 307 (43.6%) 260 (41.5%) 221 (35.5%)  
   Further education 138 (22.5%) 139 (23.8%) 194 (27.6%) 172 (27.4%) 168 (27.0%)  
   Higher education/degree 79 (12.9%) 112 (19.1%) 203 (28.8%) 195 (31.1%) 234 (37.6%)  
Time spent in education      <0.001 
   10 years or less 250 (42.5%) 208 (38.3%) 209 (30.5%) 172 (28.0%) 148 (24.5%)  
   11 to 13 years 209 (35.5%) 196 (36.1%) 279 (40.7%) 252 (41.0%) 233 (38.6%)  
   14 years or more 129 (21.9%) 139 (25.6%) 197 (28.8%) 191 (31.1%) 222 (36.8%)  
Annual household income      <0.001 
   £11,999 or less 294 (53.3%) 193 (37.0%) 175 (27.6%) 106 (18.7%) 94 (16.4%)  
   £12,000 to £28,999 194 (35.1%) 206 (39.5%) 245 (38.6%) 211 (37.3%) 211 (36.9%)  
   £29,000 or more 64 (11.6%) 123 (23.6%) 215 (33.9%) 249 (44.0%) 267 (46.7%)  
Income from benefits      <0.001 
   All 233 (37.5%) 98 (16.8%) 84 (11.9%) 32 (5.2%) 28 (4.5%)  
   Some 114 (18.3%) 120 (20.5%) 136 (19.3%) 118 (19.1%) 107 (17.3%)  
   None 275 (44.2%) 366 (62.7%) 483 (68.7%) 468 (75.7%) 482 (78.1%)  
Financial concerns       <0.001 
   Yes 299 (47.6%) 226 (39.2%) 263 (37.4%) 193 (30.7%) 170 (27.8%)  
   No 329 (52.4%) 351 (60.8%) 440 (62.6%) 436 (69.3%) 442 (72.2%)  
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Table 5.7 – Cross-tabulation of highest education level with the participant characteristics, 
demographic, health, behavioural, tumour and treatment factors 
Variable 








university  p-value 
Age group    <0.001 
   Less than 44 55 (3.5%) 81 (9.8%) 69 (8.1%)  
   45 to 54 275 (17.7%) 201 (24.3%) 162 (19.1%)  
   55 to 64 526 (33.8%) 299 (36.2%) 304 (35.8%)  
   65 to 74 491 (31.6%) 171 (20.7%) 225 (26.5%)  
   75 and over 209 (13.4%) 75 (9.1%) 89 (10.5%)  
Sex    0.31 
   Male 1130 (72.6%) 607 (73.4%) 641 (75.5%)  
   Female 426 (27.4%) 220 (26.6%) 208 (24.5%)  
Marital status    0.025 
   Single 194 (12.5%) 111 (13.5%) 98 (11.6%)  
   Separated/divorced/widowed 344 (22.2%) 149 (18.1%) 150 (17.7%)  
   Married/living with partner 1015 (65.4%) 565 (68.5%) 600 (70.8%)  
Comorbidity    <0.001 
   No comorbidity 601 (39.6%) 403 (49.8%) 410 (49.2%)  
   Mild comorbidity 547 (36.1%) 247 (30.5%) 266 (31.9%)  
   Moderate/severe comorbidity 369 (24.3%) 159 (19.7%) 157 (18.8%)  
WHO Performance Status    <0.001 
   Normal activity 702 (47.8%) 459 (57.1%) 554 (66.3%)  
   Strenuous activity restricted 427 (29.1%) 209 (26.0%) 173 (20.7%)  
   Up and about > 50%  252 (17.2%) 103 (12.8%) 84 (10.0%)  
   Confined > 50% or 100% 88 (6.0%) 33 (4.1%) 25 (3.0%)  
Smoking status    <0.001 
   Current smoker 363 (24.4%) 139 (17.6%) 124 (15.1%)  
   Former smoker 869 (58.5%) 456 (57.6%) 439 (53.4%)  
   Never smoked 254 (17.1%) 197 (24.9%) 259 (31.5%)  
Alcohol consumption    <0.001 
   Non-drinker 462 (30.8%) 200 (24.8%) 184 (22.1%)  
   Moderate 317 (21.1%) 179 (22.2%) 201 (24.2%)  
   Hazardous 512 (34.1%) 307 (38.1%) 328 (39.4%)  
   Harmful 211 (14.0%) 119 (14.8%) 119 (14.3%)  
Anatomical Site     
   Oropharynx 557 (35.8%) 362 (43.8%) 353 (41.6%)  
   Lip and oral cavity 389 (25.0%) 224 (27.1%) 232 (27.3%)  
   Larynx 379 (24.4%) 144 (17.4%) 144 (17.0%)  
   Hypopharynx 86 (5.5%) 28 (3.4%) 34 (4.0%)  
   Salivary glands 65 (4.2%) 36 (4.4%) 42 (4.9%)  
   Other 80 (5.1%) 33 (4.0%) 44 (5.2%)  
Stage     
   I 341 (22.2%) 188 (22.9%) 202 (23.9%)  
   II 280 (18.2%) 139 (17.0%) 142 (16.8%)  
   III 229 (14.9%) 101 (12.3%) 106 (12.6%)  
   IV 689 (44.8%) 392 (47.8%) 394 (46.7%)  
HPV status     
   Negative 989 (73.5%) 488 (66.9%) 498 (68.2%)  
   Positive 356 (26.5%) 241 (33.1%) 232 (31.8%)  
Treatment     
   Surgery only 327 (21.0%) 192 (23.2%) 197 (23.2%)  
   Chemoradiotherapy only 463 (29.8%) 275 (33.3%) 275 (32.4%)  
   Radiotherapy only 358 (23.0%) 143 (17.3%) 143 (16.8%)  
   Surgery and chemo/radio 389 (25.0%) 205 (24.8%) 230 (27.1%)  
   Chemotherapy only 7 (0.4%) 6 (0.7%) 1 (0.1%)  
   No treatment 12 (0.8%) 6 (0.7%) 3 (0.4%)  
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Table 5.8 – Cross-tabulation of time spent in education with the participant characteristics, 
demographic, health, behavioural, tumour and treatment factors 
Variable 
Time spent in education 
p-value 
10 years or 
less 
11 to 13 years 14 years or 
more 
Age group    <0.001 
   Less than 44 24 (2.4%) 76 (6.3%) 85 (9.4%)  
   45 to 54 104 (10.3%) 311 (25.9%) 170 (18.8%)  
   55 to 64 333 (33.1%) 441 (36.8%) 306 (33.8%)  
   65 to 74 367 (36.4%) 275 (22.9%) 237 (26.2%)  
   75 and over 179 (17.8%) 97 (8.1%) 106 (11.7%)  
Sex    <0.001 
   Male 806 (80.0%) 866 (72.2%) 625 (69.1%)  
   Female 201 (20.0%) 334 (27.8%) 279 (30.9%)  
Marital status    0.12 
   Single 124 (12.3%) 125 (10.4%) 124 (13.7%)  
   Separated/divorced/widowed 216 (21.5%) 237 (19.8%) 173 (19.2%)  
   Married/living with partner 665 (66.2%) 836 (69.8%) 606 (67.1%)  
Comorbidity    <0.001 
   No comorbidity 352 (35.7%) 559 (47.6%) 426 (48.4%)  
   Mild comorbidity 373 (37.9%) 370 (31.5%) 296 (33.6%)  
   Moderate/severe comorbidity 260 (26.4%) 245 (20.9%) 159 (18.0%)  
WHO Performance Status    <0.001 
   Normal activity 421 (44.3%) 715 (61.2%) 525 (59.7%)  
   Strenuous activity restricted 297 (31.3%) 263 (22.5%) 209 (23.8%)  
   Up and about > 50%  166 (17.5%) 146 (12.5%) 106 (12.0%)  
   Confined > 50% or 100% 66 (6.9%) 44 (3.8%) 40 (4.5%)  
Smoking status    <0.001 
   Current smoker 205 (21.2%) 225 (19.6%) 167 (19.1%)  
   Former smoker 601 (62.2%) 642 (55.9%) 462 (52.9%)  
   Never smoked 161 (16.6%) 281 (24.5%) 245 (28.0%)  
Alcohol consumption    0.56 
   Non-drinker 289 (29.6%) 298 (25.5%) 234 (26.6%)  
   Moderate 205 (21.0%) 263 (22.5%) 198 (22.5%)  
   Hazardous 350 (35.8%) 435 (37.2%) 325 (37.0%)  
   Harmful 134 (13.7%) 172 (14.7%) 122 (13.9%)  
Anatomical Site    <0.001 
   Oropharynx 343 (34.1%) 514 (42.8%) 356 (39.4%)  
   Lip and oral cavity 254 (25.2%) 297 (24.8%) 264 (29.2%)  
   Larynx 268 (26.6%) 238 (19.8%) 148 (16.4%)  
   Hypopharynx 58 (5.8%) 42 (3.5%) 42 (4.6%)  
   Salivary glands 37 (3.7%) 49 (4.1%) 48 (5.3%)  
   Other 47 (4.7%) 60 (5.0%) 46 (5.1%)  
Stage    0.49 
   I 215 (21.5%) 274 (23.0%) 210 (23.5%)  
   II 183 (18.3%) 199 (16.7%) 165 (18.5%)  
   III 154 (15.4%) 156 (13.1%) 118 (13.2%)  
   IV 447 (44.7%) 561 (47.1%) 401 (44.9%)  
HPV status    <0.001 
   Negative 652 (75.6%) 702 (66.7%) 544 (70.0%)  
   Positive 211 (24.4%) 350 (33.3%) 233 (30.0%)  
Treatment    <0.001 
   Surgery only 213 (21.2%) 254 (21.2%) 224 (24.8%)  
   Chemoradiotherapy only 273 (27.1%) 411 (34.3%) 285 (31.5%)  
   Radiotherapy only 259 (25.7%) 205 (17.1%) 163 (18.0%)  
   Surgery and chemo/radio 247 (24.5%) 319 (26.6%) 225 (24.9%)  
   Chemotherapy only 8 (0.8%) 3 (0.3%) 3 (0.3%)  
   No treatment 7 (0.7%) 8 (0.7%) 4 (0.4%)  
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Table 5.9 – Cross-tabulation of annual household income with the participant 
characteristics, demographic, health, behavioural, tumour and treatment factors 
Variable 








Age group    <0.001 
   Less than 44 39 (4.4%) 61 (5.5%) 94 (10.1%)  
   45 to 54 174 (19.7%) 175 (15.9%) 263 (28.1%)  
   55 to 64 298 (33.7%) 394 (35.7%) 358 (38.3%)  
   65 to 74 260 (29.4%) 344 (31.2%) 168 (18.0%)  
   75 and over 113 (12.8%) 130 (11.8%) 52 (5.6%)  
Sex    <0.001 
   Male 620 (70.1%) 824 (74.6%) 752 (80.4%)  
   Female 264 (29.9%) 280 (25.4%) 183 (19.6%)  
Marital status    <0.001 
   Single 203 (23.3%) 121 (11.1%) 49 (5.3%)  
   Separated/divorced/widowed 310 (35.5%) 197 (18.0%) 72 (7.8%)  
   Married/living with partner 360 (41.2%) 774 (70.9%) 808 (87.0%)  
Comorbidity    <0.001 
   No comorbidity 285 (32.7%) 507 (47.0%) 543 (59.2%)  
   Mild comorbidity 345 (39.6%) 334 (31.0%) 256 (27.9%)  
   Moderate/severe comorbidity 241 (27.7%) 237 (22.0%) 118 (12.9%)  
WHO Performance Status    <0.001 
   Normal activity 322 (38.2%) 611 (56.6%) 689 (74.4%)  
   Strenuous activity restricted 262 (31.0%) 273 (25.3%) 175 (18.9%)  
   Up and about > 50%  187 (22.2%) 151 (14.0%) 55 (5.9%)  
   Confined > 50% or 100% 73 (8.6%) 45 (4.2%) 7 (0.8%)  
Smoking status    <0.001 
   Current smoker 273 (32.3%) 199 (18.7%) 89 (10.0%)  
   Former smoker 460 (54.5%) 619 (58.2%) 508 (56.9%)  
   Never smoked 111 (13.2%) 245 (23.0%) 296 (33.1%)  
Alcohol consumption    <0.001 
   Non-drinker 279 (32.6%) 299 (27.5%) 165 (17.9%)  
   Moderate 159 (18.6%) 254 (23.3%) 219 (23.8%)  
   Hazardous 261 (30.5%) 398 (36.5%) 416 (45.2%)  
   Harmful 157 (18.3%) 138 (12.7%) 120 (13.0%)  
Anatomical Site    <0.001 
   Oropharynx 275 (31.1%) 436 (39.5%) 469 (50.2%)  
   Lip and oral cavity 248 (28.1%) 286 (25.9%) 199 (21.3%)  
   Larynx 228 (25.8%) 239 (21.6%) 141 (15.1%)  
   Hypopharynx 68 (7.7%) 37 (3.4%) 21 (2.2%)  
   Salivary glands 24 (2.7%) 54 (4.9%) 52 (5.6%)  
   Other 41 (4.6%) 52 (4.7%) 53 (5.7%)  
Stage    <0.001 
   I 208 (23.7%) 258 (23.5%) 206 (22.2%)  
   II 189 (21.5%) 172 (15.7%) 131 (14.1%)  
   III 132 (15.0%) 146 (13.3%) 124 (13.4%)  
   IV 349 (39.7%) 521 (47.5%) 465 (50.2%)  
HPV status    <0.001 
   Negative 618 (83.1%) 665 (69.5%) 478 (57.7%)  
   Positive 126 (16.9%) 292 (30.5%) 350 (42.3%)  
Treatment    <0.001 
   Surgery only 208 (23.5%) 257 (23.3%) 172 (18.4%)  
   Chemoradiotherapy only 245 (27.7%) 351 (31.8%) 362 (38.7%)  
   Radiotherapy only 221 (25.0%) 219 (19.8%) 128 (13.7%)  
   Surgery and chemo/radio 198 (22.4%) 265 (24.0%) 270 (28.9%)  
   Chemotherapy only 7 (0.8%) 5 (0.5%) 2 (0.2%)  
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Table 5.10 – Cross-tabulation of income from benefits with the participant characteristics, 
demographic, health, behavioural, tumour and treatment factors 
Variable 
Income from benefits 
p-value All Some None 
Age group    <0.001 
   Less than 44 20 (4.1%) 55 (9.0%) 128 (6.0%)  
   45 to 54 119 (24.4%) 101 (16.5%) 437 (20.6%)  
   55 to 64 194 (39.8%) 183 (29.9%) 762 (35.8%)  
   65 to 74 123 (25.3%) 164 (26.8%) 578 (27.2%)  
   75 and over 31 (6.4%) 110 (17.9%) 221 (10.4%)  
Sex    0.017 
   Male 378 (77.6%) 430 (70.1%) 1581 (74.4%)  
   Female 109 (22.4%) 183 (29.9%) 545 (25.6%)  
Marital status    <0.001 
   Single 150 (31.0%) 56 (9.2%) 199 (9.4%)  
   Separated/divorced/widowed 171 (35.3%) 147 (24.2%) 312 (14.8%)  
   Married/living with partner 163 (33.7%) 405 (66.6%) 1595 (75.7%)  
Comorbidity    <0.001 
   No comorbidity 120 (25.2%) 231 (38.4%) 1074 (51.7%)  
   Mild comorbidity 193 (40.5%) 188 (31.2%) 686 (33.0%)  
   Moderate/severe comorbidity 164 (34.4%) 183 (30.4%) 317 (15.3%)  
WHO Performance Status    <0.001 
   Normal activity 120 (26.3%) 251 (42.0%) 1377 (65.7%)  
   Strenuous activity restricted 138 (30.3%) 174 (29.1%) 492 (23.5%)  
   Up and about > 50%  123 (27.0%) 126 (21.1%) 195 (9.3%)  
   Confined > 50% or 100% 75 (16.4%) 46 (7.7%) 31 (1.5%)  
Smoking status    <0.001 
   Current smoker 194 (40.9%) 116 (19.9%) 317 (15.6%)  
   Former smoker 248 (52.3%) 343 (58.7%) 1162 (57.3%)  
   Never smoked 32 (6.8%) 125 (21.4%) 549 (27.1%)  
Alcohol consumption    <0.001 
   Non-drinker 144 (31.0%) 194 (32.7%) 502 (24.1%)  
   Moderate 69 (14.8%) 123 (20.7%) 489 (23.4%)  
   Hazardous 141 (30.3%) 202 (34.0%) 823 (39.5%)  
   Harmful 111 (23.9%) 75 (12.6%) 272 (13.0%)  
Anatomical Site    <0.001 
   Oropharynx 159 (32.6%) 221 (36.1%) 893 (42.0%)  
   Lip and oral cavity 134 (27.5%) 162 (26.4%) 531 (25.0%)  
   Larynx 128 (26.3%) 138 (22.5%) 417 (19.6%)  
   Hypopharynx 45 (9.2%) 31 (5.1%) 66 (3.1%)  
   Salivary glands 8 (1.6%) 25 (4.1%) 109 (5.1%)  
   Other 13 (2.7%) 36 (5.9%) 110 (5.2%)  
Stage    0.033 
   I 98 (20.2%) 149 (24.4%) 480 (22.8%)  
   II 104 (21.4%) 111 (18.2%) 344 (16.4%)  
   III 77 (15.8%) 90 (14.7%) 281 (13.4%)  
   IV 207 (42.6%) 261 (42.7%) 997 (47.4%)  
HPV status    <0.001 
   Negative 341 (84.0%) 392 (75.1%) 1234 (66.1%)  
   Positive 65 (16.0%) 130 (24.9%) 634 (33.9%)  
Treatment    <0.001 
   Surgery only 110 (22.6%) 138 (22.5%) 464 (21.8%)  
   Chemoradiotherapy only 139 (28.5%) 170 (27.7%) 710 (33.4%)  
   Radiotherapy only 122 (25.1%) 156 (25.4%) 357 (16.8%)  
   Surgery and chemo/radio 108 (22.2%) 144 (23.5%) 573 (27.0%)  
   Chemotherapy only 4 (0.8%) 2 (0.3%) 8 (0.4%)  
   No treatment 4 (0.8%) 3 (0.5%) 14 (0.7%)  
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Table 5.11 – Cross-tabulation of financial concerns with the participant characteristics, 
demographic, health, behavioural, tumour and treatment factors 
Variable 
Financial concerns p-value 
Yes No  
Age group   <0.001 
   Less than 44 115 (9.7%) 91 (4.4%)  
   45 to 54 376 (31.8%) 271 (13.2%)  
   55 to 64 500 (42.3%) 643 (31.4%)  
   65 to 74 150 (12.7%) 724 (35.3%)  
   75 and over 40 (3.4%) 322 (15.7%)  
Sex   0.002 
   Male 912 (77.2%) 1484 (72.4%)  
   Female 269 (22.8%) 567 (27.6%)  
Marital status   <0.001 
   Single 186 (16.0%) 221 (10.8%)  
   Separated/divorced/widowed 236 (20.2%) 401 (19.7%)  
   Married/living with partner 744 (63.8%) 1417 (69.5%)  
Comorbidity   0.005 
   No comorbidity 559 (48.7%) 861 (42.8%)  
   Mild comorbidity 357 (31.1%) 708 (35.2%)  
   Moderate/severe comorbidity 231 (20.1%) 444 (22.1%)  
WHO Performance Status   <0.001 
   Normal activity 554 (48.0%) 1192 (59.3%)  
   Strenuous activity restricted 328 (28.4%) 486 (24.2%)  
   Up and about > 50%  208 (18.0%) 241 (12.0%)  
   Confined > 50% or 100% 64 (5.5%) 91 (4.5%)  
Smoking status   <0.001 
   Current smoker 299 (26.4%) 330 (16.8%)  
   Former smoker 615 (54.2%) 1140 (58.2%)  
   Never smoked 220 (19.4%) 489 (25.0%)  
Alcohol consumption   0.004 
   Non-drinker 305 (26.4%) 546 (27.3%)  
   Moderate 231 (20.0%) 452 (22.6%)  
   Hazardous 418 (36.2%) 746 (37.3%)  
   Harmful 200 (17.3%) 254 (12.7%)  
Anatomical Site   <0.001 
   Oropharynx 546 (46.2%) 728 (35.5%)  
   Lip and oral cavity 268 (22.7%) 562 (27.4%)  
   Larynx 187 (15.8%) 496 (24.2%)  
   Hypopharynx 60 (5.1%) 80 (3.9%)  
   Salivary glands 49 (4.1%) 94 (4.6%)  
   Other 71 (6.0%) 91 (4.4%)  
Stage   <0.001 
   I 185 (15.8%) 548 (27.0%)  
   II 186 (15.8%) 371 (18.3%)  
   III 179 (15.2%) 268 (13.2%)  
   IV 624 (53.2%) 844 (41.6%)  
HPV status   <0.001 
   Negative 665 (65.5%) 1306 (73.0%)  
   Positive 351 (34.5%) 483 (27.0%)  
Treatment   <0.001 
   Surgery only 193 (16.3%) 515 (25.1%)  
   Chemoradiotherapy only 460 (39.0%) 561 (27.4%)  
   Radiotherapy only 184 (15.6%) 457 (22.3%)  
   Surgery and chemo/radio 330 (27.9%) 496 (24.2%)  
   Chemotherapy only 5 (0.4%) 10 (0.5%)  
   No treatment 9 (0.8%) 12 (0.6%)  
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5.3.5 Overall survival results 
5.3.5.1 Follow-up 
The median follow-up time of the whole cohort was 4.8 years (IQR = 4.3 to 5.9 years) and 
1.6 years (IQR = 0.8 to 2.9 years) for those who were alive and for those who had died by 
the end of the follow-up period, respectively.  
5.3.5.2 Three-year overall survival for the whole cohort and by the participant 
characteristics and demographic factors 
Three-year overall survival for the whole cohort, participant characteristics, and patient 
demographics are displayed in Table 5.12. The Kaplan-Meier results for the probability of 
death over time since the participants’ diagnosis for the whole cohort, participant 
characteristics, and demographic data are displayed in Figure 5.2 to Figure 5.5. Three-
year survival for the cohort was 76.3% (95% CI = 74.9% to 77.7%). Those who were aged 
75 and over had the lowest three-year overall survival at 64.7% (95% CI = 59.9% to 
69.0%) compared to those who were less than 44 who had three-year overall survival of 
85.2% (95% CI = 79.7% to 89.4%). Males had lower three-year overall survival than 
females at 75.5% (95% CI = 73.7% to 77.1%) and 78.8% (95% CI = 76.0% to 81.3%), 
respectively. The people who were separated, divorced, or widowed had the lowest three-
year overall survival at 67.8% (95% CI = 64.2% to 71.1%) compared to the people who 
were married or living with a partner who had the highest three-year overall survival at 
79.5% (95% CI = 77.7% to 81.1%).  






Whole cohort 76.3 (74.9, 77.7) - 
Age group  <0.001 
   Less than 44 85.2 (79.7, 89.4)  
   45 to 54 82.0 (78.8, 84.7)  
   55 to 64 77.8 (75.3, 80.0)  
   65 to 74 73.7 (70.8, 76.4)  
   75 and over 64.7 (59.9, 69.0)  
Sex  0.006 
   Male 75.5 (73.7, 77.1)  
   Female 78.8 (76.0, 81.3)  
Marital status  <0.001 
   Single 73.8 (69.3, 77.7)  
   Separated/divorced/widowed 67.8 (64.2, 71.1)  
   Married/living with partner 79.5 (77.7, 81.1)  
   Unknown 72.7 (57.0, 83.5)  
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Figure 5.2 – Kaplan-Meier plot for overall survival for the whole cohort 
 
Figure 5.3 – Kaplan-Meier plot for overall survival for age group  
 
Figure 5.4 – Kaplan-Meier plot for overall survival for sex  
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Figure 5.5 – Kaplan-Meier plot for overall survival for marital status  
 
5.3.5.3 Three-year overall survival by the health and behavioural factors 
The results for three-year overall survival for the health and behavioural factors are 
displayed in Table 5.13. The Kaplan-Meier plots for overall survival by the health and 
behavioural factors are displayed in Figure 5.6 to Figure 5.9. Those who had moderate to 
severe comorbidities had the lowest three-year overall survival at 62.4% (95% CI = 58.8% 
to 83.0%) compared to those who had no comorbidity who had three-year overall survival 
of 83.8% (95% CI = 81.9% to 85.6%). As WHO Performance Status reduced, the three-
year overall survival results also reduced from 84.1% (95% CI = 82.3% to 85.7%) for 
those who were of normal activity at the time of their diagnosis, to 50.6% (95% CI = 
42.8% to 57.9%) for those who were confined to a bed or chair for at least 50% of their 
waking hours. Those who were current smokers at the time of their diagnosis had the 
lowest three-year overall survival of 65.5% (95% CI = 61.9% to 69.0%), compared to 
those who were former smokers at 76.6% (95% CI = 74.6% to 78.5%). Those who had 
never smoked in their lifetime had the highest three-year overall survival of 84.6% (95% 
CI = 81.8% to 87.0%). There was not a trend in three-year overall survival by alcohol 
consumption for those who were non-drinkers to those who were hazardous drinkers, with 
non-drinkers having the lowest three-year overall survival at 75.9% (95% CI = 72.9% to 
78.5%), compared to hazardous drinkers at 77.2% (95% CI = 74.7% to 79.5%). However, 
those who drank to harmful levels had the lowest three-year overall survival at 69.9% 
(95% CI = 65.6% to 73.8%).  
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Comorbidity  <0.001 
   No comorbidity 83.8 (81.9, 85.6)  
   Mild comorbidity 75.6 (73.0, 78.0)  
   Moderate/severe comorbidity 62.4 (58.8, 65.8)  
   Unknown 74.7 (63.2, 83.0)  
WHO Performance Status  <0.001 
   Normal activity 84.1 (82.3, 85.7)  
   Strenuous activity restricted 72.2 (69.1, 75.1)  
   Up and about > 50%  67.5 (63.0, 71.5)  
   Confined > 50% or 100% 50.6 (42.8, 57.9)  
   Unknown 64.2 (56.3, 71.0)  
Smoking status  <0.001 
   Current smoker 65.5 (61.8, 69.0)  
   Former smoker 76.6 (74.6, 78.5)  
   Never smoked 84.6 (81.8, 87.0)  
   Unknown 79.8 (73.0, 85.0)  
Alcohol consumption  <0.001 
   Non-drinker 75.9 (72.9, 78.5)  
   Moderate 81.5 (78.5, 84.1)  
   Hazardous 77.2 (74.7, 79.5)  
   Harmful 69.9 (65.6, 73.8)  
   Unknown 64.9 (55.2, 72.9)  
 
Figure 5.6 – Kaplan-Meier plot for overall survival for comorbidity  
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Figure 5.7 – Kaplan-Meier plot for overall survival for WHO Performance Status 
 
Figure 5.8 – Kaplan-Meier plot for overall survival for smoking status  
 
Figure 5.9 – Kaplan-Meier plot for overall survival for alcohol consumption  
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5.3.5.4 Three-year overall survival by the tumour and treatment factors 
The results for three-year overall survival for the tumour and treatment factors are 
displayed in Table 5.14. The Kaplan-Meier plots for overall survival by the health and 
behavioural factors are displayed in Figure 5.1 to Figure 5.13. The participants who were 
diagnosed with cancer of the hypopharynx had the lowest three-year survival at 48.1% 
(95% CI = 40.2% to 55.6%). In contrast, the people who were diagnosed with cancer of 
the salivary gland had the highest three-year overall at 85.0% (95% CI = 78.2% to 89.9%). 
As the stage of the cohorts’ tumours increased, the three-year overall survival decreased 
from 89.1% (95% CI = 86.7% to 91.1%) to 69.3% (95% CI = 69.3%) for those diagnosed 
with stage I and stage IV tumours, respectively. Interestingly, those who had not had their 
tumours staged had the lowest three-year overall survival at 61.3% (95% CI = 42.0% to 
75.9%), which suggests that the people who had not had their tumours staged may have 
had tumours that were stage IV. The people who were HPV positive had a higher three-
year overall survival than the people who were HPV negative which was 88.1% (95% CI = 
85.8% to 90.1%) compared with 72.2% (95% CI = 70.2% to 74.0%), respectively.  






Anatomical Site  <0.001 
   Oropharynx 81.7 (79.5, 83.7)  
   Lip and oral cavity 71.4 (68.4, 74.3)  
   Larynx 79.1 (76.0, 81.9)  
   Hypopharynx 48.1 (40.2, 55.6)  
   Salivary glands 85.0 (78.2, 89.9)  
   Other 67.3 (59.6, 73.7)  
Stage  <0.001 
   I 89.1 (86.7, 91.1)  
   II 78.9 (75.4, 82.0)  
   III 75.9 (71.8, 79.5)  
   IV 69.3 (67.0, 71.6)  
   Unknown 61.3 (42.0, 75.9)  
HPV status  <0.001 
   Negative 72.2 (70.2, 74.0)  
   Positive 88.1 (85.8, 90.1)  
   Unknown 73.2 (68.9, 77.0)  
Treatment  <0.001 
   Surgery only 85.2 (82.5, 87.6)  
   Chemoradiotherapy only 77.1 (74.4, 79.5)  
   Radiotherapy only 73.2 (69.8, 76.3)  
   Surgery and chemo/radio 72.8 (69.7, 75.7)  
   Chemotherapy only 13.3 (2.2, 34.6)  
   No treatment 13.6 (3.4, 30.9)  
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Figure 5.10 – Kaplan-Meier plot for overall survival for anatomical site  
 
Figure 5.11 – Kaplan-Meier plot for overall survival for tumour stage 
 
Figure 5.12 – Kaplan-Meier plot for overall survival for HPV status  
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Figure 5.13 – Kaplan-Meier plot for overall survival for treatment modality 
 
5.3.5.5 Three-year overall survival by the socioeconomic status factors 
The results for three-year overall survival for the tumour and treatment factors are 
displayed in Table 5.15. The Kaplan-Meier plots for overall survival by the health and 
behavioural factors are displayed in Figure 5.14 to Figure 5.19. The participants who were 
from the most deprived IMD Category had the lowest three-year overall survival of 71.2% 
(95% CI = 67.6% to 74.5%) compared to approximately 77% for all of the other IMD 
Categories. Those who had obtained an education level of up to secondary school had 
the lowest three-year overall survival at 74.2% (95% CI = 71.9% to 76.3%), compared with 
79.4% (95% CI = 76.5% to 82.0%) for those who had a higher education or had obtained 
a degree. Likewise, people who had spent fewer years in education also had lower three-
year overall survival at 73.2% (95% CI = 70.3% to 75.8%) for those who had spent 10 
years or less in education, compared with 78.9% (95% CI = 76.5% to 81.1%) for those 
who had spent 11 to 13 years in education. Interestingly, the people who had spent 14 
years or more in education had a slightly lower three-year overall survival than those who 
had spent 11 to 13 years in education at 76.3% (95% CI = 73.4% to 79.0%). There was a 
trend in three-year overall survival across the amount of annual household income the 
people earned. As the annual household income increased, the patient’s three-year 
overall survival also increased from 70.3% (95% CI = 67.1% to 73.1%) to 83.7% (95% CI 
= 81.2% to 86.0%) for those who earned £11,999 or less and those who earned £29,000 
or more, respectively. The same trend can be observed for the proportion of income the 
participants’ received from benefits. As the proportion of benefits the participants’ received 
reduced, the three-year overall survival increased from 68.4% (95% CI = 64.1% to 72.3%) 
to 79.9% (95% CI = 78.2% to 81.6%) for those who earned all of their income from 
benefits and those who earned none of their income from benefits, respectively. There 
was no clear difference between the people who did and did not have financial concerns 
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of living with or after cancer with three-year overall survival of 76.5% (95% CI = 73.9% to 
78.8%) and 76.7% (95% CI = 74.9% to 78.5%), respectively. 





IMD Category  0.002 
   1 – Most deprived 71.2 (67.6, 74.5)  
   2 77.9 (74.4, 81.0)  
   3 77.8 (74.6, 80.6)  
   4 77.4 (74.0, 80.4)  
   5 – Least deprived 77.3 (73.9, 80.3)  
   Unknown 77.7 (67.2, 85.1)  
Highest education level  <0.001 
   Up to secondary school 74.2 (71.9, 76.3)  
   Further education 77.8 (74.8, 80.4)  
   Higher education/degree 79.4 (76.5, 82.0)  
   Unknown 74.5 (68.0, 79.9)  
Time in education  <0.001 
   10 years or less 73.2 (70.3, 75.8)  
   11 to 13 years 78.9 (76.5, 81.1)  
   14 years or more 76.3 (73.4, 79.0)  
   Unknown 76.6 (71.6, 80.8)  
Household income  <0.001 
   £11,999 or less 70.3 (67.1, 73.1)  
   £12,000 to £28,999 77.6 (75.0, 79.9)  
   £29,000 or more 83.7 (81.2, 86.0)  
   Unknown 70.8 (66.7, 74.5)  
Income from benefits  <0.001 
   All 68.4 (64.1, 72.3)  
   Some 71.8 (68.0, 75.2)  
   None 79.9 (78.2, 81.6)  
   Unknown 72.0 (65.4, 77.5)  
Financial concerns   0.102 
   Yes 76.5 (73.9, 78.8)  
   No 76.7 (74.9, 78.5)  
   Unknown 71.6 (65.0, 77.3)  
Figure 5.14 – Kaplan-Meier plot for overall survival for IMD Category  
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Figure 5.15 – Kaplan-Meier plot for overall survival for highest education level  
 
Figure 5.16 – Kaplan-Meier plot for overall survival for time spent in education  
 
Figure 5.17 – Kaplan-Meier plot for overall survival for total annual household income  
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Figure 5.18 – Kaplan-Meier plot for overall survival for income from benefits 
 
Figure 5.19 – Kaplan-Meier plot for overall survival for financial concerns  
 
5.3.6 Explanations for inequality in survival  
The Cox proportional hazards models that were adjusted for the potential explanatory 
factors are displayed in Table 5.16 and Table 5.17 prior to multiple imputation, and in 
Table 5.18 and Table 5.19 following multiple imputation. 
5.3.6.1 IMD Category 
Following adjustment by age and sex, both prior to and post MI, the participants remained 
at a higher risk of all-cause mortality if they resided in areas of the most deprived IMD 
Category (pre-MI HR = 1.50, 95% CI = 1.24 to 1.81; post-MI HR = 1.49, 95% CI = 1.23 to 
1.80). Prior to multiple imputation and following adjustment by age and sex with: (a) 
comorbidity, (b) smoking status, (c) alcohol consumption, or (d) tumour and treatment 
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factors combined, there was an attenuation in inequality by IMD Category (particularly 
following the adjustment for smoking status) but inequality by IMD Category remained 
strong. When the model was adjusted by age, sex and all of the health and behavioural 
factors combined including comorbidity, smoking status and alcohol consumption, there 
was no longer inequality in all-cause mortality by IMD Category (most deprived HR = 1.07, 
95% CI = 0.88 to 1.31). Following multiple imputation, results were comparable to those of 
the models prior to multiple imputation for IMD Category.  
5.3.6.2 Highest education level attained 
Following adjustment by age and sex, both prior to and post multiple imputation, the 
participants remained at a higher risk of all-cause mortality if they attained an education 
level of up to secondary school (pre-MI HR = 1.26, 95% CI = 1.08 to 1.47; post-MI HR = 
1.26, 95% CI = 1.08 to 1.47). Following adjustment by age and sex with: (a) comorbidity, 
or (b) alcohol consumption, there was a slight attenuation in inequality by highest 
education level attained but the inequality remained strong. When the model was adjusted 
by age, sex and smoking status, the participants who attained an education level up to 
secondary school were no longer at a higher risk of all-cause mortality (HR = 1.13, 95% CI 
0.95 to 1.32) than those who had continued to higher education or degree. Similar results 
were also observed when the model was adjusted by all of the tumour and treatment 
factors combined (HR = 1.13, 95% CI 0.97 to 1.33), however there was not one tumour or 
treatment factor that attenuated the inequality by highest education level attained. 
Following multiple imputation, the results were comparable to those prior to multiple 
imputation.  
5.3.6.3 Time spent in education 
Following age and sex adjustment, there was no longer a difference in all-cause mortality 
for the participants who had spent less time in full-time education, which would be 
expected given the higher proportion of older people who had remained in education for 
less time. 
5.3.6.4 Annual household income 
Participants were more at risk of all-cause mortality after age and sex adjustment if they 
earned less than £11,999 per annum (pre-MI HR = 2.00, 95% CI = 1.67 to 2.40; post-MI 
HR = 1.92, 95% CI = 1.61 to 2.28). Following adjustment by age and sex with: (a) 
comorbidity, (b) smoking status, (c) alcohol consumption, (d) health and behavioural 
factors, (e) tumour and treatment factors, or (f) all of the potential explanatory factors, 
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there was a slight attenuation in inequality by annual household income (particularly by 
smoking status or all of the health and behavioural factors), however the inequality 
remained strong. Even after full adjustment, the people who earned less then £11,999 
remained 34% (HR = 1.34, 95% CI = 1.01 to 1.63) more at risk of all-cause mortality than 
those who earned more than £29,000. The results from the imputed models were 
comparable to those prior to imputation.  
5.3.6.5 Income from benefits 
Participants were more at risk of all-cause mortality after age and sex adjustment if they 
earned all of their income from benefits (pre-MI HR = 1.93, 95% CI = 1.64 to 2.26; post-MI 
HR = 1.91, 95% CI 1.63 to 2.25). Following adjustment by age and sex with:  
(a) comorbidity, (b) smoking status, (c) alcohol consumption, (d) health and behavioural 
factors, (e) tumour and treatment factors, or (f) all of the potential explanatory factors, 
there was attenuation in inequality by the proportion of income that the participants 
received from benefits, however inequality remained strong. Even after full adjustment, 
the participants who earned all of their income from benefits were 35% (HR = 1.35, 95% 
CI = 1.14 to 1.60) more at risk of all-cause mortality than those who earned none of their 
income from benefits. Following multiple imputation, results were comparable to those 
prior to imputation.  
5.3.6.6 Financial concerns 
Prior to multiple imputation, there was a difference between the participants who had 
financial concerns of living with or after cancer following age and sex adjustment (HR = 
1.19, 95% CI = 1.04 to 1.37). However, following multiple imputation, the difference 
between the people with and without financial concerns following age and sex adjustment 
was reversed (HR = 0.83, 95% CI = 0.73 to 0.96). Following adjustment by age and sex 
with: (a) comorbidity, or (b) alcohol consumption, there was attenuation in the difference 
by financial concerns, but inequality remained. However, when the model was adjusted by 
age, sex and smoking status, the participants who had financial concerns were no longer 
at a higher risk of all-cause mortality (HR = 1.12, 95% CI = 0.97 to 1.28). Similar results 
were also observed when the model was adjusted by age, sex, and a) health and 
behavioural factors (HR = 1.07, 95% CI = 0.93 to 1.24), or b) tumour and treatment factors 
combined (HR = 1.01, 95% CI = 0.88 to 1.17), however there was not one tumour or 
treatment factor that attenuated the inequality by financial concerns. Following imputation, 
results were comparable to those prior to imputation. 
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Table 5.16 – Cox Proportion Hazards models for each socioeconomic status factors prior to multiple imputation  
Variable 
Age and sex adjusted Age, sex, and comorbidity 
adjusted 
Age, sex, and smoking 
adjusted 
Age, sex, and alcohol 
adjusted 
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value 
IMD Category         
   1 – Most deprived 1.50 (1.24, 1.81) <0.001 1.32 (1.09, 1.60) 0.005 1.22 (1.00, 1.48) 0.046 1.40 (1.16, 1.70) 0.001 
   2 1.13 (0.92, 1.38) 0.007 1.06 (0.86, 1.30) 0.596 1.00 (0.81, 1.23) 0.991 1.09 (0.89, 1.34) 0.392 
   3 1.11 (0.91, 1.35) 0.129 1.05 (0.87, 1.28) 0.598 1.04 (0.85, 1.26) 0.710 1.08 (0.89, 1.32) 0.431 
   4 0.98 (0.80, 1.20) 0.347 0.94 (0.77, 1.16) 0.577 0.93 (0.75, 1.14) 0.464 0.95 (0.77, 1.17) 0.629 
   5 – Least deprived 1.00 (Ref.) - 1.00 (Ref.) - 1.00 (Ref.) - 1.00 (Ref.) - 
   Unknown 1.18 (0.79, 1.76) 0.291 1.08 (0.73, 1.61) 0.699 1.03 (0.69, 1.54) 0.874 1.09 (0.73, 1.62) 0.686 
Highest education level         
   Up to secondary school 1.26 (1.08, 1.47) 0.003 1.20 (1.03, 1.40) 0.019 1.13 (0.96, 1.32) 0.123 1.24 (1.06, 1.45) 0.005 
   Further education 1.07 (0.89, 1.29) 0.510 1.04 (0.86, 1.25) 0.741 1.04 (0.87, 1.25) 0.680 1.07 (0.89, 1.28) 0.540 
   Higher education/degree 1.00 (Ref.) - 1.00 (Ref.) - 1.00 (Ref.) - 1.00 (Ref.) - 
   Unknown 1.25 (0.96, 1.62) 0.099 1.19 (0.92, 1.55) 0.182 1.14 (0.88, 1.49) 0.331 1.18 (0.90, 1.53) 0.224 
Time in education         
   10 years or less 1.10 (0.94, 1.29) 0.244 1.05 (0.90, 1.24) 0.519 1.06 (0.90, 1.24) 0.500 1.10 (0.94, 1.29) 0.248 
   11 to 13 years 0.97 (0.82, 1.14) 0.676 0.94 (0.80, 1.11) 0.489 0.97 (0.82, 1.14) 0.682 0.97 (0.83, 1.14) 0.719 
   14 years or more 1.00 (Ref.) - 1.00 (Ref.) - 1.00 (Ref.) - 1.00 (Ref.) - 
   Unknown 1.19 (0.96, 1.49) 0.116 1.18 (0.95, 1.47) 0.142 1.18 (0.94, 1.48) 0.149 1.16 (0.93, 1.45) 0.181 
Household income         
   £11,999 or less 2.00 (1.67, 2.40) <0.001 1.76 (1.47, 2.12) <0.001 1.64 (1.36, 1.97) <0.001 1.92 (1.60, 2.31) <0.001 
   £12,000 to £28,999 1.47 (1.22, 1.76) <0.001 1.39 (1.16, 1.66) <0.001 1.32 (1.10, 1.58) 0.003 1.45 (1.21, 1.74) <0.001 
   £29,000 or more 1.00 (Ref.) - 1.00 (Ref.) - 1.00 (Ref.) - 1.00 (Ref.) - 
   Unknown 1.87 (1.52, 2.30) <0.001 1.71 (1.39, 2.10) <0.001 1.64 (1.33, 2.02) <0.001 1.77 (1.43, 2.18) <0.001 
Income from benefits         
   All 1.93 (1.64, 2.26) <0.001 1.63 (1.39, 1.92) <0.001 1.61 (1.37, 1.89) <0.001 1.82 (1.55, 2.13) <0.001 
   Some 1.47 (1.26, 1.71) <0.001 1.34 (1.14, 1.57) <0.001 1.39 (1.19, 1.63) <0.001 1.45 (1.24, 1.69) <0.001 
   None 1.00 (Ref.) - 1.00 (Ref.) - 1.00 (Ref.) - 1.00 (Ref.) - 
   Unknown 1.24 (0.97, 1.58) 0.088 1.13 (0.88, 1.44) 0.336 1.16 (0.91, 1.48) 0.242 1.17 (0.92, 1.51) 0.194 
Financial concerns          
   Yes 1.19 (1.04, 1.37) 0.013 1.14 (0.99, 1.31) 0.062 1.12 (0.97, 1.28) 0.127 1.17 (1.02, 1.35) 0.024 
   No 1.00 (Ref.) - 1.00 (Ref.) - 1.00 (Ref.) - 1.00 (Ref.) - 
   Unknown 1.13 (0.89, 1.44) 0.301 1.10 (0.87, 1.40) 0.424 1.08 (0.85, 1.37) 0.523 1.06 (0.83, 1.35) 0.626 
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Table 5.17 – Cox Proportion Hazards models for each socioeconomic status factors prior to multiple imputation  
Variable 
Age, sex, health, and 
behavioural factors adjusted* 
Age, sex, tumour, and 
treatment factors adjusted^ 
Fully adjusted+ 
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value 
IMD Category       
   1 – Most deprived 1.07 (0.88, 1.31) 0.480 1.37 (1.13, 1.66) 0.001 1.08 (0.88, 1.31) 0.473 
   2 0.94 (0.76, 1.15) 0.550 1.10 (0.89, 1.35) 0.380 0.95 (0.77, 1.16) 0.597 
   3 0.98 (0.81, 1.08) 0.872 1.07 (0.88, 1.30) 0.510 0.97 (0.79, 1.18) 0.744 
   4 0.88 (0.72, 1.08) 0.218 0.93 (0.76, 1.15) 0.519 0.84 (0.68, 1.03) 0.101 
   5 – Least deprived 1.00 (Ref.) - 1.00 (Ref.) - 1.00 (Ref.) - 
   Unknown 0.92 (0.62, 1.38) 0.688 0.95 (0.64, 1.43) 0.817 0.72 (0.48, 1.09) 0.120 
Highest education level       
   Up to secondary school 1.09 (0.93, 1.27) 0.265 1.13 (0.97, 1.33) 0.109 1.00 (0.86, 1.18) 0.882 
   Further education 1.02 (0.85, 1.22) 0.875 1.05 (0.88, 1.26) 0.584 1.00 (0.84, 1.21) 0.893 
   Higher education/degree 1.00 (Ref.) - 1.00 (Ref.) - 1.00 (Ref.) - 
   Unknown 1.07 (0.82, 1.40) 0.616 1.18 (0.91, 1.54) 0.208 1.04 (0.79, 1.36) 0.788 
Time in education       
   10 years or less 1.03 (0.87, 1.20) 0.757 1.05 (0.89, 1.23) 0.574 0.99 (0.84, 1.17) 0.895 
   11 to 13 years 0.95 (0.81, 1.12) 0.528 1.02 (0.87, 1.20) 0.802 1.02 (0.86, 1.20) 0.835 
   14 years or more 1.00 (Ref.) - 1.00 (Ref.) - 1.00 (Ref.) - 
   Unknown 1.15 (0.92, 1.43) 0.236 1.21 (0.97, 1.52) 0.087 1.17 (0.93, 1.47) 0.173 
Household income       
   £11,999 or less 1.46 (1.21, 1.76) <0.001 1.67 (1.39, 2.01) <0.001 1.34 (1.01, 1.63) 0.003 
   £12,000 to £28,999 1.26 (1.05, 1.52) 0.012 1.33 (1.10, 1.59) 0.002 1.17 (0.97, 1.41) 0.100 
   £29,000 or more 1.00 (Ref.) - 1.00 (Ref.) - 1.00 (Ref.) - 
   Unknown 1.46 (1.18, 1.80) 0.001 1.48 (1.20, 1.83) <0.001 1.25 (1.00, 1.55) 0.047 
Income from benefits       
   All 1.36 (1.15, 1.60) <0.001 1.69 (1.44, 1.99) <0.001 1.35 (1.14, 1.60) 0.001 
   Some 1.27 (1.08, 1.49) 0.003 1.40 (1.19, 1.63) <0.001 1.27 (1.09, 1.49) 0.003 
   None 1.00 (Ref.) - 1.00 (Ref.) - 1.00 (Ref.) - 
   Unknown 1.03 (0.81, 1.33) 0.788 1.09 (0.85, 1.40) 0.483 0.96 (0.75, 1.24) 0.768 
Financial concerns        
   Yes 1.07 (0.93, 1.24) 0.319 1.01 (0.88, 1.17) 0.847 0.94 (0.81, 1.08) 0.371 
   No 1.00 (Ref.) - 1.00 (Ref.) - 1.00 (Ref.) - 
   Unknown 1.01 (0.79, 1.29) 0.936 0.96 (0.75, 1.22) 0.716 0.90 (0.71, 1.16) 0.424 
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Table 5.18 – Cox Proportion Hazards models for each socioeconomic status factors following multiple imputation  
Variable 
Age and sex adjusted Age, sex, and comorbidity 
adjusted 
Age, sex, and smoking 
adjusted 
Age, sex, and alcohol 
adjusted 
HR (95% CI) 
p-value 
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p- 
value 
IMD Category         
   1 – Most deprived 1.49 (1.23, 1.80) <0.001 1.32 (1.09, 1.60) 0.005 1.20 (0.99, 1.46) 0.066 1.42 (1.17, 1.72) <0.001 
   2 1.13 (0.92, 1.38) 0.240 1.06 (0.87, 1.30) 0.563 0.99 (0.81, 1.22) 0.938 1.10 (0.89, 1.34) 0.376 
   3 1.11 (0.92, 1.35) 0.282 1.06 (0.87, 1.29) 0.554 1.03 (0.85, 1.26) 0.746 1.09 (0.90, 1.32) 0.383 
   4 1.11 (0.92, 1.35) 0.816 0.94 (0.77, 1.16) 0.581 0.92 (0.75, 1.13) 0.442 0.95 (0.78, 1.17) 0.654 
   5 – Least deprived 1.00 (Ref.) - 1.00 (Ref.) - 1.00 (Ref.) - 1.00 (Ref.) - 
Highest education level         
   Up to secondary school 1.26 (1.08, 1.47) 0.003 1.21 (1.03, 1.41) 0.018 1.12 (0.96, 1.31) 0.151 1.26 (1.08, 1.47) 0.004 
   Further education 1.07 (0.89, 1.28) 0.496 1.03 (0.86, 1.24) 0.711 1.03 (0.86, 1.24) 0.712 1.06 (0.89, 1.27) 0.509 
   Higher education/degree 1.00 (Ref.) - 1.00 (Ref.) - 1.00 (Ref.) - 1.00 (Ref.) - 
Time in education         
   10 years or less 1.10 (0.94, 1.30) 0.229 1.06 (0.90, 1.24) 0.486 1.05 (0.90, 1.23) 0.534 1.11 (0.94, 1.30) 0.216 
   11 to 13 years 0.98 (0.83, 1.15) 0.766 0.96 (0.81, 1.12) 0.582 0.97 (0.83, 1.14) 0.727 0.98 (0.83, 1.16) 0.834 
   14 years or more 1.00 (Ref.) - 1.00 (Ref.) - 1.00 (Ref.) - 1.00 (Ref.) - 
Household income         
   £11,999 or less 1.92 (1.61, 2.28) <0.001 1.71 (1.43, 2.04) <0.001 1.57 (1.31, 1.87) <0.001 1.86 (1.56, 2.22) <0.001 
   £12,000 to £28,999 1.43 (1.20, 1.70) <0.001 1.35 (1.14, 1.61) 0.001 1.29 (1.08, 1.53) 0.004 1.41 (1.19, 1.68) <0.001 
   £29,000 or more 1.00 (Ref.) - 1.00 (Ref.) - 1.00 (Ref.) - 1.00 (Ref.) - 
Income from benefits         
   All 1.91 (1.63, 2.25) <0.001 1.63 (1.38, 1.93) <0.001 1.60 (1.36, 1.89) <0.001 1.85 (1.57, 1.18) <0.001 
   Some 1.45 (1.25, 1.69) <0.001 1.33 (1.14, 1.55) <0.001 1.37 (1.18, 1.60) <0.001 1.44 (1.24, 1.68) <0.001 
   None 1.00 (Ref.) - 1.00 (Ref.) - 1.00 (Ref.) - 1.00 (Ref.) - 
Financial concerns          
   Yes 0.83 (0.73, 0.96) 0.011 0.87 (0.76, 1.00) 0.053 0.90 (0.78, 1.03) 0.125 0.85 (0.74, 0.98) 0.021 
   No 1.00 (Ref.) - 1.00 (Ref.) - 1.00 (Ref.) - 1.00 (Ref.) - 
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Table 5.19 – Cox Proportion Hazards models for each socioeconomic status factors following multiple imputation  
Variable 
Age, sex, health, and 
behavioural factors 
adjusted* 
Age, sex, tumour, and 
treatment factors adjusted^ 
Fully adjusted+ 
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value 
IMD Category       
   1 – Most deprived 1.08 (0.89, 1.31) 0.453 1.34 (1.10, 1.62) 0.003 1.06 (0.87, 1.30) 0.565 
   2 0.94 (0.76, 1.15) 0.539 1.08 (0.88, 1.33) 0.472 0.93 (0.75, 1.14) 0.478 
   3 0.99 (0.81, 1.20) 0.915 1.06 (0.87, 1.30) 0.550 0.97 (0.79, 1.18) 0.731 
   4 0.89 (0.72, 1.09) 0.245 0.92 (0.75, 1.13) 0.452 0.84 (0.69, 1.04) 0.104 
   5 – Least deprived 1.00 (Ref.) - 1.00 (Ref.) - 1.00 (Ref.) - 
Highest education level       
   Up to secondary school 1.09 (0.93, 1.27) 0.292 1.14 (0.98, 1.34) 0.082 1.02 (0.87, 1.20) 0.799 
   Further education 1.01 (0.84, 1.21) 0.899 1.04 (0.87, 1.25) 0.658 1.00 (0.83, 1.21) 0.971 
   Higher education/degree 1.00 (Ref.) - 1.00 (Ref.) - 1.00 (Ref.) - 
Time in education       
   10 years or less 1.02 (0.87, 1.20) 0.768 1.05 (0.89, 1.24) 0.541 0.99 (0.84, 1.17) 0.951 
   11 to 13 years 0.96 (0.81, 1.13) 0.594 1.02 (0.86, 1.20) 0.852 1.01 (0.86, 1.19) 0.895 
   14 years or more 1.00 (Ref.) - 1.00 (Ref.) - 1.00 (Ref.) - 
Household income       
   £11,999 or less 1.42 (1.18, 1.70) <0.001 1.61 (1.34, 1.94) <0.001 1.32 (1.09, 1.59) 0.004 
   £12,000 to £28,999 1.23 (1.04, 1.47) 0.019 1.29 (1.08, 1.54) 0.005 1.15 (0.96, 1.37) 0.123 
   £29,000 or more 1.00 (Ref.) - 1.00 (Ref.) - 1.00 (Ref.) - 
Income from benefits       
   All 1.38 (1.16, 1.64) <0.001 1.67 (1.42, 1.97) <0.001 1.36 (1.14, 1.62) <0.001 
   Some 1.26 (1.08, 1.47) 0.004 1.37 (1.18, 1.61) <0.001 1.25 (1.07, 1.46) 0.005 
   None 1.00 (Ref.) - 1.00 (Ref.) - 1.00 (Ref.) - 
Financial concerns        
   Yes 0.93 (0.81, 1.07) 0.295 0.97 (0.84, 1.12) 0.699 1.04 (0.91, 1.20) 0.541 
   No 1.00 (Ref.) - 1.00 (Ref.) - 1.00 (Ref.) - 
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5.4 Discussion  
Inequality in survival of people with head and neck cancer was observed via several 
measurements of socioeconomic status including IMD Category, highest education level, 
number of years spent in education, annual household income, proportion of income from 
benefits, and financial concerns of living with or after cancer. The smoking status of the 
participants had a strong effect on the inequality by IMD Category, however adjustment 
for age, sex, health, and behavioural factors fully explained the inequality observed by 
IMD Category. Similar results were observed for highest education attained and financial 
concerns, however adjustment by smoking status was able to fully explain the inequality 
by these factors alone, both in the models prior to and following multiple imputation. 
Inequality by the amount of time the participants spent in education could be fully 
explained by age, which was to be expected due to the high proportion of people over the 
age of 65 in this cohort (n = 1,362/39.6%). Inequality by annual household income and the 
proportion of income from benefits attenuated following the adjustment of all of the 
potential explanatory factors, however even after full adjustment, inequality remained 
strong in both models prior to and following multiple imputation.  
Previous work investigated inequality in long-term survival as part of the SAHNC – a 
clinical cohort study of people with head and neck cancer in Scotland diagnosed between 
1999 and 2001 (Ingarfield et al., 2018). A gradient in overall survival, disease-specific 
survival, and net survival was observed after one year, five years, and 12 years. Inequality 
by all-cause mortality and disease-specific mortality was no longer evident following the 
adjustment of combined patient, tumour, and treatment factors. The SAHNC study 
investigated people with head and neck cancer from Scotland who were diagnosed 
approximately 15 years before the HN5000 cohort, which only included people from 
England. Survival has differed between both countries for many years (Office for National 
Statistics, 2019), suggesting that people in England have a longer life expectancy than 
those in Scotland. In contrast to the HN5000, the SAHNC study investigated survival 
using the area-based Carstairs 2001 Index (Carstairs and Morris, 1989; McLoone, 2000) 
which derives deprivation on low social class, lack of car ownership, overcrowding, and 
male unemployment, and therefore cannot be directly compared to English IMD 
Categories. In addition, due to the long follow-up period, one limitation of the SAHNC 
study was that it was recruited ahead of the discovery of the association of HPV positivity 
and improved prognosis (Kreimer et al., 2005; Ragin and Taioli, 2007; Wang et al., 2015), 
and as a result, HPV data were not available in the SAHNC study. Moreover, the SAHNC 
study did not have the advantage of the use of individual measurements of socioeconomic 
status.  
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Other UK-based studies have investigated the impact of socioeconomic status on survival 
of people with head and neck cancer, and suggest that inequality is only apparent for the 
first 18 months, and can be explained by people from lower socioeconomic status 
statuses having tumours of higher stage, worse comorbidities, or poorer access to 
healthcare (Paterson et al., 2002; Andersen et al., 2008; Ellis et al., 2012). In our study, 
this was not the case, particularly for annual household income and the proportion of 
income the participants received from benefits. However, it was clear that comorbidity 
attenuated the inequality by each socioeconomic status factors but did not explain the 
inequality alone and smoking considerably attenuated inequality more than any other 
factor for IMD Category and highest education level received. In this study, tumour stage 
alone did not seem have any influence on survival for any of the socioeconomic status 
factors.  
There are several limitations to this study. Firstly, the proportion of participants across the 
IMD groups was even, suggesting an under-representation of the people from the most 
deprived areas in this study. As a result, this study may underestimate the true extent of 
inequality in survival of people with head and neck cancer. Secondly, the participants 
were given the option of taking home their baseline questionnaire to complete and return 
with a pre-paid envelope. As a result, a proportion of 21% of the participants did not return 
their baseline questionnaires and were therefore excluded from this analysis. We 
compared the groups of people who did and did not return their questionnaire and 
discovered that people who did not return their questionnaire were more likely to be from 
the more deprived IMD Categories (Appendix 5.2). Previous studies have also implied that 
non-respondents tend to be from backgrounds of lower socioeconomic status and have 
less time and capacity to participate in research (Fry et al., 2017; James et al., 2018). 
Thirdly, after excluding a proportion of people who did not return their questionnaire, those 
with missing data for alcohol consumption and stage were at a higher risk of all-cause 
mortality compared to the healthier groups of individuals. However, we performed multiple 
imputation to overcome this issue. Finally, although we linked these data to mortality data, 
we were unable to obtain information on the cause of the participants’ death. Therefore, 
we were only able to investigate inequality in survival using all-cause mortality. However, 
due to the short-term follow-up period of this study, it is likely that a high proportion of 
deaths would be attributed to head and neck cancer, and therefore all-cause and disease-
specific mortality results would be unlikely to be substantially different (Ingarfield et al., 
2019).  
This study has several strengths. Firstly, this was a large, prospective, clinical cohort 
study which provided a range of measurements of socioeconomic status including area-
based and individual measurements. Due to the extent of data collected via medical 
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records and participant questionnaires, this study allowed investigations into many of the 
potential explanatory factors of inequality in survival of people with head and neck cancer 
via a wide range of factors including participant characteristics, demographics, 
behavioural, health, tumour, and treatment factors. 
5.4.1 Conclusion 
This study discovered that inequality by an area-based measurement of IMD Category 
could be mostly explained by smoking status, and fully explained by a combination of age, 
sex, health, and behavioural factors. The same results were observed for the highest 
education level that was attained by the study population; however, age alone explained 
the inequality by the number of years spent in education. In this study, we were unable to 
explain inequality by annual household income or proportion of income of benefits that the 
participants received. This study adds to the literature by exploring inequality in survival of 
people with head and neck cancer using both area-based and individual measurements of 
socioeconomic status, and by investigating the explanations for the inequalities observed. 
To our knowledge, this is the first study to investigate the inequality in survival of people 
with head and neck cancer in such depth using both area-based and individual 






This chapter begins with a review of the aims and objectives of this thesis, followed by 
summary of the collective thesis findings from the four studies that were conducted 
throughout this thesis in relation to the prior knowledge and gaps that were identified in 
the literature review that was carried out in Chapter 1. This chapter goes on to discuss the 
thesis strengths and limitations, and finally makes recommendations for policy, practice, 
and further research on socioeconomic inequalities in head and neck cancer outcomes 
and survival. Finally, the thesis will end with a conclusion section.    
6.2 Aims and objectives of the thesis 
This thesis aimed to inform patients, clinicians, policy makers, and the public in the UK 
that are involved with head and neck cancer on the magnitude of socioeconomic 
inequality observed in survival of people with head and neck cancer and what factors 
might explain these inequalities. A series of epidemiological studies of multiple existing 
UK cohort studies explored this topic from different angles. These findings could inform 
policy and practice in the further development and delivery of head and neck cancer 
services. This thesis aimed to explore the potential mechanisms and causal relationships 
between deprivation and survival in people with head and neck cancer, as outlined in 
Figure 6.1.  
Throughout this thesis, the socioeconomic, patient, tumour, and treatment factors were 
selected and driven by the data availability in each of the studies that were carried out in 
Chapter 2 to Chapter 5. The socioeconomic factors of interest in Chapter 2, which 
included data from the Scottish Cancer Registry included Carstairs 1991 categories and 
SIMD 2004 categories. However, due to limitations around the use and linkage of data 
from the Scottish Cancer Registry, it was not possible to investigate associations with 
patient, tumour, and treatment factors with socioeconomic inequality in survival of people 
with head and neck cancer, and this chapter was limited to a descriptive analyses. 
Throughout Chapter 3 and Chapter 4, which utilised data from the SAHNC prospective 
clinical cohort study, the area-based Carstairs 2001 categories were considered as the 
socioeconomic factor. In addition, multiple patient, tumour, and treatment factors were 
considered for their association with survival (Chapter 3) and their association with 
socioeconomic inequality in survival of people with head and neck cancer. The patient 
Chapter 6: Discussion 
230 
factors in these studies included: age at diagnosis, sex, smoking status, alcohol 
consumption, and WHO Performance Status. The tumour factors were the anatomical site 
and stage of the tumour, while the treatment factors that were included were the treatment 
modality that the patient received and the geographical location within the Scottish health 
board that the patients received their treatment. Chapter 5 utilised data from the HN5000 
cohort study further refined both socioeconomic factors and patient, tumour, and 
treatment factors into modifiable and non-modifiable explanatory factors. The 
socioeconomic factors in this study included the area-based English IMD categories, and 
several individual measurements of socioeconomic status including highest education 
level attained, number of years spent in full-time education, total annual household 
income, proportion of income from benefits, and whether the participants had any financial 
concerns of living with or after cancer. The “patient factors” of interest in this study were 
refined into demographic data (age and sex), health status data (comorbidity and WHO 
Performance Status), and behavioural factors data (smoking status and alcohol 
consumption). The tumour factors included the anatomical site of the tumour, tumour 
stage, and HPV status, while the treatment factors just included the treatment modality 
that the patients received for their tumour. Throughout each study, age and sex were 
considered as confounding factors, while full models looked for the independent risk 
factors via full adjustment. In addition, these factors were also considered as both 
modifiable (for example, behavioural factors including smoking status and alcohol 
consumption) and non-modifiable (for example, tumour and treatment factors).  
Figure 6.1 – Conceptual diagram displaying the causal relationships between deprivation 
and survival in people with head and neck cancer 
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6.3 Main findings of the thesis 
6.3.1 Previous gaps in the literature 
Chapter 1 provided a thorough literature review on studies from around the globe that 
investigated socioeconomic inequality in survival of people with head and neck cancer. 
These studies showed evidence of socioeconomic inequalities, with lower socioeconomic 
status and poorer circumstances being associated with worse survival of people with head 
and neck cancer. However, explanations for this socioeconomic inequality were yet to be 
thoroughly explored in terms of investigating potential underlying explanatory patient, 
tumour, and treatment factors. In particular, the underlying determinants of inequality in 
survival were not grouped as per factors that might be more modifiable (for example, 
through behaviours such as smoking and alcohol) compared with factors that might be 
less amenable to control (for example, tumour site, stage, and treatment regimens). In 
addition, none of the studies from the UK explored socioeconomic inequality in survival of 
people with head and neck cancer using individual measurements of socioeconomic 
status such as household income or education level. Additionally, few of the studies that 
were included in the literature review investigated the long-term impact of inequality in 
survival of people with head and neck cancer beyond five-years, and few studies 
examined the trend of inequality in survival of people with head and neck cancer over 
time. No study formally analysed the extent of absolute and relative inequalities in survival 
using metrics including RII and SII as per IARC 2019 recommendations (Conway et al., 
2019), and there was a lack of clarity and consistency in the survival metric to use 
throughout the studies.  
6.3.2 Trends over time in inequality in survival 
The aim of Chapter 2 was to describe the trends over calendar time and follow-up time of 
inequality in survival of people with head and neck cancer in Scotland who were 
diagnosed between 1986 and 2015 on the Scottish Cancer Registry. Socioeconomic 
inequality in net survival was measured by utilising the area-based Carstairs 2001 
Categories. Inequality was evident for all time periods (after one year, five years, and 10 
years) following diagnosis, with survival consistently favouring those who were from the 
least deprived regions of Scotland. However, the inequalities that were observed for 
people who were diagnosed between the years of 2011 and 2015 was higher than it was 
for any of the patients who were diagnosed before this time period and, in addition, 
socioeconomic inequalities became stronger over the follow-up period for all periods of 
diagnosis.  
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Chapter 4 also explored the trends in inequality over follow-up time of people who were 
recruited to the SAHNC cohort study; a large prospective national clinical cohort study in 
Scotland between the years of 1999 and 2001. Like the results found in Chapter 2, 
inequality in disease-specific survival became worse over the follow-up time from one 
years, five years, and 12 years after diagnosis, but the same trend was not apparent for 
overall survival and net survival estimates. However, following adjustment for age and 
sex, this trend for disease-specific survival was no longer apparent. In addition, the results 
for the net survival analysis demonstrated a gradient across the Carstairs 2001 
Categories after one year and five years, but this gradient disappeared by 12 years, 
suggesting that some of the inequality in long-term survival was partly attributable to 
background mortality. 
6.3.3 Determinants of survival of people with head and neck cancer 
The primary aim of Chapter 3 was to determine the factors that are independently 
associated with survival of people with head and neck cancer that were recruited to the 
SAHNC. Survival was examined at three time points – one year, five years, and 12 years 
after a diagnosis of head and neck cancer. Prior to adjustment, poor overall survival, 
disease-specific survival, and net survival were associated with age, poor deprivation 
status, current or previous smoking status, current or previous alcohol consumption, and 
worse WHO Performance Status. In addition, poor survival was also more strongly 
associated with tumours of the hypopharynx, tumours of higher stage, and treatment with 
chemotherapy. However, in a mutually adjusted forward stepwise Cox proportional 
hazards model, the patient, tumour, and treatment factors that were associated with one-
year, five-year, and 12-year all-cause mortality following the forced inclusion of age at 
diagnosis, tumour stage, and treatment modality included WHO Performance Status, 
alcohol consumption, anatomical site, and smoking status. The results for the mutually 
adjusted models for disease-specific survival differed slightly, in that after one year the 
factors that had an independent association with disease-specific mortality after the forced 
inclusion of age at diagnosis, tumour stage, and treatment modality included WHO 
Performance Status, alcohol consumption, and Scottish Cancer Network. However, by 
five years and 12 years, the factors that had an independent association with disease-
specific mortality after the forced inclusion of age at diagnosis, tumour stage, and 
treatment modality included WHO Performance Status, alcohol consumption, and 
anatomical site, which was the same as the results for all-cause mortality. Interestingly, 
socioeconomic status did not have an independent association with all-cause mortality or 
disease-specific mortality following mutual adjustment.  
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6.3.4 Explanations for inequality in survival utilising an area-based 
measurement of socioeconomic status 
To add to the research that was carried out in Chapter 3, the aim of Chapter 4 was to 
explore the underlying causes of inequality in survival for those who were recruited to the 
SAHNC cohort study. Following multiple individual adjustments of various patient, tumour, 
and treatment factors, none of the individually adjusted models fully explained 
socioeconomic inequality in survival. However, when the model was fully adjusted by all of 
the patient, tumour, and treatment factors combined, the inequality in survival attenuated, 
suggesting that inequality in survival of people with head and neck cancer is not 
straightforward, and that many factors play a combined effect in socioeconomic inequality 
in head and neck cancer survival.  
6.3.5 Explanations for inequality in survival utilising both an area-based 
measurement and individual measurements of socioeconomic status 
The aim of Chapter 5 was to explore the underlying determinants of inequality in short-
term survival of people with head and neck cancer by utilising both an area-based 
measurement and several individual measurements of socioeconomic status. This study 
utilised data from the HN5000 cohort study; a prospective clinical cohort study of people 
diagnosed with head and neck cancer in England between the years of 2011 and 2015. 
Inequality in survival of people with head and neck cancer was observed via several 
measurements of socioeconomic status including IMD Category, highest education level 
attained, number of years spent in education, annual household income, proportion of 
income from benefits, and financial concerns of living with or after cancer. The smoking 
status of the participants had a strong effect on inequality by IMD Category, however 
similarly to the results observed in Chapter 4, adjustment for age, sex, health, and 
behavioural factors fully explained socioeconomic inequality observed by IMD Category. 
Adjustment by smoking status was able to fully explain the associations with highest 
education level the participants attained, and whether they had any financial concerns as 
a result of living with or after cancer. Survival associations with the amount of time the 
participants spent in education could be fully explained by age, while the relationship 
between survival and annual household income and the proportion of income from 
benefits attenuated following the adjustment of all potential explanatory factors, however 
even after full adjustment, the inequalities associated with these factors remained strong.   
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6.3.6 Whole thesis findings 
As a whole, this thesis demonstrated strong and consistent socioeconomic inequality in 
survival of people with head and neck cancer. Moreover, these inequalities appeared to 
become worse over calendar time and also across follow-up period time one year, five 
years, and ten years after a diagnosis of head and neck cancer (Chapter 2). Chapter 3 
found that socioeconomic status was not an independent predictor of survival in a cohort 
of people with head and neck cancer who were diagnosed in Scotland between the years 
of 1999 and 2001, while Chapter 4 investigated the underlying factors that may explain 
the original inequality that was observed in overall survival, disease-specific survival, and 
net survival estimates. Chapter 4 also highlighted that in models that were adjusted by 
various patient, tumour, and treatment factors, none of the factors could individually 
explain the socioeconomic inequality in survival alone, suggesting that socioeconomic 
inequality in survival of people with head and neck cancer is complex with multiple factors 
having a combined effect, including background mortality in the long-term follow-up (via 
net survival estimates). However, the studies that were carried out in Chapter 2 to Chapter 
4 only utilised area-based socioeconomic measurements – mainly Carstairs deprivation 
index categories.  
Chapter 5 added to this picture by exploring inequality by using both an area-based (IMD 
Category) and individual measurements of socioeconomic status including highest 
education level attained, number of years spent in education, annual household income, 
proportion of income from benefits, and financial concerns of living with or after cancer in 
England. Only data from England in the UK HN5000 cohort could be included in this 
analysis, as it was not possible to pool and standardise the varying measurements of IMD 
(including SIMD and Welsh IMD) across the UK. This study determined that inequalities 
were present for all of the measurements of socioeconomic status, however inequality in 
highest education level, number of years spent in education, and financial concerns of 
living with or after cancer were explained (fully attenuated) by other factors such as age 
and smoking status. Inequalities across both annual household income and the proportion 
of income from benefits partially attenuated following the adjustment of all of the potential 
explanatory factors, however, even after full adjustment, these inequalities could not be 
fully explained by a combination of the potential patient, tumour, or treatment factors that 
were included in this study.  
The secondary aim of Chapter 3 was to compare methods of measurements of survival 
via the use of overall survival, disease-specific survival, and net survival estimates. The 
substantial differences between these survival metrics demonstrated the overestimation of 
deaths that are specific to head and neck cancer when using overall survival, and the 
underestimation of disease-specific mortality when using death certificates when people 
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have died only from head and neck cancer. These results suggest that people are dying of 
other causes that are related to their head and neck cancer but that are not as a direct 
result of their cancer. Therefore, the use of net survival provides a good compromise to 
traditional methods to estimate the true burden of head and neck cancer in long-term 
follow-up studies. As a result, throughout Chapter 2 to Chapter 4, net survival estimates 
have been provided alongside overall survival and disease-specific survival results to 
compare and contrast the outcomes of people with head and neck cancer. However, in 
Chapter 5, it was not possible to utilise net survival estimations since lifetables for this 
time point have not yet been generated.  
6.4 Comparisons with other studies 
6.4.1 Trends over calendar time  
Of the studies that were included in the literature review that was carried out in Chapter 1, 
only five of the studies investigated the trends over time in inequality in survival of people 
with head and neck cancer. One of these studies included patients who were diagnosed 
with cancer of the larynx on the Scottish Cancer Registry (Shack et al., 2007), three other 
studies utilised data from cancer registries in England (Paterson et al., 2002; Coleman et 
al., 2004; Rachet et al., 2008), and one further study utilised data from the British 
Columbia Cancer Registry (Auluck et al., 2016). No study was found that provided 
comparisons of inequality in survival of people with head and neck cancer by follow-up 
period.  
Coleman et al. (2004) analysed cancer registry data on 2.2 million individuals who had 
been diagnosed with one of the 20 most common cancers in England and Wales between 
the years of 1986 and 1999, including 5,666 men with cancer of the larynx. Relative 
survival up to five-years and a “deprivation gap” was presented for each of the cancer 
sites. Coleman and colleagues discovered that the deprivation gap in relative survival for 
males with cancer of the larynx was increasing, and in the period of 1996-1999 reached 
17% in favour of those from the least deprived areas. A small report by Rachet et al. 
(2008) investigated survival of men with cancer of the larynx in England and Wales. 
Rachet and colleagues took a deeper look at the 17% deprivation gap of males from the 
earlier article (Coleman et al., 2004) and reported that this gap had increased by 3.7% 
every five years, with survival consistently in favour of those from the least deprived 
areas. In addition, this paper investigated 10-year relative survival and discovered that the 
gap in 10-year relative survival for men diagnosed in the early 1990s was also wide at 
11%, in favour of the people from the least deprived regions.  
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Shack et al. (2007) investigated the socioeconomic inequality in survival of people with 
cancer in Scotland. This study included a cohort of 357,658 adults with any primary 
cancer registered on the Scottish Cancer Registry between the years of 1986 and 2000 
and followed-up to 2005, including a sub-group of 1,128 men with laryngeal cancer. The 
authors reported five-year relative survival and the “deprivation gap” was presented again. 
This study demonstrated that the deprivation gap in five-year relative survival was at 
nearly 11% for men with cancer of the larynx in favour of those from the least deprived 
areas of Scotland and, in addition, was becoming approximately 3% wider every five 
years. Paterson et al. (2002) investigated trends for 20,131 people who were diagnosed 
with head and neck cancer from four regional cancer registries in England and Wales 
between the years of 1981 and 1994. This study examined the effect of deprivation on 
one-year and five-year relative survival using Carstairs 1991 Categories from several 
perspectives including age group, sex, and calendar year. Paterson and colleagues 
investigated the association of deprivation with survival by grouping the data into the 
years 1981-1985, 1986-1990 and 1991-1994 and found that the effect of deprivation on 
relative survival was stronger in the period of 1981-1985 and 1991-1994, with survival 
favouring the people who were from the least deprived areas.  
These results coincide with the study that was conducted in Chapter 2 which 
demonstrated a widening in the inequality in survival of people with head and neck 
cancer, and this was also evident for those with cancer of the larynx, and for males and 
females separately. However, in the study conducted in this thesis, the SII and RII were 
used to quantify inequality as opposed to a “deprivation gap”, which are recommended 
measurements for analysing inequality as proposed by IARC (International Agency for 
Research on Cancer, 2019).  
6.4.2 Explanations for inequality in survival utilising area-based 
measurements of socioeconomic status 
Only three studies that were included in the literature review extensively explored the 
underlying determinants of socioeconomic inequality in survival of people with head and 
neck cancer by utilising area-based measurements of socioeconomic status (Molina et al., 
2008; Robertson et al., 2010; Chu et al., 2016). These studies included underlying 
potential explanatory factors such as various patient, tumour, and treatment factors for 
their relationship with inequality in survival.  
The only study from the UK which investigated the explanations for socioeconomic 
inequality in survival of people with head and neck cancer was conducted by Robertson et 
al. (2010). This study utilised the SAHNC cohort, which was also used in Chapter 3 and 
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Chapter 4 of this thesis. In the study by Robertson et al. (2010), socioeconomic status was 
measured using 2001 Deprivation Category (DEPCAT) scores which were categorised 
into three groups (affluent, intermediate, and deprived) while in the studies carried out in 
this thesis, Carstairs 1991 Categories were utilised which provided five groups for levels 
of socioeconomic indication. However, Robertson et al. (2010) only investigated all-cause 
mortality and disease-specific mortality up to five years post-diagnosis, whereas the study 
conducted in this thesis investigated survival up to 12-years along with a comparison of 
overall survival and disease-specific survival with net survival estimates. Robertson et al. 
(2010) found that the people who were in the deprived group experienced a 33% (HR = 
1.33, 95% CI = 1.06 to 1.68) increased risk of all-cause mortality compared to those from 
the most affluent group after five years. The similar study in Chapter 3 of this thesis found 
that those from the most deprived area exhibited a slightly higher excess risk of all-cause 
mortality of 43% (HR = 1.43, 95% CI = 1.15 to 1.76) in a minimally adjusted model for age 
and sex, compared to those from the least deprived areas in analyses using Carstairs 
1991 Categories after five years. However, this is likely to be related to the differing 
groups for socioeconomic status that was used in the study conducted in this thesis. In 
addition, in the study that was carried out in this thesis, inequality in 12-year survival was 
also investigated. Robertson et al. (2010) reported that socioeconomic status was no 
longer an independent predictor of all-cause or disease-specific mortality following the 
adjustment for other baseline covariates including WHO Performance Status, tumour 
stage, age at diagnosis, anatomical site of the tumour, smoking status, and alcohol 
consumption, which was also reported in this thesis. However, to add to this research, the 
study carried out in this thesis on the SAHNC delved further into the explanations for the 
lack of inequality after adjustment in Chapter 4 with the aim to extract further 
understanding of explanatory factors for socioeconomic inequality in survival. Following 
multiple individual adjustments of various patient, tumour, and treatment factors, none of 
the models that adjusted individually by each baseline covariable were able to fully explain 
the inequality. However, when the models were adjusted by multiple patient, tumour, and 
treatment factors, the inequalities fully attenuated, which suggests that the socioeconomic 
inequality in survival of patients with head and neck cancer is multifactorial. 
Another similar study that explored the underlying explanations for inequality in survival of 
people with head and neck cancer outside of the UK was conducted by Chu et al. (2016), 
who explored the prognostic importance of neighbourhood-level socioeconomic status on 
the overall survival of 2,124 people with newly diagnosed head and neck cancer. The 
patients were diagnosed at the Toronto’s Princess Margaret Cancer Centre between the 
years of 2003 and 2010. The authors reported that although low socioeconomic status 
was associated with poorer survival in a univariate model, it was no longer associated with 
poorer survival following the adjustment for other variables including age, gender, stage, 
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comorbidity, smoking status, alcohol use, and HPV type 16 status. The authors outlined 
that those of lower socioeconomic status were more likely to have comorbidities, tumours 
of higher stage, and were more likely to be smokers and alcohol users. However, Chu et 
al. (2016) had the advantage of including HPV type 16 status as an explanatory factor for 
inequality which, due to the long-term follow-up of the SAHNC data, was not available for 
the thesis.   
Conversely, the thesis findings differed with a study from the USA that had also 
thoroughly explored the underlying explanations for inequality in survival of people with 
head and neck cancer. Molina et al. (2008) investigated the association of community 
poverty level with the survival of 20,915 people diagnosed with head and neck cancer in 
Florida between the years of 1998 and 2002. The authors investigated five-year overall 
survival using a variety of demographic, social, and clinical information and recorded 
socioeconomic status using community poverty levels. The authors discovered that area-
based socioeconomic status remained an independent predictor of survival in a stepwise 
multivariate Cox regression analysis which included participant demographics (age, 
gender, race, ethnicity, tobacco use and alcohol consumption), comorbidities, clinical 
characteristics (tumour grade, stage, and location of treatment) and treatment modality.  
6.4.3 Explanations for inequality in survival utilising individual 
measurements of socioeconomic status 
Only one study that was included in the literature review extensively explored the 
underlying explanations of socioeconomic inequality in survival of people with head and 
neck cancer by utilising individual measurements of socioeconomic status, which were 
similar to the measurements utilised throughout the study undertaken in Chapter 5 of this 
thesis. The study, conducted by Abrahão et al. (2020), investigated the predictors of 
survival in a cohort of 1,463 people diagnosed with SCC of the head and neck from 
Argentina, Brazil, Colombia, and Uruguay between the years of 2011 and 2017. 
Participants for the study were collected from the InterCHANGE study, a multicentre case-
control study to investigate the risk factors and outcomes of people with SCC of the head 
and neck. Patients were followed up to 2018 and the authors reported three-year overall 
survival outcomes and included the education level of the patients as an exploratory 
factor. In a univariate Cox proportional hazards model, those who were “illiterate” were 
more at risk of all-cause mortality compared to those with “superior” education levels. 
However, in a multivariate model including age, sex, ethnicity, cancer stage, smoking 
history, alcohol consumption, and anatomical site, education level was no longer a 
predictor of survival. In the study that was carried out in Chapter 5 of this thesis, education 
was defined as the number of years spent in education and the highest qualification 
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attained by the patients. In this study, education was a predictor of three-year survival in a 
univariate model with survival favouring those with higher levels of education, which was 
similar to the results observed in the paper by Abrahão et al. (2020). However, in the 
study in this thesis, age alone fully explained the inequality observed for the number of 
years spent in education, while smoking status was able to fully explain the inequality by 
highest education attained.  
6.5 Overall thesis strengths and limitations 
The strengths and limitations of each study are outlined in the discussions within each 
chapter. However, there are several strengths and limitations to this thesis as a whole.  
6.5.1 Thesis limitations 
One limitation of this thesis is the slight variations in the inclusion criteria of head and neck 
cancer across the three studies that were utilised throughout the analyses in this thesis. 
There are many different definitions of head and neck cancer, which was discussed in 
Chapter 1 (Section 1.3.1), and Appendix 6.1 displays the differences in the ICD-10 
inclusion criteria across the studies included in this thesis. In the HN5000 study, the lip 
and the oral cavity were grouped due to low numbers of people with cancer of the lip in 
this study. While in the Scottish Cancer Registry and SAHNC cohort, these subgroups of 
the head and neck were analysed separately. In addition, in the HN5000 study, the study 
team considered tumours of the “minor salivary gland” which were classified as any ICD-
10 code with the tumour histology recorded as “salivary gland”. Due to differing clinical 
input, this was not considered throughout the analyses in the Scottish Cancer Registry or 
the SAHNC cohort. The final difference related to tumours of the nasopharynx, nasal 
cavity, and sinuses, which were included in the SAHNC cohort (albeit, a combined 
grouping) and the HN5000 study. However, these tumours were not requested as part of 
the Public Benefit and Privacy Panel (PBPP) application form for the Scottish Cancer 
Registry.  
A further limitation of this thesis related to the different groupings of treatment modalities 
that were considered throughout each chapter, which are highlighted in Appendix 6.2. 
These differences are largely due to changes over time with guidance on how best to treat 
head and neck cancers, which had led from a shift away from chemotherapy and towards 
the use of chemoradiotherapy (NICE, 2017). Some minor differences in the categorisation 
of treatment modality were also due to low numbers, which needed to therefore be 
combined with other groups to allow for accurate analyses.  
Chapter 6: Discussion 
240 
A further limitation of the analyses that were carried out in Chapter 3 and Chapter 4 which 
utilised the SAHNC cohort study, included the non-proportional hazards that were 
observed in the long-term follow-up study. Proportional hazards occur when the ratio of 
the hazards between the groups of the variable that are included in the Cox Proportional 
Hazards Model are the same over follow-up time. This was not the case for the SAHNC 
cohort study, and the hazards were displayed over various follow-up times including after 
one year, five years, and 12 years of a diagnosis of head and neck cancer. The 
implication of non-proportional hazards may lead to an underestimation or overestimation 
of the relative risk for covariates over time (Schemper, 1992). An alternative method to 
using Cox Proportional Hazards Regression in a non-proportional setting could have been 
to display conditional survival measurements, which present survival outcomes based on 
the condition that a person has already survived to a certain point (Hieke et al., 2015). 
This eliminates the issue surrounding non-proportional hazards since the baseline hazard 
function is not considered (Xu and O'Quigley, 2002). 
One limitation to Chapter 5 was also the under-representation of people from the most 
deprived areas in this study, since it would have been expected to have observed higher 
numbers of people in the most deprived group (Purkayastha et al., 2016). As a result, this 
study may underestimate the true extent of inequality in survival of people with head and 
neck cancer. However, in a paper written by epidemiologists Rothman et al. (2013), the 
authors state that representativeness is not a reasonable aim for scientific studies since a 
representative sample may not be generalisable to all of the individual subgroups of a 
population. The authors also concluded that “…the main road to general statements on 
nature is through studies that control skilfully for confounding variables and thereby 
advance our understanding of causal mechanisms. Representative sampling does not 
take us down that road”. Moreover, this could only therefore be of real concern if there 
were very small numbers or no cases in a particular group (for example, those from 
deprived areas), which was not the case in the HN5000 cohort study.  
Further limitations of this thesis are the various types of potential biases that can occur in 
these types of routine national databases and cohort studies (including the SAHNC and 
the HN5000). Such biases include differential misclassification of outcomes, measurement 
error in potential exposures, confounders and mediators, ecological fallacy in area-based 
measurements, immortal time bias in cohort studies, and confounding by indication. 
Differential misclassification of outcomes is a recognised issue in studies that use routine 
administrative data and occurs when the health outcome is not equal between people who 
are exposed or are unexposed (Rothman et al., 2008; Chen et al., 2019). However, 
Cancer Registry data are population-wide with high quality and completeness and 
therefore, differential misclassification is unlikely to be an issue in terms of the primary 
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exposure and outcomes, including cancer diagnosis and survival. Similarly, in the near 
population-wide coverage of the SAHNC cohort, the issue of SES exposure data would be 
minimal, however full data capture of patient, tumour, and treatment data may have been 
impacted differentially across the socioeconomic status groups due to differential 
treatment uptake which may impact and underestimate the outcome. Ecological fallacy is 
an information bias when an individuals’ socioeconomic status is misclassified based on 
their area of residence. This may cause bias in studies that include area-based 
measurements of socioeconomic status since all individuals in one area of residence may 
not share the same socioeconomic characteristics (Greenland and Morgenstern, 1989; 
Walter, 1991). Ecological fallacy is well recognised as an issue in this thesis throughout 
the analyses that included the Scottish Cancer Registry and the SAHNC cohort which 
both utilised area-based measurements of socioeconomic status. However, the main aim 
of Chapter 5 which utilised the HN5000 cohort, was to explore both individual and area-
based measurements of socioeconomic status, and to compare these outcomes – and 
multiple individual measures were used. A strong inter-relationship of area and individual 
socioeconomic measures was observed. Ecological area-based measures can also be 
considered advantageous since they capture the area and environmental aspects of 
socioeconomic deprivation, for example, including access to services, healthy food, and 
cultural aspects. Immortal time bias occurs when the participants included in a study do 
not experience the outcome of interest when this outcome is measured at a later date in 
the study (Rothman et al., 2008). Immortal time bias is a bias in which the person-time at 
risk of an event includes a period of time during which the individual cannot experience 
the event (Suissa, 2007; Faillie and Suissa, 2015). This typically occurs in 
pharmacoepidemiology studies when an individual has a delay between their date of 
diagnosis and the start of their treatment. If the event (for example, death) occurs during 
this time, the individual is either misclassified to a treated group, or is excluded from the 
analysis. This typically occurs during the time lapse in between a patient receiving a 
diagnosis and beginning their allocated treatment regimen. Should a participant die during 
this time, their treatment allocation would remain as the “planned treatment”, although the 
individual did not receive any treatment before dying, and therefore should be re-allocated 
as such. Therefore, there was a period of immortal time in these studies when the 
participants could not experience death. However, the impact of immortal time bias is 
likely to be small in the Scottish Cancer Registry as the case ascertainment and 
completeness of these data is high (Public Health Scotland, 2020a). In addition, in the 
SAHNC and HN5000 cohorts, many of the patients who were either not fit for treatment of 
curative intent or were given non-curative treatment, were assessed by clinical teams, and 
were correctly allocated into a no treatment group. Therefore, immortal time bias was 
unlikely to be an issue in the SAHNC and HN5000 cohorts.  
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6.5.2 Thesis strengths 
The studies that were performed as a part of this thesis contribute to the knowledge and 
understanding of inequality in survival of people with head and neck cancer. Chapter 2 
aimed to describe the trends over time in inequality in survival of people diagnosed with 
head and neck cancer in Scotland by utilising data from the Scottish Cancer Registry. 
Trends over time were explored for people who were diagnosed between the years of 
1986 and 2015. This allowed trends in survival in the short-term, mid-term, and long-term 
to be investigated over time and by calendar time, which was a strength of this study. 
However, due to the limitations of cancer registry data (such as lack of staging information 
and behavioural data), the underlying factors of inequality could not be explored.  
The next analyses undertaken in Chapter 3 and Chapter 4 utilised data from the SAHNC, 
which was a cohort study of people who were diagnosed with head and neck cancer in 
Scotland between the years of 1999 and 2001. This data provided a snapshot of 77% 
incident cases of head and neck cancer that were recorded on the Scottish Cancer 
Registry during the same period. Inequality in survival of people with head and neck 
cancer was explored in the short-term, mid-term, and long-term in the same way as the 
methods that were conducted as a part of Chapter 2, and additionally, the underlying 
factors of inequality could be explored. However, one of the major limitations of this study 
was the absence of HPV data, which over the last two decades has been associated with 
the rising incidence of people with head and neck cancer, particularly for those with 
cancers of the oropharynx, who have a considerably better prognosis. In addition, it was 
only possible to measure socioeconomic status in the studies in Chapter 2 to Chapter 4 by 
using the area-based Carstairs and Morris index, which is derived from Census data and 
considers the proportion of male unemployment, those in social classes IV and V, lack of 
car ownership, and overcrowding in a dwelling. However, Carstairs and Morris categories 
may not accurately represent rural and urban populations since it may be essential for 
these people to own cars in these areas (Valentova, 2011). Moreover, the SAHNC could 
not be linked to the more updated, small area SIMD index.  
This led this thesis into Chapter 5, which explored the underlying causes of inequality in 
the HN5000 cohort study, by using both an area-based measurement of socioeconomic 
status and several individual measurements of socioeconomic status. This included the 
highest education level obtained, number of years spent in education, total annual 
household income, proportion of income from benefits, and whether the patients had any 
financial concerns of living with or after their diagnosis of head and neck cancer. In 
addition, a more thorough exploration of the potential underlying determinants of 
socioeconomic inequality in survival of people with head and neck cancer was possible, 
which included data on the HPV status of the patients in the study. However, the main 
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limitation of this study was the recency of this cohort who were diagnosed between the 
years of 2011 and 2014, with follow-up to 2018, and therefore it was only possible to 
investigate inequality in survival in the short-term (three years). In addition, these data 
could not be linked to cause of death information for disease-specific survival, and 
lifetables for this time period had not yet been generated at the time of this analysis. 
Therefore, it was also not possible to explore net survival outcomes for this cohort.  
In the literature review that was carried out in Chapter 1, few of the studies that were 
included explored the underlying causes inequality in survival of people with head and 
neck cancer, and therefore, this remained poorly understood. Although some of the UK-
based studies explored multivariate models which included socioeconomic status as a 
potential explanatory variable for survival of people with head and neck cancer, this thesis 
has provided the first UK-based study that explored the underlying causes of 
socioeconomic inequality in depth with the aim to understand the factors explaining 
inequality in survival of people with head and neck cancer. In particular, explanations for 
this inequality were yet to be thoroughly investigated by exploring potential patient, 
tumour, and treatment factors, including potential underlying determinants which were not 
grouped as per factors that might be more modifiable (for example, through behaviours 
such as smoking and alcohol) compared with factors that might be less amenable to 
control (for example, tumour site, stage, and treatment regimens). In addition, this thesis 
provides the world’s first study that explored socioeconomic inequality in survival of 
people with head and neck cancer, while also examining the exact underlying factors of 
inequality in survival using a variety of measurements of inequality including both area-
based and individual measurements of socioeconomic status such as annual household 
income and the proportion of income from benefits (HN5000 study).  
A further strength of this thesis is the use of modern net survival to explore survival of 
people with head and neck cancer. Net survival is defined as the excess mortality 
between the observed mortality of a group of people under investigation and the expected 
mortality of a disease-free group in the population with the same demographic 
characteristics as the study group (Pohar Perme et al., 2012). Net survival is useful when 
cause of death information is unknown and provides a more accurate representation of 
the mortality from a disease of interest by disentangling other causes of death. 
Throughout this thesis, net survival was estimated by utilising the stns command in stata, 
which implements the Pohar-Perme estimator (Pohar Perme et al., 2012) and provides a 
non-parametric unbiased estimator of net survival (Clerc-Urmes et al., 2014). 
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6.6 Recommendations 
This section covers recommendations for practice, policy, and research in turn which are 
based on the findings from the thesis. 
6.6.1 Recommendations for practice 
Improved access to Welfare Benefit Services  
The financial burden of cancer on patients is significant – from reducing working hours or 
stopping work entirely, to paying towards additional costs of utility bills and travel 
expenses for frequent specialist appointments (Pearce et al., 2001). In addition, this thesis 
has confirmed that people with lower levels of annual household income and who claim 
higher levels of benefits are at an increased risk of dying following a diagnosis of head 
and neck cancer. Therefore, in a cohort of patients who were already more at risk of 
developing head and neck cancer due to their socioeconomic position, these patients are 
not only more likely to have the diagnosis of cancer and consequently have to endure the 
gruelling treatment regimens of living with cancer, this thesis has confirmed that these 
patients are also at a higher risk of dying following their diagnosis of head and neck 
cancer. For those who were already more likely to be of more deprived demographics, the 
financial burden of a diagnosis of head and neck cancer on these patients is therefore 
substantial.  
Macmillan Cancer Support provides thorough information on where financial assistance 
may be claimed by cancer patients, including those with head and neck cancer, to assist 
with the additional costs of living with cancer (Macmillan Cancer Support, 2020). This 
includes detailed information on claiming benefits (such as low-income benefits, disability 
benefits, and benefits for people of pension age), help with children’s costs (such as 
Disability Living Allowance), help with bills and housing costs (such as Universal Credit 
and Housing Benefits), and help with health costs (such as financial assistance grants 
from Macmillan Cancer Support). However, in an earlier systematic review by Adams et 
al. (2006), among those who had been referred to welfare advice services, it was found 
that there was substantial underclaiming of welfare benefits across all healthcare settings.  
More recently welfare benefit services have been embedded into clinical and oncological 
care settings (The Beatson, 2021), and are available on referral from local authorities or 
other charitable organisations (Moffatt et al., 2010). Further development, and evaluation 
where services already exist, of welfare benefit programmes linked specifically to head 
and neck cancer services needs to be undertaken to encourage, enable, and ensure that 
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these people are taking up the support that they are entitled to. In particular, these 
services need to effectively target those who are most likely to benefit from these 
programmes, such as those who have a lower income or are from more deprived 
communities.  
Improved assessment of socioeconomic circumstances at the time of diagnosis 
Rogers and colleagues (2014) have produced a Patient Concerns Inventory, developed 
for head and neck cancer clinics to assist patients in highlighting any concerns they may 
have, or to indicate whether they wish to see other services within the Multidisciplinary 
Team (Rogers and Lowe, 2014; Rogers et al., 2016a). They reported that the Patient 
Concerns Inventory was found to be suitable for use in clinic by both patients and staff, 
and two thirds of the patients found that the inventory helped them communicate their 
concerns with their consultant. For the above-mentioned improvements to welfare benefit 
services to be able to become more effective at targeting the patients who are most at 
need of these services, the recording of social and economic variables at the time of 
diagnosis as part of a holistic assessment could be undertaken for all patients with a new 
diagnosis of head and neck cancer. Further assessments could be incorporated to collect 
detailed information on patients’ financial position before, during, and after a diagnosis of 
and treatment for head and neck cancer, including information about their annual 
household income, whether they are claiming any income from benefits, and whether their 
income has reduced as a result of their diagnosis of cancer. This would not only allow for 
targeted interventions to ensure those with lower levels of income are able to access and 
take up the welfare benefits that they are entitled to but would also allow further 
investigations into these existing inequalities to be undertaken for future comparative 
research.  
Improved smoking cessation services and alcohol prevention services 
Tobacco use and alcohol consumption to some extent explained the inequalities that were 
observed in the survival of people with head and neck cancer observed in the thesis. It is 
currently good practice to refer head and neck cancer patients who are tobacco and 
alcohol users to smoking or alcohol cessation services. For example, the current Scottish 
Quality Performance Indicator for head and neck cancer records referral to smoking 
cessation services (Healthcare Improvement Scotland, 2013). However, it is not possible 
to routinely determine how many patients take up this service and as a result, a referral is, 
to some extent, a passive process. Therefore, more engaging or embedded prevention 
advice services following NICE guidelines within the head and neck cancer team may be 
more effective, including considering these services as part of the allied health and clinical 
services for people with head and neck cancer (NICE, 2011a; NICE, 2018). Furthermore, 
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these prevention services could be extended to include alcohol brief interventions, which 
have been shown to be effective in primary care settings (O'Donnell et al., 2014). 
6.6.2 Recommendations for policy  
Primary prevention of tobacco use 
Despite reduced rates of smoking in Scotland and across the UK (Scottish Government, 
2020), inequalities in the distribution of smoking remain wide, with higher levels of 
smoking observed in communities that are of a more deprived classification. Further 
primary prevention and policy control is therefore warranted. In 2008, the Scottish 
Government introduced a smoking prevention action plan: Scotland’s Future is Smoke 
Free. Despite the ban on smoking in public places which was introduced in Scotland in 
2006, and the increase in the age of sale of tobacco products from 16 to 18 in 2007, the 
Scottish Government remains committed to improving mechanisms that will ultimately 
discourage children and young adults from taking up smoking. The Scottish Government 
aimed to target school children by using a holistic approach to health and wellbeing in 
Scottish schools through the Health Promoting School and a Curriculum of Excellence 
(Scottish Government, 2008c). The plan has been reviewed every five years, and ten 
years on, Raising Scotland’s tobacco-free generation (Scottish Government, 2018c) aims 
for a “tobacco-free” generation by 2034 (defined as a rate of smokers of 5% or less). 
Across the rest of the UK, in 2019 the UK Government announced ambitions for England 
to be “smoke-free” by 2030 (as defined by a smoking rate of 6% or less) with the aim to 
publish a new Tobacco Control Plan for England in July 2021.  
Action on Smoking and Health (ASH) (2019) provide the secretariat for the All Party 
Parliamentary Group (APPG) on Smoking and Health. The aim of the APPG is to “monitor 
and discuss the health and social effects of smoking; to review potential changes in 
existing legislation to reduce levels of smoking; to assess the latest medical techniques to 
assist in smoking cessation; and to act as a resource for the group’s members on all 
issues relating to smoking and public health”. The No Tobacco unit (TFI) section of the 
Department of Health and Promotion at the WHO works closely with countries across the 
globe to plan and implement tobacco control activities (World Health Organization (WHO), 
2019) with the aim to reduce the burden of tobacco smoking on health. These actions 
need to continue to be pushed forward with the aim to improve health, protect future 
generations, and ultimately, reduce inequality. 
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Primary prevention of alcohol consumption 
In 2018, the Scottish Government introduced a minimum price of 50 pence per unit of 
alcohol with the aim to “save lives, reduce hospital admissions and, ultimately, have 
positive impacts across the whole health system in Scotland” (Scottish Government, 
2018a). As a result, this minimum pricing per unit of alcohol aims to ensure that alcohol is 
sold at sensible prices by leading to drinks with higher alcoholic percentages being sold at 
higher unit values. Within 20 years, the Scottish Government had modelled that this will 
lead to 120 fewer alcohol-related deaths per year and 2,000 fewer alcohol-related hospital 
admissions per year (Angus et al., 2016; Scottish Government, 2018a). Additionally, the 
Alcohol Framework 2018: Preventing Harm from Improving Scotland’s Health (Scottish 
Government, 2018b) aims to evaluate the impact of the introduction of the minimum unit 
pricing.  
Socioeconomic reform 
The Scottish Government has long aimed to improve life expectancy at birth in the most 
deprived regions of Scotland from the Achieving Our Potential: A Framework to tackle 
poverty and income inequality in Scotland (Scottish Government, 2008a). The Equally 
Well report of the ministerial Task Force on health inequalities in Scotland was launched 
in 2008 with the aim of tackling the significant health inequalities in Scotland (Scottish 
Government, 2008b). The Task Force aims to understand the underlying causes of health 
inequalities in Scotland to be able to take action to make Scotland “Smarter, Wealthier 
and Fairer, Greener, Safer and Stronger and, ultimately, Healthier”. Health Inequalities 
Policy Review for the Scottish Ministerial Task Force on Health Inequalities (Beeston et 
al., 2014) was set up to describe the underlying factors that drive inequalities in health in 
Scotland and “commends the policy principle of proportionate universalism (the whole 
population having access as of right to benefits and opportunities, but greater investment 
for those in more disadvantaged circumstances) and notes that policies to reduce 
inequalities in health need to extend beyond health care to cover numerous other sectors 
such as environmental regulation, and education, housing, employment, welfare and 
transport needs”. The report highlights that downstream interventions to tackle inequality 
which rely on individual engagement are likely to be ineffective compared to more 
upstream interventions by improving environments and life circumstances of people from 
more deprived areas.  
The Institute of Health Equity aims to highlight the social determinants of health and 
improve health equity by considering four areas including “influencing global, national and 
local policies; advising on and learning from practice; building the evidence base; and 
capacity building” (Institute of Health Equity, 2021). The Marmot Review: Fair Society, 
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Healthy Lives reported that people in England could have lived between 1.3 and 2.5 
million additional years of life had premature deaths due to health inequalities not existed 
(Marmot et al., 2010). The report outlined that six key objectives needed to be tackled to 
reduce health inequalities which included: “give every child the best start in life; enable all 
children, young people and adults to maximise their capabilities to have control over their 
lives; create fair employment and good work for all; ensure healthy standard of living for 
all; create and develop healthy and sustainable places and communities; strengthen the 
role and impact of ill health prevention” (Marmot et al., 2010).  
Improved surveillance for head and neck cancer diagnoses 
The Scottish Cancer Registry is collected by the Information Service Division of the NHS 
Scotland (now Public Health Scotland), with the aim to “collect, validate, analyse and store 
accurate, timely and comprehensive data on cancer” (ISD Scotland, 2010b). The 
database holds information such as personal and demographic data, and details on the 
tumour diagnosis, including the anatomical site of the tumour and its histology. However, 
detailed information on the person’s tumour, including vital information on the stage of 
their tumour, is not collected for those with head and neck cancer malignancies. Staging 
information is currently collected for people with cancers of the breast, colorectum, or 
cervix, however due to the complex nature of cancers of the head and neck, which often 
present at various stages, depending on the anatomical subsite of the head and neck that 
the primary tumour is found, this information would be invaluable to future research 
involving head and neck cancer. In addition, due to the association of HPV and head and 
neck cancer, it would be important to consider this alongside all new diagnoses, 
particularly for those with cancer of the oropharynx.  
Assessing the impact of COVID-19 on cancer outcomes and inequality in survival 
The recommended referral time for a cancer screening examination in the UK is two 
weeks (NICE, 2021). However, in June 2020 following the peak of the COVID-19 
pandemic, more than 2.4 million people in the UK were awaiting vital cancer screening, 
tests, or treatment for their cancer due to the disruption that COVID-19 has caused on 
cancer services in the UK (Cancer Research UK, 2020). This included approximately 2.1 
million people awaiting cancer screening tests, nearly 300,000 people waiting for an 
urgent referral to a cancer team, and more than 21,000 people awaiting treatment for their 
cancer (Cancer Research UK, 2020). In October 2020, there were more than nine times 
the usual amount of people waiting six weeks or more for endoscopy test, and 11 times 
more people waiting six weeks or more for radiology tests (such as MRI and CT scans) for 
cancer diagnostics (NHS England, 2021). Prompt screening and early diagnosis of cancer 
leads to improved treatment outcomes and therefore, improved survival. Data on the 
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impact of the COVID-19 pandemic on cancer diagnostics, treatment, and prognosis are 
yet to be available, including survival and inequality in survival of people with head and 
neck cancer, but there are likely to be significant impacts. It is imperative that the impact 
of COVID-19 on survival outcomes of cancer diagnoses is thoroughly monitored and 
evaluated immediately following the COVID-19 pandemic, including comparisons of 
inequality in survival of people with cancer. However, the recovery of services needs to be 
prioritised, including re-establishing the primary care and secondary care interfaces.  
6.6.3 Recommendations for further research  
Further evaluation of welfare benefit programmes 
Further evaluation of welfare benefit programmes that are presently linked to head and 
neck cancer services need to be undertaken to explore whether the patients are 
encouraged, and are able, to take up the support that they are entitled to. In particular, 
research needs to be undertaken to ensure that those who are most likely to benefit from 
these programmes, such as those who have a lower income or are from more deprived 
communities, are having these discussions with healthcare professionals, including the 
best means to approach people of these demographics.  
Quality Performance Indicators 
The intentions with the Scottish Cancer Registry study were to link the data to the new 
Quality Performance Indicators which provide detailed information in several prognostic 
indicators of head and neck cancer. This linkage would have allowed the opportunity to 
explore underlying drivers of socioeconomic inequality in survival of people with head and 
neck cancer in Scotland in recent years. In addition, the linkage would have allowed for 
pilot studies to establish a framework for future evaluations into the impact of the 
introduction of the QPIs on inequality in survival of people with head and neck cancer. 
However, limitations and delays around the access of the Quality Performance Indicators 
meant that only the East of Scotland data were available at the time of these analyses, 
and so this analysis was not possible within the scope of the thesis – although this work is 
still a recommended next step for research in this area.  
SMR00 and SMR01 data linkage 
Further analyses with the Scottish Cancer Registry could investigate linkage to SMR00 
and SMR01 databases, which include detailed information on inpatient and outpatient 
treatment. This could allow further analyses on diagnoses and hospital admissions for 
other conditions to infer alcohol-related comorbidities and smoking-related comorbidities. 
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These data could be extracted to investigate the effects of specific comorbidities on 
inequality in survival of people with head and neck cancer.  
Further research with the HN5000 cohort 
The HN5000 cohort study provided valuable knowledge on several measurements of 
individual and area-based socioeconomic status. However, since the study was so recent, 
this meant that only short-term follow-up was provided. Therefore, future research into 
socioeconomic inequality in survival could be performed to explore the effects of inequality 
at five years and longer when the database has matured. In addition, further outcomes 
could be explored with the HN5000 cohort that related to inequalities in survival and 
quality of life.  
The HEAD and neck cancer in South America and Europe (HEADSpAcE) study 
The HEADSpAcE study is a project that is funded by the European Union Horizon 2020 
programme that brings together a consortium of 15 institutions in the study of head and 
neck cancer from January 2019 (International Agency for Research on Cancer, 2021). 
The HEADSpAcE study will aim to determine the reasons for the late stage at diagnosis of 
people with head and neck cancer, and in particular aims to determine the most 
appropriate method of diagnosing HPV-positive head and neck cancer. In addition, the 
study aims to provide genomic evidence of predictors of outcomes of people with head 
and neck cancer, with the aim to improve care and reduce treatment-related morbidity. 
The HEADSpAcE study will provide a unique opportunity to explore the underlying causes 
of inequality in survival of people with head and neck cancer across the globe, including 
considering various genomic factors. Importantly, a planned workstream will focus on 
inequalities in late stage of diagnosis, and health care system factors associated with late-
stage diagnosis. However, this study is going to be fundamentally impacted by the 
COVID-19 pandemic. 
Between- and within-country comparisons of lower income regions across the 
globe 
Despite the burden of both incidence and mortality of head and neck cancers being 
greatest in lower income countries, particularly in South East Asia (Ferlay et al., 2020), 
there is a lack of research on head and neck cancer survival or outcomes from this part of 
the world. Inequalities between countries exist and are well recognised (International 
Agency for Research on Cancer, 2019), and further research needs to be undertaken to 
investigate inequalities in survival in these regions of the globe, and between countries 
across the world.  
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6.7 Conclusions 
This thesis has examined socioeconomic inequality in survival of people with head and 
neck cancer. First, a thorough literature review was conducted to frame the rationale for 
the thesis, which included studies that investigated inequality in survival of people with 
head and neck cancer in the UK, Europe, the Americas, and other parts of the globe. 
Collectively, it was evident that inequality in survival for people with head and neck cancer 
existed. However, few studies explored the potential underlying explanatory factors for 
inequality in survival of people with head and neck cancer, namely, as per factors that 
might be more modifiable (for example, through behaviours such as smoking and alcohol) 
compared with factors that might be less amenable to control (for example, tumour site, 
stage, and treatment regimens). No study previously aimed to pinpoint the exact potential 
underlying causes of inequality in survival of people with head and neck cancer, and no 
study in the UK explored socioeconomic inequality in survival by utilising individual 
measurements of socioeconomic status or by using the IARC recommended 
measurements for inequality such as the SII or the RII.  
The thesis studied socioeconomic inequality in survival of people with head and neck 
cancer in the UK using data from three sources – the Scottish Cancer Registry, the 
SAHNC cohort study, and the HN5000 cohort study of people in England. As a whole, this 
thesis reported that inequality in survival of people with head and neck cancer is a 
persistent problem, a problem which seems to be getting worse – despite general 
improvements in head and neck cancer survival. Moreover, the main premise of this 
thesis was to explore explanatory factors of socioeconomic inequality in survival of people 
with head and neck cancer. Although socioeconomic inequality in survival utilising an 
area-based measurement of socioeconomic status was explained by various underlying 
factors, inequality by annual household income and the proportion of income from benefits 
only attenuated following the adjustment of all potential explanatory factors for patients in 
England. However, even after full adjustment, inequality in survival by annual household 
income and the proportion of income from benefits could not be explained by any of the 
potential underlying factors that were included in this study. Therefore, further 
investigations considering individual measurements of patients’ income following a 
diagnosis of cancer should be conducted.  
In addition, a number of recommendations were drawn including in relation to developing 
and evaluating welfare benefit services and preventative services within multidisciplinary 
teams; further upstream action on smoking, alcohol, and underlying socioeconomic 
policies; and in a number of directions for future research that are worth considering.  
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This thesis has provided a comprehensive examination of socioeconomic inequalities in 
survival of people with head and neck cancer – a relatively underexplored field. The 
research involved in-depth analyses of multiple datasets and from a number of 
perspectives. It has shown that inequalites in survival are a substantial and growing 
problem, and has endeavored to explore the explanatory factors. This work provides a 
platfrom through which policy and practice development, along with evaluation and 
research, can be based to reduce inequalities in survival and improve outcomes for 
people who are diagnosed with head and neck cancer. 
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Appendix 1.2  – Anatomical subsites of the head and neck based on ICD-10 Version 2010 
Main site 
   Subsite 
ICD-10 
Code 
Malignant neoplasms of lip C00 
   External upper lip    C00.0 
   External lower lip    C00.1 
   External lip, unspecified    C00.2 
   Upper lip, inner aspect    C00.3 
   Lower lip, inner aspect    C00.4 
   Lip, unspecified, inner aspect    C00.5 
   Commissure of lip    C00.6 
   Overlapping lesion of lip    C00.8 
   Lip, unspecified    C00.9 
Malignant neoplasm of base of tongue C01 
Malignant neoplasm of other and unspecified part of tongue C02 
   Dorsal surface of tongue    C02.2 
   Border of tongue    C02.1 
   Ventral surface of tongue    C02.2 
   Anterior two-thirds of tongue, part unspecified    C02.3 
   Lingual tonsil    C02.4 
   Overlapping lesion of tongue    C02.8 
   Tongue, unspecified    C02.9 
Malignant neoplasm of gum C03 
   Upper gum    C03.0 
   Lower gum    C03.1 
   Gum, unspecified    C03.9 
Malignant neoplasm of floor of mouth C04 
   Anterior floor of mouth    C04.0 
   Lateral floor of mouth    C04.1 
   Overlapping lesion of floor of mouth    C04.8 
   Floor of mouth, unspecified    C04.9 
Malignant neoplasm of palate C05 
   Hard palate    C05.0 
   Soft palate    C05.1 
    Uvula    C05.2 
   Overlapping lesion of palate    C05.8 
   Palate, unspecified    C05.9 
Malignant neoplasm of other and unspecified parts of mouth C06 
   Cheek mucosa    C06.0 
   Vestibule of mouth    C06.1 
   Retromolar area    C06.2 
   Overlapping lesion of other and unspecified parts of mouth    C06.8 
   Mouth, unspecified    C06.9 
Malignant neoplasm of parotid gland C07 
Malignant neoplasm of other and unspecified major salivary glands C08 
   Submandibular gland    C08.0 
   Sublingual gland    C08.1 
   Overlapping lesion of major salivary glands    C08.8 
   Major salivary glands, unspecified    C08.9 
Malignant neoplasm of tonsil C09 
   Tonsillar fossa    C09.0 
   Tonsilla pillar (anterior)(posterior)    C09.1 
   Overlapping lesion of tonsil    C09.8 
   Tonsil, unspecified    C09.9 
Malignant neoplasm of oropharynx C10 
   Vallecula    C10.0 
   Anterior surface of epiglottis    C10.1 
   Lateral wall of oropharynx    C10.2 
   Posterior wall of oropharynx    C10.3 
   Branchial cleft    C10.4 
   Overlapping lesion of oropharynx    C10.8 
   Oropharynx, unspecified    C10.9 
Malignant neoplasm of nasopharynx C11 
   Superior wall of nasopharynx    C11.0 
   Posterior wall of nasopharynx    C11.1 
   Lateral wall of nasopharynx    C11.2 
   Anterior wall of nasopharynx    C11.3 
   Overlapping lesion of nasopharynx    C11.8 
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Malignant neoplasm of piriform sinus C12 
Malignant neoplasm of hypopharynx C13 
   Postcricoid region    C13.0 
   Aryepiglottic fold, hypopharyngeal aspect    C13.1 
   Posterior wall of hypopharynx    C13.2 
   Overlapping lesion of hypopharynx    C13.8 
   Hypopharynx, unspecified    C13.9 
Malignant neoplasm of other and ill-defined sites in the lip, oral cavity and pharynx C14 
   Pharynx, unspecified    C14.0 
   Waldeyer ring    C14.2 
   Overlapping lesion of lip, oral cavity, and pharynx    C14.9 
Malignant neoplasm of nasal cavity and middle ear C30 
   Nasal cavity    C30.0 
   Middle ear    C30.1 
Malignant neoplasm of accessory sinuses C31 
   Maxillary sinus    C31.0 
   Ethmoidal sinus    C31.1 
   Frontal sinus     C31.2 
   Sphenoidal sinus    C31.3 
   Overlapping lesion of accessory sinus    C31.8 
   Accessory sinus, unspecified    C31.9 
Malignant neoplasm of larynx C32 
   Glottis    C32.0 
   Supraglottis    C32.1 
   Subglottis    C32.2 
   Laryngeal cartilage    C32.3 
   Overlapping lesion of larynx    C32.8 
   Larynx, unspecified    C32.9 
Malignant neoplasm of other and ill-defined sites C76 
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England, UK Registry data 25,903 







Deprivation had an independent effect on 
survival. 




Registry data 8,671 
Larynx (males 
and females) 
1971-1990 Relative survival 
Carstairs 1991 
Category 
A gap of 9.3% in relative survival between 
those from the least and most deprived 
areas, in favour of the patients from the least 
deprived area.  




Registry data 20,131 
All head and 
neck cancer 
1981-1994 Relative survival 
Carstairs 1991 
Category 
Survival was substantially worse for those 
from the most deprived areas, but not for the 
patients who were below 39 years.  




Registry data 5,666 
Larynx 
(males) 





Deprivation gap of 17% in favour of the least 
deprived, which was the highest of all 
cancers included in the study.  
Shack et al. 
(2007) 
Scotland, UK Registry data 1,128 
Larynx 
(males) 




Deprivation gap was 11% and became wider 
by approximately 3% every five years.  
Warnakulasuriya 
et al. (2007) 




Difference in survival, favouring the less 
deprived group. However, socioeconomic 
inequality attenuated following adjustment for 
stage and treatment.  




Registry data  5,666 
Larynx 
(males) 





Deeper look into earlier study which reported 
a deprivation gap of 17%. This study 
reported that this gap increased by 3.7% 
every five years. The gap in 10-year survival 
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Anandan et al. 
(2008) 
Scotland, UK Registry data 556 Nasopharynx 1975-2001 Relative survival 
Carstairs 1991 
Category 
Difference between those from the least 
deprived and most deprived areas, with 
survival in favour of those who were least 
deprived. 
Robertson et al. 
(2010) 
Scotland, UK SAHNC 1,901 









The patients from the most deprived area 
experienced a 33% increased risk of all-
cause mortality. However, following 
adjustment for WHO Performance Status, 
stage, age, anatomical site, smoking status 
and alcohol consumption, SES was no 
longer an independent predictor of survival.  
Ellis et al. (2012) 
England and 
Wales, UK 
Registry data 29,420 
Larynx (males 
and females) 
1991-2006 Relative survival 
IMD/WIMD 
Categories 
No difference in survival between the least 
deprived and most deprived females. 
However, difference was much clearer for 
males with a deprivation gap of 7% and 13% 
after one and five years, respectively. 





523 Oral cavity 2008-2012 Overall survival IMD Category No gradient in survival across IMD quintiles.  
Rosso et al. 
(1996) 
Italy, Europe Registry data 568 
All head and 
neck cancer 
1985-1987 Case fatality ratio Education No trend by education was apparent.  
Boffetta et al. 
(1997) 
Italy, Europe Unclear 355 Larynx 1979-1982 Overall survival 
Education and 
occupation 
A statistically insignificant association 
between education level and survival 
following adjustment for anatomical site, 
stage, and smoking.  






All head and 
neck cancer 
1994-1996 Overall survival 
Income and 
occupation 
A statistically insignificant association 
between family income and occupational 
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Registry data 4,857 
All head and 
neck cancer 
1994-2003 Relative survival 
Education, income, 
work market, social 
class, housing 
tenure, dwelling 
size, district type 
Improved survival observed for most patients 
who had higher levels of education, higher 
levels of income, were homeowners and 
lived-in larger dwelling sizes.  




Registry data 3,928 
All head and 
neck cancer 
1987-2013 Relative survival 
Household income 
the year prior to 
diagnosis 
Improvement in survival more prominent in 
those who had higher income levels, 
particularly for those with cancer of the head 
and neck. Inequality in survival of people 
with head and cancer had increased over 
time.  
Konski et al. 
(2003) 
USA RCT 1,073 
All head and 
neck cancer - 
advanced 
stage 




Improved survival for those who had 
graduated from high school or had a general 





















No difference observed between those who 
resided in areas of lower or higher education 
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All head and 
neck cancer 
1998-2002 Overall survival 
Neighbourhood-
level: poverty 
Area-based socioeconomic status was an 
independent predictor of survival following 
adjustment for participant demographics 
(age, gender, race, ethnicity, tobacco use 
and alcohol consumption), comorbidities, 
clinical characteristics (tumour grade, stage, 
and location of treatment) and treatment 
modality. 
Chu et al. (2011) 
California, 
USA 
Registry data 53,544 
All head and 
neck cancer 





Those who were of lower socioeconomic 
status were more at risk of cancer-specific 
deaths, and those with cancer of the 
oropharynx had the greatest difference in 
survival between the lowest and highest 
socioeconomic groups. This association 
continued to be significant after the 
adjustment for additional baseline covariates 
including stage, age, and year of diagnosis. 
















For those with oropharyngeal cancer, a high 
level of neighbourhood deprivation was 
associated with poor overall survival even 
following the adjustment of additional 
covariates such as age, sex, stage, smoking 
status, and annual household income.  













Following adjustment for demographic and 
clinical information, socioeconomic inequality 
remained between those who resided in the 
poorer areas of Florida, who had a 
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Megwalu (2017) USA 
SEER 
Database 







Worse five-year overall and disease-specific 
survival was observed for people residing in 
areas with lower rates of high school 
completion, bachelor’s degree completion, 
percentage of families living below the 
poverty line, high unemployment rates, low 
percentage of individuals working in white-
collar professions and low socioeconomic 
indices. Multivariate analysis was performed 
which confirmed that this observation 
remained for people from low socioeconomic 
neighbourhoods following adjustment for 
age, sex, race, marital status, year of 
diagnosis, cancer site, stage, and treatment.  




All head and 










Those who resided in areas of lower median 
income had a lower overall survival and 
disease-specific survival in multivariate 
analyses following the adjustment for age, 
sex, race, marital status, insurance status, 
cancer subsite, stage, and treatment. 











and high school 
diploma 
Clear trend in survival across median 
household income groups – those who 
resided in areas of lower median household 
income had a lower overall survival than 
those who live in areas of higher median 
household incomes. The same trend was 
also apparent for those who resided in areas 
with a lower proportion high school diploma 
attainment. Following the adjustment for 
insurance status, race, comorbidity, cancer 
site and stage, the socioeconomic inequality 
no longer remained for either median 
household income or the proportion of 
people who attained a high school diploma.  
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The participants who resided in areas with 
lower median household income had poorer 
90-day survival following adjustment for 
comorbidity, stage, tumour site, HPV status, 
facility type, waiting times for treatment and 
treatment type. 




Registry data 15,731 
All head and 
neck cancer 
1982-1991 Overall survival 
Median household 
income 
Strong associations between income and 
overall survival for people with head and 
neck cancer, favouring those with higher 
levels of income. In addition, those who 
earned lower income also experienced 
higher rates of death. 









The authors reported cause-specific survival 
and discovered that the individuals with 
cancer of the glottis who resided in areas of 
lower income had substantially worse 
survival than those who were from areas of 
higher income. However, this difference was 
not clear for those with cancer of the 
supraglottic. 










Small difference across the median income 
groups for overall survival and disease-
specific survival for those who were recorded 
in the Ontario Cancer Registry. Results for 
the individuals who were diagnosed in 
Regional Cancer Centres did not 
demonstrate substantial differences in 
overall and disease-specific survival across 




Appendix 1.3 continued – Summary of all of the studies from the literature review on socioeconomic inequality in survival of people with head and neck 
cancer 
McDonald et al. 
(2014) 
Canada Registry data 30,228 
All head and 
neck cancer 
1992-2005 Overall survival 
Average household 
income 
Lower income was strongly associated with 
worse survival outcomes for all those with 
head and neck cancer. Gap in 
socioeconomic inequality increased over 
time.  
















Significantly better disease-specific survival 
for men with cancer of the oropharynx who 
resided in affluent areas. 






All head and 
neck cancer 
2003-2010 Overall survival 
Neighbourhood-
level SES 
Although low socioeconomic status was 
associated with poorer survival in a 
univariate model, it was no longer associated 
with poorer survival following the adjustment 
for other variables including age, gender, 
stage, comorbidity, smoking status, alcohol 
use and HPV type 16 status. 
















For people with cancer of the oral cavity, 
oropharynx, and hypopharynx the risk of 
death from head and neck cancer increased 
as the number of years the participant spent 
in education increased. However, the results 
were contrasting for those with cancer of the 
larynx since these people had a lower risk of 
disease-specific mortality as the number of 





Appendix 1.3 continued – Summary of all of the studies from the literature review on socioeconomic inequality in survival of people with head and neck 
cancer 


















In a univariate Cox proportional hazards 
model, those who were “illiterate” were 44% 
more at risk of all-cause mortality compared 
to those with “superior” education levels (HR 
= 1.44, 95% CI = 0.63 to 3.32). However, in a 
multivariate model including age, sex, rate, 
cancer stage, smoking history, alcohol 
consumption and anatomical site, education 
level was no longer a predictor of survival.   





1,010 Oral cavity 1995-2002  Overall survival Education level 
No observed difference in survival between 
those who had varying levels of education. 




defined by the 
labour enrolee 
category as part of 
an insurance fee 
submission, and 
neighbourhood-
level SES from the 
Taiwan census 
Differences between the socioeconomically 
advantaged and disadvantaged groups, with 
survival favouring the advantaged groups. In 
addition, people of lower socioeconomic 
position remained at a higher risk of all-
cause mortality following adjustment for age, 
gender, comorbidity, urbanisation, area of 
residence, treatment modality, hospital 
characteristics and year of diagnosis. 
Chang et al. 
(2013) 
Taiwan NHIRB 4,691 Nasopharynx 2002-2006  Overall survival 
Individual-level 
defined by the 
labour enrolee 
category as part of 
an insurance fee 
submission, and 
neighbourhood-
level SES from the 
Taiwan census 
Socioeconomic status remained a significant 
predictor of survival when adjusting by 
factors including age, gender, comorbidity, 
urbanisation, area of residence, treatment, 




Appendix 1.3 continued – Summary of all of the studies from the literature review on socioeconomic inequality in survival of people with head and neck 
cancer 
Chien et al. 
(2018) 




1992-2011 Net survival Income 
The authors investigated five-year net 
survival proportions and reported that 
socioeconomic inequality existed for people 
with cancer of the larynx, oral cavity, and 
oropharynx. 
Lai et al. (2018) Taiwan NHIRB 40,985 
 All head and 
neck cancer 
2000-2013 Overall survival Income 
The authors reported that low income or 
living in residential areas of lower 
socioeconomic status had a detrimental 
effect on survival, regardless of the location 
in Taiwan that the person lived. 
Yu et al. (2008) Australia Registry data 6,331 
 All head and 
neck cancer 




derived from the 
1996 Census 
The authors confirmed socioeconomic 
inequality in five-year relative survival for 
both men and women from an area-based 
measurement of socioeconomic status. 
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Died by 30th September 
2017 (Row %) 
Total 17,508 (100.0%) 13,040 (74.5%) 
Age at incidence   
   Less than 45 903 (5.2%) 395 (43.7%) 
   45 to 54 3,212 (18.3%) 1,992 (62.0%) 
   55 to 64 5,694 (32.5%) 4,126 (72.5%) 
   65 to 74 5,008 (28.6%) 4,081 (81.5%) 
   75 and over 2,691 (15.4%) 2,446 (90.9%) 
ICD group   
   Oral cavity 5,162 (29.5%) 3,849 (74.6%) 
   Larynx 6,133 (35.0%) 4,632 (75.5%) 
   Oropharynx 2,437 (13.9%) 1,569 (64.4%) 
   Hypopharynx 1,190 (6.8%) 1,084 (91.1%) 
   Lip 1,009 (5.8%) 695 (68.9%) 
   Salivary gland 603 (3.4%) 409 (67.8%) 
   Other 974 (5.6%) 802 (82.3%) 
Pathology   
   SCC 15,448 (88.2%) 11,570 (74.9%) 
   Non-SCC 2,060 (11.8%) 1,470 (71.4%) 
Treatment   
   Surgery only 2,823 (16.1%) 1,507 (53.4%) 
   Radiotherapy only 2,346 (13.4%) 1,608 (68.5%) 
   Surgery and radiotherapy 1,904 (10.9%) 1,362 (71.5%) 
   Chemoradiotherapy 1,873 (10.7%) 1,125 (60.1%) 
   Surgery and chemoradiotherapy 1,147 (6.6%) 647 (56.4%) 
   Chemotherapy +/- surgery 403 (2.3%) 323 (80.1%) 
   No treatment 1,211 (6.9%) 1,130 (93.3%) 
   Unknown 5,801 (33.1%) 5,338 (92.0%) 
Year group   
   1986-1990 2,280 (13.0%) 2,154 (94.5%) 
   1991-1995 2,694 (15.4%) 2,468 (91.6%) 
   1996-2000 2,925 (16.7%) 2,516 (86.0%) 
   2001-2005 2,962 (16.9%) 2,270 (76.6%) 
   2006-2010 3,202 (18.3%) 2,056 (64.2%) 
   2011-2015 3,445 (19.7%) 1,576 (45.7%) 
Network of residence   
   West of Scotland (WoSCAN) 9,095 (51.9%) 7,016 (77.1%) 
   East of Scotland (SCAN) 4,311 (24.6%) 3,055 (70.9%) 
   North of Scotland (NOSCAN) 4,102 (23.4%) 2,969 (72.4%) 
Carstairs 1991 Category   
   1 – Least deprived 2,506 (14.3%) 1,686 (67.3%) 
   2 3,109 (17.8%) 2,201 (70.8%) 
   3 3,403 (19.4%) 2,527 (74.3%) 
   4 3,720 (21.2%) 2,801 (75.3%) 








Died by 30th September 
2017 (Row %) 
Total 7,270 (100.0%) 5,282 (72.7%) 
Age at incidence   
   Less than 45 479 (6.6%) 146 (30.5%) 
   45 to 54 1,026 (14.1%) 561 (54.7%) 
   55 to 64 1,907 (26.2%) 1,292 (67.8%) 
   65 to 74 1,980 (27.2%) 1,582 (79.9%) 
   75 and over 1,878 (25.8%) 1,701 (90.6%) 
ICD group   
   Oral cavity 3,027 (41.6%) 2,179 (72.0%) 
   Larynx 1,573 (21.6%) 1,222 (77.7%) 
   Oropharynx 942 (13.0%) 635 (67.4%) 
   Hypopharynx 396 (5.4%) 363 (91.7%) 
   Lip 370 (5.1%) 253 (68.4%) 
   Salivary gland 572 (7.9%) 311 (54.4%) 
   Other 390 (5.4%) 319 (81.8%) 
Pathology   
   SCC 5,955 (81.9%) 4,473 (75.1%) 
   Non-SCC 1,315 (18.1%) 809 (61.5%) 
Treatment   
   Surgery only 1,561 (21.5%) 771 (49.4%) 
   Radiotherapy only 750 (10.3%) 553 (73.7%) 
   Surgery and radiotherapy 858 (11.8%) 555 (64.7%) 
   Chemoradiotherapy 539 (7.4%) 305 (56.6%) 
   Surgery and chemoradiotherapy 355 (4.9%) 185 (52.1%) 
   Chemotherapy +/- surgery 149 (2.0%) 116 (77.9%) 
   No treatment 617 (8.5%) 597 (96.8%) 
   Unknown 2,441 (33.6%) 2,200 (90.1%) 
Year group   
   1986-1990 977 (13.4%) 879 (90.0%) 
   1991-1995 1,066 (14.7%) 978 (91.7%) 
   1996-2000 1,226 (16.9%) 1,035 (84.4%) 
   2001-2005 1,264 (17.4%) 942 (74.5%) 
   2006-2010 1,317 (18.1%) 819 (62.2%) 
   2011-2015 1,420 (19.5%) 629 (44.3%) 
Network of residence   
   West of Scotland (WoSCAN) 3,755 (51.7%) 2,818 (75.0%) 
   East of Scotland (SCAN) 1,843 (25.4%) 1,307 (70.9%) 
   North of Scotland (NOSCAN) 1,672 (23.0%) 1,157 (69.2%) 
Carstairs 1991 Category   
   1 – Least deprived 1,117 (15.4%) 722 (64.6%) 
   2 1,378 (19.0%) 979 (71.0%) 
   3 1,415 (19.5%) 1,023 (72.3%) 
   4 1,536 (21.1%) 1,149 (74.8%) 




Appendix 2.5 – Baseline characteristics and proportion of deaths for people with cancer of 




Died by 30th September 
2017 (Row %) 
Total 8,189 (100.0%) 6,028 (73.6%) 
Age at incidence   
   Less than 45 508 (6.2%) 220 (43.3%) 
   45 to 54 1,481 (18.1%) 930 (62.8%) 
   55 to 64 2,438 (29.8%) 1,717 (70.4%) 
   65 to 74 2,191 (26.8%) 1,738 (79.3%) 
   75 and over 1,571 (19.2%) 1,423 (90.6%) 
Sex   
   Male 5,162 (63.0%) 3,849 (74.6%) 
   Female 3,027 (37.0%) 2,179 (72.0%) 
Pathology   
   SCC 7,397 (90.3%) 5,498 (74.3%) 
   Non-SCC 792 (9.7%) 530 (66.9%) 
Treatment   
   Surgery only 2,327 (28.4%) 1,182 (50.8%) 
   Radiotherapy only 424 (5.2%) 373 (88.0%) 
   Surgery and radiotherapy 1,014 (12.4%) 758 (74.8%) 
   Chemoradiotherapy 579 (7.1%) 315 (54.4%) 
   Surgery and chemoradiotherapy 524 (6.4%) 321 (61.3%) 
   Chemotherapy +/- surgery 161 (2.0%) 127 (78.9%) 
   No treatment 638 (7.8%) 613 (96.1%) 
   Unknown 2,522 (30.8%) 2,339 (92.7%) 
Year group   
   1986-1990 954 (11.6%) 906 (95.0%) 
   1991-1995 1,177 (14.4%) 1,092 (92.8%) 
   1996-2000 1,319 (16.1%) 1,151 (87.3%) 
   2001-2005 1,460 (17.8%) 1,110 (76.0%) 
   2006-2010 1,597 (19.5%) 1,016 (63.6%) 
   2011-2015 1,682 (20.5%) 753 (44.8%) 
Network of residence   
   West of Scotland (WoSCAN) 4,208 (51.4%) 3,197 (76.0%) 
   East of Scotland (SCAN) 2,060 (25.2%) 1,465 (71.1%) 
   North of Scotland (NOSCAN) 1,921 (23.5%) 1,366 (71.1%) 
Carstairs 1991 Category   
   1 – Least deprived 1,278 (15.6%) 840 (65.7%) 
   2 1,520 (18.6%) 1,061 (69.8%) 
   3 1,575 (19.2%) 1,150 (73.0%) 
   4 1,714 (20.9%) 1,301 (75.9%) 









Died by 30th September 
2017 (Row %) 
Total 3,379 (100.0%) 2,204 (65.2%) 
Age at incidence   
   Less than 45 209 (6.2%) 79 (37.8%) 
   45 to 54 860 (25.5%) 427 (49.7%) 
   55 to 64 1,202 (35.6%) 783 (65.1%) 
   65 to 74 779 (23.1%) 616 (79.1%) 
   75 and over 329 (9.7%) 299 (90.9%) 
Sex   
   Male 2,437 (72.1%) 1,569 (64.4%) 
   Female 942 (27.9%) 635 (67.4%) 
Pathology   
   SCC 3,010 (89.1%) 2,005 (66.6%) 
   Non-SCC 369 (10.9%) 199 (53.9%) 
Treatment   
   Surgery only 319 (9.4%) 173 (54.2%) 
   Radiotherapy only 373 (11.0%) 277 (74.3%) 
   Surgery and radiotherapy 384 (11.4%) 232 (60.4%) 
   Chemoradiotherapy 694 (20.5%) 338 (48.7%) 
   Surgery and chemoradiotherapy 512 (15.2%) 166 (32.4%) 
   Chemotherapy +/- surgery 124 (3.7%) 90 (72.6%) 
   No treatment 253 (7.5%) 249 (98.4%) 
   Unknown 720 (21.3%) 679 (94.3%) 
Year group   
   1986-1990 272 (8.0%) 258 (94.9%) 
   1991-1995 332 (9.8%) 316 (95.2%) 
   1996-2000 468 (13.9%) 396 (84.6%) 
   2001-2005 541 (16.0%) 396 (73.2%) 
   2006-2010 751 (22.2%) 446 (59.4%) 
   2011-2015 1,015 (30.0%) 392 (38.6%) 
Network of residence   
   West of Scotland (WoSCAN) 1,686 (49.9%) 1,163 (69.0%) 
   East of Scotland (SCAN) 855 (25.3%) 529 (61.9%) 
   North of Scotland (NOSCAN) 838 (24.8%) 512 (61.1%) 
Carstairs 1991 Category   
   1 – Least deprived 511 (15.1%) 289 (56.6%) 
   2 647 (19.1%) 390 (60.3%) 
   3 645 (19.1%) 414 (64.2%) 
   4 703 (20.8%) 473 (67.3%) 









Died by 30th September 
2017 (Row %) 
Total 7,706 (100.0%) 5,854 (76.0%) 
Age at incidence   
   Less than 45 210 (2.7%) 96 (45.7%) 
   45 to 54 1,123 (14.6%) 704 (62.7%) 
   55 to 64 2,513 (32.6%) 1,817 (72.3%) 
   65 to 74 2,513 (32.6%) 2,027 (80.7%) 
   75 and over 1,347 (17.5%) 1,210 (89.8%) 
Sex   
   Male 6,133 (79.6%) 4,632 (75.5%) 
   Female 1,573 (20.4%) 1,222 (77.7%) 
Pathology   
   SCC 7,076 (91.8%) 5,305 (75.0%) 
   Non-SCC 630 (8.2%) 549 (87.1%) 
Treatment   
   Surgery only 671 (8.7%) 376 (56.0%) 
   Radiotherapy only 1,914 (24.8%) 1,169 (61.1%) 
   Surgery and radiotherapy 844 (11.0%) 583 (69.1%) 
   Chemoradiotherapy 507 (6.6%) 331 (65.3%) 
   Surgery and chemoradiotherapy 242 (3.1%) 179 (74.0%) 
   Chemotherapy +/- surgery 104 (1.3%) 86 (82.7%) 
   No treatment 493 (6.4%) 435 (88.2%) 
   Unknown 2,931 (38.0%) 2,695 (91.9%) 
Year group   
   1986-1990 1,131 (14.7%) 1,075 (95.0%) 
   1991-1995 1,345 (17.5%) 1,230 (91.4%) 
   1996-2000 1,392 (18.1%) 1,189 (85.4%) 
   2001-2005 1,320 (17.1%) 1,009 (76.4%) 
   2006-2010 1,303 (16.9%) 812 (62.3%) 
   2011-2015 1,215 (15.8%) 539 (44.4%) 
Network of residence   
   West of Scotland (WoSCAN) 4,227 (54.9%) 3,296 (78.0%) 
   East of Scotland (SCAN) 1,932 (25.1%) 1,397 (72.3%) 
   North of Scotland (NOSCAN) 1,547 (20.1%) 1,161 (75.0%) 
Carstairs 1991 Category   
   1 – Least deprived 938 (12.2%) 668 (71.2%) 
   2 1,245 (16.2%) 938 (75.3%) 
   3 1,513 (19.6%) 1,135 (75.0%) 
   4 1,699 (22.0%) 1,275 (75.0%) 
   5 – Most deprived 2,311 (30.0%) 1,838 (79.5%) 
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Appendix 2.8 – Cross-tabulation of Carstairs 1991 Category with baseline characteristics for males 
Variable 
Carstairs 1991 Category (row %)  
1 – Least 
deprived 2 3 4 





Age at incidence      <0.001 
   Less than 45 142 (5.7%) 167 (5.4%) 174 (5.1%) 188 (5.1%) 232 (4.9%)  
   45 to 54 417 (16.6%) 530 (17.0%) 595 (17.5%) 694 (18.7%) 976 (20.5%)  
   55 to 64 721 (28.8%) 983 (31.6%) 1,124 (33.0%) 1,256 (33.8%) 1,610 (33.8%)  
   65 to 74 715 (28.5%) 899 (28.9%) 957 (28.1%) 1,087 (29.2%) 1,350 (28.3%)  
   75 and over 511 (20.4%) 530 (17.0%) 553 (16.3%) 495 (13.3%) 602 (12.6%)  
ICD group      <0.001 
   Oral cavity 760 (30.3%) 885 (28.5%) 973 (28.6%) 1,086 (29.2%) 1,458 (30.6%)  
   Larynx 789 (31.5%) 1021 (32.8%) 1219 (35.8%) 1,329 (35.7%) 1,775 (37.2%)  
   Oropharynx 363 (14.5%) 456 (14.7%) 457 (13.4%) 531 (14.3%) 630 (13.2%)  
   Hypopharynx 151 (6.0%) 202 (6.5%) 212 (6.2%) 290 (7.8%) 335 (7.0%)  
   Lip 181 (7.2%) 251 (8.1%) 239 (7.0%) 185 (5.0%) 153 (3.2%)  
   Salivary gland 138 (5.5%) 128 (4.1%) 119 (3.5%) 109 (2.9%) 109 (2.3%)  
   Other 124 (4.9%) 166 (5.3%) 184 (5.4%) 190 (5.1%) 310 (6.5%)  
Pathology      <0.001 
   SCC 2,134 (85.2%) 2,714 (87.3%) 2,997 (88.1%) 3,337 (89.7%) 4,266 (89.4%)  
   Non-SCC 372 (14.8%) 395 (12.7%) 406 (11.9%) 383 (10.3%) 504 (10.6%)  
Treatment      <0.001 
   Surgery only 441 (17.6%) 580 (18.7%) 573 (16.8%) 576 (15.5%) 653 (13.7%)  
   Radiotherapy only 381 (15.2%) 376 (12.1%) 459 (13.5%) 500 (13.4%) 630 (13.2%)  
   Surgery and radiotherapy 299 (11.9%) 386 (12.4%) 380 (11.2%) 385 (10.3%) 454 (9.5%)  
   Chemoradiotherapy 232 (9.3%) 327 (10.5%) 352 (10.3%) 433 (11.6%) 529 (11.1%)  
   Surgery and chemoradiotherapy 198 (7.9%) 238 (7.7%) 214 (6.3%) 237 (6.4%) 260 (5.5%)  
   Chemotherapy +/- surgery 52 (2.1%) 52 (1.7%) 93 (2.7%) 82 (2.2%) 124 (2.6%)  
   No treatment 142 (5.7%) 172 (5.5%) 224 (6.6%) 253 (6.8%) 420 (8.8%)  
   Unknown 761 (30.4%) 978 (31.5%) 1,108 (32.6%) 1,254 (33.7%) 1,700 (35.6%)  
Network      <0.001 
   West of Scotland (WoSCAN) 845 (33.7%) 963 (31.0%) 1,360 (40.0%) 1,926 (51.8%) 4,001 (83.9%)  
   East of Scotland (SCAN) 703 (28.1%) 1,001 (32.2%) 1,080 (31.7%) 1,204 (32.4%) 323 (6.8%)  




Appendix 2.9 – Cross-tabulation of Carstairs 1991 Category with baseline characteristics for females 
Variable 
Carstairs 1991 Category (row %)  
1 – Least 
deprived 2 3 4 





Age at incidence      <0.001 
   Less than 45 90 (8.1%) 91 (6.6%) 91 (6.4%) 97 (6.3%) 110 (6.0%)  
   45 to 54 148 (13.2%) 175 (12.7%) 198 (14.0%) 202 (13.2%) 303 (16.6%)  
   55 to 64 256 (22.9%) 335 (24.3%) 356 (25.2%) 437 (28.5%) 523 (28.7%)  
   65 to 74 306 (27.4%) 379 (27.5%) 378 (26.7%) 409 (26.6%) 508 (27.9%)  
   75 and over 317 (28.4%) 398 (28.9%) 392 (27.7%) 391 (25.5%) 380 (20.8%)  
ICD group      <0.001 
   Oral cavity 518 (46.4%) 635 (46.1%) 602 (42.5%) 628 (40.9%) 644 (35.3%)  
   Larynx 149 (13.3%) 224 (16.3%) 294 (20.8%) 370 (24.1%) 536 (29.4%)  
   Oropharynx 148 (13.2%) 191 (13.9%) 188 (13.3%) 172 (11.2%) 243 (13.3%)  
   Hypopharynx 49 (4.4%) 72 (5.2%) 62 (4.4%) 89 (5.8%) 124 (6.8%)  
   Lip 77 (6.9%) 73 (5.3%) 84 (5.9%) 77 (5.0%) 59 (3.2%)  
   Salivary gland 126 (11.3%) 118 (8.6%) 122 (8.6%) 100 (6.5%) 106 (5.8%)  
   Other 50 (4.5%) 65 (4.7%) 63 (4.5%) 100 (6.5%) 112 (6.1%)  
Pathology      <0.001 
   SCC 853 (76.4%) 1,112 (80.7%) 1,138 (80.4%) 1,282 (83.5%) 1,570 (86.1%)  
   Non-SCC 264 (23.6%) 266 (19.3%) 277 (19.6%) 254 (16.5%) 254 (13.9%)  
Treatment      <0.001 
   Surgery only 291 (26.1%) 293 (21.3%) 333 (23.5%) 338 (22.0%) 306 (16.8%)  
   Radiotherapy only 86 (7.7%) 136 (9.9%) 146 (10.3%) 172 (11.2%) 210 (11.5%)  
   Surgery and radiotherapy 142 (12.7%) 181 (13.1%) 174 (12.3%) 152 (9.9%) 209 (11.5%)  
   Chemoradiotherapy 63 (5.6%) 106 (7.7%) 103 (7.3%) 119 (7.7%) 148 (8.1%)  
   Surgery and chemoradiotherapy 64 (5.7%) 72 (5.2%) 76 (5.4%) 68 (4.4%) 75 (4.1%)  
   Chemotherapy +/- surgery 14 (1.3%) 26 (1.9%) 26 (1.8%) 32 (2.1%) 51 (2.8%)  
   No treatment 91 (8.1%) 116 (8.4%) 125 (8.8%) 127 (8.3%) 158 (8.7%)  
   Unknown 366 (32.8%) 448 (32.5%) 432 (30.5%) 528 (34.4%) 667 (36.6%)  
Network      <0.001 
   West of Scotland (WoSCAN) 377 (33.8%) 431 (31.3%) 570 (40.3%) 811 (52.8%) 1,566 (85.9%)  
   East of Scotland (SCAN) 305 (27.3%) 488 (35.4%) 451 (31.9%) 482 (31.4%) 117 (6.4%)  




Appendix 2.10 – Cross-tabulation of Carstairs 1991 Category with baseline characteristics for people with cancer of the oral cavity 
Variable 
Carstairs 1991 Category (row %)  
1 – Least 
deprived 2 3 4 





Age at incidence      <0.001 
   Less than 45 77 (6.0%) 99 (6.5%) 107 (6.8%) 109 (6.4%) 116 (5.5%)  
   45 to 54 218 (17.1%) 235 (15.5%) 293 (18.6%) 293 (17.1%) 442 (21.0%)  
   55 to 64 362 (28.3%) 435 (28.6%) 446 (28.3%) 535 (31.2%) 660 (31.4%)  
   65 to 74 330 (25.8%) 426 (28.0%) 417 (26.5%) 451 (26.3%) 567 (27.0%)  
   75 and over 291 (22.8%) 325 (21.4%) 312 (19.8%) 326 (19.0%) 317 (15.1%)  
Sex      <0.001 
   Male 760 (59.5%) 885 (58.2%) 973 (61.8%) 1,086 (63.4%) 1,458 (69.4%)  
   Female 518 (40.5%) 635 (41.8%) 602 (38.2%) 628 (36.6%) 644 (30.6%)  
Pathology      <0.001 
   SCC 1,136 (88.9%) 1,360 (89.5%) 1,402 (89.0%) 1,545 (90.1%) 1,954 (93.0%)  
   Non-SCC 142 (11.1%) 160 (10.5%) 173 (11.0%) 169 (9.9%) 148 (7.0%)  
Treatment      <0.001 
   Surgery only 413 (32.3%) 439 (28.9%) 463 (29.4%) 495 (28.9%) 517 (24.6%)  
   Radiotherapy only 64 (5.0%) 76 (5.0%) 75 (4.8%) 87 (5.1%) 122 (5.8%)  
   Surgery and radiotherapy 155 (12.1%) 204 (13.4%) 208 (13.2%) 202 (11.8%) 245 (11.7%)  
   Chemoradiotherapy 78 (6.1%) 106 (7.0%) 114 (7.2%) 127 (7.4%) 154 (7.3%)  
   Surgery and chemoradiotherapy 101 (7.9%) 100 (6.6%) 102 (6.5%) 107 (6.2%) 114 (5.4%)  
   Chemotherapy +/- surgery 18 (1.4%) 23 (1.5%) 35 (2.2%) 37 (2.2%) 48 (2.3%)  
   No treatment 92 (7.2%) 105 (6.9%) 121 (7.7%) 126 (7.4%) 194 (9.2%)  
   Unknown 357 (27.9%) 467 (30.7%) 457 (29.0%) 533 (31.1%) 708 (33.7%)  
Network      <0.001 
   West of Scotland (WoSCAN) 435 (34.0%) 468 (30.8%) 626 (39.7%) 899 (52.5%) 1,780 (84.7%)  
   East of Scotland (SCAN) 375 (29.3%) 495 (32.6%) 516 (32.8%) 539 (31.4%) 135 (6.4%)  





Appendix 2.11 – Cross-tabulation of Carstairs 1991 Category with baseline characteristics for people with cancer of the oropharynx 
Variable 
Carstairs 1991 Category (row %)  
1 – Least 
deprived 2 3 4 





Age at incidence      0.45 
   Less than 45 37 (7.2%) 43 (6.6%) 40 (6.2%) 36 (5.1%) 53 (6.1%)  
   45 to 54 121 (23.7%) 167 (25.8%) 170 (26.4%) 161 (22.9%) 241 (27.6%)  
   55 to 64 170 (33.3%) 228 (35.2%) 231 (35.8%) 270 (38.4%) 303 (34.7%)  
   65 to 74 125 (24.5%) 141 (21.8%) 137 (21.2%) 172 (24.5%) 204 (23.4%)  
   75 and over 58 (11.4%) 68 (10.5%) 67 (10.4%) 64 (9.1%) 72 (8.2%)  
Sex      0.22 
   Male 363 (71.0%) 456 (70.5%) 457 (70.9%) 531 (75.5%) 630 (72.2%)  
   Female 148 (29.0%) 191 (29.5%) 188 (29.1%) 172 (24.5%) 243 (27.8%)  
Pathology      <0.001 
   SCC 425 (83.2%) 579 (89.5%) 575 (89.1%) 641 (91.2%) 790 (90.5%)  
   Non-SCC 86 (16.8%) 68 (10.5%) 70 (10.9%) 62 (8.8%) 83 (9.5%)  
Treatment      <0.001 
   Surgery only 42 (8.2%) 66 (10.2%) 63 (9.8%) 63 (9.0%) 85 (9.7%)  
   Radiotherapy only 54 (10.6%) 60 (9.3%) 72 (11.2%) 85 (12.1%) 102 (11.7%)  
   Surgery and radiotherapy 82 (16.0%) 80 (12.4%) 72 (11.2%) 66 (9.4%) 84 (9.6%)  
   Chemoradiotherapy 96 (18.8%) 135 (20.9%) 132 (20.5%) 152 (21.6%) 179 (20.5%)  
   Surgery and chemoradiotherapy 95 (18.6%) 119 (18.4%) 106 (16.4%) 103 (14.7%) 89 (10.2%)  
   Chemotherapy +/- surgery 14 (2.7%) 20 (3.1%) 27 (4.2%) 24 (3.4%) 39 (4.5%)  
   No treatment 32 (6.3%) 39 (6.0%) 43 (6.7%) 46 (6.5%) 93 (10.7%)  
   Unknown 96 (18.8%) 128 (19.8%) 130 (20.2%) 164 (23.3%) 202 (23.1%)  
Network      <0.001 
   West of Scotland (WoSCAN) 153 (29.9%) 190 (29.4%) 258 (40.0%) 342 (48.6%) 743 (85.1%)  
   East of Scotland (SCAN) 130 (25.4%) 213 (32.9%) 214 (33.2%) 237 (33.7%) 61 (7.0%)  




Appendix 2.12 – Cross-tabulation of Carstairs 1991 Category with baseline characteristics for people with cancer of the larynx 
Variable 
Carstairs 1991 Category (row %)  
1 – Least 
deprived 2 3 4 





Age at incidence      <0.001 
   Less than 45 21 (2.2%) 26 (2.1%) 41 (2.7%) 46 (2.7%) 76 (3.3%)  
   45 to 54 106 (11.3%) 173 (13.9%) 202 (13.4%) 259 (15.2%) 383 (16.6%)  
   55 to 64 251 (26.8%) 381 (30.6%) 505 (33.4%) 583 (34.3%) 793 (34.3%)  
   65 to 74 334 (35.6%) 412 (33.1%) 495 (32.7%) 544 (32.0%) 728 (31.5%)  
   75 and over 226 (24.1%) 253 (20.3%) 270 (17.8%) 267 (15.7%) 331 (14.3%)  
Sex      <0.001 
   Male 789 (84.1%) 1,021 (82.0%) 1,219 (80.6%) 1,329 (78.2%) 1,775 (76.8%)  
   Female 149 (15.9%) 224 (18.0%) 294 (19.4%) 370 (21.8%) 536 (23.2%)  
Pathology      0.90 
   SCC 862 (91.9%) 1,146 (92.0%) 1,391 (91.9%) 1,566 (92.2%) 2,111 (91.3%)  
   Non-SCC 76 (8.1%) 99 (8.0%) 122 (8.1%) 133 (7.8%) 200 (8.7%)  
Treatment      <0.001 
   Surgery only 66 (7.0%) 117 (9.4%) 147 (9.7%) 156 (9.2%) 185 (8.0%)  
   Radiotherapy only 281 (30.0%) 317 (25.5%) 387 (25.6%) 426 (25.1%) 503 (21.8%)  
   Surgery and radiotherapy 112 (11.9%) 152 (12.2%) 172 (11.4%) 184 (10.8%) 224 (9.7%)  
   Chemoradiotherapy 44 (4.7%) 78 (6.3%) 100 (6.6%) 121 (7.1%) 164 (7.1%)  
   Surgery and chemoradiotherapy 27 (2.9%) 39 (3.1%) 48 (3.2%) 47 (2.8%) 81 (3.5%)  
   Chemotherapy +/- surgery 10 (1.1%) 13 (1.0%) 20 (1.3%) 22 (1.3%) 39 (1.7%)  
   No treatment 55 (5.9%) 60 (4.8%) 98 (6.5%) 112 (6.6%) 168 (7.3%)  
   Unknown 343 (36.6%) 469 (37.7%) 541 (35.8%) 631 (37.1%) 947 (41.0%)  
Network      <0.001 
   West of Scotland (WoSCAN) 341 (36.4%) 428 (34.4%) 635 (42.0%) 875 (51.5%) 1,948 (84.3%)  
   East of Scotland (SCAN) 274 (29.2%) 430 (34.5%) 499 (33.0%) 575 (33.8%) 154 (6.7%)  





Appendix 2.13 – Overall survival by each baseline characteristic 
Variable 
One-year overall 
survival (95% CI) 
Five-year overall 
survival (95% CI) 
10-year overall 
survival (95% CI) 
Total 75.1 (74.6, 75.7) 47.0 (46.4, 47.6) 32.1 (31.4, 32.7) 
Age at incidence    
   Less than 45 89.6 (87.8, 91.1) 73.0 (70.6, 75.3) 65.8 (63.1, 68.4) 
   45 to 54 84.0 (82.8, 85.0) 59.7 (58.2, 61.2) 47.9 (46.3, 49.5) 
   55 to 64 79.5 (78.6, 80.4) 51.3 (50.1, 52.4) 36.1 (34.9, 37.3) 
   65 to 74 72.8 (71.7, 73.8) 42.6 (41.4, 43.8) 25.0 (23.9, 26.2) 
   75 and over 59.0 (57.5, 60.4) 27.0 (25.7, 28.3) 11.6 (10.6, 12.6) 
Sex    
   Male 75.7 (75.0, 76.3) 46.2 (45.5, 47.0) 31.3 (30.6, 32.1) 
   Female 73.8 (72.8, 74.8) 48.8 (47.6, 50.0) 33.8 (32.6, 35.0) 
ICD group    
   Oral cavity 73.3 (72.4, 74.3) 45.1 (44.0, 46.2) 30.8 (29.7, 31.9) 
   Larynx 80.8 (79.9, 81.6) 52.1 (51.0, 53.2) 34.4 (33.3, 35.5) 
   Oropharynx 74.3 (72.7, 75.7) 48.0 (46.3, 49.7) 34.3 (32.4, 36.1) 
   Hypopharynx 53.3 (50.8, 55.7) 19.6 (17.7, 21.7) 10.7 (9.1, 12.4) 
   Lip 92.9 (91.4, 94.1) 69.1 (66.5, 71.5) 48.1 (45.3, 50.8) 
   Salivary gland 82.0 (79.7, 84.1) 55.5 (52.6, 58.4) 45.3 (42.3, 48.3) 
   Other 58.0 (55.3, 60.6) 29.1 (26.7, 31.6) 19.6 (17.4, 21.9) 
Treatment    
   Surgery only 88.9 (87.9, 89.8) 66.4 (64.9, 67.8) 48.8 (47.1, 50.5) 
   Radiotherapy only 79.2 (77.8, 80.6) 49.7 (47.9, 51.5) 32.7 (30.9, 34.6) 
   Surgery and radiotherapy 85.0 (83.6, 86.3) 51.3 (49.4, 53.2) 33.8 (31.9, 35.8) 
   Chemoradiotherapy 81.7 (80.1, 83.2) 49.7 (47.6, 51.7) 33.7 (31.3, 36.1) 
   Surgery and chemoradiotherapy 87.3 (85.5, 88.9) 54.5 (51.8, 57.0) 40.8 (37.9, 43.7) 
   Chemotherapy +/- surgery 56.9 (52.6, 60.9) 30.9 (27, 34.8) 21.1 (17.6, 24.8) 
   No treatment 17.3 (15.6, 19.1) 7.9 (6.7, 9.2) 5.3 (4.3, 6.5) 
   Unknown 72.9 (71.9, 73.9) 42.1 (41.0, 43.1) 27.7 (26.7, 28.6) 
Network of residence    
   West of Scotland (WoSCAN) 73.3 (72.5, 74.0) 44.5 (43.7, 45.4) 29.2 (28.4, 30.1) 
   East of Scotland (SCAN) 77.6 (76.5, 78.6) 50.5 (49.3, 51.8) 36.1 (34.8, 37.4) 
   North of Scotland (NOSCAN) 76.7 (75.6, 77.8) 48.7 (47.4, 50.0) 34.3 (33.0, 35.6) 
Year group    
   1986-1990 74.9 (73.4, 76.3) 44.2 (42.4, 45.8) 29.2 (27.6, 30.7) 
   1991-1995 72.1 (70.6, 73.5) 40.8 (39.2, 42.4) 27.0 (25.6, 28.4) 
   1996-2000 74.5 (73.1, 75.8) 45.9 (44.4, 47.4) 30.7 (29.3, 32.1) 
   2001-2005 75.7 (74.4, 77.0) 47.7 (46.2, 49.2) 33.7 (32.3, 35.1) 
   2006-2010 75.9 (74.7, 77.2) 49.8 (48.4, 51.3) 34.9 (33.4, 36.4) 
   2011-2015 77.0 (75.8, 78.2) 52.0 (50.5, 53.6) N/A 
Carstairs Category    
   1 – Least deprived 78.6 (77.2, 79.9) 53.1 (51.4, 54.7) 38.4 (36.7, 40.1) 
   2 77.2 (75.9, 78.4) 49.9 (48.4, 51.4) 35.5 (34.0, 37.1) 
   3 77.4 (76.2, 78.5) 48.0 (46.5, 49.4) 32.6 (31.1, 34.0) 
   4 74.0 (72.8, 75.2) 46.8 (45.4, 48.1) 32.1 (30.7, 33.4) 
   5 – Most deprived 71.1 (70.0, 72.2) 41.1 (39.9, 42.4) 26.0 (24.9, 27.1) 
SII (95% CI) 9.0 (4.4, 13.6) 14.0 (8.2, 19.9) 14.6 (8.1, 21.0) 









survival (95% CI) 
Five-year 
disease-specific 




Total 80.2 (79.7, 80.7) 61.8 (61.1, 62.4) 56.0 (55.3, 56.7) 
Age at incidence    
   Less than 45 91.4 (89.8, 92.7) 78.3 (75.9, 80.4) 73.8 (71.3, 76.2) 
   45 to 54 86.5 (85.4, 87.5) 68.7 (67.3, 70.2) 63.4 (61.8, 65.0) 
   55 to 64 83.5 (82.7, 84.4) 64.1 (62.9, 65.2) 58.1 (56.8, 59.3) 
   65 to 74 78.5 (77.5, 79.5) 59.4 (58.2, 60.6) 52.7 (51.3, 54.1) 
   75 and over 67.3 (65.8, 68.7) 48.9 (47.3, 50.5) 43.0 (41.2, 44.8) 
Sex    
   Male 80.7 (80.1, 81.3) 61.4 (60.6, 62.2) 55.5 (54.7, 56.4) 
   Female 78.9 (77.9, 79.9) 62.6 (61.5, 63.8) 57.1 (55.8, 58.3) 
ICD group    
   Oral cavity 78.2 (77.3, 79.1) 59.0 (57.8, 60.1) 52.6 (51.4, 53.9) 
   Larynx 85.6 (84.8, 86.4) 68.6 (67.5, 69.7) 62.2 (61.0, 63.4) 
   Oropharynx 78.3 (76.9, 79.7) 59.6 (57.8, 61.3) 53.9 (51.9, 55.8) 
   Hypopharynx 59.3 (56.8, 61.8) 30.2 (27.7, 32.7) 24.9 (22.3, 27.6) 
   Lip 98.3 (97.4, 98.9) 94.3 (92.9, 95.5) 93.0 (91.3, 94.4) 
   Salivary gland 87.4 (85.3, 89.2) 70.4 (67.5, 73.0) 66.3 (63.2, 69.2) 
   Other 64.5 (61.8, 67.1) 38.9 (36.1, 41.7) 32.3 (29.4, 35.2) 
Treatment    
   Surgery only 92.4 (91.6, 93.1) 82.9 (81.7, 84.1) 78.2 (76.7, 79.6) 
   Radiotherapy only 83.4 (82.1, 84.7) 66.7 (64.9, 68.4) 61.5 (59.4, 63.4) 
   Surgery and radiotherapy 88.2 (87.0, 89.4) 64.2 (62.3, 66.1) 56.6 (54.4, 58.7) 
   Chemoradiotherapy 84.2 (82.7, 85.6) 62.2 (60.1, 64.2) 55.9 (53.3, 58.3) 
   Surgery and chemoradiotherapy 89.1 (87.4, 90.6) 65.0 (62.4, 67.4) 60.9 (58.0, 63.6) 
   Chemotherapy +/- surgery 63.5 (59.2, 67.5) 42.4 (38.0, 46.8) 36.2 (31.7, 40.8) 
   No treatment 24.4 (22.2, 26.6) 15.0 (13.1, 17.0) 13.8 (12.0, 15.8) 
   Unknown 79.0 (78.1, 79.9) 57.4 (56.3, 58.5) 50.9 (49.7, 52.1) 
Network of residence    
   West of Scotland (WoSCAN) 78.6 (77.9, 79.3) 59.7 (58.8, 60.6) 52.9 (51.9, 53.9) 
   East of Scotland (SCAN) 82.1 (81.1, 83.0) 64.3 (63.0, 65.5) 60.0 (58.6, 61.3) 
   North of Scotland (NOSCAN) 81.7 (80.6, 82.7) 63.7 (62.4, 65.0) 58.5 (57.1, 60.0) 
Year group    
   1986-1990 81.2 (79.8, 82.5) 61.0 (59.2, 62.8) 55.4 (53.5, 57.3) 
   1991-1995 78.3 (76.9, 79.6) 55.3 (53.6, 57.0) 48.2 (46.5, 50.0) 
   1996-2000 78.5 (77.2, 79.7) 57.0 (55.5, 58.6) 50.6 (48.9, 52.2) 
   2001-2005 79.3 (78.1, 80.6) 62.0 (60.4, 63.5) 57.1 (55.5, 58.7) 
   2006-2010 81.3 (80.1, 82.5) 65.6 (64.1, 67.0) 61.0 (59.4, 62.6) 
   2011-2015 82.0 (80.9, 83.1) 68.5 (67.1, 69.9) N/A 
Carstairs Category    
   1 – Least deprived 83.7 (82.5, 84.9) 67.2 (65.5, 68.8) 62.3 (60.5, 64.1) 
   2 81.9 (80.7, 83.0) 64.5 (63.0, 65.9) 59.4 (57.7, 61.0) 
   3 81.9 (80.7, 82.9) 62.9 (61.4, 64.3) 57.4 (55.8, 58.9) 
   4 79.2 (78.0, 80.3) 61.2 (59.7, 62.5) 55.1 (53.6, 56.6) 
   5 – Most deprived 76.6 (75.5, 77.6) 56.6 (55.3, 57.9) 49.8 (48.4, 51.2) 
SII (95% CI) 8.8 (5.1, 12.6) 12.6 (8.6, 16.6) 19.1 (9.6, 28.5) 




Appendix 2.15   – Overall survival by Carstairs 1991 Category per year group of diagnosis for the whole cohort 
 Year of diagnosis 
Carstairs 1991 Category 1986-1990 1991-1995 1996-2000 2001-2005 2006-2010 2011-2015 
One-year overall survival 
(95% CI) 
      
   1 – Least deprived 77.4 (73.3, 80.9) 73.0 (68.9, 76.7) 80.1 (76.7, 83.0) 80.9 (77.6, 83.8) 78.0 (74.6, 81.0) 81.2 (78.3, 83.8) 
   2 75.9 (72.1, 79.2) 74.7 (71.3, 77.9) 78.7 (75.5, 81.6) 75.8 (72.7, 78.6) 76.5 (73.5, 79.3) 80.5 (77.9, 82.9) 
   3 78.4 (75.0, 81.5) 75.9 (72.6, 78.9) 76.8 (73.8, 79.6) 77.4 (74.3, 80.1) 78.1 (75.3, 80.7) 78.3 (75.5, 80.8) 
   4 71.5 (68.0, 74.7) 71.6 (68.4, 74.5) 71.7 (68.6, 74.5) 76.0 (73.1, 78.6) 76.7 (73.9, 79.2) 76.0 (73.2, 78.6) 
   5 – Most deprived 73.5 (70.5, 76.2) 67.9 (65.0, 70.6) 69.8 (67.0, 72.4) 71.8 (69.0, 74.3) 72.9 (70.2, 75.3) 71.8 (69.1, 74.2) 
SII (95% CI) 6.1 (-6.1, 18.2) 8.6 (-3.0, 20.2) 14.1 (9.1, 19.1) 9.0 (-0.2, 18.1) 5.7 (-2.2, 13.6) 12.2 (7.5, 16.9) 
RII (95% CI) 0.08 (-0.08, 0.24) 0.12 (-0.04, 0.28) 0.19 (0.12, 0.26) 0.12 (0.00, 0.24) 0.08 (-0.03, 0.18) 0.16 (0.10, 0.22) 
Five-year overall survival 
(95% CI) 
      
   1 – Least deprived 46.3 (41.7, 50.8) 43.1 (38.7, 47.3) 51.4 (47.4, 55.3) 57.0 (53.0, 60.9) 56.0 (52.1, 59.7) 62.4 (58.6, 66.0) 
   2 45.4 (41.2, 49.5) 42.9 (39.1, 46.6) 51.4 (47.6, 55.0) 47.6 (44.1, 51) 52.7 (49.2, 56.0) 57.5 (53.9, 60.9) 
   3 46.7 (42.7, 50.6) 43.4 (39.8, 47.1) 47.2 (43.7, 50.5) 48.7 (45.2, 52.1) 50.2 (46.9, 53.4) 52.3 (48.8, 55.8) 
   4 44.4 (40.7, 48.1) 42.5 (39.1, 45.9) 45.6 (42.3, 48.9) 48.4 (45.1, 51.6) 50.7 (47.5, 53.8) 48.4 (44.9, 51.9) 
   5 – Most deprived 40.5 (37.3, 43.7) 35.4 (32.5, 38.3) 39.2 (36.3, 42.0) 41.8 (38.9, 44.7) 44.2 (41.3, 47.0) 47.1 (43.9, 50.2) 
SII (95% CI) 7.5 (-0.3, 15.4) 9.9 (-2.8, 22.6) 16.2 (8.9, 23.6) 14.1 (-1.5, 29.8) 13.0 (4.3, 21.7) 19.2 (10.5, 27.9) 
RII (95% CI) 0.17 (0.00, 0.35)  0.24 (-0.07, 0.55) 0.35 (0.19, 0.52) 0.30 (-0.03, 0.62) 0.26 (0.09, 0.43) 0.36 (0.20, 0.53) 
10-year overall survival 
(95% CI) 
      
   1 – Least deprived 34.6 (30.2, 38.9) 29.4 (25.4, 33.4) 34.9 (31.2, 38.6) 43.3 (39.3, 47.2) 41.2 (37.1, 45.3) N/A 
   2 30.3 (26.5, 34.1) 29.6 (26.2, 33.1) 36.9 (33.3, 40.5) 34.9 (31.6, 38.2) 38.7 (35.0, 42.3) N/A 
   3 30.8 (27.2, 34.5) 27.8 (24.5, 31.1) 31.4 (28.3, 34.6) 34.7 (31.5, 38.0) 35.0 (31.6, 38.3) N/A 
   4 28.2 (24.9, 31.6) 29.0 (26.0, 32.2) 30.9 (27.9, 34.0) 34.4 (31.3, 37.4) 35.9 (32.7, 39.2) N/A 
   5 – Most deprived 25.6 (22.8, 28.4) 22.1 (19.6, 24.6) 24.1 (21.6, 26.6) 26.8 (24.2, 29.4) 29.2 (26.4, 32.1) N/A 
SII (95% CI) 10.1 (4.5, 15.6) 9.2 (-2.2, 20.5) 15.1 (4.3, 26.0) 16.4 (2.3, 30.5) 13.7 (4.7, 22.7) N/A 




Appendix 2.16 – Overall survival by Carstairs 1991 Category per year group of diagnosis for males 
 Year of diagnosis 
Carstairs 1991 Category 1986-1990 1991-1995 1996-2000 2001-2005 2006-2010 2011-2015 
One-year overall  
survival (95% CI) 
      
   1 – Least deprived 78.3 (73.3, 82.5) 73.8 (68.8, 78.1) 82.4 (78.5, 85.6) 80.4 (76.2, 84.0) 81.1 (77.2, 84.4) 80.0 (76.4, 83.1) 
   2 77.2 (72.6, 81.1) 77.5 (73.4, 81.0) 80.6 (76.7, 83.9) 75.0 (71.2, 78.3) 77.5 (73.8, 80.7) 83.5 (80.5, 86.2) 
   3 79.1 (75.0, 82.7) 78.9 (75.1, 82.2) 76.7 (73.1, 79.9) 77.7 (74.0, 81.0) 78.8 (75.4, 81.8) 78.3 (75.0, 81.2) 
   4 70.9 (66.7, 74.8) 72.7 (69.0, 76.1) 72.2 (68.5, 75.6) 75.3 (71.8, 78.4) 77.4 (74.1, 80.3) 75.8 (72.5, 78.8) 
   5 – Most deprived 74.1 (70.6, 77.2) 68.4 (65.0, 71.6) 70.0 (66.8, 73.1) 71.2 (67.9, 74.2) 72.4 (69.3, 75.3) 71.9 (68.7, 74.8) 
SII (95% CI) 7.0 (-7.8, 21.9) 10.8 (-6.0, 27.6) 16.7 (12.0, 21.2) 9.1 (-1.3, 19.5) 9.3 (0.5, 18.1) 13.1 (2.8, 23.5) 
RII (95% CI) 0.09 (-0.10, 0.29) 0.15 (0.08, 0.37) 0.22 (0.16, 0.28) 0.12 (-0.02, 0.26) 0.12 (0.01, 0.24) 0.17 (0.04, 0.30) 
Five-year overall  
survival (95% CI) 
      
   1 – Least deprived 46.0 (40.3, 51.4) 42.9 (37.7, 48.1) 51.4 (46.6, 55.9) 56.3 (51.3, 61.0) 57.2 (52.6, 61.6) 63.0 (58.6, 67.2) 
   2 44.6 (39.6, 49.5) 43.3 (38.7, 47.8) 52.3 (47.7, 56.7) 46.6 (42.4, 50.6) 52.6 (48.5, 56.7) 58.5 (54.3, 62.5) 
   3 44.8 (40.0, 49.4) 43.9 (39.6, 48.1) 45.8 (41.7, 49.7) 49.0 (44.7, 53.1) 50.5 (46.6, 54.4) 52.0 (47.8, 56.0) 
   4 41.6 (37.2, 46.0) 41.9 (37.9, 45.9) 43.0 (39.0, 46.9) 47.1 (43.2, 50.9) 50.9 (47.1, 54.6) 46.2 (42.0, 50.4) 
   5 – Most deprived 39.6 (35.9, 43.3) 34.3 (31.0, 37.7) 39.5 (36.1, 42.8) 39.8 (36.4, 43.2) 42.4 (39.0, 45.7) 45.7 (41.8, 49.4) 
SII (95% CI) 8.4 (4.5, 12.4) 11.9 (-2.1, 25.8) 16.9 (9.2, 24.5) 15.9 (-0.5, 32.3) 16.2 (4.5, 27.9) 22.0 (9.2, 34.8) 
RII (95% CI) 0.20 (0.11, 0.29) 0.29 (0.05, 0.64) 0.37 (0.20, 0.54) 0.34 (-0.01, 0.69) 0.33 (0.09, 0.56) 0.42 (0.18, 0.67) 
10-year overall  
survival (95% CI) 
      
   1 – Least deprived 32.4 (27.2, 37.6) 30.0 (25.2, 34.8) 33.7 (29.3, 38.1) 42.2 (37.3, 47.0) 40.4 (35.5, 45.2) N/A 
   2 28.6 (24.2, 33.2) 30.1 (26.0, 34.3) 36.9 (32.6, 41.3) 34.9 (31.0, 38.8) 38.7 (34.3, 43.0) N/A 
   3 28.5 (24.4, 32.9) 28.8 (25.0, 32.8) 29.5 (25.9, 33.1) 34.7 (30.8, 38.7) 35.7 (31.7, 39.7) N/A 
   4 25.8 (22.0, 29.7) 29.6 (26.0, 33.3) 30.1 (26.5, 33.8) 34.4 (30.8, 38.1) 36.7 (32.9, 40.6) N/A 
   5 – Most deprived 23.8 (20.7, 27.1) 20.3 (17.5, 23.2) 24.2 (21.3, 27.2) 25.8 (22.8, 28.9) 27.6 (24.4, 30.9) N/A 
SII (95% CI) 9.8 (5.3, 14.3) 12.3 (-3.1, 27.9) 13.9 (1.3, 26.5) 16.8 (2.8, 30.8) 15.0 (2.1, 28.0) N/A 





Appendix 2.17 – Overall survival by Carstairs 1991 Category per year group of diagnosis for females 
 Year of diagnosis 
Carstairs 1991 Category 1986-1990 1991-1995 1996-2000 2001-2005 2006-2010 2011-2015 
One-year overall  
survival (95% CI) 
      
   1 – Least deprived 75.5 (67.8, 81.6) 71.3 (63.6, 77.7) 74.4 (67.4, 80.2) 82.0 (75.9, 86.7) 70.6 (63.7, 76.5) 84.3 (78.9, 88.4) 
   2 73.0 (65.7, 79.0) 68.6 (61.8, 74.4) 74.7 (68.3, 79.9) 77.9 (72.0, 82.7) 74.4 (68.5, 79.4) 73.9 (68.5, 78.5) 
   3 76.9 (70.1, 82.3) 67.7 (60.6, 73.8) 77.2 (71.2, 82.2) 76.7 (71.1, 81.4) 76.6 (71.2, 81.2) 78.2 (72.8, 82.7) 
   4 72.8 (66.2, 78.4) 68.6 (62.1, 74.1) 70.4 (64.6, 75.5) 77.6 (72.0, 82.1) 75.1 (69.6, 79.7) 76.5 (71.1, 81.0) 
   5 – Most deprived 71.9 (65.9, 77.0) 66.5 (60.7, 71.7) 69.2 (63.9, 73.9) 73.3 (67.9, 77.9) 74.1 (68.9, 78.6) 71.5 (66.4, 76.0) 
SII (95% CI) 4.1 (-5.6, 13.8) 4.6 (-0.6, 9.7) 8.5 (-3.9, 20.8) 8.6 (0.6, 16.6) -2.6 (-13.4, 8.1) 10.9 (-7.8, 29.6) 
RII (95% CI) 0.06 (0.08, 0.19) 0.07 (-0.01, 0.14) 0.12 (-0.05, 0.29) 0.11 (0.01, 0.22) -0.04 (-0.18, 0.11) 0.14 (-0.10, 0.39) 
Five-year overall  
survival (95% CI) 
      
   1 – Least deprived 47.0 (38.9, 54.7) 43.3 (35.5, 50.9) 51.7 (44.1, 58.7) 58.5 (51.3, 65.0) 53.1 (45.8, 59.8) 61.0 (53.7, 67.6) 
   2 47.1 (39.6, 54.3) 42.0 (35.3, 48.6) 49.3 (42.5, 55.8) 50.2 (43.7, 56.4) 52.8 (46.4, 58.8) 55.0 (48.3, 61.2) 
   3 51.1 (43.7, 58.0) 42.2 (35.1, 49.0) 50.9 (44.2, 57.2) 48.1 (41.9, 54.0) 49.3 (43.3, 55.0) 53.3 (46.5, 59.5) 
   4 51.0 (44.0, 57.6) 44.1 (37.6, 50.4) 51.5 (45.4, 57.2) 51.7 (45.5, 57.6) 50.2 (44.2, 55.9) 53.6 (47.1, 59.6) 
   5 – Most deprived 43.0 (36.9, 48.9) 38.4 (32.7, 44.1) 38.4 (33.2, 43.6) 47.2 (41.5, 52.7) 49.2 (43.6, 54.6) 50.4 (44.6, 56.0) 
SII (95% CI) 4.2 (-15.4, 23.7) 4.7 (-6.1, 15.6) 14.9 (-8.9, 38.7) 9.4 (-7.8, 26.8) 4.9 (-0.9, 10.7) 10.8 (1.5, 20.1) 
RII (95% CI) 0.09 (-0.32, 0.50) 0.11 (-0.15, 0.37) 0.31 (-0.19, 0.81) 0.19 (-0.15, 0.53) 0.10 (-0.02, 0.21) 0.20 (0.03, 0.37) 
10-year overall  
survival (95% CI) 
      
   1 – Least deprived 73.0 (68.9, 76.7) 77.4 (73.3, 80.9) 73.0 (68.9, 76.7) 77.4 (73.3, 80.9) 73.0 (68.9, 76.7) N/A 
   2 33.9 (27.0, 41.0) 28.5 (22.5, 34.8) 36.9 (30.5, 43.3) 34.9 (28.9, 41.0) 38.7 (32.1, 45.3) N/A 
   3 36.0 (29.2, 42.9) 25.0 (19.1, 31.3) 36.6 (30.3, 42.9) 34.7 (29.0, 40.5) 33.2 (26.9, 39.6) N/A 
   4 34.0 (27.6, 40.5) 27.5 (21.9, 33.4) 32.8 (27.4, 38.4) 34.2 (28.5, 40.0) 34.1 (28.1, 40.1) N/A 
   5 – Most deprived 30.1 (24.6, 35.8) 27.0 (22.0, 32.3) 23.8 (19.3, 28.5) 29.4 (24.3, 34.6) 33.5 (27.7, 39.4) N/A 
SII (95% CI) 9.2 (0.0, 18.5) 1.2 (-5.9, 8.4) 18.2 (4.2, 32.2) 15.4 (-0.8, 31.6) 10.5 (-2.6, 23.5) N/A 





Appendix 2.18 – Overall survival by Carstairs 1991 Category per year group of diagnosis for people with cancer of the oral cavity 
 Year of diagnosis 
Carstairs 1991 Category 1986-1990 1991-1995 1996-2000 2001-2005 2006-2010 2011-2015 
One-year overall  
survival (95% CI) 
      
   1 – Least deprived 72.8 (64.1, 79.7) 72.1 (64.7, 78.2) 73.5 (66.9, 79.0) 83.3 (77.7, 87.6) 76.8 (70.9, 81.7) 81.8 (77.0, 85.6) 
   2 72.1 (64.6, 78.3) 70.2 (63.9, 75.5) 77.1 (71.0, 82.1) 70.8 (64.8, 76.0) 71.3 (65.8, 76.1) 81.6 (77.0, 85.3) 
   3 69.3 (61.9, 75.5) 72.2 (65.6, 77.8) 74.3 (68.5, 79.2) 75.4 (70.0, 80.0) 79.5 (74.7, 83.5) 76.1 (71.0, 80.5) 
   4 63.5 (56.4, 69.7) 68.4 (62.2, 73.8) 67.3 (61.2, 72.6) 74.9 (69.9, 79.3) 74.6 (69.6, 78.9) 76.5 (71.6, 80.7) 
   5 – Most deprived 70.6 (64.9, 75.5) 65.5 (59.9, 70.5) 69.8 (64.9, 74.2) 71.3 (66.4, 75.7) 72.5 (67.8, 76.6) 70.6 (65.7, 74.9) 
SII (95% CI) 4.1 (-15.7, 23.9) 8.2 (0.1, 16.2) 8.7 (-6.6, 24.0) 8.8 (-12.7, 30.2) 3.1 (-15.3, 21.4) 14.2 (5.2, 23.1) 
RII (95% CI) 0.06 (-0.23, 0.34) 0.12 (0.00, 0.23) 0.12 (-0.09, 0.33) 0.12 (-0.17, 0.40) 0.04 (-0.20, 0.29) 0.18 (0.07, 0.30) 
Five-year overall  
survival (95% CI) 
      
   1 – Least deprived 35.2 (26.9, 43.5) 39.0 (31.7, 46.2) 46.1 (39.1, 52.7) 58.6 (51.8, 64.7) 55.3 (48.7, 61.3) 63.0 (56.8, 68.5) 
   2 37.0 (29.7, 44.3) 41.2 (34.9, 47.3) 46.6 (40.0, 53.0) 44.4 (38.2, 50.3) 50.9 (45.0, 56.4) 61.1 (55.3, 66.5) 
   3 40.2 (33.0, 47.3) 39.7 (33.1, 46.3) 44.4 (38.2, 50.3) 48.8 (42.9, 54.4) 54.1 (48.6, 59.3) 52.7 (46.5, 58.5) 
   4 39.5 (32.7, 46.2) 38.9 (32.8, 44.9) 40.8 (34.8, 46.7) 43.7 (38.3, 49.0) 47.0 (41.6, 52.3) 48.3 (42.2, 54.2) 
   5 – Most deprived 36.9 (31.3, 42.5) 33.5 (28.3, 38.8) 39.4 (34.4, 44.4) 39.1 (34.1, 44.1) 42.9 (38.0, 47.8) 44.2 (38.4, 49.9) 
SII (95% CI) -1.1 (-12.1, 9.9) 8.2 (-2.7, 19.2) 10.1 (4.9, 15.3) 18.9 (-2.9, 40.5) 14.9 (1.7. 28.1) 25.4 (17.3, 33.6) 
RII (95% CI) -0.03 (-0.32, 0.26) 0.22 (-0.07, 0.50) 0.23 (0.11, 0.36) 0.41 (-0.06, 0.88) 0.30 (0.03, 0.57) 0.48 (0.32, 0.63) 
10-year overall  
survival (95% CI) 
      
   1 – Least deprived 26.4 (19.0, 34.3) 27.3 (20.9, 34.1) 31.4 (25.1, 37.8) 47.7 (41.0, 54.1) 37.0 (30.0, 44.0) N/A 
   2 22.4 (16.4, 29.0) 27.7 (22.2, 33.5) 30.5 (24.6, 36.6) 35.0 (29.2, 40.8) 38.5 (32.6, 44.5) N/A 
   3 24.6 (18.5, 31.1) 23.0 (17.5, 28.9) 33.9 (28.1, 39.7) 35.1 (29.6, 40.6) 35.6 (29.9, 41.3) N/A 
   4 24.5 (18.8, 30.6) 26.3 (21.0, 31.9) 25.0 (19.9, 30.4) 29.7 (24.8, 34.7) 32.8 (27.5, 38.1) N/A 
   5 – Most deprived 22.7 (18.0, 27.7) 21.6 (17.2, 26.3) 23.9 (19.7, 28.4) 24.8 (20.5, 29.3) 33.3 (28.5, 38.3) N/A 
SII (95% CI) 2.4 (-5.1, 10.0) 7.0 (-3.3, 17.3) 11.4 (-4.1, 27.0) 24.4 (7.9, 40.8) 6.6 (-0.3, 13.6) N/A 





Appendix 2.19 – Overall survival by Carstairs 1991 Category per year group of diagnosis for people with cancer of the oropharynx 
 Year of diagnosis 
Carstairs 1991 Category 1986-1990 1991-1995 1996-2000 2001-2005 2006-2010 2011-2015 
One-year overall  
survival (95% CI) 
      
   1 – Least deprived 70.6 (52.2, 83.0) 57.8 (42.1, 70.6) 85.9 (75.4, 92.2) 80.7 (70.8, 87.5) 75.9 (67.0, 82.7) 83.6 (76.9, 88.6) 
   2 68.6 (54.0, 79.5) 74.1 (60.8, 83.5) 69.9 (58.8, 78.5) 76.9 (67.7, 83.7) 83.0 (75.7, 88.3) 82.6 (76.8, 87.1) 
   3 77.8 (62.6, 87.4) 56.7 (43.2, 68.1) 76.8 (67.0, 84.1) 79.5 (70.7, 85.8) 81.3 (73.9, 86.7) 78.4 (71.9, 83.6) 
   4 54.3 (42.0, 65.1) 59.2 (46.8, 69.5) 70.7 (60.2, 78.8) 73.4 (64.0, 80.7) 78.9 (71.9, 84.4) 79.5 (73.0, 84.6) 
   5 – Most deprived 66.2 (54.2, 75.7) 63.3 (52.9, 71.9) 65.9 (57.0, 73.4) 66.1 (57.2, 73.6) 69.9 (62.7, 75.9) 72.8 (67.0, 77.8) 
SII (95% CI) 11.1 (-35.9, 58.1) 2.1 (-36.3, 40.6) 19.0 (-7.0, 45.0) 17.1 (1.3, 32.8) 10.9 (-13.5, 35.3) 13.3 (4.1, 22.4) 
RII (95% CI) 0.17 (-0.54, 0.88) 0.03 (0.58, 0.65) 0.26 (-0.10, 0.62) 0.23 (0.02, 0.44) 0.14 (-0.17, 0.46) 0.17 (0.05, 0.28) 
Five-year overall  
survival (95% CI) 
      
   1 – Least deprived 32.4 (17.6, 48.0) 31.1 (18.4, 44.7) 50.7 (38.6, 61.6) 54.5 (43.6, 64.2) 52.6 (43.1, 61.2) 69.3 (60.8, 76.3) 
   2 35.3 (22.6, 48.2) 39.7 (27.2, 51.9) 34.9 (24.9, 45.1) 50.0 (40.3, 59.0) 64.5 (56.0, 71.8) 60.8 (52.6, 68.1) 
   3 31.1 (18.4, 44.7) 18.3 (9.8, 29.0) 50.5 (40.1, 60.0) 46.4 (37.0, 55.3) 54.2 (45.7, 61.9) 60.6 (52.7, 67.6) 
   4 30.0 (19.8, 40.9) 31.0 (20.7, 41.8) 40.2 (30.2, 50.0) 53.2 (43.4, 62.0) 52.4 (44.5, 59.7) 57.9 (49.7, 65.3) 
   5 – Most deprived 31.1 (21.0, 41.7) 30.6 (21.8, 39.8) 32.6 (24.7, 40.7) 43.3 (34.6, 51.7) 45.2 (37.9, 52.1) 54.0 (47.4, 60.1) 
SII (95% CI) 4.0 (-5.3, 13.3) 3.0 (-38.7, 44.8) 17.0 (-21.9, 55.8) 9.6 (-11.2, 30.4) 16.0 (-12.6, 44.7) 16.2 (5.2, 27.3) 
RII (95% CI) 0.13 (-0.17, 0.42) 0.10 (-1.28, 1.49) 0.42 (-0.54, 1.37) 0.20 (-0.23, 0.62) 0.30 (-0.24, 0.84) 0.27 (0.09, 0.46) 
10-year overall  
survival (95% CI) 
      
   1 – Least deprived 26.5 (13.2, 41.8) 26.7 (14.9, 40.0) 38.0 (26.9, 49.1) 42.0 (31.7, 52.1) 48.1 (38.7, 56.8) N/A 
   2 27.5 (16.1, 40.0) 24.1 (14.1, 35.7) 26.5 (17.6, 36.3) 38.0 (28.9, 47.0) 50.9 (41.7, 59.4) N/A 
   3 22.2 (11.5, 35.1) 10 (4.1, 19.1) 34.7 (25.4, 44.3) 36.6 (27.8, 45.5) 42.5 (34.2, 50.5) N/A 
   4 18.6 (10.5, 28.4) 22.5 (13.7, 32.8) 28.3 (19.5, 37.7) 39.4 (30.3, 48.5) 41.4 (33.7, 49.0) N/A 
   5 – Most deprived 13.5 (6.9, 22.3) 11.2 (6.0, 18.4) 20.9 (14.4, 28.3) 26.0 (18.7, 33.8) 28.7 (21.9, 35.8) N/A 
SII (95% CI) 18.5 (11.5, 25.5) 16.1 (-17.0, 49.2) 17.3 (-7.2, 41.8) 16.1 (-6.1, 38.3) 26.0 (5.9, 46.1) N/A 





Appendix 2.20 – Overall survival by Carstairs 1991 Category per year group of diagnosis for people with cancer of the larynx 
 Year of diagnosis 
Carstairs 1991 Category 1986-1990 1991-1995 1996-2000 2001-2005 2006-2010 2011-2015 
One-year overall  
survival (95% CI) 
      
   1 – Least deprived 80.1 (72.6, 85.8) 79.7 (72.5, 85.3) 84.0 (77.8, 88.6) 79.9 (72.6, 85.4) 85.0 (78.5, 89.7) 83.1 (76.0, 88.3) 
   2 84.4 (78.3, 89.0) 83.2 (77.5, 87.5) 84.8 (79.2, 89.0) 81.6 (76.0, 86.0) 80.5 (74.4, 85.2) 82.4 (76.1, 87.1) 
   3 85.8 (80.2, 89.9) 83.5 (78.4, 87.5) 83.5 (78.5, 87.3) 79.7 (74.1, 84.2) 82.6 (77.5, 86.7) 84.0 (79.0, 88.0) 
   4 80.0 (74.2, 84.6) 82.6 (77.8, 86.5) 79.1 (74.3, 83.1) 82.5 (77.5, 86.4) 82.6 (77.7, 86.5) 77.6 (72.0, 82.1) 
   5 – Most deprived 80.2 (75.7, 83.9) 77.5 (73.1, 81.2) 78.1 (73.7, 81.8) 79.8 (75.6, 83.5) 77.0 (72.4, 80.9) 76.6 (71.9, 80.7) 
SII (95% CI) 4.1 (-9.9, 18.0) 5.6 (-7.4, 18.7) 9.3 (3.0, 15.7) 0.6 (-7.0, 8.1) 7.6 (-3.9, 19.1) 9.8 (-0.2, 20.0) 
RII (95% CI) 0.05 (-0.12, 0.22) 0.07 (-0.09, 0.23) 0.11 (0.04, 0.19) 0.01 (-0.09, 0.10) 0.09 (-0.05, 0.24) 0.12 (0.00, 0.25) 
Five-year overall  
survival (95% CI) 
      
   1 – Least deprived 48.9 (40.5, 56.9) 49.7 (41.5, 57.3) 58.6 (51.0, 65.3) 56.5 (48.3, 63.9) 66.9 (59.0, 73.6) 64.2 (55.3, 71.7) 
   2 55.0 (47.4, 61.9) 48.2 (41.4, 54.6) 61.6 (54.7, 67.8) 51.7 (45.1, 57.9) 53.3 (46.4, 59.8) 56.7 (48.4, 64.2) 
   3 52.0 (44.9, 58.6) 54.6 (48.4, 60.4) 54.0 (47.9, 59.6) 53.7 (47.2, 59.7) 51.3 (45.1, 57.1) 52.0 (44.9, 58.7) 
   4 52.2 (45.5, 58.4) 54.5 (48.7, 60.0) 51.8 (46.3, 57.1) 56.8 (50.9, 62.4) 58.0 (52.2, 63.4) 48.8 (41.7, 55.5) 
   5 – Most deprived 47.7 (42.6, 52.7) 45.3 (40.5, 50.1) 46.3 (41.4, 51.2) 47.4 (42.4, 52.2) 48.9 (43.8, 53.9) 49.3 (43.1, 55.2) 
SII (95% CI) 5.6 (-8.5, 19.7) 5.3 (-18.8, 29.5) 18.1 (7.5, 28.7) 8.1 (-11.3, 27.6) 13.0 (-15.9, 41.8) 15.4 (-1.4, 32.2) 
RII (95% CI) 0.11 (-0.17, 0.39) 0.11 (-0.38, 0.59) 0.34 (0.14, 0.54) 0.15 (0.22, 0.53) 0.24 (-0.29, 0.77) 0.29 (-0.03, 0.61) 
10-year overall  
survival (95% CI) 
      
   1 – Least deprived 33.3 (25.7, 41.1) 32.7 (25.4, 40.1) 35.4 (28.5, 42.3) 35.1 (27.6, 42.6) 49.7 (41.3, 57.6) N/A 
   2 34.4 (27.6, 41.4) 33.6 (27.5, 39.9) 44.5 (37.8, 51.1) 35.9 (29.8, 42.0) 35.5 (28.5, 42.6) N/A 
   3 31.4 (25.1, 37.8) 38.1 (32.2, 43.9) 32.4 (27.0, 37.9) 37.8 (31.8, 43.8) 35.3 (29.0, 41.6) N/A 
   4 31.3 (25.4, 37.3) 37.5 (32.0, 42.9) 37.6 (32.4, 42.8) 42.1 (36.3, 47.8) 38.7 (32.5, 44.8) N/A 
   5 – Most deprived 30.3 (25.7, 35.0) 28.7 (24.4, 33.1) 28.5 (24.1, 33.0) 28.7 (24.3, 33.2) 27.8 (22.9, 32.9) N/A 
SII (95% CI) 4.7 (0.3, 9.1) 6.5 (-15.6, 28.6) 12.5 (-13.9, 38.8) 8.0 (-20.6, 36.7) 18.6 (-7.9, 45.2) N/A 





Appendix 2.21   – Disease-specific survival by Carstairs 1991 Category per year group of diagnosis for the whole cohort 
 Year of diagnosis 
Carstairs 1991 Category 1986-1990 1991-1995 1996-2000 2001-2005 2006-2010 2011-2015 
One-year disease-specific  
survival (95% CI) 
      
   1 – Least deprived 84.3 (80.5, 87.4) 79.3 (75.4, 82.6) 83.3 (80.1, 86.0) 84.8 (81.6, 87.4) 84.2 (81.1, 86.8) 85.7 (82.9, 88.0) 
   2 82.4 (78.9, 85.4) 80.2 (76.9, 83.1) 82.4 (79.3, 85.1) 78.9 (75.9, 81.6) 82.3 (79.4, 84.7) 84.7 (82.2, 86.8) 
   3 84.3 (81.1, 87.0) 80.5 (77.3, 83.3) 80.6 (77.7, 83.2) 80.6 (77.6, 83.2) 82.9 (80.3, 85.2) 82.7 (80.1, 85.0) 
   4 78.1 (74.7, 81.0) 78.1 (75.0, 80.8) 75.9 (72.9, 78.7) 79.5 (76.7, 82.1) 81.5 (78.8, 83.8) 81.4 (78.8, 83.8) 
   5 – Most deprived 79.2 (76.4, 81.7) 75.3 (72.5, 77.9) 74.2 (71.5, 76.7) 75.8 (73.1, 78.3) 78.0 (75.4, 80.3) 77.5 (74.9, 79.8) 
SII (95% CI) 7.2 (-3.0, 17.5) 6.3 (-0.6, 13.1) 12.7 (7.8, 17.6) 8.4 (-1.5, 18.2) 7.0 (1.4, 12.7) 10.3 (6.4, 14.2) 
RII (95% CI) 0.09 (-0.03, 0.21) 0.08 (-0.01, 0.17) 0.16 (0.10, 0.22) 0.11 (-0.02, 0.23) 0.09 (0.02, 0.16) 0.13 (0.08, 0.17) 
Five-year disease-specific  
survival (95% CI) 
      
   1 – Least deprived 63.0 (58.1, 67.5) 59.3 (54.6, 63.7) 62.4 (58.3, 66.2) 70.2 (66.2, 73.8) 70.7 (66.9, 74.2) 73.9 (70.3, 77.1) 
   2 63.1 (58.6, 67.2) 56.6 (52.5, 60.5) 62.4 (58.5, 66.0) 62.8 (59.2, 66.1) 68.2 (64.7, 71.4) 71.2 (67.9, 74.2) 
   3 64.8 (60.7, 68.7) 55.7 (51.7, 59.4) 58.6 (55.0, 62.0) 62.4 (58.8, 65.8) 66.6 (63.2, 69.7) 69.1 (65.7, 72.2) 
   4 59.9 (56.0, 63.7) 55.5 (51.8, 59.0) 56.1 (52.6, 59.4) 63.2 (59.8, 66.3) 65.2 (62.0, 68.3) 66.7 (63.3, 69.8) 
   5 – Most deprived 56.8 (53.3, 60.2) 52.0 (48.7, 55.2) 50.6 (47.5, 53.6) 56.1 (53.0, 59.1) 60.6 (57.6, 63.5) 63.9 (60.7, 66.8) 
SII (95% CI) 9.3 (-1.0, 19.5) 8.0 (3.3, 12.6) 16.0 (10.1, 21.9) 13.6 (-0.1, 27.3) 11.9 (7.5, 16.3) 12.3 (11.3, 13.3) 
RII (95% CI) 0.15 (-0.02, 0.32) 0.14 (0.06, 0.23) 0.28 (0.18, 0.38) 0.22 (-0.02, 0.44) 0.18 (0.11, 0.25) 0.18 (0.16, 0.19) 
10-year disease-specific  
survival (95% CI) 
      
   1 – Least deprived 59.5 (54.4, 64.2) 52.0 (47.0, 56.8) 57.4 (53.1, 61.3) 66.0 (61.9, 69.9) 66.4 (62.3, 70.2) N/A 
   2 58.1 (53.4, 62.5) 50.4 (46.2, 54.5) 56.2 (52.2, 60.0) 58.7 (54.9, 62.2) 64.5 (60.7, 67.9) N/A 
   3 58.4 (54.0, 62.6) 49.6 (45.5, 53.5) 53.0 (49.3, 56.6) 57.7 (53.9, 61.2) 61.6 (57.9, 65.1) N/A 
   4 54.4 (50.2, 58.4) 48.7 (44.9, 52.4) 49.5 (45.9, 53.0) 56.9 (53.4, 60.3) 60.5 (57.0, 63.9) N/A 
   5 – Most deprived 50.5 (46.8, 54.0) 43.6 (40.1, 47.0) 42.5 (39.3, 45.6) 51.2 (48.0, 54.4) 55.6 (52.4, 58.8) N/A 
SII (95% CI) 12.0 (5.3, 18.6) 10.1 (3.7, 16.6) 19.6 (12.8, 26.3) 15.2 (4.6, 25.7) 13.1 (8.7, 17.4) N/A 
RII (95% CI) 0.22 (0.10, 0.34) 0.21 (0.08, 0.34) 0.39 (0.25, 0.52) 0.25 (0.08, 0.45) 0.21 (0.14, 0.29) N/A 
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Appendix 2.22 – Disease-specific survival by Carstairs 1991 Category per year group of diagnosis for males 
 Year of diagnosis 
Carstairs 1991 Category 1986-1990 1991-1995 1996-2000 2001-2005 2006-2010 2011-2015 
One-year disease-specific  
survival (95% CI) 
      
   1 – Least deprived 85.7 (81.1, 89.2) 80.1 (75.4, 84.1) 85.9 (82.2, 88.8) 85.0 (81.1, 88.2) 86.9 (83.3, 89.7) 85.1 (81.7, 87.8) 
   2 83.6 (79.4, 87.1) 83.4 (79.6, 86.6) 84.3 (80.7, 87.3) 78.0 (74.3, 81.2) 83.2 (79.8, 86.1) 87.1 (84.2, 89.4) 
   3 83.5 (79.6, 86.7) 83.0 (79.4, 86.0) 80.4 (77.0, 83.4) 81.1 (77.5, 84.2) 83.8 (80.7, 86.5) 82.5 (79.3, 85.2) 
   4 77.0 (72.9, 80.6) 79.3 (75.7, 82.4) 76.7 (73.1, 79.9) 79.4 (76.0, 82.3) 82.7 (79.6, 85.3) 81.2 (78.1, 84.0) 
   5 – Most deprived 78.5 (75.2, 81.5) 75.9 (72.6, 78.8) 74.1 (70.9, 77.1) 75.6 (72.4, 78.5) 77.1 (74.1, 79.8) 78.2 (75.3, 80.9) 
SII (95% CI) 10.0 (-0.7, 20.6) 8.4 (-2.9, 19.7) 15.6 (12.2, 19.1) 8.3 (-4.1, 20.6) 10.6 (1.8, 19.4) 10.4 (2.7, 18.2) 
RII (95% CI) 0.12 (-0.01, 0.25) 0.11 (-0.04, 0.25) 0.20 (0.15, 0.24) 0.10 (-0.05, 0.26) 0.13 (0.02, 0.24) 0.13 (0.03, 0.22) 
Five-year disease-specific  
survival (95% CI) 
      
   1 – Least deprived 64.9 (58.9, 70.3) 61.7 (56.0, 66.9) 63.1 (58.3, 67.6) 69.5 (64.5, 73.9) 72.4 (67.9, 76.4) 74.9 (70.7, 78.6) 
   2 64.4 (59.0, 69.3) 58.5 (53.5, 63.1) 64.3 (59.6, 68.5) 62.1 (57.8, 66.1) 69.9 (65.8, 73.7) 71.3 (67.3, 75.0) 
   3 63.6 (58.5, 68.1) 55.9 (51.3, 60.3) 56.8 (52.5, 60.8) 62.2 (57.8, 66.2) 66.7 (62.7, 70.4) 70.1 (66.2, 73.7) 
   4 58.4 (53.6, 62.9) 55.0 (50.6, 59.1) 54.1 (49.8, 58.1) 61.7 (57.7, 65.5) 65.0 (61.2, 68.6) 65.1 (61.0, 68.9) 
   5 – Most deprived 56.9 (52.8, 60.8) 50.3 (46.4, 54.1) 50.3 (46.6, 53.8) 54.0 (50.3, 57.6) 58.3 (54.7, 61.7) 63.3 (59.5, 66.9) 
SII (95% CI) 11.6 (5.2, 18.0) 13.2 (8.6, 17.8) 18.2 (9.2, 27.2) 15.6 (2.4, 28.9) 17.2 (11.2, 23.2) 14.6 (9.7, 19.6) 
RII (95% CI) 0.19 (0.08, 0.30) 0.24 (0.16, 0.32) 0.32 (0.16, 0.48) 0.26 (0.04, 0.48) 0.26 (0.17, 0.35) 0.21 (0.14, 0.29) 
10-year disease-specific  
survival (95% CI) 
      
   1 – Least deprived 61.4 (55.1, 67.1) 53.9 (47.8, 59.6) 57.9 (52.9, 62.7) 65.7 (60.5, 70.4) 67.1 (62.0, 71.6) N/A 
   2 58.0 (52.2, 63.4) 52.4 (47.2, 57.3) 58.0 (53.1, 62.6) 58.2 (53.8, 62.4) 67.9 (63.6, 71.8) N/A 
   3 56.7 (51.3, 61.7) 50.1 (45.4, 54.7) 49.9 (45.5, 54.1) 57.0 (52.4, 61.3) 62.5 (58.2, 66.6) N/A 
   4 53.3 (48.3, 58.1) 47.8 (43.3, 52.1) 48.2 (43.9, 52.4) 56.1 (51.9, 60.2) 61.8 (57.8, 65.6) N/A 
   5 – Most deprived 48.8 (44.4, 53.0) 41.3 (37.2, 45.3) 41.5 (37.8, 45.2) 49.4 (45.5, 53.1) 53.8 (50.0, 57.4) N/A 
SII (95% CI) 15.5 (12.3, 18.7) 16.1 (9.8, 22.4) 22.0 (12.8, 31.2) 16.9 (5.9, 28.0) 17.7 (6.8, 28.6) N/A 




Appendix 2.23 – Disease-specific survival by Carstairs 1991 Category per year group of diagnosis for females 
 Year of diagnosis 
Carstairs 1991 Category 1986-1990 1991-1995 1996-2000 2001-2005 2006-2010 2011-2015 
One-year disease-specific  
survival (95% CI) 
      
   1 – Least deprived 81.4 (74.0, 86.8) 77.4 (69.8, 83.3) 77.0 (70.1, 82.5) 84.3 (78.5, 88.7) 77.8 (71.0, 83.1) 87.1 (81.9, 90.8) 
   2 79.6 (72.7, 85.0) 73.0 (66.3, 78.6) 78.3 (72.1, 83.3) 81.0 (75.4, 85.5) 80.1 (74.5, 84.6) 79.4 (74.2, 83.6) 
   3 86.3 (80.3, 90.6) 73.5 (66.4, 79.3) 81.1 (75.3, 85.7) 79.5 (74.0, 83.9) 80.7 (75.5, 85.0) 83.3 (78.3, 87.3) 
   4 80.6 (74.3, 85.5) 74.8 (68.6, 80.0) 74.2 (68.5, 79.0) 79.9 (74.5, 84.3) 78.5 (73.2, 82.9) 81.9 (76.9, 86.0) 
   5 – Most deprived 81.0 (75.4, 85.4) 73.8 (68.1, 78.7) 74.3 (69.1, 78.8) 76.4 (71.2, 80.9) 80.3 (75.4, 84.4) 75.5 (70.5, 79.8) 
SII (95% CI) 0.5 (-14.3, 15.4) 1.9 (-6.5, 10.4) 5.8 (-7.6, 19.3) 8.3 (2.4, 14.2) -1.3 (-7.9, 5.3) 10.3 (-6.2, 26.9) 
RII (95% CI) 0.01 (-0.18, 0.19) 0.03 (-0.09, 0.14) 0.08 (-0.10, 0.25) 0.10 (0.03, 0.18) -0.02, (-0.10, 0.07) 0.13 (-0.08, 0.33) 
Five-year disease-specific  
survival (95% CI) 
      
   1 – Least deprived 59.5 (50.7, 67.2) 54.4 (45.7, 62.2) 60.6 (52.9, 67.5) 71.6 (64.6, 77.4) 66.7 (59.3, 73.1) 71.6 (64.5, 77.5) 
   2 60.0 (52.0, 67.2) 52.4 (45.0, 59.2) 58.3 (51.2, 64.7) 64.3 (57.6, 70.2) 64.3 (57.7, 70.1) 70.9 (65.2, 75.9) 
   3 67.9 (60.1, 74.5) 55.0 (47.2, 62.2) 63.6 (56.7, 69.8) 62.9 (56.5, 68.6) 66.2 (60.0, 71.7) 66.8 (60.1, 72.7) 
   4 63.5 (56.2, 70.0) 56.8 (49.8, 63.2) 60.4 (54.1, 66.0) 66.6 (60.4, 72.1) 65.8 (59.7, 71.2) 70.4 (64.3, 75.7) 
   5 – Most deprived 56.9 (50.1, 63.2) 56.6 (50.2, 62.5) 51.4 (45.6, 56.9) 61.5 (55.5, 66.9) 67.1 (61.3, 72.2) 64.9 (59.2, 69.9) 
SII (95% CI) 3.4 (-21.2, 28.0) -4.7 (-11.0, 1.7) 10.6 (-10.6, 31.9) 8.2 (-7.8, 24.2) -1.6 (-7.1, 3.9) 7.3 (-3.6, 18.3) 
RII (95% CI) 0.06 (-0.34, 0.46) -0.08 (-0.20, 0.03) 0.18 (-0.18, 0.55) 0.13 (-0.12, 0.37) -0.02 (-0.11, 0.06) 0.11 (-0.05, 0.27) 
10-year disease-specific  
survival (95% CI) 
      
   1 – Least deprived 55.9 (47.0, 63.9) 48.2 (39.4, 56.4) 55.9 (48.0, 63.1) 66.8 (59.5, 73.2) 64.7 (57.1, 71.3) N/A 
   2 57.8 (49.6, 65.1) 46.0 (38.5, 53.2) 52.3 (45.1, 59.1) 59.6 (52.5, 66.0) 57.2 (49.9, 63.8) N/A 
   3 62.5 (54.3, 69.6) 48.1 (40, 55.6) 61.3 (54.2, 67.6) 59.1 (52.4, 65.1) 59.2 (52.0, 65.8) N/A 
   4 57.0 (49.3, 64.1) 51.0 (43.8, 57.8) 52.2 (45.8, 58.3) 58.8 (52.0, 64.9) 57.3 (50.1, 63.9) N/A 
   5 – Most deprived 54.6 (47.6, 61) 50.0 (43.3, 56.2) 45.1 (39.2, 50.9) 56.0 (49.7, 61.8) 60.8 (54.3, 66.7) N/A 
SII (95% CI) 3.4 (13.3, 20.0) -4.6 (-12.3, 3.2) 13.5 (-12.7, 39.7) 10.4 (-0.7, 21.5) 2.1 (-13.9, 18.2) N/A 
RII (95% CI) 0.06 (-0.23, 0.35) -0.09 (-0.25, 0.07) 0.26 (-0.24, 0.76) 0.17 (-0.01, 0.36) 0.04 (-0.23, 0.31) N/A 
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Appendix 2.24 – Disease-specific survival by Carstairs 1991 Category per year group of diagnosis for people with cancer of the oral cavity 
 Year of diagnosis 
Carstairs 1991 Category 1986-1990 1991-1995 1996-2000 2001-2005 2006-2010 2011-2015 
One-year disease-specific  
survival (95% CI) 
      
   1 – Least deprived 80.6 (72.3, 86.7) 78.9 (71.8, 84.5) 76.4 (69.9, 81.7) 85.8 (80.4, 89.8) 82.4 (76.8, 86.8) 87.1 (82.8, 90.4) 
   2 79.9 (72.7, 85.4) 76.3 (70.2, 81.2) 81.6 (75.8, 86.2) 74.5 (68.6, 79.4) 78.6 (73.4, 83.0) 84.5 (80.2, 88.0) 
   3 76.4 (69.2, 82.1) 77.1 (70.7, 82.3) 77.0 (71.3, 81.7) 77.3 (72.0, 81.8) 83.1 (78.5, 86.8) 81.2 (76.3, 85.2) 
   4 72.2 (65.1, 78.0) 76.2 (70.2, 81.1) 71.8 (65.7, 76.9) 77.6 (72.6, 81.8) 79.6 (74.8, 83.6) 80.8 (76.1, 84.7) 
   5 – Most deprived 77.5 (72.0, 82.0) 71.6 (66.1, 76.4) 75.1 (70.2, 79.3) 75.6 (70.7, 79.7) 75.2 (70.5, 79.2) 75.3 (70.5, 79.4) 
SII (95% CI) 4.9 (-11.5, 21.2) 7.9 (0.2, 15.6) 6.0 (-10.4, 22.4) 7.2 (-12.2, 26.6) 7.4 (6.2, 20.9) 14.0 (8.1, 19.8) 
RII (95% CI) 0.06 (-0.15, 0.28) 0.10 (0.00, 0.21) 0.08 (-0.14, 0.29) 0.09 (-0.15, 0.34) 0.09 (-0.08, 0.26) 0.17 (0.10, 0.24) 
Five-year disease-specific  
survival (95% CI) 
      
   1 – Least deprived 53.2 (43.1, 62.4) 51.6 (43.2, 59.3) 59.1 (51.7, 65.7) 71.2 (64.6, 76.8) 67.9 (61.3, 73.6) 75.3 (69.4, 80.1) 
   2 53.9 (45.4, 61.7) 52.7 (45.8, 59.1) 59.1 (52.0, 65.5) 61.0 (54.5, 66.8) 64.4 (58.3, 69.8) 72.0 (66.4, 76.8) 
   3 55.0 (47.0, 62.4) 49.2 (41.8, 56.1) 55.2 (48.7, 61.2) 60.0 (53.9, 65.5) 68.0 (62.5, 72.9) 64.9 (58.6, 70.4) 
   4 56.5 (48.8, 63.5) 50.8 (44.0, 57.3) 51.8 (45.3, 58.0) 59.1 (53.3, 64.5) 60.4 (54.8, 65.6) 65.6 (59.7, 70.9) 
   5 – Most deprived 51.8 (45.3, 57.9) 47.5 (41.5, 53.4) 51.3 (45.8, 56.5) 53.8 (48.2, 59.0) 57.0 (51.8, 61.9) 58.6 (52.5, 64.3) 
SII (95% CI) 1.8 (-9.0, 12.6) 5.7 (-1.4, 12.7) 11.4 (4.8, 17.9) 17.3 (2.4, 32.2) 13.6 (-0.5, 27.7) 20.2 (10.5, 29.9) 
RII (95% CI) 0.03 (-0.17, 0.23) 0.11 (-0.03, 0.25) 0.21 (0.09, 0.33) 0.29 (0.04, 0.54) 0.22 (-0.01, 0.44) 0.30 (0.16, 0.45) 
10-year disease-specific  
survival (95% CI) 
      
   1 – Least deprived 49.1 (38.8, 58.7) 45.8 (37.4, 53.8) 53.0 (45.4, 60.0) 67.2 (60.2, 73.2) 62.3 (55.0, 68.7) N/A 
   2 48.3 (39.3, 56.7) 46.3 (39.3, 53.1) 50.2 (42.9, 57.1) 56.3 (49.5, 62.5) 60.5 (53.9, 66.4) N/A 
   3 47.1 (38.7, 55.0) 39.5 (32.1, 46.7) 52.6 (46.0, 58.7) 55.5 (49.3, 61.3) 61.4 (54.9, 67.2) N/A 
   4 49.1 (41.0, 56.6) 44.9 (38.0, 51.6) 43.1 (36.4, 49.5) 52.2 (46.1, 57.9) 53.9 (47.5, 59.8) N/A 
   5 – Most deprived 45.1 (38.4, 51.6) 40.3 (34.1, 46.4) 43.3 (37.6, 48.8) 47.5 (41.7, 53.1) 51.7 (46.1, 56.9) N/A 
SII (95% CI) 4.3 (-3.0, 11.6) 6.5 (-7.9, 20.8) 13.7 (-0.8, 28.1) 20.6 (6.3, 34.9) 14.5 (3.8, 25.1) N/A 





Appendix 2.25 – Disease-specific survival by Carstairs 1991 Category per year group of diagnosis for people with cancer of the oropharynx 
 Year of diagnosis 
Carstairs 1991 Category 1986-1990 1991-1995 1996-2000 2001-2005 2006-2010 2011-2015 
One-year disease-specific  
survival (95% CI) 
      
   1 – Least deprived 83.2 (64.1, 92.6) 64.9 (48.7, 77.2) 88.6 (78.5, 94.1) 84.8 (75.3, 90.9) 81.9 (73.4, 87.9) 85.9 (79.4, 90.5) 
   2 71.9 (57.3, 82.3) 79.9 (66.6, 88.3) 70.7 (59.6, 79.3) 79.4 (70.4, 85.9) 85.5 (78.5, 90.4) 84.8 (79.2, 89.0) 
   3 79.8 (64.7, 88.9) 60.3 (46.6, 71.6) 79.6 (69.9, 86.5) 82.0 (73.5, 88.0) 84.5 (77.4, 89.5) 82.2 (75.9, 87.0) 
   4 60.6 (47.7, 71.3) 66.8 (54.0, 76.7) 73.4 (63.0, 81.3) 76.5 (67.2, 83.5) 82.6 (75.8, 87.6) 82.8 (76.6, 87.5) 
   5 – Most deprived 68.8 (56.8, 78.0) 70.4 (60.1, 78.6) 69.9 (61.0, 77.1) 71.8 (62.8, 79.0) 76.9 (69.9, 82.4) 77.4 (71.7, 82.1) 
SII (95% CI) 17.1 (-22.6, 56.9) 0.4 (-40.0, 40.8) 16.3 (-14.0, 46.7) 14.5 (2.5, 26.6) 8.1 (-6.1, 22.3) 10.2 (3.1, 17.4) 
RII (95% CI) 0.24 (-0.32, 0.80) 0.01 (-0.59, 0.59) 0.22 (-0.19, 0.62) 0.19 (0.03, 0.34) 0.10 (-0.07, 0.27) 0.12 (0.04, 0.21) 
Five-year disease-specific  
survival (95% CI) 
      
   1 – Least deprived 54.0 (33.8, 70.5) 49.1 (33.0, 63.3) 57.6 (44.7, 68.5) 67.6 (56.3, 76.5) 64.7 (54.8, 72.9) 76.1 (67.9, 82.5) 
   2 51.1 (35.8, 64.6) 44.5 (31.0, 57.1) 42.8 (31.7, 53.3) 62.6 (52.3, 71.3) 73.7 (65.4, 80.3) 71.3 (63.8, 77.5) 
   3 46.0 (30.0, 60.5) 23.6 (13.2, 35.8) 61.0 (50.0, 70.3) 59.9 (49.9, 68.5) 67.7 (59.1, 74.9) 69.1 (61.6, 75.4) 
   4 37.4 (25.5, 49.2) 43.2 (30.7, 55.2) 51.9 (40.8, 61.8) 62.7 (52.7, 71.2) 65.0 (56.9, 71.9) 67.9 (60.0, 74.7) 
   5 – Most deprived 36.3 (25.1, 47.6) 47.2 (36.1, 57.5) 41.5 (32.5, 50.2) 54.1 (44.6, 62.6) 59.0 (51.0, 66.1) 64.9 (58.5, 70.6) 
SII (95% CI) 23.8 (10.7, 36.9) -4.5 (-61.4, 52.3) 14.2 (-30.3, 58.7) 13.4 (-1.2, 28.0) 12.4 (-10.0, 34.7) 12.7 (7.2, 18.2) 
RII (95% CI) 0.55 (0.25, 0.86) -0.11 (-1.47, 1.25) 0.28 (-0.60, 1.17) 0.22 (-0.02, 0.46) 0.19 (-0.15, 0.53) 0.18 (0.10, 0.26) 
10-year disease-specific  
survival (95% CI) 
      
   1 – Least deprived 54.0 (33.8, 70.5) 42.1 (26.1, 57.3) 51.0 (38.1, 62.4) 62.7 (50.9, 72.4) 63.6 (53.6, 71.9) N/A 
   2 51.1 (35.8, 64.6) 35.7 (22.9, 48.7) 39.7 (28.8, 50.4) 58.9 (48.4, 68) 68.9 (59.6, 76.5) N/A 
   3 35.6 (20.3, 51.2) 17.2 (8.3, 28.8) 56.6 (45.3, 66.4) 55.0 (44.7, 64.1) 62.6 (53.3, 70.5) N/A 
   4 33.2 (21.6, 45.3) 39.2 (26.8, 51.3) 46.1 (35.0, 56.5) 59.4 (49.2, 68.2) 61.2 (52.7, 68.6) N/A 
   5 – Most deprived 24.3 (14.6, 35.5) 28.0 (17.2, 39.8) 33.7 (24.9, 42.6) 51.4 (41.7, 60.3) 54.0 (45.7, 61.5) N/A 
SII (95% CI) 37.8 (20.0, 55.6) 9.7 (-42.5, 62.0) 17.9 (-26.8, 62.6) 11.0 (-4.3, 26.3) 15.1 (-1.8, 32.0) N/A 





Appendix 2.26 – Disease-specific survival by Carstairs 1991 Category per year group of diagnosis for people with cancer of the larynx 
 Year of diagnosis 
Carstairs 1991 Category 1986-1990 1991-1995 1996-2000 2001-2005 2006-2010 2011-2015 
One-year disease-specific  
survival (95% CI) 
      
   1 – Least deprived 86.7 (79.7, 91.4) 83.9 (77.0, 88.9) 87.6 (81.8, 91.7) 84.7 (77.9, 89.6) 91.0 (85.2, 94.6) 90.8 (84.7, 94.6) 
   2 90.8 (85.4, 94.3) 87.0 (81.7, 90.8) 86.6 (81.2, 90.6) 83.9 (78.5, 88.1) 85.9 (80.4, 90.0) 87.9 (82.2, 91.9) 
   3 90.9 (85.9, 94.1) 86.7 (81.9, 90.3) 86.2 (81.5, 89.7) 83.4 (78.0, 87.5) 86.9 (82.2, 90.5) 89.3 (84.8, 92.5) 
   4 85.0 (79.6, 89.1) 85.8 (81.2, 89.3) 83.6 (79.1, 87.2) 85.7 (81.0, 89.3) 88.0 (83.6, 91.3) 85.1 (80.1, 88.9) 
   5 – Most deprived 84.7 (80.6, 88.1) 85.3 (81.4, 88.5) 80.8 (76.5, 84.4) 82.2 (78.0, 85.6) 83.7 (79.5, 87.2) 84.1 (79.7, 87.6) 
SII (95% CI) 6.7 (-6.4, 19.9) 0.5 (-5.6, 6.6) 8.9 (5.8, 12.1) 2.2 (-5.2, 9.6) 6.0 (-4.3, 16.3) 8.1 (1.6, 14.7) 
RII (95% CI) 0.08 (-0.07, 0.23) 0.01 (-0.07, 0.08) 0.11 (0.07, 0.14) 0.03 (0.06, 0.12) 0.07 (-0.05, 0.19) 0.09 (-0.02, 0.17) 
Five-year disease-specific  
survival (95% CI) 
      
   1 – Least deprived 66.4 (57.4, 73.9) 68.2 (59.8, 75.3) 68.5 (60.9, 74.9) 69.4 (61.0, 76.3) 84.8 (78.0, 89.6) 83.7 (76.3, 89.0) 
   2 70.5 (62.8, 76.9) 65.8 (58.6, 72.0) 69.6 (62.8, 75.5) 67.1 (60.5, 72.8) 75.2 (68.4, 80.7) 78.7 (71.8, 84.1) 
   3 73.3 (66.2, 79.2) 65.4 (59.0, 71.0) 62.4 (56.2, 67.9) 68.0 (61.5, 73.6) 70.8 (64.6, 76.2) 81.9 (76.1, 86.4) 
   4 66.5 (59.7, 72.5) 66.8 (60.9, 72.0) 62.9 (57.2, 68.0) 71.9 (66.0, 76.8) 74.4 (68.8, 79.3) 75.6 (69.3, 80.7) 
   5 – Most deprived 66.5 (61.2, 71.3) 62.7 (57.4, 67.5) 58.2 (53.0, 63.0) 63.3 (58.2, 68.0) 68.9 (63.6, 73.6) 75.0 (69.7, 79.5) 
SII (95% CI) 4.2 (-11.9, 20.4) 5.4 (-2.1, 12.8) 13.7 (3.7, 23.6) 5.6 (-12.3, 23.5) 13.6 (-6.3, 33.4) 10.1 (-1.4, 21.5) 
RII (95% CI) 0.06 (-0.17, 0.30) 0.08 (-0.03, 0.20) 0.22 (0.06, 0.37) 0.08 (-0.18, 0.35) 0.18 (-0.09, 0.45) 0.13 (-0.02, 0.28) 
10-year disease-specific  
survival (95% CI) 
      
   1 – Least deprived 61.5 (51.8, 69.7) 61.1 (51.9, 69.0) 61.3 (53.3, 68.4) 64.4 (55.5, 71.9) 82.6 (75.2, 88.0) N/A 
   2 63.7 (55.3, 70.9) 57.1 (49.5, 64.0) 62.7 (55.4, 69.0) 64.3 (57.4, 70.4) 71.6 (64.1, 77.9) N/A 
   3 66.8 (58.9, 73.5) 59.3 (52.7, 65.4) 53.0 (46.5, 59.0) 63.8 (57.0, 69.8) 66.4 (59.6, 72.3) N/A 
   4 61.2 (53.9, 67.7) 57.3 (51.0, 63.1) 57.3 (51.5, 62.8) 65.9 (59.7, 71.5) 70.8 (64.7, 76.0) N/A 
   5 – Most deprived 59.9 (54.1, 65.2) 53.5 (47.8, 58.8) 48.4 (42.9, 53.6) 57.4 (51.8, 62.5) 64.3 (58.6, 69.5) N/A 
SII (95% CI) 5.1 (-8.2, 18.4) 8.0 (-0.3, 16.3) 16.0 (-2.6, 34.7) 8.7 (-6.8, 24.2) 15.6 (-7.6, 38.7) N/A 





Appendix 2.27 – Net survival by the nearest Carstairs Category per year group of diagnosis for the whole cohort 
  Year group of diagnosis  
Carstairs 1991 Category 1986-1990 1991-1995 1996-2000 2001-2005 2006-2010 2011-2015 
One-year net  
survival (95% CI) 
      
   1 – Least deprived 82.8 (78.2, 87.5) 77.5 (72.7, 82.3) 84.7 (81.1, 88.4) 81.9 (77.9, 85.9) 82.7 (79.0, 86.4) 81.6 (78.2, 85.0) 
   2 80.7 (76.4, 85.0) 80.7 (76.8, 84.7) 83.2 (79.5, 86.9) 76.9 (73.3, 80.6) 79.3 (75.8, 82.9) 85.2 (82.3, 88.1) 
   3 82.0 (78.0, 86.0) 82.5 (78.8, 86.1) 79.9 (76.4, 83.4) 80.5 (76.9, 84.1) 81.0 (77.7, 84.2) 79.7 (76.5, 82.9) 
   4 74.8 (70.6, 78.9) 75.8 (72.1, 79.6) 74.7 (71.1, 78.4) 77.7 (74.3, 81.1) 79.3 (76.1, 82.5) 77.4 (74.1, 80.6) 
   5 – Most deprived 78.3 (74.9, 81.8) 72.1 (68.7, 75.5) 72.6 (69.3, 75.9) 74.6 (71.3, 77.8) 74.6 (71.5, 77.7) 73.9 (70.9, 77.0) 
SII (95% CI) 6.6 (-7.3, 20.5) 10.7 (-5.8, 27.1) 16.5 (11.4, 21.6) 6.9 (-3.8, 17.7) 8.7 (-0.2, 17.6) 12.5 (1.1, 23.9) 
RII (95% CI) 0.08 (-0.09, 0.26) 0.14 (-0.08, 0.35) 0.21 (0.15, 0.28) 0.09 (-0.05, 0.23) 0.11 (0.0, 0.22) 0.16 (0.01, 0.30) 
Five-year net  
survival (95% CI) 
      
   1 – Least deprived 55.5 (48.4, 62.6) 54.7 (47.8, 61.6) 59.8 (54.1, 65.5) 60.9 (55.5, 66.3) 63.0 (57.9, 68.2) 67.7 (62.8, 72.7) 
   2 54.4 (47.7, 61.1) 52.2 (46.5, 58.0) 60.9 (55.5, 66.3) 53.0 (48.2, 57.8) 58.0 (53.1, 62.9) 63.8 (59.1, 68.4) 
   3 54.5 (48.4, 60.5) 53.1 (47.6, 58.5) 56.0 (51.0, 60.9) 56.7 (51.6, 61.8) 57.7 (53.2, 62.3) 57.3 (52.6, 62.0) 
   4 52.7 (47.0, 58.3) 50.5 (45.6, 55.5) 50.5 (45.7, 55.2) 53.3 (48.8, 57.9) 57.5 (53.2, 61.8) 50.6 (45.7, 55.5) 
   5 – Most deprived 49.0 (44.1, 53.8) 42.5 (38.2, 46.9) 47.7 (43.5, 51.8) 48.1 (43.9, 52.3) 48.5 (44.7, 52.4) 50.7 (46.2, 55.2) 
SII (95% CI) 8.4 (2.1, 13.6) 15.0 (2.5, 27.5) 17.9 (9.6, 26.2) 12.5 (-1.8, 26.8) 15.6 (2.1, 29.2) 22.9 (10.3, 35.5) 
RII (95% CI) 0.16 (0.06, 0.26) 0.30 (0.05, 0.56) 0.33 (0.18, 0.49) 0.23 (-0.03, 0.50) 0.28 (0.04, 0.52) 0.40 (0.18, 0.62) 
10-year net  
survival (95% CI) 
      
   1 – Least deprived 47.9 (38.7, 57.1) 38.2 (27.9, 48.5) 47.7 (40.4, 55.0) 50.8 (44.7, 56.8) 47.7 (39.3, 56.1) N/A 
   2 40.8 (33.1, 48.5) 47.3 (39.5, 55.2) 50.3 (43.1, 57.6) 47.4 (41.3, 53.6) 48.9 (42.4, 55.4) N/A 
   3 41.7 (33.6, 49.7) 40.6 (34.1, 47.1) 43.0 (35.7, 50.4) 47.6 (41.1, 54.2) 44.6 (35.2, 54.0) N/A 
   4 44.5 (37.0, 51.9) 45.3 (39.1, 51.5) 43.1 (37.4, 48.8) 46.4 (41.2, 51.6) 49.2 (43.6, 54.9) N/A 
   5 – Most deprived 37.8 (31.9, 43.7) 32.6 (27.7, 37.5) 34.2 (29.5, 39.0) 38.3 (33.3, 43.2) 37.6 (32.9, 42.3) N/A 
SII (95% CI) 8.4 (-7.4, 24.2) 11.4 (-18.7, 41.4) 18.8 (4.3, 33.3) 14.2 (2.0, 26.3) 12.0 (-9.3, 33.3) N/A 




Appendix 2.28 – Overall survival by the nearest Carstairs Category per year group of diagnosis for the whole cohort 
  Year group of diagnosis  
Carstairs 1991 Category 1986-1990 1991-1995 1996-2000 2001-2005 2006-2010 2011-2015 
One-year net  
survival (95% CI) 
      
   1 – Least deprived 77.4 (73.3, 80.9) 73.0 (68.9, 76.7) 82.0 (78.6, 84.9) 81.1 (77.7, 84.1) 79.5 (76.0, 82.5) 82.4 (79.5, 84.9) 
   2 75.9 (72.1, 79.2) 74.7 (71.3, 77.9) 77.9 (74.6, 80.9) 75.5 (72.2, 78.5) 74.1 (70.9, 77.0) 80.4 (77.6, 82.9) 
   3 78.4 (75.0, 81.5) 75.9 (72.6, 78.9) 76.0 (72.9, 78.9) 77.5 (74.5, 80.2) 79.2 (76.4, 81.7) 77.7 (74.9, 80.3) 
   4 71.5 (68.0, 74.7) 71.6 (68.4, 74.5) 72.0 (69.0, 74.8) 76.3 (73.4, 79.0) 75.1 (72.1, 77.7) 75.0 (72.1, 77.6) 
   5 – Most deprived 73.5 (70.5, 76.2) 67.9 (65.0, 70.6) 70.0 (67.3, 72.5) 71.6 (69.0, 74.1) 73.7 (71.2, 76.1) 72.6 (70.1, 74.9) 
SII (95% CI) 6.1 (-6.1, 18.2) 8.6 (-3.0, 20.2) 14.7 (9.8, 19.5) 9.1 (-1.5, 19.7) 5.3 (-7.5, 18.0) 12.6 (11.4, 13.7) 
RII (95% CI) 0.08 (-0.08, 0.24) 0.12 (-0.04, 0.28) 0.20 (0.13, 0.26) 0.12 (-0.02, 0.26) 0.07 (-0.10, 0.24) 0.16 (0.15, 0.18) 
Five-year net  
survival (95% CI) 
      
   1 – Least deprived 46.3 (41.7, 50.8) 43.1 (38.7, 47.3) 53.7 (49.5, 57.7) 55.8 (51.7, 59.7) 58.0 (53.9, 61.8) 60.7 (56.8, 64.3) 
   2 45.4 (41.2, 49.5) 42.9 (39.1, 46.6) 49.3 (45.5, 53.0) 48.2 (44.5, 51.7) 49.2 (45.7, 52.7) 59.9 (56.2, 63.4) 
   3 46.7 (42.7, 50.6) 43.4 (39.8, 47.1) 47.2 (43.7, 50.6) 49.5 (46.0, 52.9) 52.0 (48.7, 55.1) 51.8 (48.3, 55.3) 
   4 44.4 (40.7, 48.1) 42.5 (39.1, 45.9) 45.7 (42.4, 48.9) 48.2 (44.9, 51.4) 47.2 (44.0, 50.4) 46.0 (42.4, 49.5) 
   5 – Most deprived 40.5 (37.3, 43.7) 35.4 (32.5, 38.3) 39.8 (37.1, 42.5) 41.8 (39.0, 44.6) 46.7 (44.0, 49.5) 46.3 (43.2, 49.2) 
SII (95% CI) 7.5 (-0.3, 15.4) 9.9 (-2.8, 22.6) 16.1 (10.1, 22.1) 13.8 (0.9, 26.7) 11.0 (-3.3, 25.4) 21.0 (7.1, 34.9) 
RII (95% CI) 0.17 (0.00, 0.35)  0.24 (-0.07, 0.55) 0.35 (0.21, 0.48) 0.29 (0.02, 0.56) 0.22 (-0.07, 0.51) 0.40 (0.14, 0.67) 
10-year net  
survival (95% CI) 
      
   1 – Least deprived 34.6 (30.2, 38.9) 29.4 (25.4, 33.4) 36.6 (32.6, 40.5) 40.7 (36.7, 44.7) 42.3 (38.0, 46.6) N/A 
   2 30.3 (26.5, 34.1) 29.6 (26.2, 33.1) 34.3 (30.7, 37.9) 35.8 (32.4, 39.3) 38.1 (34.5, 41.7) N/A 
   3 30.8 (27.2, 34.5) 27.8 (24.5, 31.1) 32.3 (29.0, 35.6) 35.6 (32.3, 38.9) 36.3 (33.0, 39.6) N/A 
   4 28.2 (24.9, 31.6) 29.0 (26.0, 32.2) 30.6 (27.7, 33.7) 34.7 (31.6, 37.8) 31.4 (28.1, 34.7) N/A 
   5 – Most deprived 25.6 (22.8, 28.4) 22.1 (19.6, 24.6) 25.0 (22.7, 27.5) 27.0 (24.5, 29.6) 31.0 (28.3, 33.8) N/A 
SII (95% CI) 10.1 (4.5, 15.6) 9.2 (-2.2, 20.5) 14.2 (9.1, 19.4) 14.8 (3.5, 26.1) 13.9 (6.3, 21.4) N/A 





Appendix 2.29 – Disease-specific survival by the nearest Carstairs Category per year group of diagnosis for the whole cohort 
 Year of diagnosis 
Carstairs 1991 Category 1986-1990 1991-1995 1996-2000 2001-2005 2006-2010 2011-2015 
One-year disease-specific  
survival (95% CI) 
      
   1 – Least deprived 85.7 (81.1, 89.2) 80.1 (75.4, 84.1) 85.9 (82.2, 88.8) 85.0 (81.1, 88.2) 86.9 (83.3, 89.7) 85.1 (81.7, 87.8) 
   2 83.6 (79.4, 87.1) 83.4 (79.6, 86.6) 84.3 (80.7, 87.3) 78.0 (74.3, 81.2) 83.2 (79.8, 86.1) 87.1 (84.2, 89.4) 
   3 83.5 (79.6, 86.7) 83.0 (79.4, 86.0) 80.4 (77.0, 83.4) 81.1 (77.5, 84.2) 83.8 (80.7, 86.5) 82.5 (79.3, 85.2) 
   4 77.0 (72.9, 80.6) 79.3 (75.7, 82.4) 76.7 (73.1, 79.9) 79.4 (76.0, 82.3) 82.7 (79.6, 85.3) 81.2 (78.1, 84.0) 
   5 – Most deprived 78.5 (75.2, 81.5) 75.9 (72.6, 78.8) 74.1 (70.9, 77.1) 75.6 (72.4, 78.5) 77.1 (74.1, 79.8) 78.2 (75.3, 80.9) 
SII (95% CI) 10.0 (-0.7, 20.6) 8.4 (-2.9, 19.7) 15.6 (12.2, 19.1) 8.3 (-4.1, 20.6) 10.6 (1.8, 19.4) 10.4 (2.7, 18.2) 
RII (95% CI) 0.12 (-0.01, 0.25) 0.11 (-0.04, 0.25) 0.20 (0.15, 0.24) 0.10 (-0.05, 0.26) 0.13 (0.02, 0.24) 0.13 (0.03, 0.22) 
Five-year disease-specific  
survival (95% CI) 
      
   1 – Least deprived 64.9 (58.9, 70.3) 61.7 (56.0, 66.9) 63.1 (58.3, 67.6) 69.5 (64.5, 73.9) 72.4 (67.9, 76.4) 74.9 (70.7, 78.6) 
   2 64.4 (59.0, 69.3) 58.5 (53.5, 63.1) 64.3 (59.6, 68.5) 62.1 (57.8, 66.1) 69.9 (65.8, 73.7) 71.3 (67.3, 75.0) 
   3 63.6 (58.5, 68.1) 55.9 (51.3, 60.3) 56.8 (52.5, 60.8) 62.2 (57.8, 66.2) 66.7 (62.7, 70.4) 70.1 (66.2, 73.7) 
   4 58.4 (53.6, 62.9) 55.0 (50.6, 59.1) 54.1 (49.8, 58.1) 61.7 (57.7, 65.5) 65.0 (61.2, 68.6) 65.1 (61.0, 68.9) 
   5 – Most deprived 56.9 (52.8, 60.8) 50.3 (46.4, 54.1) 50.3 (46.6, 53.8) 54.0 (50.3, 57.6) 58.3 (54.7, 61.7) 63.3 (59.5, 66.9) 
SII (95% CI) 11.6 (5.2, 18.0) 13.2 (8.6, 17.8) 18.2 (9.2, 27.2) 15.6 (2.4, 28.9) 17.2 (11.2, 23.2) 14.6 (9.7, 19.6) 
RII (95% CI) 0.19 (0.08, 0.30) 0.24 (0.16, 0.32) 0.32 (0.16, 0.48) 0.26 (0.04, 0.48) 0.26 (0.17, 0.35) 0.21 (0.14, 0.29) 
10-year disease-specific  
survival (95% CI) 
      
   1 – Least deprived 61.4 (55.1, 67.1) 53.9 (47.8, 59.6) 57.9 (52.9, 62.7) 65.7 (60.5, 70.4) 67.1 (62.0, 71.6) N/A 
   2 58.0 (52.2, 63.4) 52.4 (47.2, 57.3) 58.0 (53.1, 62.6) 58.2 (53.8, 62.4) 67.9 (63.6, 71.8) N/A 
   3 56.7 (51.3, 61.7) 50.1 (45.4, 54.7) 49.9 (45.5, 54.1) 57.0 (52.4, 61.3) 62.5 (58.2, 66.6) N/A 
   4 53.3 (48.3, 58.1) 47.8 (43.3, 52.1) 48.2 (43.9, 52.4) 56.1 (51.9, 60.2) 61.8 (57.8, 65.6) N/A 
   5 – Most deprived 48.8 (44.4, 53.0) 41.3 (37.2, 45.3) 41.5 (37.8, 45.2) 49.4 (45.5, 53.1) 53.8 (50.0, 57.4) N/A 
SII (95% CI) 15.5 (12.3, 18.7) 16.1 (9.8, 22.4) 22.0 (12.8, 31.2) 16.9 (5.9, 28.0) 17.7 (6.8, 28.6) N/A 




Appendix 2.30 – Net survival by the SIMD 2004 Category per year group of diagnosis for the 
whole cohort 
 Year group of diagnosis 
Carstairs 1991 Category 2001-2005 2006-2010 2011-2015 
One-year net  
survival (95% CI) 
   
   1 – Least deprived 84.5 (79.2, 89.9) 71.4 (64.9, 77.9) 85.5 (80.6, 90.4) 
   2 79.7 (74.2, 85.1) 76.3 (70.8, 81.8) 75.7 (70.6, 80.9) 
   3 79.6 (74.4, 84.9) 78.5 (73.4, 83.6) 79.6 (74.5, 84.6) 
   4 79.4 (74.2, 84.5) 76.9 (71.7, 82.1) 78.7 (73.6, 83.7) 
   5 – Most deprived 75.5 (70.4, 80.7) 75.4 (70.4, 80.4) 72.5 (67.6, 77.5) 
SII (95% CI) 8.9 (1.1, 16.7) -2.8 (-16.0, 10.4) 11.1 (-7.5, 29.7) 
RII (95% CI) 0.11 (0.01, 0.21) -0.04 (-0.21, 0.14) 0.14 (-0.10, 0.38) 
Five-year net  
survival (95% CI) 
   
   1 – Least deprived 64.2 (56.5, 72.0) 56.1 (48.4, 63.7) 65.1 (56.7, 73.4) 
   2 56.8 (49.2, 64.3) 58.0 (50.8, 64.2) 60.6 (53.2, 68.0) 
   3 55.1 (47.9, 62.3) 54.5 (47.7, 61.2) 56.8 (48.9, 64.6) 
   4 57.8 (50.7, 64.8) 56.8 (50.1, 63.5) 57.4 (49.8, 65.0) 
   5 – Most deprived 53.1 (46.6, 59.7) 54.8 (48.5, 61.0) 54.2 (47.5, 61.0) 
SII (95% CI) 9.8 (-4.9, 24.5) 2.1 (-5.5, 9.7) 12.1 (4.1, 20.1) 
RII (95% CI) 0.17 (-0.09, 0.43) 0.04 (-0.10, 0.17) 0.21 (0.07, 0.34) 
10-year net  
survival (95% CI) 
   
   1 – Least deprived 53.2 (44.0, 62.4) 49.4 (40.3, 58.5) N/A 
   2 45.7 (36.9, 54.6) 49.5 (40.2, 58.8) N/A 
   3 49.8 (40.3, 59.2) 41.3 (32.9, 49.8) N/A 
   4 41.1 (33.1, 49.1) 49.7 (40.1, 59.3) N/A 
   5 – Most deprived 37.1 (30.0, 44.2) 42.6 (34.6, 50.6) N/A 
SII (95% CI) 18.5 (2.3, 34.7) 6.4 (-15.2, 28.1) N/A 





Appendix 2.31 – Overall survival by the SIMD 2004 Category per year group of diagnosis for 
the whole cohort 
 Year group of diagnosis 
Carstairs 1991 Category 2001-2005 2006-2010 2011-2015 
One-year net  
survival (95% CI) 
   
   1 – Least deprived 84.5 (81.0, 87.5) 80.0 (76.3, 83.1) 84.8 (81.7, 87.3) 
   2 79.6 (76.4, 82.5) 79.5 (76.4, 82.3) 80.0 (77.2, 82.6) 
   3 74.8 (71.6, 77.7) 76.3 (73.3, 79.0) 79.9 (77.2, 82.3) 
   4 74.6 (71.8, 77.2) 76.3 (73.5, 78.7) 73.7 (71.0, 76.2) 
   5 – Most deprived 71.8 (69.3, 74.2) 71.8 (69.3, 74.1) 71.7 (69.2, 74.0) 
SII (95% CI) 14.1 (4.8, 23.5) 10.2 (4.5, 15.9) 16.2 (8.6, 23.7) 
RII (95% CI) 0.19 (0.06, 0.31) 0.13 (0.06, 0.21) 0.21 (0.11, 0.31) 
 9.0 (-0.2, 18.1) 5.7 (-2.2, 13.6) 12.2 (7.5, 16.9) 
 0.12 (0.00, 0.24) 0.08 (-0.03, 0.18) 0.16 (0.10, 0.22) 
Five-year net  
survival (95% CI) 
   
   1 – Least deprived 58.4 (53.8, 62.6) 61.6 (57.4, 65.5) 63.4 (59.2, 67.4) 
   2 54.5 (50.7, 58.1) 55.8 (52.1, 59.4) 59.6 (55.9, 63.1) 
   3 47.9 (44.4, 51.3) 49.1 (45.7, 52.4) 52.9 (49.3, 56.4) 
   4 46.1 (43.0, 49.2) 50.5 (47.4, 53.5) 47.7 (44.3, 51.0) 
   5 – Most deprived 41.1 (38.4, 43.8) 41.7 (39.0, 44.3) 44.1 (41.0, 47.1) 
SII (95% CI) 21.1 (14.3, 27.8) 22.1 (8.5, 35.6) 25.1 (19.3, 30.9) 
RII (95% CI) 0.43 (0.29, 0.57) 0.44 (0.17, 0.71) 0.48 (0.37, 0.59) 
 14.1 (-1.5, 29.8) 13.0 (4.3, 21.7) 19.2 (10.5, 27.9) 
 0.30 (-0.03, 0.62) 0.26 (0.09, 0.43) 0.36 (0.20, 0.53) 
10-year net  
survival (95% CI) 
   
   1 – Least deprived 44.9 (40.5, 49.3) 47.4 (42.9, 51.8) N/A 
   2 40.8 (37.1, 44.5) 41.4 (37.4, 45.3) N/A 
   3 33.6 (30.3, 36.9) 35.0 (31.6, 38.5) N/A 
   4 33.1 (30.2, 36.0) 35.3 (32.1, 38.4) N/A 
   5 – Most deprived 26.3 (23.9, 28.7) 26.0 (23.4, 28.5) N/A 
SII (95% CI) 22.2 (13.4, 31.0) 24.1 (11.9, 36.4) N/A 
RII (95% CI) 0.64 (0.39, 0.90) 0.68 (0.33, 1.02) N/A 
 16.4 (2.3, 30.5) 13.7 (4.7, 22.7)  







Appendix 2.32 – Disease-specific survival by the SIMD 2004 Category per year group of 
diagnosis for the whole cohort 
 Year group of diagnosis 
Carstairs 1991 Category 2001-2005 2006-2010 2011-2015 
One-year net  
survival (95% CI) 
   
   1 – Least deprived 84.3 (78.5, 88.7) 77.8 (71.0, 83.1) 87.1 (81.9, 90.8) 
   2 81.0 (75.4, 85.5) 80.1 (74.5, 84.6) 79.4 (74.2, 83.6) 
   3 79.5 (74.0, 83.9) 80.7 (75.5, 85.0) 83.3 (78.3, 87.3) 
   4 79.9 (74.5, 84.3) 78.5 (73.2, 82.9) 81.9 (76.9, 86.0) 
   5 – Most deprived 76.4 (71.2, 80.9) 80.3 (75.4, 84.4) 75.5 (70.5, 79.8) 
SII (95% CI) 8.3 (2.4, 14.2) -1.3 (-7.9, 5.3) 10.3 (-6.2, 26.9) 
RII (95% CI) 0.10 (0.03, 0.18) -0.02, (-0.10, 0.07) 0.13 (-0.08, 0.33) 
Five-year net  
survival (95% CI) 
   
   1 – Least deprived 71.6 (64.6, 77.4) 66.7 (59.3, 73.1) 71.6 (64.5, 77.5) 
   2 64.3 (57.6, 70.2) 64.3 (57.7, 70.1) 70.9 (65.2, 75.9) 
   3 62.9 (56.5, 68.6) 66.2 (60.0, 71.7) 66.8 (60.1, 72.7) 
   4 66.6 (60.4, 72.1) 65.8 (59.7, 71.2) 70.4 (64.3, 75.7) 
   5 – Most deprived 61.5 (55.5, 66.9) 67.1 (61.3, 72.2) 64.9 (59.2, 69.9) 
SII (95% CI) 8.2 (-7.8, 24.2) -1.6 (-7.1, 3.9) 7.3 (-3.6, 18.3) 
RII (95% CI) 0.13 (-0.12, 0.37) -0.02 (-0.11, 0.06) 0.11 (-0.05, 0.27) 
10-year net  
survival (95% CI) 
   
   1 – Least deprived 66.8 (59.5, 73.2) 64.7 (57.1, 71.3) N/A 
   2 59.6 (52.5, 66.0) 57.2 (49.9, 63.8) N/A 
   3 59.1 (52.4, 65.1) 59.2 (52.0, 65.8) N/A 
   4 58.8 (52.0, 64.9) 57.3 (50.1, 63.9) N/A 
   5 – Most deprived 56.0 (49.7, 61.8) 60.8 (54.3, 66.7) N/A 
SII (95% CI) 10.4 (-0.7, 21.5) 2.1 (-13.9, 18.2) N/A 
RII (95% CI) 0.17 (-0.01, 0.36) 0.04 (-0.23, 0.31) N/A 
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Did not return 
questionnaire p-value 
Total 3,440 1,154  
Age group   0.840 
   Less than 44 210 (6.1%) 70 (6.1%)  
   45 to 54 676 (19.7%) 224 (19.4%)  
   55 to 64 1,192 (34.7%) 384 (33.3%)  
   65 to 74 940 (27.3%) 322 (27.9%)  
   75 and over 422 (12.3%) 154 (13.3%)  
Sex   0.006 
   Male 2,526 (73.4%) 894 (77.5%)  
   Female 914 (26.6%) 260 (22.5%)  
Comorbidity   <0.001 
   No comorbidity 1,484 (44.1%) 407 (36.0%)  
   Mild comorbidity 1,149 (34.1%) 400 (35.4%)  
   Moderate/severe comorbidity 732 (21.8%) 324 (28.6%)  
Anatomical Site   0.580 
   Oropharynx 1,334 (38.8%) 445 (38.6%)  
   Lip and oral cavity 900 (26.2%) 289 (25.0%)  
   Larynx 728 (21.2%) 254 (22.0%)  
   Hypopharynx 160 (4.7%) 64 (5.5%)  
   Salivary glands 147 (4.3%) 40 (3.5%)  
   Other 171 (5.0%) 62 (5.4%)  
Stage   0.030 
   I 788 (23.1%) 219 (19.1%)  
   II 593 (17.4%) 216 (18.8%)  
   III 473 (13.9%) 156 (13.6%)  
   IV 1,555 (45.6%) 557 (48.5%)  
HPV status   0.011 
   Negative 2,114 (70.9%) 681 (75.2%)  
   Positive 867 (29.1%) 224 (24.8%)  
Treatment   <0.001 
   Surgery only 765 (22.2%) 222 (19.2%)  
   Chemoradiotherapy only 1,064 (30.9%) 346 (30.0%)  
   Radiotherapy only 702 (20.4%) 256 (22.2%)  
   Surgery and chemo/radio 872 (25.3%) 291 (25.2%)  
   Chemotherapy only 15 (0.4%) 13 (1.1%)  
   No treatment 22 (0.6%) 26 (2.3%)  
IMD Category   <0.001 
   1 – Most deprived 674 (20.1%) 300 (26.5%)  
   2 616 (18.4%) 258 (22.8%)  
   3 746 (22.2%) 230 (20.3%)  
   4 664 (19.8%) 169 (14.9%)  







Appendix 6.1 – ICD codes inclusion criteria for each study 
f 
Scottish Audit of Head and 
Neck Cancer 
Head and Neck 5000 
Lip (C00) Lip (C00) 
lip (C00) and oral cavity (C02-
C04, C05.0, C06) 
oral cavity (C02-C04, C05.0, 
C06) 
oral cavity (C02-C04, C05.0, 
C06) 
 Grouped above 
oropharynx (C01, C05.1, 
C05.2, C09, C10) 
oropharynx (C01, C05.1, 
C05.2, C09, C10) 
oropharynx (C01, C05.1, 
C05.2, C09, C10) 
hypopharynx (C12, C13) hypopharynx (C12, C13) hypopharynx (C12, C13)  
larynx (C32, C10.1) larynx (C32, C10.1) larynx (C32, C10.1) 
salivary glands (C07, C08) salivary glands (C07, C08) 
major salivary glands (C07, 
C08) 
 Not considered  Not considered 
minor salivary glands (any 
ICD-10 code with histology 
recorded as “salivary gland”) 
 Not included 
nasopharynx, nasal cavity, 
and sinuses (C11, C30.0, 
C31) 
nasopharynx (C11) 
 Not included  Grouped above Nasal cavity (C30.0) 
 Not included  Grouped above Sinuses (C31) 
other sites of the head and 
neck (C14.0, C30.1, C41.1, 
C69.5) 
other ill-defined areas of the 
head and neck (C14, C30.1, 
C41, C44, C76, C77) 
other sites of the head and 
neck (C14.0, C30.1, C41.1, 
C69.5) 
 
Appendix 6.2 – Treatment groupings for each study 
Scottish Cancer Registry 
Scottish Audit of Head and Neck 
Cancer 
Head and Neck 5000 
Surgery only Surgery only Surgery only 
Radiotherapy only Radiotherapy only Radiotherapy only 
Surgery and radiotherapy Surgery and radiotherapy  Combined below 
Separated below Combined below 





Chemotherapy only, chemotherapy 
combined with surgery, 
chemotherapy combined with      
radiotherapy, and chemotherapy 
combined with both surgery and 
radiotherapy 
Separated 
Chemoradiotherapy only Combined above Chemoradiotherapy only 
Surgery and chemoradiotherapy Combined above Combined above 
Chemotherapy with or without 
surgery 
Combined above Combined above 
Combined above Combined above Chemotherapy only 
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